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INTRODUCTION
Medical aerospace research has offered scientists a
unique challenge. They have had to ascertain whether space-
flight is safe for humans and what the effects of weightless-
ness are; they have had to predict whether physiological
changes would be progressive and could pose safety questions
to longer missions or whether the changes represented a new
homeostatic equilibrium. Their efforts to address these
problems have been severely circumscribed by the inherent
nature of the research. The opportunities to study the effects
of this unique environment have been few and infrequent, the
population small. Because of conflicting demands on the
AL	 astronaut's time and because of the practical and physiological
limitations to the biological specimens which can be obtained,
techniques have often been less refined than desired. Fortu-
nately, bedrest has been found to be a useful model for
simulating many of the physiological effects ofweightlessness.
Bedrest projects have enabled researchers to increase their
i
fund of knowledge without the constraints of population size i
which characterizes spaceflight. In ground--based studies
various parameters can be isolated and analyzed.
Since Skylab gave medical investigators one of their first
opportunities for extensive and carefully controlled medical
research not only pre- and postflight, but infligh*`, it seemed
natural to extend these investigations to ground-based studies.
f1
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As a followup to Skylab, a two-phase bedrest project was plan-
ned involving a total of twelve subjects, six bedrested for
two weeks and six for four weeks. The first phase is now
complete and the second is scheduled for next summer.
Project Design
The project was designed to approximate as closely as
possible the medical testing and dietary control of Skylab.
During the entire test period, three weeks pre, two weeks
bedrest, and two weeks post, the subjects ate measured amounts
of the Skylab diet and drank deionized water to recreate the
metabolic balance studies of Skylab. j
As in Skylab water intake and output were recorded daily 	 j
l
but insensible water loss was not measured. All urine and
excrement were collected for analysis of contained minerals
and hormones, etc. The medical testing program pre- and
postbedrest was similar to that of Skylab, including most of
the same experiments; lower body negative pressure testing
the orthostatic intolerance noted after both spaceflights and
bedrest, bicycle ergometry testing the cardiovascular response
to graded exercise, postural equilibrium, vestibular studies
and electromyograms,. Fluid and electrolyte shifts and balance
were documented with intake and output records and radionuc:Lide
studies. In addition, the subjects were followed and tested
5
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by a psychiatrist who watched for signs of mental stress in
the test environment and changes in mental status.	 None was
found during the seven week investigation. 	 Individual methods
and protocols are described in the reports of the individual
principal investigators.
The subjects were bedrested in two-four bed wards at The
Methodist Hospital.	 For the pre- and postcontrol period, they
lived in a special housing facility. 	 Subjects were allowed
relative freedom to pursue normal activity during the control
period, pre- and postbedrest.. 	 During bedrest they could have
visitors, watch. TV, read books and magazines.	 This freedom
enhanced their motivation and kept them mentally and physically
alert, a situation more nearly approximating the busy challenging
environment of the astronauts than would an isolation study. i
In the house environment, they lived with a group of individuals
i
who had the same restrictions on life style as they did.	 They
were therefore not tempted by food or beverages of which they
could not partake.- They were required to be in the housing
facility by 11:00 PM every evening.	 The subjects complied
with the rules and no infraction of the study rules were
observed or reported to the project personnel.
Subject Selection
The six subjects of the first 'phase were`noxmal, healthy
-] -- -77J
I ;i
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paid volunteers whose mean age was 30. 	 Subjects were sought
through two student placement offices connected with Houston
universities, Rice University and the University of Houston,
and through the Texas Employment Commission.	 All applicants
were asked to complete a Methodist Hospital employee applica-
tion form after which each potential subject had an interview
of about an hour's duration with the project coordinator.
	
The
interview included an explanation of the project purpose, the
nature of the medical experiments and questions concerning the
subject's medical history, educational and work background and
ambitions.	 The diet to be used during the program was shown
to the applicants, and any food aversions or allergies were
noted.	 The primary criteria used to determine which applicants
would be sent for physicals were;
1.	 Age.	 We wanted a group with a mean age of at least
30.	 Subjects of this age group are more difficult to find
than a younger population.	 Many adults whom--we would consider
dependable and conscientious have family, work or personal
commitments which prevented their being subjects. 	 Fewer in
this age group are free of physical defects.
2.	 Size.	 Subjects under six feet were sought because
that is the -height limit for the astronaut corps.	 The weights
of the subjects had to fall within ±10%'0f the-ideal-ranae
r::
5 I ! J 1	 i	 1
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published by the Metropolitan Life Insurance Company (Stati-
stical Bulletin 40:1, 1959).
3. Food preferences. Because the diet was a very
important part of the metabolic studies, it was necessary to
seek subjects who could and would eat everything given them.
Subjects with known food allergies and/or a known aversion to
a major menu item were ruled out.
4.	 Attitude.
	
Because the subjects were not to be iso-
lated, but were to be allowed to attend classes and visit
family and friends, mature, conscientious, highly motivated
individuals were sought who could be trusted to rigidly adhere
to the diet, to collect all excrement and not to smoke or take
drugs during the study.	 Subject motivation was additionally
important because in several of the medical experiments attitude
and motivation can play a large role in the subject's response,
particularly his desire to regain a normal physical state
postbedrest.	 Individuals were naturally sought who would
wholeheartedly complete any task they had begun.
5.	 Physical Fitness.	 All subjects were asked to run a
mile and a half on a track at a nearby university. 	 The time
taken was measured. 	 A subject was considered to be in adequate
physical condition if his time fell in the good to excellent
range according to the tables published by Cooper*.
t	 1
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Only eight of the 30 applicants filled the above criteria
and were considered as potential candidates. A physician
examined each subject and took a medical history. The appli-
cants were examined by a psychiatrist and they filled out a
MMPI. No psychiatric aberration was found in the test group.
Tuberculin tests were performed. The medical screening tests
included a stress EKG using a treadmill, a SMA--12, CBC and
urinalysis. Each subject was asked to sign an informed consent
form which had been approved by the College's Human Use
Committee.
Results of Physicals
The six male subjects selected were described as follows
by the medical examination team.
Subject 1 is a 32-year old lawyer. He gave a history
of ing a ruptured tympanic membrane at age 15,
which has healed. He is taking no medication and he
denies drug allergy. He does no regular physical
activity and is a light smoker, averaging a pack every
five days. (He and Subject 3 did not smoke during
the study. The remainder of the subjects were noa-
smokers )
On physical examination his height is 180 cm, weight
68.6 kg, blood pressure 130/90 and pulse 80. The
general physical examination is unremarkable.
Subject is a 27-year old who has just finished his
'egree i n history and polite, -al :science and works
sometimes as an automechaniL_ He wears corrective
lenses for astygmati.sm. He takes no medication and
denies drug allergy. At tho 4qo of three w, nthg
had surgical correction of a pyloric stenosis and
f ~'
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at the age of five he had a tonsillectomy. He was
wounded in Viet Nam with a grenade fragment injuring
his left leg which has left no residual deformity.
He states that he swims and plays handball and tennis.
on physical examination, his height is 182 cm, weight
70.4 kg, blood pressure 140/75 and pulse 88. The
general physical examination is unremarkable.
S^ub^'ect 3 is a 37-year old university professor. He
acm.its to inner ear involvement associated with
respiratory infections. He takes no medication.
There is a possible allergic reaction to sulfa. He
had a tonsillectomy at age 7. He had an automobile
accident 6 months ago which caused a "herniated
cervical disc." There was some associated paresthesias
and muscle atrophy, but he states that this has subse-
quentlycleared.
His time on the mile was excellent and he states that
he jogs or plays handball several times a week. He
smoked approximately lk packs a day until the begin-
ning of the study.
On physical examination, his height is 175 cm, weight
68.6 kg, blood pressure 120/80 and pulse 96. The
physical examination is unremarkable. No neurological
abnormality is found.
Subject 4 is a. 25-year old law student. He had a
cartilage removed from his right knee about seven
years ago, but has apparently been able to play
football and participate in wrestling, etc. since
that time. He had a tonsillectomy done twine in
the past. His major physical activity is tennis.
on physical examination, height 170 cm, weight 65.3
kg, blood pressure 140/90 and pulse 100. There is
some anterior-posterior instability of the right
knee joint.
Subject 5 is a 32-year old railroad car mechanic.
He admits to seasonal allergies with sneezing in
October and November. He denies taking medication
and has no drug allergy. He had a tonsillectomy.
48
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In December of 1963 he had a cartilage removed
from his left knee. He was subsequently accepted
into the Marine Corps and upon jumping over a
seven-foot wall, he reinjured the knee.
This subject participates in no sports. He previously
lifted weights and his major physical activity is
related to his job and carpentry work, which he does
as a hobby.
His height is 169 cm, weight 81.3 kg, blood pres-
sure 135/90, pulse 78. There is probable weak-
ness of the right inguinal ring. The left knee
reveals a healed surgical incision. The knee
join'- is stable.
Sub'ect 6 is a 30-year old university student who
Toads mail for the postal service 3-4 hours a day.
His history is negative. He is taking no medica-
tion and denies allergy. He had a tonsillectomy
at age 14. He bicycles some and his job requires
strenuous exertion.
on physical examination his height is 175 cm,
weight 63.6 kg, blood pressure 130/70 and pulse
76. The general examination is unremarkable.
t
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BEDREST STUDY MENU PLAN
A baseline 6-day cycle of menus to be evaluated by all subjects was planned
for the bedrest study utilizing the nutritional constraints specified for
Skylab. These general Skylab constraints are listed in Table 1 along with
the nutritional levels of the baseline bedrest study menu cycle, Five (5)
days prior to the beginning of the study subjects consumed the baseline
menus and evaluated each food item. A sample food evaluation record which
was used by each subject to score the baseline menu is depicted in Table 2.
During the ambulatory control phase of the study, the baseline menu was
modified for each subject to accommodate personal preferences, eating habits,
and daily energy requirements. One of the subjects was found to be allergic
to shellfish and became nauseous upon eating shrimp cocktail and/or lobster
newburg. Daily energy requirements were determined for each subject using
the method of adjusting caloric allowances for adults recommended by the
Food and Nutrition Beard of the National Research Council (Recommended Dietary
Allowances, 7th Revised Edition, 1968, p. 5). This method is based upon age,
body weight, and height, and recommends greater calorie allowances for
increasing height and weight of individuals, but within given height-weight
categories. Further adjustments for declining energy requirements for
increasing age are also included.
.	 J
a
Individual menus conformed to the general Skylab nutritional requirements.
The Skylab nutritional requirements, as shown in Table 1, indicate the overall
range of specific nutrients. After menu selection, this overall range is
reduced for the daily variation in a given menu cycle. For example, Table 1
10	 ,
t illustrates that the protein level for the Skylab experiments should be
controlled at 90-125 ± 10 g. The individual menu cycles, as planned,
ranged from 93 t 6 to 116 
t 
8 g protein. Skylab requirements and levels
in individual menu cycles for other controlled nutrients are also listed
in Table 1. Nutrient levels for individual bedrest menus are listed for
each subject in Tables 3-8.
During the bedrest phase of the study, individual menus were again revised
for some subjects due to changes in food preferences; however, nutritional
levels of the revised menus were maintained within the individual levels
established during the pre-bedrest phase of the study. Six-day menu cycles
for each subject are shown in Tables 9-14.
Food utilized for the bedrest study was that manufactured for Skylab and had
been analyzed for nutrient elements of interest in the Mineral Balance
Experiment, M071. The food items used are listed in Table 15. Lot B food,
which was the flight lot for the Skylab Food System, was used primarily;
however, a number of items from Lot A, the development and test lot, were
also incorporated into the menus due to the lack of available supplies of
Lot B foods. Types of food included rehydratables, thermostabilized, natural
farm and frozen. Food was assembled into meals and transported to the site
of food preparation for the study. When menus were revised for an individual,,
the food necessary to support the changes was transported to the site of the
study and substitutions were made in the meal packs	 Food was prepared and
served at the site of the study according to menus and instructions supplied
by NASA. A sample of the daily tally sheet which provided the menu,
preparation instructions and space for recording any additional food consumed
1
r
or residue not consumed is included in Table 16. Data was collected by
Baylor personnel and transmitted to NASA approximately weekly. If special
problems were encountered, information was relayed by telephone. Dye markers
(Carmine Red and FDC Blue #1) were administered at approximately 6-day
intervals as shown in Table 17 to mark the repetition of each menu cycle.
The intervals were determined by selecting the first day of the study, the
	
l
first day of bedresty and the first day of post-bedrest as marker days from
which to calculate the subsequent 6-day periods. Each subject received -a
3
multi-vitamin tablet (Upjohn-Sigtabs) daily to simulate the dietary intake
_a
of SL-3 and SL-4 and to compensate for anticipated vitamin deterioration in
i
foods,
i
1t
1
1j
3
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a
1
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TABLE 1.
	
PLANNED NUTRITIONAL LEVELS OF BEDREST MENUS -	 ---^
---
Skylab
Basel i ne
Bedrest
SUBJECTS
Nutrient Requi rements Menus 3 6 5
Calories 2250-4250 2800 2900 2800 3100 2800 2800 2800
Protein g 90-125-10 101	 10.5 108-6 98=7 11618 93-6 101{5 103-=8
Calcium mg 750-850116 77419 796110 77217 822±10 805±7 770t7 770±5
Phosphorus mg 1500-17001120 1534-96 16611103 1542±107 1722}122 15901112 1560±100 1575150
Magnesium mg 300-4001100 292±57 354-37 285-50 290+40 327}65 290153 300}4O
Potassium mg >2740 3540400 3976}311 3554+414 42841388 3200+-330 3530+545 32301440
Sodium mg 3000-6000-500 6000-500 61001500 4760±500 6150}500 5500-500 6000±500 6100#500`
c,
13
TABLE 2
NASA-JOHNSON SPACE CENTER
FOOD EVALUATION RECOPC
Bed Rest Study Food CoMatihility Test
MMU	 1	 VEAL Breakfast
Name	 Date
Food Rating:
1. l,,e v cul d like to find out your feelin g s reaardi ng the OOL's	 t^^u
below. Please rate each item according to ' the fol io%iina code.
2. If there is a reason why you jic ^vt i cul arl v i i ke or disli ke a
briefly state it in the third column, along with your comn.ents fnd
suggestions.
EATI NG CODE:
n - Like extremely	 6	 Like slightly	 3 - Dislil.	 °o^cr•:itrl.;
B - Like very much	 5 - Neither like nor
	 2 - Di sl i kic ver, truc!;
1	 Like rioderately	 dislike	 1 - Dislike ey.^•cn,t1,,
4 - Dislike slightly
a
a
ITEM	 RATING	 CQ `; C_° „ ^_
P:inea^ple
Sorambled Eggs
Bacon
Race Krispies
Cocoa
5. Please commient on this meal:
A. ' Was the quantity of food too small? 	 too large?	 adF,r ate?
6. Would you liY-,e to svritch air food items to another meal? If so } vrhich
items to which meal.? It' must be a meal 011 - this same day.
w
7. Have you had either" 	 much or not enough to eat today?
8„ if you-have .had too much to eat, Tease indicate the item or items you
, Would LnM-1 to delete from your monu._
kTABLE 3.	 LEVELS OF SKYLAB-CONTROLLED NUTRIENTS IN BEDREST STUDY - PHASE I MENUS
Subject I — - --
Menu
Day Calories Protein Ca Phos Mg K Na	 -
g ,mg mg mg mg mg
1 2915 111,8 789 1764 355 3959 5600
2 2872 114.4 801 1724 391 3830 6357
3 2926 114.0 787 1704 367 4287 6600
4 2881 107.1 800 1559 320 3904 6609
5 2900 101.9 787 1625 317 3670 5600
6 2895 108.5 806 1585 362 3666 5600	 i
Range
4
2872-2926 101.9-114.0 787-806 1559-1764 317-391 3666-4287 5600-6600
I	 Menu 108.0 6.1 796±10 1661-103 354-37 3976±311 6100±500
_Tolerance
Skylab 110.0¢10 796±16 1660-120 350±100 >2740 6000-500
Tolerance
Skylab 100-120 780-812 1540-1780 250-450 >2740 5500-6600
Range
TABLE 4. LEVELS OF SKYLAB-CONTROLLED NUTRIENTS IN BEDREST STUDY - PHASE I MENUS
Subject 2
Menu
Day Calories Protein Ca Phos Mg K Na
Ek..
g mg mg mg mg mg	
. - ---
4
1 2860 98.4 767 1577 277 3612 4753
2 2860 98.0 774 1510 334 3171 4260
3 2834 96.6 778 1648 302 3967 5260
4 2790 94.4 777 1435 286 3018 4867
5 2786 90.3 765 1438 235 3140 4260
6
I
2763 104.8 759 1579 287 3596 4260	
-
f	 Range 2763-2860 90.3-104.8 759-778 1435-1648 235-334 3140-3967 4260-5260
P	 Menu 97,6*7.3 77217 1542±107 285*50 3554+414 476Q}500k	 Tolerance
Skylab 98-^0 772-16 1582-120 300-100 x2740 4760-500
Tolerance
Skylab 88-108 760-792 1422-16.62 200-400 >2740 4260-5260
	 -
Range
TABLE 5e LEVELS OF SKYLAB-CONTROLLED NUTRIENTS _IN BEDREST STUDY-PHASE I MENUS
Subject 6
Menu
Day Calories Protein Ca	 Phos Mg K Na
9 mg	 mg mg mg mg
1 2798 92.6 798	 1546 262 2873 5000
f,	 2 2774 91. 3 812	 1476 392 3528 5000
3 2808 90. 0 810	 1700 361 3537 5931
4 2825 87.2 806	 1544 327 3167 5000_
2830 98 4 805	 ?678 277 3120 5000
6	 2753 94.3 802 1573 280 3147 5000
f
F.
Range,	 2753-2830 87.2-98.4 798-812 1476-1700 262-392 2873-3537 5000-6000
Menu 92.8+ 5.6 805-7 1590-112 327-65 3205+332 5500-500
Tolerance
Skylab 93-^10 805-16 1590-120 300-100 X2740 5500500
Tolerance
Skylab 83- 103 789-821 1470-1706 200-400 >2740 5000-6000
Range
f`
_a
1All,
A .
TABLE 6,	 LEVELS OF SKYLAB-CONTROLLED NUTRIENTS IN BEDREST STUDY-PHASE I MENUS
Subject 4
Menu
Day Calories Protein Ca Phos Mg K Na
9 m9 mg mg mg mg
1 2925 100.4 766 1591 281 3245 5500
F	 2
F
2853 102.7 767 1625 339 3325 5500
3 2715 105.5 777 1658 314 4076 5500
h
P	
4
k
2900 105.2 773 1463 289 3630 6505
4	 5 2859 97.1 771 1590 323 3824 5500
6 2775 105.0 763 1579 237 2989 5500
t	 '	 Range 2715-2925 97.1-105.5 763-777 1463-1658 237-339 2989-4076 5500-6505
Menu 101.3-4.2 770-7 1561±98 289-52 3533-544 6000{500	 j
f	 Tolerance
x
Skylab 101}10 770116 1561-120 300 100 >2740 6000{500
It	 Tolerancey
3	 Skylab 91-101 754-786 1441-1681 200-400 >2740 5500-6500
Range
TABLE 7. LEVELS OF SKYLAB-CONTROLLED NUTRIENTS IN BEDREST STUDY-PHASE I MENUS
Subject 5
Menu
Day Cal ori es Protein Ca Phos Mg K Na
9 mg mg mg mg mg
1 2835 95.9 772 1558 338 3531 5600
2 2840 110.4 773 1611 326 3223 6378
3 2800 108.3 774 1621 300 30543 5600
4 2834 108.5 774 1602 281 3384 6025
5 2855 101.8 772 1579 310 3671 5600
6 2800 110.2 765 1525 260 2789 5600
Range 2800-2855 95.9-110.4 765-774 1525-1621 260-338 2789-3671 5600-6378
Menu 103.2t7.3 770t5 1573-48 299-39 5990t390
Tolerance
Skylab 103tlO 770 16 1573-120 30OtlOO >2740 6000-500
Tolerance
Skylab 93-113 754-786 1453-1693 200-400 >2740 5500-6500
Range
tN
i
TABLE 8.	 LEVELS OF SKYLAB-CONTROLLED NUTRIENTS IN BEDREST STUDY-PHASE I MENUS
Su:bjec.^t 3
Menu
Day Calories Protein Ca Phos Mg K Na
9 mg mg mg mg mg
1 3226 123.6 825 1843 332 4297 5640
2 3160 114.3 825 1784 413 4014 6295
3 3066 119.4 832 1774 374 4671 6031
4 3143 108.5 819 1600 358 4388 6639
5 3125 116.8 819 1732 346 4047 5640
6 3116 123.9 812 1773 396 3896 5640
	 I
Range 3066-3226 108.5-123.9 812-832 1600-1843 332-413 3896-4671 5640-6640
Menu 116.2±7.7 822}10 1722-122 291-41 4284+388 6140-500
Tolerance
Skylab 116{10 822116 1722+ 120 300±100 >2740 60001500
Tolerance
Skyl ab 106-126 806-838 1602-1842 200-400 >2740 5500-6500
Range
TABLE 9. BEDREST STUDY - i Ubject 1
	Meal	 Menu 1
	
A	 Bacon Squares
Scrambled Eggs
Rice Krispies
Cocoa
	
$_	 Turkey Rice Soup
Tuna Salad Sandwich Spread
Bread
Sliced Strawberries
Vanilla Ice Cream
Orange Drink
f
k
	C	 Roast Beef	 Cubed Turkey with Gravy
Mashed Sweet Potatoes	 Mashed Potatoes
Buttered Asparagus
	
Soda Crackers
Peach Ambrosia
	
Butter
Coffee
	
	
Pineapple Chunks
Coffee
Snacks Peanuts
	
Diced Peaches
Diced Reaches	 Dried Beef
Coffee
	
	
Buttered Roll
Peach Ambrosia
Strawberry Drink
Menu 3
Canadian Bacon and Applesauce
Scrambled Eggs
Sugar Coated Cornflakes
Coffee
Chili
Buttered Asparagus
Soda Crackers
Butter
Pineapple Chunks
Tea with Lemon and Sugar
Pea Soup
Beef Nash
Stewed Tomatoes
Sliced Strawberries
Coffee
Dry Roasted Peanuts
Tuna Salad Spread
Bread
Orange Drink
Grapefruit Juice
Menu 2
Diced Pears
Coffee Cake
Chocolate Instant Breakfast
Coffee
Pork Loin with Dressing and Gravy
Buttered Asparagus
Applesauce
Tea with Lemon and Sugar
TABLE 9. BEDREST STUDY - Subject 1 (Continued)
Meal Menu 4 Menu 5 Menu 6
A Diced Peaches Scrambled Eggs Diced Peaches
Sausage Sugar Coated Cornflakes Sausage	 -
Rice Krispies Coffee Cake Scrambled Eggs
Coffee Grapefruit Drink Catsup
Coffee Rice Krispies
Coffee
B Not Dogs with Tomato Sauce Cream of Tomato Soup Pea Soup
Salmon SaladPork and Potatoes Spaghetti and Meat Sauce
Green Beans with Mushroom Sauce Soda Crackers Soda Crackers
Soda.. Crackers Diced Pears Pineapple ChunksP
Butter Tea with Lemon and Sugar Tea with Lemon and Sugar
Orange Drink
C Chicken Chunks with Gravy Roast Beef Lobster Newburg
Mashed Potatoes Macaroni and Cheese. Stewed Tomatoes
Stewed Tomatoes Asparagus Peach Ambrosia
Diced Pears Diced Peaches Tea with Lemon and Sugar
Grapefruit Juice Cocoa
Snacks Dry Roasted Peanuts Peanut Butter Peanut Butter
Cheese Crackers Bread Bread
Diced PearsCoffee Coffee
Coffee
TABLE 10. BEDREST STUDY -:Subject 6
Meal	 Menu 1	 Menu 2
A	 Canadian. Bacon and Applesauce 	 Diced Pears
Scrambled Eggs	 Coffee Cake
Rice irispies	 Chocolate Instant Breakfast
Cocoa	 Apple Drink
Menu 3
Pineapple Chunks
Scrambled Eggs
Sugar Coated Cornflakes
Cocoa
	
B	 Turkey Rice Soup
Tuna Salad Sandwich Spread
White Bread
Sliced Strawberries
Vanilla Ice Cream
Strawberry Drink
s
	
C	 Roast Beef
Macaroni and Cheese
Asparagus-
Peach Ambrosia
Grape Drink_
	
Snacks	 Pineapple Chunks
Apple Drink
Cherry Drink
Pork Loinwith Dressing and Gravy	 Turkey Rice Soup
Green Beans with Mushroom Sauce
	 Peanut Butter
Applesauce	 White Bread
Grape Drink	 Lemon Pudding
Strawberry Drink
Chicken Chunks with Gravy
Mashed Potatoes
Cream Style Corn
Diced Peaches
Cocoa
Dry Roasted Peanuts
Pea Soup
Chicken and Rice
Stewed Tomatoes
Sliced Strawberries
Grapefruit Juice
Dry Roasted Peanuts
Strawberry Drink
TABLE 10.	 BEDRES`E" STUDY - 	 Subject 6 (Cone' d)
Meal Menu 4 Menu 5 Menu 6
A Applesauce Scrambled Eggs Dined Peaches
Rice Krispies Cornflakes Scrambled Eggs
Coffee Cake Coffee Cake, Rice Krispies
Chocolate Instant Breakfast Grapefruit Drink Cocoa
Apple Drink Cocoa
R Pork and Potatoes Spaghetti with Meat Sauce Pea Soup
Buttered Roll Creamed Peas Salmon Salad
Diced Peaches Diced Pears White Bread
Grape Drink Grape Drink Pineapple Chunks
Cherry Drink
W
C Cubed Turkey, and Gravy Roast Beef Lobster Newburg
Mashed Potatoes Macaroni and Cheese Pork and Potatoes
' Cream Style Corr Asparagus Asparagus
Soda Crackers Lemon Pudding Peach Ambrosia
CIO Dined pears Strawberry Drink Grape Drink
Cherry Drink
Stacks Grape Drink Peanut Butter Lemon Pudding
Apple Drink White Bread
TABLE 11.	 BEDREST STUDY	 Subject 4
Meal Menu 1 Menu 2 Menu 3
A Diced Pears Diced Pears Canadian Bacon and Applesauce
Bacon Bits Coffee Cake Scrambled Eggs
Scrambled Eggs Chocolate Instant Breakfast Cornflakes
Rice Krispies Strawberry Drink Grapefruit Drink
Cocoa
B Turkey Rice Soup Pork Loin with Dressing and Gravy Chili
Peanut Butter Asparagus Asparagus
Bread Applesauce Biscuit
Sliced Strawberries Lemon Pudding Lemon Pudding
Vanilla Ice Cream Grape Drink Apple Drink	 j
Strawberry Drink
C Roast Beef Cubed Turkey with Gravy Shrimp Cocktail
German Potato Salad flashed. Potatoes Beef Hash
Asparagus Cream Style Corn Stewed Tomatoes
Diced Peaches Buttered Roll Sliced Strawberries
Strawberry Drink Peach Ambrosia
Cherry Drink
Snacks Lemon Pudding Dry Roasted Peanuts
Strawberry Drink
Dinner Mints
TABLE 11, BEDREST STUD;' - ,s-abject  4 (Cont d)
	
Meal	 Menu	 Menu 5
	
Menu b
	A	 Applesauce	 Diced Peaches	 Diced Peaches
Sausage	 Scrambled Eggs	 Sausage
Rice Krispies	 Cornflakes	 Scrambled Eggs
Apple Drink	 Coffee Cake	 Rice Krispies
Grapefruit Drink
	
Strawberry Drink
B	 Hot ,Dogs with Tomato Sauce	 Spaghetti with Meat Sauce
Pork and Potatoes	 Stewed Tomatoesp	
Green Beans with Mushroom Sauce Diced Pears
Strawberry Drink	 Grape Drink
E,
C	 Chicken and Gravy	 Roast Beef
Mashed Potatoes	 Macaroni and Cheese
Stewed Tomatoes	 Asparagus
Diced Pears	 Peach Ambrosia
Grapefruit Juice
	
Cocoa
e
Snacks	 Cheese Crackers	 Dry Roasted Peanuts
Dry Roasted Peanuts	 Applesauce
Pea Soup
Salmon Salad
Soda. Crackers
Diced Pears
Cherry Drink
SJC
Lobster Newburg
Pork and Potatoes
Asparagus
Peach Ambrosia
Grape Drink
Lemon Pudding
LOPT
TABLE 12.
	
BEDREST STUDY Subject 5
Meal Menu I- Menu 2 Menu 3
A Pineapple Chunks Diced Pears Canadian Bacon and Applesauce
Scrambled Eggs Coffee Cake Scrambled Eggs
Rice Krispies Chocolate Instant Breakfast Rice Krispies
Cocoa Grapefruit Drink
B Turkey Rice Soup Pork Loin with Dressing and Gravy Chili
Tuna Salad Sandwich Spread Applesauce Asparagus
Bread Asparagus Bread
Sliced Strawberries Lemon Pudding Lemon Pudding
Vanilla Ice Cream Grape Drink Apple Drink
Strawberry Drink iM
C Roast Beef Cubed Turkey with Gravy Shrimp Cocktail
Sweet Potatoes Mashed Potatoes Beef Hash
Asparagus Pineapple Chunks Green Beans with Mushroom Sauce
Peach Ambrosia Strawberry Drink Sliced Strawberries
Apple Drink Strawberry Drink
Snacks Dry ROLsted Peanuts Dried Beef Dry Roasted Peanuts
Buttered Roll Dinner Mints
Lemon Drops
TABLE 12. BEDREST STUDY	 Subject 5 (font' dl	 Y R
Meal Menu 4 Menu 5 Menu 6
A Sausage Scrambled Eggs Sausage
Rive Krispies Sugar Coated Cornflakes Scrambled Eggs
Strawberry Drink Coffee Cake Rice Krispies
Grapefruit Drink Apple Drink
B Hot Dogs with Tomato Sauce Tomato Soup Pea Soup
Pork and Potatoes Spaghetti with Meat Sauce Salmon Salad
Green Beans with Mushroom Sauce Bread Bread
Biscuit Diced Pears Pineapple Chunks
Strawberry Drink Strawberry Drink Cherry Drink
i
C Chicken and Rice Roast Beef Lobster Newburg
Mashed Potatoes German Potato Salad Pork and Potatoes
Asparagus Asparagus Asparagus
Diced Fears Pineapple Chunks Peach Ambrosia
i
Grapefruit Juice Cocoa Grape Drink
3
Snacks Dry Roasted Peanuts Dry Roasted Peanuts lemon Pudding
Cheese Crackers
i
TABLE 13.
	
BEDREST STUDY - Subject _2
Meal Menu 1 Menu 2 Menu 3
A Diced Pears Diced Pears Canadian Bacon and Applesauce
Bacon Squares Coffee Cake Scrambled Eggs
Scrambled Eggs Chocolate Instant Breakfast Sugar Coated Cornflakes
_Rice Krispies Coffee with Sugar Grapefruit Drink
Cocoa Coffee with Sugar
B Turkey Rice Soup Pork Loin with Dressing and Gravy Chili
Tuna Salad Sandwich Spread A	 lesaucePP Asparagus
Bread Asparagus Lemon Pudding
Sliced Strawberries Lemon Pudding Apple Drink
Vanilla Ice Cream Grape Drink
Orange Drink
C Roast Beef Cubed Turkey with Gravy Beef Hash	 3
Mashed Sweet Potatoes Mashed Potatoes Stewed Tomatoes
Asparagus Pineapple ChunksPPe Sliced Strawberries
Peach Ambrosia Coffee wish	 agart Cocoa
Coffee with Sugar
-
Snacks Lemon Pudding Buttered Roll Peanut Butter
Coffee with Sugar Lemon Drops Bread
r
Strawberry Drink Orange Drink
x
TABLE 13. BEDREST STUDY -Subject 2 (font' d)
Meal Menu 4 Menu 5 Menu 6
A Sausage Scrambled Eggs Diced Pears
Scrambled Eggs Sugar Coated Cornflakes Scrambled Eggs
Rice Krispies Coffee. Cake Rice Krispies
Coffee with Sugar Grapefruit Drink Coffee with Sugar
Coffee with Sugar
B Pork and Potatoes Cream of Tomato Soup Pea Soup
Green Beans with Mushroom Sauce Spaghetti and Meat Sauce Salmon Salad
Soda Crackers Bread Bread
Grape Drink Diced Pears Pineapple Chunks
Grape Drink Orange Drink
W
C Chicken Chunks with Gravy Roast Beef Filet Mignon
Mashed Potatoes Macaroni and Cheese Green Beans with Mushroom Sauce
' Asparagus Asparagus Stewed Tomatoes
^`" Diced Pears Cocoa Peach Ambrosia
Grapefruit Juice Strawberry Drink
1
Snacks Cheese Crackers Lemon Drops Lemon Pudding
Dry Roasted Peanuts Coffee with Sugar Coffee with Sugar
Dinner Mints
Diced Peaches
Apple Drink
Coffee with Sugar
TABLE 14.	 BEDREST STUDY - subject 3
Meal	 Menu 1 Menu 1	 (Revised 5-30-75) Menu 2 Menu 3
A 	 Applesauce Applesauce Diced Pears Scrambled Eggs
Scrambled Eggs Scrambled Eggs Coffee Cake Sugar Coated Cornflakes
Rice Krispies Rice Krispies Chocolate Instant Breakfast Grapefruit Drink
Cocoa Cocoa Coffee Coffee	 ---
Coffee Coffee
B	 Turkey Rice Soup Turkey Rice Soup Pork Loin with Dressing and Gravy Chili
Salmon Salad Salmon Salad Buttered Asparagus Buttered Asparagus
Soda Crackers Soda' Crackers Applesauce Soda Crackers
Sliced Strawberri es Sliced Strawberries Grape Drink Applesauce
Vanilla Ice Cream Vanilla Ice Cream Coffee Tea with Lemon and Sugar
Orange Drink Orange Drink Coffee ^a
Coffee Coffee
C	 Roast Beef Roast Beef Cubed Turkey with Gravy
Mashed Sweet Potatoes Mashed Potatoes Mashed Potatoes
Buttered Asparagus Buttered Asparagus Pineapple Chunks
Cn	 Peach Ambrosia Peach Ambrosia Coffee
Coffee Coffee
Snacks	 Bacon Bits Bacon Bits Diced Peaches
Tuna Salad Sandwich Spread Tuna Salad Sandwich Spread Dried Beef
Bread Bread Buttered Roll
Diced Peaches Diced Peaches Peach Ambrosia
Tea with Lemon and Sugar Tea with Lemon and Sugar Orange Drink
Coffee Coffee Coffee
Tea with Lemon and Sugar
Lemon Drops
Shrimp Cocktail
Beef Hash
Stewed Tomatoes
Sliced Strawberries
Coffee
Canadian Bacon and Applesauce
Dry Roasted Peanuts
Tuna Salad Sandwich Spread
Bread
Diced Peac.hes
Orange Drink
Tea with Lemon and Sugar
TABLE 14. BEDREST STUDY - subject 3 (Cont'd)
Meal Menu 4 Menu 4 (Revised 5-30-75) Menu 5 Menu 6
A Sausage Sausage Scrambled Eggs Diced Peaches
Rice Krispies Sugar Coated Cornflakes Sugar Coated Cornflakes Sausage
Coffee X 2 Coffee X 2 Coffee Cake Scrambled Eggs
Grapefruit Drink Catsup
Coffee Rice Krispies
Coffee
B Pork and Potatoes Salmon Salad Cream of Tomato Soup Pea Soup
Green Beans with Pork and Potatoes Spaghetti and Meat Sauce Salmon Salad
Mushroom Sauce Green Beans with Diced Pears Biscuit
Soda Crackers Mushroom Sauce Grape Drink Pineapple Chunks
Butter Soda Crackers Coffee Tea with Lemon and Sugar
Applesauce Butter Coffee
Orange Drink Applesauce
Coffee Orange Drink
CJCoffee N
z	 C Chicken Chunks withGravy, Chicken Chunks with Gravy Roast Beef Lobster Newburg
Mashed Potatoes Mashed Potatoes Macaroni and Cheese Pork and Potatoes
Stewed Tomatoes Stewed Tomatoes Asparagus Asparagus
Diced Pears Cream Style Corn Pineapple Chunks Peach Ambrosia
Grapefruit Juice Diced Pears Cocoa Grape Drinkny
Coffee Grapefruit Juice Coffee Coffee
Coffee
i
Snacks Cheese Crackers Cheese Crackers Bacon Bits Peanut Butter
Dry Roasted Peanuts Dry Roasted Peanuts Peanut Butter Bread
Hot Dogs with Tomato Sauce Diced Peaches Bread Diced Pears
Diced Peaches Tea with Lemon and Sugar Tea with Lemon and Sugar Coffee
Tea with Lemon and Sugar Coffee Coffee
Coffee
rTABLE15, SKYLAB FOODS USED FOR BEDREST STUDY
-PHASE I
Food
No.
1 Salt (Reagent Grade)
2 Grapefruit Juice	 (Lot A)	 (B)
3 Tuna Salad Sandwich Spread (Lot B) (T)
4 Lemon Pudding
	
(Lot B)	 (T)
5 Dry Roasted Peanuts (Lot B) (N)
6 Vanilla Ice Cream (Lot A)
	 (F)
7 Sugar Cookies	 (Lot A)	 (C)
8 Salt-free Butter (N)
11 Cheddar Cheese Crackers
	
(Lot B)	 (C)
12 Dinner Mints	 (Lot B)	 (N)
13 Sausage Patties	 (Lot B)	 (R)
14 Cornflakes	 (Lot A)	 (R)
15 Cornflakes	 (Lot B)	 (R)
16 Scrambled Eggs	 (Lot B)	 (R)
17 Bacon	 (Lot A)	 (C)
18 Filet Mignon
	
(Lot A)	 (F)
19 Frozen Bread (Lot A)	 (F)
20 Catsup	 (Lot B)	 (N)
22 Asparaqus	 (Lot B)	 (R)
23 Lemonade	 (Lot B)	 (B)
24 Buttered Roll	 (Lot B)	 (LF)
25 Salmon Salad	 (Lot B)	 (R)
26 Pork Loin w/Dressing and Gravy (Lot A)	 (F)
27 Strawberries	 (Lot B)	 (R)
28 Vanilla Wafers	 (Lot B)	 (N)
30 Canadian Bacon and Applesauce (Lot A) 	 (R)
31 Coffee Cake (Lot A) (F)
-32 Mashed Potatoes	 (Lot B	 (R)
33 Peanut Butter (Lot B) 	 (T)
34 Chili	 (Lot B)	 (T)
35 Tomato Soup (Lot A) (R)
36 Fruit Jam (Lot A)	 (T)
37 Pea Soup (Lot B)	 (R)
38 Pineapple (Lot B)
	 (T)
39 Lobster Newburg (Lot B) (F)
40 Turkey and Gravy (Lot B) (T)
41 Lemon Drops (Lot B) (N)
B = Beverage	 F = Frozen
T = Thermostabilized	 C = Compressed
N = Natural Form	 R = Rehydratable
r,
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TABLE15. SKYLAB FOODS USED FOR BEDREST STUDY-PHASE I (CONTINUED)
Food
No.
42	 Grape Drink (Lot B) (B)
43	 Applesauce (Lot B) (T)
44	 Hot Dogs w/Tomato Sauce (Lot B) (T)
46	 Peaches (Lot B) (T)
47	 Pears (Lot B) (T)
48	 Biscuits (lot B) (N)
49	 German Potato Salad (Lot B) (R)
50	 Chocolate Instant Breakfast (Lot B) (B)
51	 Shrimp Cocktail (Lot B) (R)
52	 Turkey Rice Soup (Lot A ^R)
53	 Turkey Rice Soup (Lot B^ R)
54	 Rice Krispies (Lot B) (R)
55	 Chicken and Rice (Lot B) (R)
56	 Creamed Peas (Lot A) (R)
57	 Chicken and Gravy (Lot A) (R)
58	 Cocoa (tot. B) (B)
59	 Pork and Potatoes (Lot B) (R)
60	 Orange Drink (Lot B) (B)
61	 Sweet Potatoes (Lot B) (R) i
62	 Coffee (Lot A) (B)
63	 Beef Hash (Lot B) (R)
64	 Stewed Tomatoes (Lot B) (T)
65	 Cream Style Corn (Lot A) (R)
66	 Tea w/Lemon and Sugar (Lot B) (B)
67	 Dried Beef (Lot B) (T)
68	 Prime Rib (Lot A) (F)
69	 Peach Ambrosia (Lot B) (R) i
72	 lipaghetti (Lot B) (R)
73	 Green Beans (Lot A) (R)
74	 Macaroni and Cheese (Lot B) (R)
75	 Canned Bread (Lot B) (T)
76	 Butter Cookies (Lot A) (N)
77	 Apple Drink (Lot B) (B)
78	 Cherry Drink (Lot B) (B
79	 Grapefruit Drink Lot fl ^B^
80	 Strawberry Drink tot B)8
81	 Coffee w/Sugar (Lot B) (B)
B == FrozenBeverage	 F	  e
T = 7hermostabilized 	 C Compressed
N Natural Form	 R = Rehydratable
i
Table 16
COMPOSITION OF A SIGTAB TABLET
Vitamin A ....................... 	 5,000 In
Vitamin D ........................««...... 400 In
Thiamine Mononitrate ............................
Riboflavin ......................................
Ascorbic Acid
(as sodium ascorbate) .........................
Niacinamide .....................................
Pyridoxine Hydrochloride ........................
Calcium Pan:tothenate ........ .. .................
Folic Acid ..................................... 0.033 mg
Cobalamin
(as cobalamin concentrate) ... ...
	 ......... 4 mcg
Vitamin E ............ .................... 15 Int. Units
f
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THE EFFECTS OF 14-DAYS HORIZONTAL BEDREST
ON SUSCEPTIBILITY TO CORIOLIS MOTION SICKNESS,
i POSTURAL STABILITY AND NEURO-MUSCULAR REFLEX ACTIVI"
r	 1
t	
1	 {^	 p
INTRODUCTION
Pre-, in- and postflight observations and data obtained during
the recently completed Skylab missions revealed a number of interrelated
clinical, behavioral and sensory-physiological responses presumably
caused by prolonged exposure to the weightless space flight environment.
First, upon initial entry into weightlessness, five of the nine crewmen
experienced symptoms characteristic of motion sickness. Symptoms ranged
from mild (stomach awareness) to severe (vomiting) and in most cases
i
persisted for three to five days. Adaptation to the weightless environ-
ment occurred by approximately mission day seven for all of the crewmen
and subsequent tests utilizing the Skylab M131 Rotating Litter Chair
showed surprisingly that all of the crewmen had become virtually immune
to experimentally induced motion sickness. Of particular relevance to
the present study were the results of motion sensitivity tests conducted
postflight.. These tests revealed that relative to their preflight base-
line levels; all of the crewmen were less susceptible to motion sickness
during the postflight period. Although considerable variability was
present among the crewmen, the magnitude and duration of this change was
related in a slightly pos itive'fashion to the duration of O-g exposure.
Also, in crewmen who did not take anti-motion sickness medication prior
to splash-down, a brief period (8-24 hours) during which symptoms, spon-
taneously occurred with head movements, preceeded the measured increase
in tolerance to vestibularstress. In all cases, continued postflight
2testing indicated that a return to approximate preflight levels of
susceptibility to Coriolis motion sickness did eventually occur. A
number of hypotheses have been advanced to explain the Skylab motion
sickness findings, however, it is generally agreed that available data
are inadequate to unequivocally define the mechanism or mechanisms
underlying the changes which occurred.
Related to the above findings was the observation that all
of the Skylab crewmen experienced a marked postflight deficit in postural
stability. Quantitative measurements indicated that the change was most
pronounced when the crewman was deprived of visual cues and was required
to maintain a stable, upright posture solely on the basis of vestibular
and tactile-kinesthetic sensory inputs. In all cases, complete recovery
to preflight levels of postural equilibrium performance and locomotar
ability occurred within approximately ten days after splashdown. It has
been postulated that these changes were most likely the manifestation of
alterations in the central nervous system integration of sensory inputs
from the visual, vestibular, and tactile-kinesthetic sensory modalities
which had occurred during the weightless space flight exposure. Measured
alterations'in neuro-muscular function, including the long loop myogenic
reflex response; may also have contributed to the postflight changes
observed in postural equilibrium.
In general, Skylab served to underscore that prolonged exposure
to weightlessness can`resvt in significant modifications in neuro-sensory
and neuro-muscular function and cause highly undesirable responses such
as the motion sickness syndrome. Data obtained from the Skylab neurophysiology
3r
experiments, however, fell far short of providing explanations for the
phenomena observed. It is recognized that much additional research
using a variety of experimental approaches is needed to develop the
information necessary to answer the questions raised by Skylab.
One such approach is the use of supine bedrest which many
believe to represent a physiological analog of weightlessness.. With
this fact in mind the present study was designed to determine if the
types of neuro-sensory and neuro-muscular alterations that were
observed following the Skylab missions would also occur to some
degree following exposure to prolonged supine bedrest.
PROCEDURES
Motion Sickness Susceptibilit,y
This portion of the study utilized procedures and hardware
identical to those developed for Skylab Experiment M131, Human Vesti-
bular Function.	 ;
Approximately one week prior to the first pre-bedrest test
each subject completed a -standard motion experience questionnaire.' This
questionnaire provided needed information concerning the subject's motion
sickness history, and was used to calculate the rotating chair velocity
for his first test. Immediately prior to the first experimental session
each subject was given verbal instructions on how to recognize and report 	
i
his symptoms. During the test, the blindfolded subject was seated in the
rotating chair device and rotated at'the predetermined constant velocity.
While rotating, the subject executed standardized head movement in the
.	 i
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four cardinal directions. These head movements were performed in sets,
each set consistin g
 of five head movements. Each set was separated by
a 20 second period of no head movements. During the test, the subject
was carefully monitored for signs and symptoms indicative of early
motion sickness. The test was terminated when the subject manifested
a low grade motion sickness (referred to a Malaise IIa) or after the
performance of 150 head movements, whichever occurred first. The
entire test procedure was typically completed in 20 minutes or less.
Pre-bedrest data were obtained on each subject at F-30, F-15 and F-5.
With exceptions noted under results, post-bedrest data were obtained
at R+O, R+2 and R+7. This test was always performed following the daily
completion of all other biomedical tests included in the bedrest study.
Postural Equilibrium
Postural equilibrium was tested using a standard laboratory
method developed for the Skylab flights.
The test employed a series of narrow metal rails on which the
subject was required to maintain an upright posture with his feet tan-
domly aligned and arms folded across his chest. The rails were .75,
1.25, 1.75, and 2.25 inches wide. In addition, a tape served as the
foot-guide alignment when the subject was required to stand on the floor.
	
	 1
s
Each subject was fitted with military-type sloes for this test, to rule
eout. differences in footw ar as a variable. Performance on this task
was measured under two sets of conditions. In the first, the subject
J
was required to maintain postural equilibrium on the rail (or floor)
with his eyes open. In -the second condition, he attempted to balance
Ulm
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with his eyes closed. In both cases, performance was scored in terms of
time (in seconds) on the rail before losing balance. On a given rail i
size, three test trials with a maximum required duration of 50 seconds
each were allowed. If the time limit was reached in the first two trials,
a third was not performed, and a perfect score of 100 seconds was recorded.
If the subject failed to obtain a perfect score, the two largest time
values for the three trials were summed to obtain the final score. Dur-
ing a test session, a minimum of two rail sizes were used in both the
i
eyes open . and eyes closed conditions. The total duration of this test
did not exceed 20 minutes.
Electromyography (EMG)
Surface EMG activity was recorded using Beckman skin electrodes
placed over the belly of the gastrocnemius muscle. Using an AC^DC pre-
amplifier and amplifier, monosynaptic potential (MSP) and muscle stretch
responses (MSR) were recorded from this electrode site. To obtain MSPs
the subject was seated with the leg flexed at the knee, foot supported
by the toes and the heel at a 90 0 angle with the floor.. While in this
position, 16 MSPs were elicited by tapping lightly with a hammer a thin
bar placed over the appropriate tendon. The latency of the MSRs'was
obtained while the subject was seated with his foot restrained in a.metal
foot rest at a right angle to his leg. To elicit an involuntary MSR,
the subject was asked to be prepared to resist any stretching force.
Then, at random and unexpected times, manual force (a slap by the experi-
menter to the sole of the metal foot restraint) was suddenly applied and.
maintained by the experimenter to dorsiflex, the foot. Voluntary response
'l3
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times (MSR voluntary latency) was measured by requesting the subject to
plantar-flex his foot as quickly as possible following a sharp, brief
tap to the metal foot restraint. Sixteen involuntary and 16 voluntary
MSR latencies were recorded.
The sharp sound (either hammer tap or slap) of the applied
stimulus was used to indicate the onset of the stimulus and to trigger
an oscilloscope on which the EMG response was displayed. Fach separate
response was photographed from the oscilloscope and both the stimulus
trigger (microphonic pulse generated from the sound) and the response
was recorded on a tape recorder for later analysis. The total time
to record these data during a test session did not exceed 20 minutes.
The combined EMG-postural equilibrium tests were run on each subject
at F-30, F-15 and F-5 and again at R+O, R+2 and R+7. When the subjects
arrived in the laboratory for the R+0 combined EMG-postural equilibrium
tests, they were still supine and had not been upright (either sitting
1
or standing) since the beginning of the 14-day bedrest period. i
RESULTS
Motion Sickness Susceptibility
The pre and post-bedrest results for this,test are summarized
in Table I., For each subject the chair speed (RPM) and number of head
movements (HM) required to reach the Malaise Ha level of motion sickness
are shown. The computed Coriolis Sickness Susceptibility Index (CSSI)
is also given. Data for subjects 5 and 6 are missing on R+0 because ai
the scheduled time of the test, 'these subjects complained of symptoms
which were very near or at the MIla level of motion sickness and the
test was, therefore, cancelled for that day.
1.
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Evaluation of the pre-bedrest data indicates that, with the
exception of subject 4, all of the subjects were moderately to highly
susceptible to Coriolis motion sickness. Subject 4 proved to be mod-
erately insusceptible and indeed it was necessary to increase the
chair speed on successive pre-bedrest tests days in order to achieve
a level of vestibular stress that would result in the manifestation of
symptoms. 'For purposes of comparison, it is significant to note that
during prefl ,ight testing the typical Skylab astronaut rode the rotating
chair at 20 RPM, performed 70 head movements and had a CSSI of 24.8.
When tested on R+O, all of the subjects showed slight to
moderate increases in susceptibility relative to their pre--bedrest`
baselines. This change was most prominent in subject 4. As previously
indicated, subjects 5 and 6 were excused from R+O testing because of
the presence of motion sickness type symptoms that developed gradually
during the course of other R+0 biomedical test activities. Tests per 	 3
formed on R+2 yielded more variable results. Subjects l and 3 became 	
A
slightly more susceptible than they had been on R+O. Subjects 2 and 5
	 3
showed levels of susceptibility approximately equal to their pre-bedrest
levels'. Subject 4 was still more susceptible . than he had been pre-
bedrest, but was improved relative to R+O, and subject 6 was less sus-
ceptible than he had been during any of the pre-bedrest tests. On R+7,
subje-t ' l was approximately as susceptible and subjects 3 and 5 were
slightly more susceptible than they had, been preflight. Subjects 2, 4
and 6 on the other hand were less susceptible on R+7 than they had been
pre-bedrest;_a very marked increase in tolerance was demonstrated by
subject-4.
-
_
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Postural Eauilibrium
Pre- and post-bedrest data obtained on each of the six subjects
are presented in figures 1-6. In these figures eyes open and eyes closed
postural equilibrium performance on each of the rail sizes used, plus the
floor, is plotted as a function of test day.
The pre-bedrest data indicate that as a group, these subjects
exhibited postural equilibrium performance equal to or better than the
performance typically observed in previous populations, including the
Skylab astronauts, tested by this method. Subjects 2 and 5, and to a
slightly lesser extent subject 5, showed particularly outstanding rail
balancing ability in both the eyes open and eyes closed conditions during
the pre-bedrest tests. Also during the pre-bedrest period a majority
of the subjects displayed continued improvement on this task indicating
that learning was occurring.
When tested on R+O, four out of six subjects (2, 4, 5 and 61.
demonstrated a slight overall deficit in both eyes open and eyes closed
postural equilibrium performance relative to their pre- bedrest baseline
performance. A slight eyes closed deficit wasmeasured in subject 1
and no change was evident in subject 3 in either of the test conditions.
On R+2 subjects l and 6 continued to show a very slight deficit
on only the eyes closed test condition and subject 4 demonstrated a
slight deficit on only the eyes open condition. The remaining subjects
had improved to levels of performance equal to or better than their pre
bedrest levels. The R+7 test revealed that rail balance performance met
or exceeded pre-bedrest performance for all six subjects. i
Aside from the lack of significant findings with the rail
balancing test, all of the subjects did experience some ataxia during
the first several hours after getting out of bed. This problem was
particularly apparent when they attempted to walk around corners. Also,
although it was not evident in their rail performance, several of the
subjects reported that during the R+0 eyes closed test they were unable
to sense small displacements of the head and body or make rapid postural
adjustments. No spatial disorientation was reported; slight dizziness
or vertigo during the rail test was reported by only two subjects (3 and
6). Recovery was rapid and no difficulties were reported during or
following the R+2 test day.
E1 ectroTyography
	 t
Figure 7 illustrates the three different responses elicited from a
i
the subjects. The top 6 traces are representative of the monosynaptic
potentials (MSP) which were obtained following a sharp tap to the Achilles
i
tendon. The second set of 6 traces indicate the voluntary plantar-flexia
	 '
tion of the subject's foot in response to a sharp tap on the metal foot
restraint. The third and last set of traces show an involuntary response.
Note the similar latencies of the monosynaptic response in each•condition.
Note also the longer and more variable latency of the muscle stretch
response (MSR) associated with the voluntary condition when it is com-
pared with that of the involuntary response. These time relationships
are representative of the 6 subjects tested.
Figure 8 indicates how the latency measurements were obtained
for each condition. The time from stimulus- onset to the MSP was taken
f10
as the peripheral conduction time (PCT). Also measured from stimulus
onset were the latencies of the MSRs. These MSR latencies are expressed
as the functional stretch reflex time (FSR) for the involuntary response,
and as the voluntary response time (URT) for the voluntary response.
Central conduction times (CCT) were calculated by measuring the time from
the beginning of a MSP to the start of a MSR.
Figure 9-14 present latency measurements for all subjects during
the 6 day test. Represented on the abscissa of each figure is test day,
The same convention is used here as was employed to present test day in
both the motion sickness susceptibility and postural equilibrium tests.
Days F--30, F-15 and F-5 were pre-test measurements 30, 15 and 5 days prior
to bedrest. Days R+Q, R+2 and R+7 indicate post-test measurements. As
previously noted on test day R4,0, the subjects arrived in the laboratory
i,n a supine position and were brought upright for the first time since
the beginning of the 14--day bedrest period for these myographic measure--
ments.
The data indicate that no major observable change is present in
any of the latencies for the 6 subjects. The most consistant Latency
measured was the PCT which changed little within any one subject. The
other latencies; URT, FS,R and CCT indicate some individual variation but
were not influenced by the bedrest treatment.
Number of observations, means and the standard error of the mean
as read from left to right in each row are presented in Table 11 for each
subject and condition. Note that variability is low for the PCTs as well
as the involuntary responses. As indicated in Figure 7, variability
increases for the voluntary responses.
a
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Amplitude measurements of the EMG were obtained in two ways.
First, for the MSP, individual N I - P 1
 
amplitudes were calculated.
Second, for the MSR of both the involuntary and voluntary responses,-
16 trials for each test condition and each day were rectified, averaged
and then integrated over time. Figures 15 -20 represent N1 - P 1 ampli-
tudes i n microvolts for all subjects during the 6 day test. Increases
in N1 - P 1
 
amplitudes are evident for the day on which the subjects
ended the 14-day bedrest period for subjects 1, 2, 3, 4 and 5. No
change was evident for subject 6. Note that this change in amplitude
is for the most part considerably decreased by R+2. Table III presents
the number of observations, means and standard error of the mean of
N1 - P I
 
amplitudes for each subject in each condition, Note the low
variability of,this measurement within test day-
Figure 21 i llustrates 16 rectified and averaged voluntary responses.
Superimposed on the average is the integral of the 200 msec period. To
determine the amplitude of -the MSR only the integrated activity beginning
80 msec from stimulus onset to 180 msec is considered. ^This time is indi-
cated by the two arrows. Figure 22 plots this value for each subject's
voluntary andinvoluntary responses for each test day. Very little con-
sistency is evident in these plots nor is the increased amplitude which
was present in the N
	
PI
 
activity on R+O indicated in the MSR.
DISCUSSION
-' Atior Sickness Susce tibility
The post-bedrest increases in susceptibility to Coriolis motion
sickness observed in the present study were relatively small in magnitude
_j
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and short in duration. In this regard, these findings are somewhat rem-
inescent of the temporary postflight increase in ssuceptibility to motion
sickness observed in the Skylab 2 crewmen. In general, however, the
post-bedrest tests did not yield results like those obtained following
the Skylab missions. Most notably, the marked postflight decrease in
susceptibility seen in the Skylab crewmen was not exhibited by the bed-
rest subjects.
These findings are not unexpected if one accepts the postula-
tion that alterations in otolith function were primarily responsible for
the postflight chaaiges in the Skylab crewmen. In the absence of gravity,
the otoliths, or the CNS integration of otolith generated sensory input,
could be expected to undergo significant change. Such would not be the
case in individuals bed-rested in a 1-g environment.
To conclude at this time, however, that supine .bedrest does
not result in sensory physiological alterations like those produced by
prolonged exposure to weightless spaceflight would be premature. The i
reasons are several. First, the Skylab missions ranged from 28 to 84
days in duration, whereas, the exposure to supine bedrest was only^14-
days in duration	 It is conceivable that 28 days or Longer supine bed-
rest might result in alterations more analogous to those seen following
3
Skylab. Secondly, because of the potential significance of the fluid
shifts involved, the effects of weightlessness might be better simulated
by head-down tilt bedrest rather than supine bedrest. Such a study has
yet to be done. Finally, the Skylab crews had periodic exposure to the
rotating chair test, as well as other vestibular stimulation, and there-
fore, had more opportunity to acquire habituation to stressful cross-coupled
/? sY.
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angular acceleration. The bedrest subjects had no such opportunities;
this could in part explain their increased susceptibility past-bedrest
or at least explain their lack of decreased susceptibility.
Aside from comparisons with the Skylab data, one other factor
is worthy of consideration which may in part account for the higher than
average motion sickness susceptiblity demonstration by the bedrest sub-
jects. All pre- and post-bedrest motion sickness tests were preceeded
by the Skylab x1171 exercise tolerance test. Although the subjects were
given an opportunity to rest and never manifested overt symptoms of
fatigue, it is conceivable that the stressful exercise test did lower
their threshold to motion sickness. In future studies of this type, an
attempt should be made to avoid scheduling any stressful tests prior 'to
motion sickness susceptibility testing.
Finally, in considering the significance of the subjects' post-
bedrest responses a distinction must be made between symptoms of motion
sickness having their etiology in the vestibular system and symptoms
,characteristic of motion sickness, but not of vestibular origin. That
is, the symptoms experienced by two of the subjects which prevented their
being tested on R+O were probably not the result of vestibular hyper-
sensitivity, but instead the result of a generalized autonomic nervous
system response to the various physical stresses encountered during the
first hours after termi nati-in^ of bedrest
Postural Equilibrium
The static rail balancing test procedure employed in the present
study revealed ' short-lived and functionally insignificant changes in
!1 9
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post-bedrest postural equlibrium performance. As might be expected from
previous test situations, where change were detected they tended to be
greaten when the subject was deprived of visual cues.
No firm conclusions regarding the comparability of supine bed-
rest and weightlessness in producing sensory system modification can be
drawn from the present study. This is true largely because of the signi-
ficantly longer duration of the Skylab missions from which data are
available. Fourteen days supine bedrest may be insufficient time for the
sensory and particularly neuro-muscular system alterations presumed respon-
sible for the Skylab postflight postural disturbances to occur. It must
t
also be recognized, however, that sensory system modification during bed-
rest would include little if any otolithic contribution regardless of the
duration of bedrest. Assuming this to be true, the total patterning of
sensory system modification should be different for periods of exposure
to bedrest and weightlessness of equal duration. Therefore, even if
equal periods of' bedrest  and weightlessness produced highly similar
changes in postural responses the underlying causes could be quite dif-
ferent.
As noted, all of the subjects in this study did exhibit ataxia
on R+O even though rail performance was good. This finding suggests
that the rail test may have been insensitive to a change that was present.
Indeed, in a 14-day bedrest study conducted at the Ames Research Center
a battery of 11 body balance tests were used and only two, a rail walk
i
(eyes open) and one-leg rail balance (eyes open), revealed a post-bedrest
a
deficit in balancing performance. These combined finding indicate that
rF	 6	
,
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future bedrest tests should utilized ynamic balancing
	 g)Y	 g (e.g., walking
tests in addition to static tests of the type used in the present study.
Electromyography
The results of this investigation indicate that some change
in the amplitude of the evoked monosynaptic potential was present follow-
ing 14 days of bedrest. The amplitude change by itself does not, however,
reflect completely those changes observed following the Skylab missions.
Long term space flight and exposure to prolonged periods of
weightlessness, as experienced during Skylab, tend to generate a hyper-
reflexia. Both an increase in the Achilles tendon reflex amplitude and
an increased , gastrocnemis muscle potential as well as . a decrease in the
reflex reaction time have been reported. These changes when observed
together with an increase in postural instability support a concept
which suggests that central neural reorganization occurs in response to
environmental change. Specifically, a central nervous system "pattern
center" concept could be postulated to help understand the mechanism
encountered in the adaptation process. For example, following insertion
into orbit,_the crewmen may experience difficulty in maneuvering and find
orientation to be a problem. Shortly, however, movement from one area
of the vehicle to another would become somewhat easier. Fine motor con-
trol to determine displacement would be established. Adaptation in the
neuromuscular system would have occurred.
Once an adequate memory of the required pattern is established,
the "pattern center" would take over muscular control on an involuntary
basis. 'Return to a 1-g environment would result in a recurrence of the
16
t
i
A
learning process. Habituation to a gravity reference would begin almost
immediately and a new effective pattern in the "pattern center" would be
established. Part of this habituation processes would be reflected in
the observed postflight hyperreflex activity.
If, as the Skylab results suggest, an environment dependent
memory store (pattern center) of frequently repeated sensory inputs is
operative which registers the actual movement and allows for anticipa-
tion and compensation of each movement as it occurs is accepted; then
it is reasonable not to observe both amplitude and latency changes in
neuromuscular activity following bedrest. Specifically, i!N a 1-g envi-
ronment, it is not anticipated that new muscle responses need to be
generated during bedrest. Instead, it is more likely that those responses
which ,erve us while standing and walking in a 1-g environment will con-
tinue to operate during prolonged periods of bedrest.
Bedrest must, however, introduce some neuromuscular changes
because of the relative inactivity imposed in this condition. During
a short period such as this 14 day test one of the major changes could
be observed in the transmitter substances found in the synaptic cyto-
plasm. For example, it is possible that during bedrest,levels of
norepinephrin could drop. When the subjects are raised from a supine
position these levels could increase significantly and be reflected in
the increased amplitude of the monosynaptic muscle potentials. At this
time, a complete urine analysis is not available. Once this has been
completed, this hypothesis can be evaluated.
In sunimary, our findings do, not at this time indicate that
L.. F
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ordinary bedrest can adequately simulate prolonged exposure to weight-
lessness. However, this conclusion is only tenative. Further experi-
mentation would be valuable.
SUBJECTS
TEST 1 2	 ii 3	 I 4 5
6
DAY
RPM HM CSSI RPM Nhl CSSI ^^ RPM Ht1
I
j	 CSSI PRh1 HM CSSI RPM HM CSSI RPM HM CSSI
F-30- 7.5 60 3.8 10 20 2.1 7.5 35 2.2 7.5 150 >9.81 7,5 20 1.3 5 45 1.4
F-15	 .I 7.5 1	 45 2.9 7.5 40 2.6 7.5 55 3.5 X 12.5 150 >22.5 5 75 2.4 5 55 1.8
F-5 7.5 40 2,6 7.5 35 2.2 . 7.5 50 3.2 20 70 23.1 5 35 1.1 5 M	 70 2.2
R+0 7.5 40 2.6 7.5 25 1.6 7.5 35 2.2 20 30 9.9 - - - - -
R+2 7.5 35 2.2 7.5 30 1.9 7.5 25 1.6 20 45 14.9 5 .50 1.6 5 105 3.4
R+7 7.5 55 3.5 7.5 55 3.5 7.5 35 . 1 2.2 20 140 45.2
L5
25 0.8 '.5 55 3.5
TABLE I.
Pre- and post- bedrest motion sickness susceptibility test
results. For each subject, the chair speed (RPM) and num-
ber of head mov(^ments ON) required to reach the Malaise Na	 r
level of motion sickness are shown. The computed Coriolis
'	 Sickness Susceptibility Index (CSSI) is also given.
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1
I	 1	 ^__	
r•3o—
	 - 1'-IS _	 -:r-5	 ago 	 R^2	 alt
1
	 Q. 33,0, 0.11 ~ ^12, 34,	 0	 12, 34, 0,19
	
Ill, 34, 0.11
	
18, 33. 0.60	 10, 33, 0,19
2	 12, 37 ,
	
0	 11, 36,	 0	 12, 36,	 0	 10, 39, 0.16	 18. 17, 0.09
	 18, "38,	 0
ACII1lLE5
TENDON	 3	 12, 37,8, U.17	 1G, 3).	 0	 12, 37,	 0	 10. 40, 0,12	 10, 3.1.	 • 0	 lo. 37, 0.11
r
REP b	 4	 12, 33:S, 0.19
	
12, 34,	 0	 12, J4,
	 0	 10, 36, 0.12 '
	 18, 34, 0,11
	 is. 34,
	 0
S	 12, 32 , 0,19
	
12, 34,	 0	 12, 33,	 0	 10, 34,	 0	 18, 34, 0,34
	 10, 74, 0.12
6	 12, 34.5, 0.15 	 12, 3S, 0,25	 12, 34,	 0	 10, 35,
	 0	 18, 35, 0,11
	 10, 35,
	 0
1	 12, 34 ,	 0	 12, 35.	 0 
ii 
12, 35,	 0	 12, 35,	 0	 18, 35, 0.12	 •18, 34. 0,06
a	 10, 42 , 0.36	 12, 39. 0.30 114. 38.
	 0	 18. 39, 0.08	 18, 40, 0.12
	 18, 40, 0,20
3	 12, 39	 0.62	 12, 38, 0.42	 12, 36,	 0	 18, al l 0.14	 18, 36, 0.11
	
18, 37,
	 0
YOLUpTARY
	 4	 12, 34.3, 0.22 	 16, 34,	 0	 12, 34,	 0	 18, 35.	 0	 18, 35,	 0	 18, 35, 0.11
5	 12. 34.5, 0_30	 12, 34.	 0	 13, 35, 0.21	 18, 35,
	 0	 18. 34. 0.11
	 18. 33. 0.11
5	 12, 40.3, 2.27	 16, 35, 0.13 ^ 12. 35, 	 0	 17, 1.6. 0.59 	 it, 36, 0.11	 16. 75,	 0
j 1
	 12, 32.9, 0.03	 16, 34. 0,(19 = 15, 34, 	 0	 18, 35,	 0	 18..34. 0.11	 18, 34,	 0
1	 12	 il. 36 , 0.24	 16. 37. 0.13 y 15, 3 .3. 0.12	 18, 39, 0.14	 18. 33.	 0	 18. 30, 0.16
4 3
	 12, 37 , 0.39	 12, 36,	 0	 12, 36.	 0	 10, 37, 0.12
	
18. 36.	 0	 18, 36,
	
0
1NfGLGNTARt
	 j
I  4	 15, 32.5, 0.13	 12, 33,	 0	 12, 33, 0.15	 18, 35,	 0	 18. 35, O.iS	 17. 33. 0,12
r
	 ^
5	 12, 32 ,	 0	 12, 34.	 0	 12, 34, 0.30	 18, 34	 0	 18, 39, 0.11	 18, 33,	 0 i
6	 11, 34,11, 0,16	 12, 35,	 0 1	12, 35.	 0	 18. 35,	 0	 18, 35,	 0	 18. 35, 0.03
1	 12, IGG	 3.23	 12, 106 , 4.19I 12, 104, 3,07	 11, 95, 2.70	 18, 101, 2.32 -- —18, 91, 1.30
2	 10„100	 5.82	 12. 02.8. 4.01; 14. 85. 5.70 	 13, 80. 2.60	 18, 86, 4.16	 is, 60, 4.24
3	 12, 102	 4.75	 12, 84	 3.49! 12, 88. 4.13	 18, 69, 3.58	 18, 84, 3.58,	 18, 79. 3.35
YQLVITARY
4	 12. 92	 6.50	 16, 98 , 4_78 l2. 83, 4.20	 18, 87, 1.35	 la, 69, 2.13	 13. 79, 1.03
r
5	 12, 100	 4.92	 12, 98	 3.85 13, 103, 3.75	 18, 95, 3.14	 13, 0), 2.50'	 1 18, 90, 2.22
6	 12, 74.2, 3.49	 16, 87 , 4.46 12. 94, 4.42	 17, 67, 2.28	 17, 78, 4.79	 ( 16. 81, 3.01
) J 12, 92.5, 1.69	 16, 93 "2.21  is, 96. 2.09	 1:1, 92. 1.42	 13, 105. 3.1S	 18, 92. 1.99
2	 11, 56 , 1.47	 16, 65	 2.79 15, 59, 1.36	 13, 115, 2.09	 19. 59, 1.56	 I 10, 00, 2.95
3	 12, 30.4. 4.27	 12, 70	 3.12 12. 75, 2.13	 in. 69, 1.93	 13. 72. 1.77	 18, 11, 2.5s
INVOLUNTARY
4	 15, 78.5, 3.07	 12. 74	 3.33 12, 7n, 1.63	 18. 73. 2.27	 10, 70, 2.26	 17, G5, 2.15
5	 12, 89.9, 3.7 .1	 12, 7.1	 1,51	 12, W, 2.51	 13. 76, 1,60	 18, 71, 1.45	 18. 70, 1.31	 I
--	 --- -- - - 5	 11. S6.5, 1.63 - 12. 59 .-1.01 11. 66, 2.65	 W. $6. 2.50	 13, 55. 1.31	 13 54. 1.06
i 1	 12, 1 .10 , 3.28	 12, 141,	 4.10 12, 139, 3.07 -	 17. 130, 2.71	 13, 136. 2.34	 18. 131. 1.32I
2	 10. 112.5. S.CO	 12 12:.	 1.01 W. 123, 5.70	 i8, 112 2.60	 18, 125 4.13	 18. I:U. 4.13
3	 12, 141	 4.79	 P. 11.I.	 1.56 12, 121. 4.13	 18. 127, 3.61	 1:;. 120 MS '	 19. 116. 3.35
Y&LUNTARY
4	 12, 126	 6.53	 16, 132,	 '4.77; 12. 122, 4.20 	 18. 122.. 1.35.	 18, 124, 2.13	 13, I15. 1.99
9	 17, 135	 4. R')	 12, 132.	 3.86 13, 111 3,75	 18, 1°), 1.14	 13. 123, 2.50	 Is. 124, 2.21
6	 I: , 115	 3.65	 IG, 122.	 4.47 12 Ill, 4,•11	 17, 103, 2.19	 17, 114, 4,60	 16, 116, 3.07
1	 li, 175.4, 1.73	 16, 132, A2.10 15, 130. 7.011 	 16+.1121, t.42	 18. 139. 3.13 - -
1N, 126. 1.94w--
2	 )l. 92,7. 1,41	 16, 102.	 2.71 IS, 97. 1.34	 18. 104. Z. Ill	 18. 97. 1,56	 18, Ila, 3.05	
1
t
g	 12, llfi,	 3.81	 12, IOS.	 2.67 1$, M. 7. 13	 18, 106. 1
-
M	 iS, 100, 1.77	 18, 147. 1,55
j	 ! N
	
'171V LUNT1,RY	 4	 15, 110.	 3 . 04	 12, 107,	 3,33 12. 109, 1.66	 III, 108, 2127	 , IS, tol l x. 16	 11, 98, 2.17
`	 5	 12, 111.9. 3.14	 12, 108.	 1.01 IZ, 113, ;.44	 18. 109, 1.5$	 10, Ws. 1.40	 10, 108, 1.39
1	 ,!	 b	 Ii, 9t1,9. 1.b7	 12, 94.	 1.04! 11. 101, 2.65	 18. 91, 2.w	 16..90. 1.37	 !8. 89, 1.06
Tabl e H.a
Number of observations, means, and the standard error of the mean read
from left to right in each row for each subject in every condition. Test
day is'presented in the 6 columes. The means presented in this table
were used to construct Figure 9-14.
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•TABLE III.
TEST DAY
!	 RESPONSE
mJ F-30 F-15 F-5 R+0 RP2 R+1
1 12, 107, .003 12, 121, 004 12, 112, .005 18, 239, .008 18, 91. .002 18. 136, ,003
ACHILLES 2 12, 29.8, .002 12, 47.7, .004 12, 38, .003 18, 88, .003 18. 56, .003 18, 53. .004
TFMUON 3 '12. 49, .006 16, 53, .007 12,. 43, .004 18, 128, .008 18, 101, .005 18, 96, ,003
REFLEX
4 12, 119.5, .009 12, 116. :007 12, 86, .004 18, 31, .012 18, 95, .005 18, 183, .011
5 12, 120, .003 12, 119, .004 12, 116, .009 18, 204, .010 18, 89,' .004 18, 99, .003
6 12, 56, .006 12, 33, .002 12, 50. .003 18, 42, .002 18, 46, .003 18, 72. .004
1 12, 121, .003 12, 106, .005 12, 99, .003 17, 194, .005 18. 106, .003 18. 120, .003
2 10, 6.8. .001 12, 29.6, .004 14, 28, .002 18. 69, .004. 18. 39, .003 19, 48, .003
3 12, 21.5, .003 12, 29, .004 12, 24, .001 18,•_123, .009 18, 45, .003 18, 46, .003
VOLUNTARY
4 12. 93.4, .009 12, 68.6, .006 12, 102, .001 18, 282, .010 18. 89, .035 18, 180, .010
5 12, 48, 007 12, 90, 005 '13, 45, .005 18, 156, .008 18. 97.',006 18, 99, 1005
6 12. 14.7, .003 16, 14. .003 12, 30, .003 17, 22, .003 .17, 28, .003 16, 32, .003
_ 1 12, 99, .002 16, 102, .004 15, 97, .004 18, 151, .005 18, 96.._003 18. 90, .003
2 11, 60, '.003 16, 69, .002 15, 56, .002 18, 97, .004 18, 85, .004 18, 65, .004
INVOLUNTARY 3 12, 41, .006* 12, 104, .007 12, 49, .002 18, 141, .005 18, 68, .002 18. 71, .002
4 15, 214, .009 12, 158, .007 12, 206, .009 18, 403, .010 18, 174, .009 18. 226, .015
5 12, 196, ,011 12, 147, .005 12, 102, .010 18.'245, .010 18, 106, .00; 13, 119. .01-13
6 11, 97, .00'1 12, 49„ .004 12, 56, .003 18, 41, .003 18, 50, .002 18, 74, .004
i
i
i
Number of observations, means 'and the standard error of the mean
read from left to right in each row for each subject in every_
condition. Test day is presented in the 6 columes. Th e means
presented in this table were used to construct Figure 15-20,
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Figure 4, Pre- and past-bedrest postural equilibrium performance for subject 4.
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Figure 5. Pre- and post-bedrest postural equilibrium performance for subject 5.
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Figure 7. Monosynaptic potentials, voluntary responses and
involuntary responses. Total sweep time as indicated
is 200 msec with 2V per division equal to lmv.
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Figure 8.
r
MUMNAPTIC POTENTIAL
HP)	 MUSCLE STRETCH RESPONSE
(MSR)
i
PERIPHERAL	 CENTRAL CONDUCTION TIME (CCT)
CONDUCTION
TIME
(PCT)
VOLUNTARY RESPONSE TIME (VRT)
FUNCTIONAL STRETCH REFLEX TIME (FSR)
Figure 8. Peripheral conduction time (PCT) is measured from the time of
stimulus onset to the beginning of the monosynaptic potential
(MSP). Also measured from the time of stimulus onset are the
voluntary response time (VRT) and functional stretch reflex
time (M) The response interval noted as central conduction
time (CCT) was measured from the start of the MSP to the start
of the muscle stretch response (MSR).
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Figure 9.	 -Response_ times obtained for subject 1.	 Test day is represented on the abscissa for each con-
dition (VRT, CCT, FSR, PCT). 	 Latency measurements .in'mseL are located on the ordinate for the
VRT, FSR and PCT conditions.	 The ordinate for CCT represents time delays of the MSR occurring
within the central nervous system. 	 Note that the CCTs were obtained for both voluntary and
involuntary conditions.	 Also note that tendon reflex times along with voluntay and involuntary
response times were included in the PCT measurements.
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Figure 10. Response time obtained for subject 2. Conventions are those given for Figure 9.
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Figure 15. Ni - P  amplitudes of the monosynaptic potentials generated
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Figure 21. Sixteen rectified and averaged voluntary responses. Superimposed on the average is the integral
of the entire 200 msec period. Only the integrated activity. beginning 80 msec and ending 180 msec
from stimulus onset was used to determine amplitude changes in the MSR. This time period is
indicated by the two arrows.
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JSC - BAYLOR BED REST STUDY I
CARDIOVASCULAR EVALUATIONS
INTRODUCTION
The effects of bed rest on the cardiovascular system are well established. Many
effects parallel closely those noted in man after a period of weightlessness. In
spite of the comprehensive evaluation on man during and after bed rest there are-
no reported bed rest studies which utilized the exact protocols, equipment, and
time schedules as were employed during Skylab. It was therefore considered reason-
able to conduct a bed rest study which employed the unique features of the Skylab
medical evaluations and to compare the results with those obtained from the Skylab
astronauts after prolonged weightlessness.
METHODS
Cardiovascular responses to a two-week bed rest period were studied in six normal
males. Test protocols were adapted from the pre- and postflight measurements from
Skylab ( 6 ) evaluations and included a lower body negative pressure (LBNP) stress
test with increments of negative pressure from 0 to 50 mmHg, over a 15-minute period
(Figure 1)
	
Before, during, and after each LBNP test vectorcardiogram, phono-
cardiogram, pneumogram, percent leg volume change, and blood pressure were ob-
tained. Leg volume and systolic time intervals (STI) were also measured at the time
of LBNP testing.
Each subject participated in three tests prior to the bed rest period in order to obtain
baseline data and to familiarize the subjects with the test protocol. After completion
I^	 4
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of two weeks absolute bed rest and before being ambulated, each subject was
tested again. Subjects were also tested on each of the two days immediately
following ambulation. LBNP tests were not performed during bed rest; however,
leg volume and STI determinations were obtained on several days during this
period.
Equipment for the study included the instrumentation from the Skylab One-9
trainer where preflight exams had been performed. The environment, however,
was not as controlled, and some of the pre- and post- bed rest data was compromised.
The major source of environmental interference came from a radio station (RF inter-
ference) and from an unknown mechanical source (vibration interference) . In
addition to loss of time code, the STI data during all LBNP tests were uninterpret-
able. Three tests were aborted because of electrical power failure to the experi-
ment room. All initial pre- bed rest tests were conducted with environmental
temperatures above desired Ii mits.
RESULTS
Tables I - V provide basic data about the individual tests for each subject both for
reference and as a measure of experimental design and environmental control: The
only notable departures from desired conditions were the somewhat elevated environ-
mentaltemperatures during the first pre- bed rest tests.
Tables VI and VII give maximal calf girths and total leg volumes, the latter having
revealed in space crews decrements of over a I itre after flight. The very negligible
f	 !
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changes in leg size during bed rest definitely do not parallel those seen during
and after space flight. Figures 2 and 3 present these data more dramatically by
including multiple serial measurements made during bed rest. A very modest
increment ( b 100 - 200 ml ) in leg volume is evident in the immediate post- bed
rest period.
Tables VII I, 1X and X present a complete overview of heart rates, ^y, tol is and dia-
stolic blood pressures for every test period of all tests on all subjects. Only group
mean resting heart rate (Table XII) was rot returned within the pre- bed rest 95%
fiducial limits by the BR + 2 test. Blood pressure did not significantly change.
Maximal percentage change in calf size during LBNP, shown in Tables XI and XII,
seems to imply an augmentation for the group mean immediately after bed rest, but
this is not statistically significant compared to pre- bed rest ficudial Limits,
i
SYSTOLIC TIME INTERVALS
Table XIII shows the individual STI (PEP/LVET) and heart rate responses during bed
rest. The pre- bed rest and post bed rest data were unacceptable for interpretation i
because of environmental interference. Heart rate tended to increase during the bed
rsst period (75 to 80). The fact that resting heart rate was elevated prior to ambula-
tion or exposure to the post bed rest environment would indicate that this finding was
the result of bed rest, per se, rather than emotion.
The PEP/LVET measurement of STl varied considerably during the two-week bed rest
period when compared with circadian rhythm of this measurement, However,
- 
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because STIs were always measured near the same time of day, the circadian
rhythmicity effect should have been minimized. Initially the group mean
PEP/LVET was 0. 32, while at the end of bed rest it was O.37 (p <.05). Therefore,
the STI data from Skylab and two weeks of bed rest are directionally similar. The
magnitude of change, however, is not as great for bed rests Furthermore, there
was no significant change in PEP/LVET at the end of one week, i.e., PEP/LVET
0.34 at seven days (p < .10) a
VEC TORCARDIOGRAM
Predictable effects of LBNP on certain VCG elements were observed. Concurrent
with elevated heart rate were decreased PR interval (p<0.05), QRS duration (NS),
and QT interval (p < 0.01). In addition, the P-wave maximal spatial vector
magnitude increased dramatically (p <0.05) while ST maximal vector magnitude
decreased (NS) and little consistent alteration occurred in QRS vector dimensions.
The J vector magnitude and the QRS-T spatial angle also increased (NS).
On the other hand, the effects of bed rest on the VCG differed in several respects
from those observed after space flight. While resting heart rate was significantly
elevated in the first post bed rest test, nei Cher PR interval nor QRS duration was
significantly further elevated in the resting state. Maximal vector magnitudes of
P-wave, QRS, and ST loops under resting supine conditions were either not signi-
ficantly elevated or decreased after bed rest; all were significantly elevated after
space flight. And though the J vector magnitude and the QRS-T spatial angle
were not significantly changed by either environmental condition, their alterations
were in opposite directions after space flight and bed-rest.
E3
DISCUSSION
	 5
The cardiovascular responses to weightlessness are fairly well established
and have been reported in a recent symposium ( b	 ).	 Basically, there is an
absolute reduction in blood volume (plasma volume) in response to what is probably
sensed as a volume expansion by receptors in the chest. Fluid moves along a pressure
gradient from the legs into the upper body, and central circulation. Part of the fluid
is stored in these spaces while the remainder is removed from the body probably as
urine and/or insensibly over one to three days of weightlessness ( 1, 2).
As long as the null gravity environment is imposed, cardiovascular function
appears to be intact — in spite of the absolute volume decrement. However, transition
to one-9 leads to problems related to the relative volume deficiency including ortho-
static intolerance ( 3, 5 )o And symptoms associated with standing or LBNP lost
at least as long as it takes the body to restabilize at an adequate blood volume for the
gravity field.
Bed rest has been used repeatly as an analog to weightlessness. Although the
body at supine rest is within a gravitational field, this force is exerted perpendicular
to the long axis. The body is deprived of the usual gravity stimulus since the gravity
vector measured in the foot-to-head axis is zero with the subjer,t in a supine position.
The bed rest model has also been used because at least some responses to it
are similar to weightlessness exposure. After three weeks of absolute bed rest, blood
volume is decreased and there are decrements in exercise and orthostatic tolerances.
Although plasma volume is regained within three or four days after ambulation, there
I
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is a definite delay in LBNP and exercise toleranced5, 7).
Results of the present study, during which subjects were exposed to two
weeks of absolute bed rest, are consistent with other studies of similar duration.
Heart rate was elevated during supine rest and especially in response to LBNP stress
compared with baseline values (Table VIII). Two of six subjects developed pre-
4
syncope during the first LBNP test after bed rest, but before ambulation. This
number is comparable to the Skylab experience in which four of nine crewmen
suffered an orthostatically induced syncopal episodes a^ er return to earth.
Of interest are the data on weights and leg volumes. There was only a
small decrement in leg volume in three of the six subjects compared with'100
percent of Skylab and ASTP crewmen. Inflight leg volume determinations during
the ASTP (nine day) mission showed that these crewmen had lost 5 ld percent of
leg volume by 32 hours after launch. Weight change was negligible in the bed
rested subjects, but weight loss was almost always noted in U. S. astronauts upon
return from weightless flight. These data suggest that there are significant differ-
ences between true weightlessness and the bed rest analog — in spite of definite
similarities in orthostatic responses.
Renting, supine PEP/LVET which is independent of heart rate change was
significantly increased after bed rest (Table XIII). The mean value was 0. 32 + .02
prior to bed rest and 0.37 t .03 afterward. The Skylab III crewmen PEP/LVET
climbed from 0.32 preflight to 0.41 postflight`. Therefore, according to this
measurement of cardiovascular integrity, the bed rest subjects had a similar, but
^' a
not equal change compared with the Skylab crewmen. It is unfortuna
STI data were uninterpretable during LBNP stress, especially since the
heart rate and blood pressure responses were similar to the astronaut di
from Skylab and Apollo Programs.
Selected elements of the vectorcardiogram showed alterations and responses to
LBNP essentially like those previously reported ( 4 ). However, under resting,
supine conditions VCG responses after bed rest differed distinctly from those after
space fl ight. If headward fluid shifts are contributing to the observed VCG changes,
there must be qualitative as well as quantitative differences between the effects of
supine bed rest and space flight.
It would appear that certain cardiovascular responses to supine bed rest are similar,
but not equal to those noted after exposure to weightlessness. The incidence of
presyncope and the overall decrement in orthostatic tolerance are almost the same.
However, other responses to bed rest seem almost opposed to those after space flight.
Mechanisms maybe quite different when one considers the leg voiume and weight
data from the two groups. At this time, it is clear only that supine bed rest does
not reproduce the entire picture observed in cardiovascular physiology after space
flight. It is possible that some degree of head--down tilt may provide a better
approximation to the cardiovascular effects of space flight.
I
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TABLE
JSC-BAYLOR BED REST STUDY 1
Cardiovascular Evaluations - Date/Time (CDT)
SUBJECT BR-20 BR-15 BR-8 BRA BR+1 BR+2
1 30 April 75 5 May 75 12 May 75 3 June 75 4 June 75 5 June 75
1' 1:19 09:03 08:49 09:36 09:05 08:43
2 30 Aprii 75 5 May 75 12 May 75 3 June 75 4 June 75 5 June 75
12:20 10:43 09:52 10:22 11:01 09:22
3 30 April 75 5 May 75 12 May 75 3 June 75 4 June 75 5 June 75
10:23 13:56 13.29 13:43 12:27 12:19
4 1 May 75 6 May 75 13 May 75 6 June 75 7 June 75 8 June 75
10:47 08:59 08:48 09:03 09:02 08:39
5 1 May 75 6 May 75 13 May 75 6 June 75 7 June 75 8 June 75
11:47 10:00 09:41 10:01 10:25 09:37
6 1 May 75 6 May 75 13 May 75 6 June 75 7 June 75 8 June 75
09:52 13:04 13:28 13:34 12:05 11:50
C
TABLE
JSC-BAYLQR BED REST STUDY
Cardiovascular Evaluations
Hours of Sleep/Hours Since Eating
SUBJECT
F.
BR-20 BR-15	 BR-8 BR+O BRfl BR+2
1 8 7	 6 8 b 5
21/2 1 1/4	 1 2 1 1
2 7 7	 7 1/2 8 71/2 9
3 1/2 2	 2 2 i/2 3 2
3 6 5.7/2	 5 4 5 5
11/4 1 1/2	 1 11/2 4 2
4 7 61/2	 7 5 1/2 7, 1/2 6
1 1/4 j	 1 1 1 1/2 1
f	 5 7 6	 7 -1/2 8 8 9
2 7	 1 1/2 1 21/2 1 1/2
6 7 8	 10 7 7 131 1/2 2	 1 1/2 2 3 3
TABLE	 III
i
JSC-BAYLOR BED REST STUDY 1
Cardiovascular Evaluations
f Weight (kg)/Oral Temperature (o E) [ a C1 ^ ^^
SUBJECT BR-20 BR-15	 BP,-8 BR +O 8Rt1 SP..2
1 68.5 68.3	 68.7 69.3 69.4
98.6 [37.001	 97.2 [36.221 97.5 [36.391 97.6 136.441 97.6 136.441	 ^-
2 70.9 71.0	 71.0 71.1 71.1 71.0
93.5 [36.941	 98.	 [36.831 9-8.6 [37.001 98.1 [36.721 98.1 [36.721
f
3 69.2 68.7	 69.7 70.0 69.3 69.7
98.7 [37.061	 98.0 [36.671 98.7 [37.061 98.2 [36.781 98.6 [37.001
4 64.4 64.9	 64.2 64.7 64.4 64.3
98.6 [37.001	 97.9 [36.611	 _ 98.7 [37.061 99.0 [37.221 97.7 [36.501
5 82.1 82.6	 81.6 82.1 82.1 82.1
98.6 [37.001	 98.0 [36.671 97. 3 [36.28 1 98.2 [36.781 98.0 [36.671
6 63.3 63.8	 64.0 65.7 65.5 65.3
98'.5 [36.941
	
97.7 [36.501 98.4 [36.891 97.7 [36.501 97.6 [36.441
TABLE IV
.1SC-BAYLOR BED REST STUDY I
C1-2. diovascular Evaluations
Room Temperature of (Beginning-End)
SUBJECT BR-20 BR-15 BR-8 BR+O BR.+I BR+2
1 76.0- 70.5- 67.5- 66.5- 63.5- 65.0-	 - T
76.0 71.5 68.5 66.5 63.5 65,0;
2 77.0- 72.5- 72,0- 67.5- 65.0- 66.5-
76.0 73.5 70.0 66.5 64.5 66.5
3 74.5- 70.5- 72.5- 69.0- 69.0+- 66.5-	 f°
75.5 71,0 70.0 69.0 67.0
4 75.5- 67..5 67,5- 65.0- 66.0- 73,5-	 j
68.0 68.0 65.5 66,5 73.0
5 76.5- 68.5- 69.5- 66.0- 70.0- 72.5-
77.5 69.0 70.0 66.0 70.0+ 73.0
6 74.5- 64,5 70.0- 70.5- 70.5- 71.75 -
I
70.5 70.0+ 71.5 71.0 72.0
9
BR-20
77.5-
78.5
79,O
76.0-
78.0
72.5-
79.0-
80 , 0+
75.2-
BR+1
67.5-
69.0
70.0-
72.5
72.5-
74.5
67.5-
71.5
70.5-
72.0+
71.5-
,74.0
B R+2
68.5-
71.0
71.0-
72.0
72.0-
73.5
75.5-
76.0
75.0-
76.0
73.5-
75.0
TABLE V
JSC-BAYLOR BED REST STUDY I
Cardiovascular Evaluations
LBNP Temperature OF (Beginning-End)
BR-15 BR-8 BR+O
71.5- 70.5- 66.5-
72.5 72.0 69.0
74.5- 79.5- 68.5-
75.4 73.5 69.5-#-
73.0-. 74.0- 7T.5-
74.5 70.0
69.5- 69.5- 68.0-
70.5 71,5 70.0
70.5- 72.5- 71.0-
72.0 73.5 72.0
71.5- 72.0- 72.0-
731 . 5 73.0-1- 71.5
r i
TABLE VI
JSC-BAYLOR BED REST STUDY 1
Cardiovascular Evaluations
Calf Circumference Left/Right (cm.)
SUBJECT BR-20 BR-15	 BR-8 BRA 0 BR+1 2BR +
1 34.29 34.61	 34.93 33.97 34.29 34.93
34.61 35.24	 35.88 33.97- 3429 34.93
2 33.02 33.66	 33.66 32.70 32,70 33.34
32.70 33.02	 33.02 32.07 32,70 32.70
3 35.88 36.20	 35.88 34.93 36.51 36.20
36.83 36.83	 35.56 36.51 37.15 36.83
`' 4 33.02 33.34
	
33.34 32.39 32.39 32.39
32.70 32.70	 33.02 31.75 31.43 32.39
5 34.93 34.93	 34.93 33.97 34.93 34.61
34.61 34.93	 34.93 33.97 34.67 33.97
6 34..29
34.61
34.61"	 34.61
34.93
33.34 34.29 34.29
34.93 33.66 34.61 34.93
;P
TABLE VII
.ISC- BAYLOR BED REST STUDY I
Cardiovascular Evaluations
1
Leg Volume Leif,/Right (ml.)
y SUBJECT, BR-15 BR-8 BR+O BR+1 BR+2
1 7274 7173 7088 7320 7571 7517
` 7661 7750 7541 7572 7744 7538
2 7516 7507 7291 7452 7316 7501
	
°F
7302 7512 7337 6990 7258 7383
a 3 7287 7382 7233 7394 7511 7508
7720 7873 7639	 _ 7478 7928 7685
4 7079 6898 7060 6945 7123 7148
6969 691.' 6719 6611 6650 6828
. 5 7263 7076 6866 7034 7205 7053`
7343 7373 7104 7126 7451 7204
6 7497 7402 7549 7538 7632 7819
7413 7655 7593 7679 7831 7939
3
TABLE	 It
JSC — BAYLOR BED REST STUDY i
i CARDIOVASCULAR EVALUATIONS - HEART RATE
Subject Test Period BR-20 BR-15	 BR- 8	 Mean SD BR+O BR+l BR+2
C 67 66	 66	 66 0.6 71 73 71	 L
1 -30 66 70	 68	 68 2.0 75 76 77
-40 76 73	 73	 74 1.7 84 86 81
-50 79 75	 71	 75 4.0 90 91 88
R 57 58	 60	 58 1.5 61 69 64
C 81 71	 66	 73 7.6 69 71 73
2 -30 86 70	 66	 74 10.6 75 72 75
=40 92 72	 72	 79 11.6 66 76 82
-50 96 78	 77	 84 10.7 92 80 85
R 76 66	 63	 68 6.8 63 66 '71
C 69	 68	 69 0.7 77 81 78
3 -30 73	 78	 76 3.5 91 88 88
-40 81	 89	 85 5.7 109 96 101
-50 85	 97	 91 8.5 108 109 109
R 62	 57	 60 3.5, 68 76 72	 cr.
C 71 66	 66	 68 2.9 72 75 694
-30 86 82	 82	 83 2.3 sho 82 76
-40 98 97	 99	 98' 1.0 113 96 88
-50 113 113	 123	 116 5.8 133 113 98
R 61 59	 57	 59 2.0 71 62 57
C 68 67	 64	 66 2.1 69 b9 73
-30 68 70	 63	 67 3.6 75 72 79	 1
-40 68 72	 70	 70 2.0 85 77 85	 -
-50 78 78	 80	 79 1.2 95 81 91R 61 63	 56	 60 3.6 68 64 69
f
C 68 68	 70	 69 1.2 77 73 73
6 -30 68 69	 71	 69 1.5 83 69 72	
v1
-40 71 68
	 75	 71 3.5 93 73 75
—50 75 84	 80	 80 4.5 142 88 82R
66 67	 66	 66 0.6 76 72 69
BR +2
99
96
93
91
102
99
94
90
91
101
100
96
c5
92
100
106
102
97
95
109
93
88
88
89
98
98
92
89
88
88
i
^UDIecr iesr rerioa nK-^u t5K- i^ ^Y.- Mean _	 SD BR +0 BR+1
C 90 97 96 94 3.8 113 106
82 91 97 90 7.6 109 107
-40 81 92 93 89 6.7 110 '	 104
-50 85 92 94 90 4.7 107 106
R 95 104 102 100 4.7 120 114
C 97 100 96 98 2^1 107 94
2 -30 96 99 95 97 21 104 87
-40 89 95 91 92 3.1 99 87
-50 86' 95 92 91 4.6 93 84
R 107 103 100 103 3.5 113 93
C 93 101 97 5.7 108 99
3, -30 91 95 93 2.8 108 100
--40 88 97 93 6.4 101 102
-50' 90 87 89 2.1 107 102
R' 92 98 95 4.2 107 104
C 113 112 113 113 0.6 115
4	 -30 114 109 107 110- 3.6 109
-40 109 105 106 107 2.1 103
-50 104 102 98 101 3.1 89
R 119 120_ 122 120 1.5 106
C 97 98 95 97 1.5 101
5	 -30 93 98 91 94 3.6 98
-40 92 ^^ 84 90 5.7 98
-50 90 89 79 86 6.1 99
R 97 99 90 95 4.7 104
C 93 105 96 98 6.2 102
6	 -30 87 101 93 94 7.0 95
f	 -40 88 93 88 90 2.9 92
-50 88 94 86 89 4.2 88
R, 97 M 99 101 4.7 102
112
107
107
104
119
93
91
90
86
95
94
86
s
85
92
BR+1
	 BR + 2
62
58
56
61
62
54
51
55
55
54
68
69
70
73
66
45
46
46
49
47
62
63
60
65
61
52
47
46
51
49
56
54
57
54
64
56
52
52
58
56
60
63
64
63
64
42
43
42
44
44
56
57
59
62
62
47
51
51
50
50
t^
TABL -X
JSC - BAYLOR BED REST STUDY
CARDIOVASCULAR EVALUATIONS - DIASTOLIC BLOOD PRESSURE
Subject Test Period BR-20 BR-15 BR- 8 Mean	 + SD BR+O
C 52 53 57 54 2.7 62
l -30 46 47 49 47 1.5 58
-40 53 50 52 52 1.5 65
-50 50 52 52 51 1.2 66
R _ 58 54 56 56 - 2.0 72
F C 56 57 55 56 1.0 60
2
-30 57 60 56 58 2.1 59
-40 58 59 56 58 1.5 63
-50 53 59 56 56 3.0 65
R 55 63 54 57 4.9 67
i
C 53 55 54 1.4 57
3 -30 56 55 56 0.7 61
-40 58 58 58 64
-50 56 53 55 2.1 60
R 50 57 54 5.0 60
C 51 46 45 47 3.2 4
4 -30 52 47 46 48 - 3.2 44
-40 50 48' 42 47 4.2 43
-50 50 48 49 1.4 41
R 50 55 50 52 2.9 60
C 54 57 56 56 1.5 64
5 -30 59 60 58 59 1.0 64
-40 53 60 54 56 3.8 66
-50'; 50 61 55 55 5.5 66
R 58 59 55 57 2.1 66
C, 42' 49 50 47 4.4 52
6 -30 43' 49 52 48 4.6 53
-40 49 46 50 48 2.1 52
-50 48 52 52 51 2.3 51
R 47 48 51 49 2.1 57
TABLE XI
JSC -"BAYLOR BED REST STUDY
i
Cardiovascular Evaluations - Percentage Leg Volume Increase (during Max. LBNP)
SUBJECT BR-20 BR-15 " BR-8	 MEAN ±	 SD	 BR+0 BR+1 BR+2
1 1.5 1.5 2.4	 1.8	 0.5	 2.4 1.6 1.6
2 1.0 1.4 1.8	 1.4	 0.4	 2.4 1.9 1.6
3 2.5 1.2	 1.9	 0.9	 3.3 3.9 2.7
*P13	 *P10
4 2.8: 2.4 2.2	 2.5	 0.3	 1.2 1.9 2.7
*P12
5
l
3.5 3.4 4.4	 3.8	 0.6	 3.4 2.3 2.7
6 1.2 0.7- 1.7	 1.2	 0.5	 2.6 2.1 1.5
C Presyncope required stopping LBNP stress at designated minute.
C.
J
E.
f^
r,
PRESSURE	
_50
mm Hg, X 50.2 54.7 53.6 52.8	 2.9	 58.2 59.0SD 1.8 4.9 1.8 10.2 9.1
MAXIMAL
	
-50i 2.0 1.9 2.3 2.1	 1.0	 2.6 2.3
LEG VOLUME SD 1.1 1.0 1.1 0.8 0.8
CHANGE,
Percentage
* p < 0.05
ii
,j
a
** p < 0.02
55.2
7.3
2.1
0.6
TA	 X!L_-
JSC - BAYLOR BED REST STUDY i
GROUP MEANS (nom) AT REST (C) AND DURING MAXIMAL (-50 mmHg) LBNP STRESS
Measurement Test Period BR-20 BR-15 BR- 8 MEAN ± SD BR+ O BR+1 BR+2
HEART C X 71.0 67.8 66.7 68.5 2.6 *75.2 **73.7 **72.8
RATE, SD 5.8 1.9 2.1 5.8 4.1 3.0
bpm
=50 X 88.2 85,5 88,0 87.5 15.0 10303 93.7 92,2
i'
SD 16.1 14.0 19.2 ' 16.0 14.1 9.9
SYSTOLIC C X 98.0 100,8 99,5 49.5 6,8 107,2 99.7 99.2
`	 BLOOD SD 8.8 6.7 7.0 6d4 7,8 4.2
4	 PRESSURE,
mm Hg' -50 X 90.6 93.7 89.3 91.0 5.2 97.2 94.5 91.0SD 7.7 4.7 6,7 8.5 10,5 2.5	 MQ
DIASTOLIC C X 51.0 52.5 53,0 52.3 4.2 57.0 57.2 52.8
BLOOD SD 5.4 4.4 4.6 7.5 8.4 6.8
71	 85
.37	 .40
69	 82
.35
	
.38
78	 77
38	 34
TABLE X(ii
JSC - BAYLOR BED REST STUDY 1
Cardiovascular Evaluations - Heart Rate and PEP/LVET During Bed Rest
DAY 1 2 3
4_
5 6 7 8 9 10 11 12
HR, bpm 72 55 65 66 63 59 61 76 65 73
PEP/LVET .35 .33 .31 .34 .37 .32 .37 ..36 ,37 .32
HR,  bpm 74 61 72 71 75 72 62 66 78 66
PEP/LV E T .30 .32 ,35 .33 .36 .34 .40 .36 .37 .31
HR , bpm 82 73 79 76 73 73 76 70 88
PEP/LVET .31 .33' .32 .35 .30 .34 .35 .33 .32
HR, bpm ' 77 76 71 68 777: 78 - 76 73 75 71
PEP/LVET .34 .37 .34 .39 .37 .35 .33 .33 .38 .39
FIR,bpm 77 71 72 65 66 68 61 67 64 65
PEP/LVET ,31 .34 .34 .31 .33 .37 .32 .35 .39 .35
Ii HR, bpm 68 65 66 57 68 68 75 b0 63 60
PEP/LVET
t
k	
i
j;
.32 .35 .31 .30 .34 .36 .32
...
.32
y
.38 035
i
13	 14
72
36
77
.40
87
.35	 J
SJSC 14-DAY QEDREST STUDY
EXERCISE STRESS TESTING
Introduction
The response to exercise stress after periods of hypokine
1-g has been 'utilized to evaluate cardiorespiratory changes ev
decreased physical activity (1,5). Exercise response tests al
been utilized before, during, and after space flight to study
adaptative responses to that unique environment (2,3,4). While it appears
that 1-g bedrest produces responses that are similar to weightlessness,
no previous studies were designed specifically to match experI'ment
protocols and measurement techniques.
The present study was designed to evaluate physiological changes
associated with weightlessness and those occurring in response to bed-
rest since bedrest has been considered an analog for weightlessness
a
The protocol incorporated the experimental systems designed for Skylab
while using a bedrest period similar in duration to the length of Apollo
missions. This papers reports results from these exercise res ponse studies.
Methods
Six male subjects were selected for age and weight similarity to
astronauts as well as for their apparent psychological suitability for
-	
u	
9
bedrest studies. A brief anthropometric description of the subjects is
given in Table 1. The subjects were maintained on a Skylab diet from
3 weeks prior to bedrest until -2 weeks following bedrest. Since
f'
t	 the Apollo and the Skylab flight crews contained three men each, the
subjects were divided into two groups of three men. The exercise
3
--	 — --	 - 
A
G3
2stress test schedules were those that we employed pre- and postflight
during Skylab. Four baseline tests were obtained prior to bedrest.
The subjects were then placed in standard hospital beds and b p drested for
14 days. The subjects were free to move in the horizontal plane during
bedrest but vertical mobility was restricted to permit only rising up onto
one elbow or lying in the horizontal plane with the head supported by no
more than two standard hospital pillows.
The subjects were stress tested immediately upon completion of bedrest
(BR+O) and on the two subsequent days (BR+1 and BR+2)._ All subjects
were tested 7 days following end of bedrest (BR+7). Two subjects
04 and #5) were tested again 14 days post-bedrest because their heart
rates remained elevated at BR+7. The experiment hardware and protocol
were described in detail previously (2).
All data from the initial baseline test were omitted from statis-
tical analyses because most subjects showed signs of anxiety reactions
as evidenced by elevated heart rates and systolic blood pressures. In
general, all 5-minutes of rest data from each test were used to compute	
1
means and standard deviations for each parameter. Data from the final
3-minutes at each exercise level were used to compute means for each
parameter and each subject on each test day. Mean data from the last
three baseline tests on each subject were lumped to determine. overall
'	 group's means and standard deviations for the group pre-bedrest responses
for each parameter. The paired t-test was used to evaluate statistical
i	 significance in the comparison of pre- bedrest responses with those
obtained post
-bedrest. This data anlysis scheme is comparable to that
	 3
U5
3
used for Skylab.	 i
Systolic time intervals (STI) were derived from simultar.cous strip-
chart recordings (chart speed = 100 mm per second) of the el&.Lrocardiogram,
vibrocardiogram, and carotid pulse trace. Each subject was monitored
continuously. Systolic time interval data were obtained between the
third and fifth minute at each protocol level. Satisfactory STI's were
obtained from only four subjects.
The following STI measurements were computed:
i
1. The QS2 interval (onset of Q-wave of ECG to the second
d	 e vibrocardio soun  of th 	 ramg
2. LVET (left ventricular ejection time) obtained from the
carotid pulse wave
3. PEP (pre-ejection period) = [QS2 - LVET]
4. IVCT (isovolumetric contraction time) = [time from the
first to the second sound	 LVET]
QS2, EVT, and PEP are functions of heart rate. The following
regression equations obtained by Weissler et , al. (6) were used to
correct the STI measurements for heart rate (hr).
QS2c	 QS 2 + 2.1 hr
i	 LVETC= LVET + 1,.7 hr
	PEPC _ PEP + 0.4 hr	
'.
The ratio PEP/LVET which 'has`been demonstreted`to be an indictor of
_i
ventricular function was also computed.
Results
Table 2 summarizes the statistically significant changes in heart
rate,, blood pressure, and stroke volume observed post-bedrest. Heart
rates were elevated at rest and at all exercise levels immediately
f
. . . ..........
ICG
4
following 14-days of bedrest. Diastolic blood pressure (DBP) and mean
arterial pressure (MAP) were elevated at rest and at both 25% 
V02 max
and 50% 
V02 max but not at 75% V02 
max' Mean cardiac exercise stroke
volume ^,ias significantly reduced immediately post-bedrest. T'-2 group
mean values for all the above parameters had reverted to norwal by the
day following the end of bedrest.
Table 3 summarizes the group mean STI measurements made pre-bedrest
and the percent changes noted immediately post-bedrest (BR+O). The
immediate post-bedrest sTi/s indicated a slightly reduced ejection'time
(not statistically significant) and an increased pre-ejection period.
Discussion
Many similarities between the physiological responses to space
flight and bedrest became apparent when comparing results from the present
-if14-day bedrest study -Co the Apollo postflight data reported 1- Rummel
et al_. (2,3). First and most striking is the fact that stati-Itically
significant changes observed on BR-O and those observed immediately
postflight'; (R+O) generally returned to normal within 24 hours. Resting
heart rates were found to be statistically significantly elevated
/viatt work)during both BR+O and R+O tests. Mechanical efficiency (V02
was unchanged for both the Apollo crewmen and the bedrest subjects. Because
there were no changes in mechanical efficiency following either bedrest or
space flight, it was possible to compare several other physiological para-
meters in terms of their relationship to heart rate. For example, oxygen
pulse
	
	
/heart beat) was significantly reduced (p < 0.05) at a heart rate(V02
1C 7.
5
x
of 160 beats/min on recovery datr (R+0) following Apollo space flights.
Similarly, bedrest subjects had significantly elevated heart rates o
BR+O at each protocol level implying reduced oxygen pulse vales.
Heart rate was a dependent variable in Skylab where we used set
work levels approximating 25%, 50%, and 75% VO2 
max 
levels fct , each
crewman. Heart rate was the controlled variable during Apollo testing,
A comparison of blood pressure and cardiac output changes noted in ;)th
studies relies upon the previously mentioned fact that no mechanical
efficiency changes were seen during either study. The group roean heart
rate for level three exercise on BR+O was 153.9 ± 7.4 beats/min which is
similar to the 160 beats/min value attained during Apollo R+O tests.
Group mean heart rate was elevated 15 beats/min, relative to rjre-bedrest,
at 75% VO2 max on BR+O. The group ►nean heart rate at 50% 
V02max on
BR+O was the same as that observed at 75% V02 
max 
prior to bedrest (146
beats/min). The correspcnding group mean systolic blood pressures (SBP)	 1.
were 167 mmHG at 50% V02 
max 
on BR+O and 173 mmHg at 75% V02 max prior
to bedrest. Based upon these data it appears that SBP was slightly
reduced for a given heart rate l evel on BR+n rel ati ve to pre-bedrest.
Apollo crewmen had substantially reduced SBP (-10%) on R+O at a heart	 3
►3
rate of 160 beats/min. Diastolic blood pressure (DBP) was found to be
reduced following the early Apollo -Flights (2), but apparently was
unchanged following the late Apollo flights (3). Diastolic brood
pressure was significantly elevated post-bedrest (BR+O) at 25% V02 max
and at 50% V02max. The parallel increases in SBP and DBP observed on
BR+O resulted in significant increases in mean arterial pressure (MAP),
g^
s
f6
l
Reduced exercise stroke volume was compensated by tachycardia in both
Apollo and bedrest subjects.
A reduced end-diastolic volume or decreased cardiac muscle con--
tractility could have produced the STI changes noted on BR+O. All
STI's returned to pre-bedrest values by BR+l. There is no evidence to
d
support the premise of long term change in cardiac contractility. A
change in total blood volume is the most plausible explanation for
reduced left ventricular end-diastolic volume which in turn could lead
to the STI changes that were observed
In summary, there was a general correspondence between the exercise
1
stress responses of six subjects following 14-days of bedrest and those
of 27 Apollo crewmen following their 10-12 day missions. The basic
protocol difference (set work levels vs_. set heart rate lever) precluded
a more rigorous comparison of most physiological parameters. In general
our observations are similar to those of Hyatt et al. (l) and Saltin
	 i
r
et al. (5) following their bedrest studies
E	 ;.
F
9
s
j
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TABLE l
t Subject Number Ht (cm) Wt (k9) Age	 (yt^^)
1 180 68.6 32
2 183 71.4 27
3 178 68.9 37
4 173 65.5 24
5 170 80.6 31
6 168 63.6 30
Group X + SD 175.3 69.8 30.2j
+6 +6.0 +4.5
a.
iTABLE 2
I
RESTINu -
PRE-BEDREST END OF BEDREST
DAY AFTER END
OF BEDREST
VARIABLE PROBABILITY PROBABILITY
MEAN +SD N MEAN LEVEL N MEAN LEVEL N
Sitting Heart Rate 82.0 +5.4 18 98.3 P < .005 6 83.3 NS 6
(Beats/Min)
Diastolic Blood
 63.9 +8.3 17 75.0 P < .01 6 66.0 NS 6(mmHg)Pressure - -
Mean Arterial
Pressure (mmHg) 78.7 +8.2
-
17 89.2 P <
-
.001 6 80.8 NS 6
' EXERCISE STRESS
Heart Rate } ^
F- a( Beats/Min)
@25%V02 max 101.2" +4.9 18 119.3 P < .001 6 103.1 NS 6
@50%V02 max 124.2 +7.2 18 145.9 P < .001 6 128.4 NS 6
@75% VD max2 144.4 +7.8 17 i58.9 P <
-
.001 4 152.2 NS 6
E
Diastolic Blood
!
Pressure (mmHg)
@25% V02max 58.2 +7.6 17 70.0 P < .02 6 61.3 NS 6
@50% 
V02 
max 60.9 +7.5 16 72.2 P < .001 6 66.2 NS 6
Mean Arterial
Pressure (n-nHg)
@25% Vo2max 84.6 +9.2 6 97.5 P .01 6 89 NS '6
@50% V02 max 93.1
±5.7 6 103.7 P <_ .02 6 95.9 NS 6
Exercise Stroke
Volume (ml) 77.5 +6.4- 6 64.2 P <- .0I 6 ^	 71.8 NS 6
VARIABLE
PRE-
BEDREST
POST-
BEDREST
%G
PRE-
BEDREST
POST-
BEDREST
%G
PRE-
BEDREST
POST-
BEDREST
%A
PRE-	 POST-
BEDREST	 BEDREST
to
QS 2c 51`4msec +1% 526msec -3% 534msec -2% 547msec NC
LVETc 38 msec -2% 404msec 15% 413msec -3% 413msec -3%
PEP 135msec *+10% 125msec *+8% 125msec NC 125msec +6%c
IVCT 42msec NC 30msec +20% {	 25msec -10% 21msec NC
PEP/LVET 0.424 *+29% 0.377 +30% 0.382 +13% 0.375 +27%

:	 r
{	 r	
4
a
{
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SKYLAB SIMULATION FOURTEEN-DAY BEDREST
HEMATOLOGY AND IMMUNOLOGY STUDIES
Stepherr L. Kimzey
r
The purpose of these studies was to compare the effect of a 14-day
i
bedrest exposure on selected hematologic and immunologic parameters in
healthy adult male subjects with, changes observed during the Skylab
flights.	 The tests and procedures employed were identical to those
conducted as part of the Skylab M112 and M115 Experiments protocols.
Blood Sampling Schedule.	 Blood samples were collected from the subjects
during the pre-bedrest phase, bedrest period, and post-bedrest according
to the general schedule outline in Table I. 	 This table also indicates
the distribution of blood samples among.the various experiments. 	 The
actual volumes of blood withdrawn and dates for sampling each group of
subjects, are listed in Table II. 
All samples were withdrawn from the vein with the subject in a
fasting state and after he had been supine for at _least 15 minutes (30'
minutes on days fluid compartments were to be measured).	 Different
anticoagulants were used, depending upon the assay to be conducted;
however, all samples were processed or stabilized within minutes of
collection.
`	 Methods.	 Standard hematologic techniques were applied for measurement
of routine parameters.	 Red cell counts were determined using an
electronic counter (Coulter) and hemoglobin spectrophotometrically using
an IL Coximeter (Model	 182).	 Total serum proteins were measured by
x
i
i
a	 4
1C
refractometry and protein electrophoresis by cellulose acetate strip
electrophoresis. Quantitation of other plasma proteins (immunoglobulins,
haptoglobin, transferrin, ceruloplasmin, alpha-2-macroglobulin, beta-l-
alpha-globulin, alpha-l-acid glycoprotein, alpha-l-antitrypsi4l) was by
the technique of electro-immuno-diffusion (Gill, et al., 1971).
Shape classification of erythrocytes by scanning electron microscopy
was by the technique of Kimzey,tt al. (1974). The red cell potassium
i content and flux into erythrocytes were determined by flame photometry
and isotope ( $5Rb) exchange (Larkin and Kimzey, 1972).
Routine Hematology_. The routine hematology data are summarized in
!	 Tables III	 VIII	 All of the changes noted during the bedrest and
post-bedrest periods are associated with the changing states of plasma
volume and red cell mass. The hemoglobin concentration was elevated in
1 four of the six subjects during the bedrest, and decreased rapidly in
all six immediately post-bedrest (Figure 1). These results are similar
to those observed in Skylab 3 and 4 (Kimzey, 1975) except that the increase z
in hemoglobin concentration following exposure to weightlessness Was
{
more pronounced than observed in this bedrest study. In spite of the
decline in red cell mass reported during the bedrest (Johnson 1975),
a
i
the reticulocyte count showed no consistent pattern throughout the
study (Figure 2). The absolute reticulocyte count and reticulocyte
3
index also remained within the pre-bedrest limits for each subject.
No changes were noted in the white blood cell count or differential,
or in theplatelet count during the study.
i
{
i^	 j	 1
•	
3
Special Hematology. Classification of red cell shapes by scanning electron
microscopy demonstrated no significant alterations in the distribution of
erythrocyte shapes during this study (Table IX). Changes in red cell
shape distributions have been observed previously during the Skylab
flights. However, most of the changes appeared to be related to mission
duration, and were significant only after 28 days in space.,;tHerefore,
a 2-week bedrest exposure might not be sufficient time for any changes
to become significant.
These studies would seem to indicate that during 14 days.,of bedrest,
there were no significant alterations in the hematological parameters
discussed above, except those associated with variations in red cell mass
3
and/or plasma volume.
i
ImmunologX Studies. The humoral immunology data are summarized in
Tables XI-XVI. There were individual variations in the concentration
of serum proteins and particularly albumin, but no consistent trend was
evident. The changes noted were most likely the result of variations
in plasma volume during the bedrest and post-bedrest period.
7
Haptoglobin, ceruloplasmin, and A2-macroglobulin did not change.
However, there was a slight decrease in transferrin in 4 of 6 subjects
during the bedrest period. The cause and significance of this observation.
are unknown at this time.
Thus it would appear that there were no consistent abnormalities'
relative to the humoral immune system as a result of exposure to bedrest
for 14 days. There was a slight depression in the transferrin levels
which cannot be explained at the present time. These patterns are con-
sistent with the results of Apollo and Skylab, where individual variations
1in plasma proteins were observed (particularly in Apollo where haptoglobin
and alpha-2-macroglobin were frequently elevated postflight),--but there
were no indications to suggest that the humoral immune system' S, functional	 g
capacity reacted to or was compromised by the weightless environment,
Summary
The results of the studies of selected hematologic and immunologic
parameters during a relatively short (14-day) bedrest exposure suggest
no significant changes, except those related to vascular fluid shifts.
These data are comparable to those from other bedrest studies of the
same duration. All of the changes reported in the Skylab experiment
resulted from exposure of 2 to 6 times the duration of this test. It
is possible that a bedrest exposure of longer duration would also cause
red cell morphological and functional alterations similar to those
characteristic of space flight. It is also conceivable that the
"simulated" weightlessness of bedrest does not result in the same stresses
as the weightlessness of space flight.
I
I
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Table I
BLOOD SAMPLING SCHEDULE
SKYLAB SIMULATION BEDREST STUDY
Sample Day Pre-Bed rest Bedrest Post-Bedrest
Experiment ` 30 21	 20 7 1 2	 7	 13 0, 1 3 7 14
M071
Biochemistry Studies 15 15 15 15 15 15 15 15
M073
!	 Endocrinology Studyr 25 25 25 25 25 25 25 25
r
M112
Immunology Studies 10 10 10 10 10 10
M113
Blood Volume Studies 20* 10 10 10 2e 10 10 10 10
M115
Hematology Studies 15 15	 5 15 15 15 15 5 15 15
Total Volume
ml/man/day 65 , 85 , 15 65 75 15	 15 ''3 85 65 65 35 65
Total Volume
ml/man/period 305 60 315
*Radioisotope Studies
i
.__-4
	BLOOD SAMPI_L FLOW SHEET 	 ^._... _
M071	 M073	 M112	 M113	 M115
t,
j
y
CLOT	 NA-EDTA	 HEPARIN	 HEPARIN	 EDTA, HEPARIN GLUT.
i	 (IN ICE)	 (STERILE)
PLN	 L LS
	 1►'
CELLULAR	 BLOOD	 ROUTINE	 RBC SHAPE
IMMUNOLOGY	 VOLUME
	
HEMAT.
	 CLASS.
CHEMISTRY, PLASMA	 CELLS	 --
IMMUNOLOGY
E
ENDOCRINOLOGY	 ELECTROLYTES,
METABOLITES
	
ESF	 K FLUX
k	 ,
Table IA
j,'
S	
p
Table II
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SKYLAS SIMULATION BEDREST STUDY I
a
BLOOD SAMPLE SCHEDULE
BLOOD SAMPLE SUBJECTS 1-3 SUBJECTS 4-6
MISSION DAY	 VOLUME DRAW	 DATE DRAW  DATE_
F-30 62 23 April e3 April
F-21 93 2 May ,-,2 May
F-20 5 3 May 3 May
F-7 70	 r 9 May 9 May
F-1 75 19 May 22 May	 1
TOTAL	 305 1
BR2 24 May30 21 May
BR8 20 27 May 30 May
BR14 35 2 June 5 June
TOTAL	 85 .
R+0 6 June90 3 June
R+l 50 4 June 7 June
R+3 80 6 June 9 June
R+6 40 9 June 12 June
R+13 60 16 June 19 June	
.,
F
TOTAL_	 320
OVERALL TOTAL'-	 710
f,
E
r	
^
. 't.
Table III
HEMATOLOGY SUMMARY DATA.
SUBJECT PREBEDREST' BEDREST POST	 BEDREST
NO.	 1 MEAN	 S.D. MEAN '	 F 'S.D. R+O R+1 R+3 R+6 R+13
RB C 4.43	 0.13" 4.80	 0.27 4.72 4.56 4.25 4.33 4.41
Retie 1.1	 0.3 1.0	 0.2 1.0 0.6 0.8 1.2 2.0 -	 ----
Hb 13.0	 0.4 14.2	 14.0 14.2 14.0 12.9 12.2 12.7
Het 39.7	 1.3 43.3	 2.1 43 41 ?8 38 39
WBC 4815'	 221 5333	 153 5500 6100 5300 4700 5600
Neut 2035	 177 2669	 335 3080 2867 2226 2256 3248
v
Lymph 2483	 245 2272	 372 2090 2806 2809 2209 2016 i
i
Table IV
HEMATOLOGY SUMMARY DATA
SUBJECT PREBEDREST'	 - BEDREST POST	 BEDREST
NO.	 2. MEAN S.D. MEAN	 S.JD. R+O R+1 R+3 R+6 R+13
RBC X4,53 ,^	 0.15 4.75	 0.13 4.66 4.59 4.25 4.67 4.60
Retic 1.5 0.3 2.1	 0.2 1.2 1.2 0.9 1.9 1.2
Hb 14.4 0.4 15.1	 0.4 14.8 14.4 13.8 14.6 14.4
Hct 41.9 1.0 44.3	 1.1 44. 41 41 43.5 42
WBC 5100 294 5200	 200 4300 3700 4200 5300 5000
Neut 3087 455 2947	 433' 1978 1813 2394 2756 2400
Lymph 1812 384 2027	 320 2193 1776 1638 2385 2450
k
f
p
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SUBJECT PREBEDREST' BEDREST . POST	 BEDREST
NO.	 3 MEAN S.D. MEAN 'SID. R+O R+1 R+3 R+6 R+13
RBC 4.83 0.20 5.03 0.02 4.94 4.70 4.53 4.53 4.48
Retic 0.7 0.2 0.7 0.1 0.8 1.0 1.6 0.8 0.9
Hb 15.4 0.4 15.7 0.2 15.6 15.0 14.3 14.4 13.8
Hct 46.0 0.7 47.3 0.6 46 44 42 42.5 41
WBC 8150 311 8166 569 7700 10000 9700 8300 7400
Neut 4313 440 3952 312 3619 4200 4656 5229 3922
Lymph 3590 454 3719 714 3388 5300 4850 2739 3330 J
Table VT
HEMATOLOGY SUMMARY DATA ..
$UBJECT PREBEDREST' BEDREST POST	 BEDREST
NO.	 4- t MEAN S. D. MEAN	 ,S .III. R+0 R+1 R+3 R+6 R+13
RBC 4.99 0.18 4.87	 0.30 4.88 4.69 4.57 4.60 4.59
Retic 1.1 0.4 1.0	 0.1 0.8 1.0 1.5 1.2 1.2
Hb 15.1 0.4 15.0	 0.4 14.9 13.9 14.0 13.3 13.5
'Hct 44.5 1.3 45.2	 0.8 45 42 42 41 41
IBC 6050 656 6167	 404 6400 6600 4700 5800 5400
Neut 4064 606 3823	 316 3456 4290 2820 3538 2916
Lymph 1819 194 2075	 254 2688 2046 1692 1914 2322
l
1
Table VII
HEMATOLOGY SUMMARY DATA
SUBJECT PREBEDREST' BEDREST POST	 BEDREST
N0. 5 ,MEAN S.O: MEAN	 S.D. R+0 R+1 R+3 R+6 R+13
RBG 4.92 0.21 4.69	 0.34 4.86 4.53 4.41 4.55 4.42
Retc 1.0 0.1 1.6	 0.4 1.3 1.5 1.5 1.5 2.1
Hb 14.2 0.5 14.3	 0.1 14.1 13.1 13.0 13.1 12.8
Hct 42.1 0.8 42.3	 0.6 43 38 38 39 39
WBC 4500 216 5000	 458 5400, 5500 5300 5500 4600
Neut 2387 552 2692	 434 2754 2970 2650 2860 1610 lu
Lymph ,1607 367' 2113	 417 2106 1925 2279 2310 2484
j
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Table VIII
HEMATOLOGY SUMMARY DATA
:SUBJECT PREBEDREST' BEDREST . POST	 BEDREST
NO.	 6. ,MEAN	 S.D. MEAN	 S.b R+O R+1 R+3 R+6 R+13t
RBE 4.48	 0.18 4.9J	 0.07 4.86 4.39 4.30 4.29 4.28
Retic 0.7	 0.1 1.1	 0-.3
1.0 1_2 1.2 1.5 1.1	 i
Hb 13.2	 0.3 14.2	 0.1 13.9 12.9 12.5 12.3 12.3
Hct 39.0	 0.0 41.3	 0.6 41 38 37 36 37
WBC 4200	 216 5000	 436 5100 5300 5200 4500 4200
Neut 1798	 162 2251	 340 2397 2597 2912 1845 1512
Lymph 2268	 117 2554	 327 2550 2544 2132 2520 2604
RED BLOOD CELL CLASSI'FICATIO'N
PREBEDREST BEDREST POST BEDREST•
Mean D. Mean S.D.. Mean S.D.
Discocyte 82.52 5.52 73.86 6.75 72.92 7.55
Knizocyte 2.70 1.41, 2.83 2.,45 3.97 2.16
Stomatocyte 3.63 2.21 5„17 2.99 4.14 3.11
`	 Spherocyte 7.86 4.82 10.86 4.69 11.68 5.00
Codocyte 0.53 0.83 1.53 1.76 1.64 2.08
Echinocyte
F	 ,
r
2.10 1.29 4.22 3.17 4.28 2.42
_Table X
1
K !FLUX I.N RBC
P.REBEQREST POST BEDRESTI_
Mean	 S.D. Mean S.D.
Total (Meq/L RBC/Hr) 1.88	 0.35 1,89 0;48
Ouabain-Insensitive 0.53	 0.13 0.45 0.06
(Meq/L RBC/Hr)
Active (Meq/L RBC/Hr) 1.36	 0.40 1.46 0.50
RBC K (Meq/L RBC) 101.00	 6.13 99.91 3.85	 j
gerum K (Meq/L) 4.19
	
0.25 4.19 0.22
d
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Table
	
XI
IMMUNOLOGY SUMMARY DATA .•
PREBEDREST BEDREST POST BEDREST
Subject ------
No,	 1 Mean S.D. Mean	 S.D. R+O R+3 R+6 R+13f t
Protein, 6.5 0 6.73	 0.30 6.7 6.1 6.2 6.5
Albumin 4.13 0.11 4.06	 0.32 3.6 3.7 3.8 3.2
Al-M 0.20 .00 0.20	 .00 0.3. 0.2 0.2 0.3
A2-M 0.50 0 0.53	 .05 0.6 0.5 0.4 0.7
B-M 0.63 .-05 0.63	 .05 0.9 0.7 0.7 0.8
G-M 1.0 ,05 1.3	 .00 1.3 1.0 1.1 1.5
' Transferin 357.66 12.5 296.33	 57.35 273 258 249 311
Hatog1obin 103.33 2.3 112.33	 10.01 96 97 106 110
Ceruloplasmin_ 27.00 2.6 34.33	 2.88 32 25 25 28	 ^.^
A2-Macro 111.66 8.0 121.33	 30.28 135 146 139 125
Iw-nmunoglobin
I 9A 137..00 7.81 132.00
	 10.58 146 142 159 143
IgG 1197.00 19.07 1061.00	 83.13 •1219 1197 1175 1231
IgM 111.66, 9.29 113.33	 _16.50 135 133 139 126	 ----^
IgD 6.0 0 6.33	 0.577 5 6 6 7
I
..... ,-	 .wa...-....a...._......:..vuv ..	 .r.....:..	 ......	 - '.	 _.. _.^_	 _...__._,. _._..^.. ^.,,_^__ u ^..i..ru......a.__.w....^......e.....r.^..._.. -	 .u...v-	 _
aTable
	
XII
IMMUNOLOGY SUMMARY DATA.-
PREBEDREST BEDREST POST BEDPEST
,Subject
No.	 2 Mean	 - S.D. 'Mean ,	 S.D. R+0 R+3 R+6 R+13
Protein 7.16 0.05 7.0
	 0.15 7.1 6.6 7.3 6.9
Albumin 4.50 0 4.23	 0.15 4.1 4.3 4.6 3.7
Al-M 0.23 0.05 0.20	 .00 0.3 0.2 0.2 0.3
A2-M 0.56 0.05 0.56	 0.05 0.6 0.4 0.5 0.6
B -M 0.70 0 0.66	 0.05 0.9 0.6 0.7 0.8
G-M' 1.16 0.05 1.40	 0 1.3 1.1 1.3 1.5
Transferin 320.33 2.30 254.66	 37.31 273 266 261 228
Haptoglobin 100.33 8.14 102.00	 0 94 102 106 91
Ceruloplasmin 24.66 1.15 31.00	 5.56 30 29 30 27
A2-Macro -. 121.66 15.30 122.33	 32.80 123 143 146 133
Immunogl obi n
IgA 153.33 5_.13 167.66	 24.58 199 175 159 149
r	 IgG 1138.00	 - 25.12 1005.,33	 33.60 1165 1242 1331 1.109
IgM' 103.66 4.04 99.33	 3.51 121 121 139 130
I gD
P
I.
5.66' 0.57 5.0	 0 6 5 5 5
f
Table XIII
IMMUNOLOGY SUMMARY DATA- -
PREBEDREST BEDREST POST` BEDREST
Subject
'No.	 3 Mean S.D. Mean ', S.D. R+0 R+3 R+6 R+13
Protein 7.03 0.20 7.16 0.05 7.1 6.6 6,7 6.6
Albumin 4.43 0.11 4.33 0.15 4.2 4.4 4.2 3.8
Al-M 0.26 0.05 0,26 0.05 0.3 0.2 0.2 0.3
A2-M 0.60 0 0.60 0.09 0.7 0.5 0.5 0.6
B-M 0.83 0.05 0.70 0 0.8 0.7 0.8 0.8
G-M 0.90 .00 1.26 0.05 1.1 0.8 1.0 1.1
Transferin 323:00 17.69 275..00 47.50 266 274 257 212
Haptoglobin 121.00 1.73 125.66 20.55 106 104 121 124
Ceruloplasmin 24.00 3.46 37.66 4.04 30 25 30 32
A2-Macro,: 104.33 3.51 113.00 17.34 146 150 145 133	 f^
a
Immunoglobin
IgA 147:33 5.68 158.66 24.94 146 142 132 133
IgG 1058.33 33.29 939.00 45.03 1219 1264 1219 932
IgM 107.66, 3,51 97.0 6.0 114 ill 132 111
IgD 5.33 0.57 5.0 0 6 5 5 5
i'
1;	 Pww-
Table XIS'
IMMUNOLOGY SUMMARY DATA-0
PREBEDREST BEDREST POST-BEDRESTSubject
No.	 4 Mean S.D. Mean S.D. R+0 R+3 R+6
^.
R+13
Protein	 .. 7.2 0.11 7.26 0.11 6.9 6.6 6.8 6.6
Albumin 4.43 0.28 4.36 0.20 4.6 4.3 4.5 3.8
A1-M 0.23 0.05 0.23 0.05 0.2 0.2 0.2 0.3
A2-M 0.63 0.05 0.60 0.10 0.5 0.5 0.5 0.6
B-M 0.80 0.00 0.70 0 0.7 0.7 0.7 0.8
G-M 1.13 0.05 1.36 0.05 0.9 0.9 0.9 1.1
Transferin 347.66 12.58 248.33 19.13 312 283 283 190
Haptoglobin 112.00 2.00 137.66 4.61 118 122 136 147	 ^..a
Ceruloplasmin 22.66 1.52 30.33 0.577 24 27 26 30
A2-Macro •. 128.66 9.07 113.00 17.57 136 120 132 132	 2V
Immunoglobin
IgA 170.00 8.54 207.66 16.19 166 156 176 199
IgG 1186.0 33.00 987.00 68.69 1131 1098 1109 1131
IgM 118.33•, 2.51 95.66 11.59 125 114 104 120
^	
Ig D 6.66 0.57 5.0 0 5 5 5 6
-	 1
r
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Table XV
IMMUNOLOGY SUMMARY DATA ••
PREBEDREST BEDREST POST'-.BEDRESTSubject -
No.	 5 Mean S.D. Mean S.D. R+0 R+3 R+6 R+13	 _w _
t
s
..
Protein, `-	 6.93 0.15 6.76 0.11 6.5 6.4 6.6 6.3
Albumin 4.26 0.3 4.03 0.25 4.2 4.1 4.2 3.6
Al -M 0.23 0.05 0.20 .00 0.2 0.2 0.2 0.2
A2-M 0.60 0.10 0.56 .05 0.5 0.5 0.6 0.6
B -M 0.76 0.05 0.70 0 0.7 0.7 0.7 0.8
G-M 1.0 0.11 1.26 0.11 0.9 0.9, 0.9 1.1
Transferin 321.66 4.61 287.66 30.85 281 291 311 228
Haptoglobin 136.00 5.29 132.66 12.89 104 106 115 137
Ceruloplasmin 21.33 0.577 30.33 2.88 28 26 30 31	 rJ
A2-Macro- • , 156.33 10.50 121.66 21.12 139 117 113 126
Immunogiobin
IgA 156.0 6.0 188.0 34.82 149 143 156 133
IgG 1123.66 25.40 961.0 128.17 , .1109 1109 1064 932
IgM 126.33• 763 92.33 6.42 140 123 127 102
IgD 7.0 0 6.0 0 5 5 5 5
-
Table XVI
1
IMMUNOLOGY SUMMARY DATA
PREBEDREST BEDREST POST'_SEDREST
Subject -
No.	 6 Mean S.D. Mean S.D. R+0 R+3 R+6 R+13
Protein 7.13 0.15 7.43 0.11 7.1 6.8 7 6.7
Albumin 4.36 0.25 4.26 0.05 4.5 4.2 4.2 3.8	
___ f
AI=M 0.20 .00 0.23 0.05 0.2 0.2 0.2 0.3
A2-M 0.60 0.10 0.66 0.05 0.5 0.5 0.7 0.6
B.-M 0.80 0.10 0.90 .00 0.8 -0.9 0.9 0.8	 i
G-M 1.16 0.05 1.36 0.05 1.1 1 1 1.2
Transferin 356.00 6.55 339..33 30.59 342 358 335 327
Naptoglobin 130.66 4.16 135.00 11.35 122 138 139. 143	 }-^
Ceru 1 opl asmi n 26.00 1.73 34.33 4.93 28 25 30 32	 ^^
A2-Macro • 134.33 7.57 113.00 17.57 132 136 136 114
Immunoglobin
IgA 173.66 6.80 15&00 43.86 175 166 159 143
IgG 1042.00 19.06 990.66 111.72 1042 998 1219 1153
IgM 114.00 2.64 95.0 6.92 135 132 128 119y I gD 8.66 0..57 9.0 0 7 6 7 8
t ••
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Cellular Immune Response of Six Healthy
Subjects during Fourteen Days of Bedrest
B. Sue Criswell
Introduction:
The cellular immune response of six volunteers was studied before
and after 14 days of bedrest. The findings from this study are to be
correlated in the future with lymphocytic changes noted during the Skylab
i
spaceflight. Briefly, the functional capacity of Lymphricytes at splashdown
of Skylab III and IV was depressed along with a suppression in the T
Lymphocyte numbers. No such changes were noted following bedrest
for a 14 day period.
Methods and Materials:
Samples of heparinized peripheral venous blood (10 cc) were
obtained and processed within 1 hr of collection. Before separation,
total leukocyte (WBC) counts were performed using a hemacytometer
and/or a Coulter Counter and differential counts were determined using
slide preparations stained with Wright's Stain.
Lymphocyte Preparation:
Ficoll-Isopaque_ gradients. Lymphocytes were also separated by
i
Ficoll-Isopaque gradient centrifugation according to the method of
Boyum (1968). Cells in the resulting suspension of mononuclear
cells were washed 3 times in MEM and then adjusted to a final
6concentration of 1 x 10 per ml.
{
ii
Lymphocyte classification:
B Lymphocyte distributions were determined by enumerating the
percent of 200 mononuclear cells with surface immunoglobulins detected
by immunofluorescent antibody technique described previously (DeFazio
•	 et al., 1975).
E rosette forming lymphocytes (T cells) were determined by the
method of Jondahl et al. (1972). One x 10 6 lymphocytes were mixed
in 0.25 ml MEM and added to 0 `.25 ml of a 0.5% sheep red blood
cell (SRBC) suspension. After mixing, the tubes were incubated at
370  for 5 min, then centrifuged at 500 g for 3 min, and incubated
in ice water for 2 hrs. Approximately half of the supernatant was removed
and the top layer of cells gently resuspended, 200 lymphocytes were
counted with 3 or more adhering SRBC used as criteria for E rosetted
3
lymphocyte. ( P X11 A%)
Lymphocyte responsiveness in micro-culture to PHA, Pokeweed fPW),
and Concanavalin A (Con A):
Purified lymphocytes (1 x 10 5
 /ml) in minimum essential medium
(MEM) containing 40 0/o fetal calf serum (FCS) were placed in. culture
plates, and the antigens were diluted in MEM containing Pen-Strep
and L-glutamire in the following concentrations: PHA — 0.01 ml/ml
MEM PWM 0.01 ml and 0.05 ml/ml MEM, Con A -` 25 µg and
50 µg/ml MEM. The diluted antigens in (0.1 ml) aliquots in duplicate
4-
I<
2.
a
3.
were placed in the appropriate well. The cultures were incubated in a
humidified CO 2 atmosphere at 37 0C for 3 days for PHA and 5 days
for Con A and PWM. On the day of harvest, samples were treated as
described below for the influenza virus antigen cultures.
Lymphocyte responsiveness to influenza virus antigen by thymidine
incorporation:
An inactivated monovalent type A influenza virus vaccine containing
1600 CCA units per ml of a Hong Kong strain (H3N2) was dialyzed
against phosphate-buffered saline (PBS) and stored at -70°C until used
for tests. Separated lymphocytes were added in 0.1 ml aliquots in
triplicate for each dilution of influenza antigen and the cultures incubated
in a humidified CO 2 incubator at 37 0C for 1, 2, or 3 days._ On the
day of harvest, the cells were pulsed for 2 hours with 1 mCi of methyl
3H-thymidine and then harvested with the MASH II automated harvester
(Microbiological Associates, Bethesda, Maryland) onto glass fiber filter
strips and then counted in a liquid scintillation counter (Packard Instruments, 	 v
Downer's Grove, Illinois). Data were expressed as counts per minute
a
(CPM) per 10 6 lymphocytes,- and the stimulated index (SI) was calculated
by dividing the mean result for stimulated cultures by that for the unstimulated 	 a
cultures. Allantoic`fluid was used separately as a control on reactivity
of each individual to chick embryo proteins.
E
f^
	 3
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Results:
White blood cell quantitation:
Figure 1 shows the mean and one standard deviation of t
white blood cell count on each perspective day pre and post—bed
No significant change was found on any occasion.
Lymphocyte classification:
Figure 2 shows the response of the total Iymphocytic pop
in the peripheral blood. As seen,_ no changes occurred.
Figure 3 displays the results of the B lymphocytes which
fluctions during the bedrest period. Though still within the normal
ranges for B cells (range 1.97-7.91) changes occurred. the day prior
to going to bed.
Figure 4 shows the T lymphocyte counts which did not change
during the bedrest period.
Lymphocyte ` responsiveness in culture to PHA, PW, and Con A:
Table 1 shows the culture findings for the nonspecific mitogens.
The stimulation indexes for all mitogens dropped at D + 0 and following
the start of bedrest. PHA and Con A cultures showed the most
significant changes with PW cultures returning very rapidly to baseline
levels. Even at the reduced Levels of stimulation, however, these
indexes still fall within normal ranges of stimulation.`
	
i
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Influenza virus antigen stimulation:
Two of the six volunteers responded to influenza virus antigen
in cultures. These two subjects were positive on two separate days.
Since this antigen is quite variable in response patterns even in known
and diagnosed influenza illnesses, changes 'or losses in reactivity are
not significant. Total lack of reactivity may reflect influenza susceptibility.
Discussion:
No statistically significant changes were found as a result of
14 days of bedrest in the cellular immune system of the six individual's.
Trends were seen in the stimulation indexes toward a decrease in
reactivity; however because of the rapid exchange of cells between
different compartments in the body variation in the indexes may be
expected.
It has been noted during spaceflight in Skylab IV that PHA
l
responsiveness-of lymphocytes was extremely depressed on splashdown.
If bedrest is a simulation of zero gravity conditions, one might theorize
a
that since nosignificant changes occurred in bedrest, then zero gravity
may not have been the cause of the earlier lymphocytic changes. On
the other hand, time in bed as time in space may be the important
factor in initiating changes since both Skylab III and IV were Longer
than ,14 days in duration.
	i	 r
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S ummary:
No significant changes occurred during 14 days of bedrest
in the cellular immune response of 6 normal male volunteers.
Perameters studied were W6C concentrations, lymphocyte numbers,
6 and T lymphocyte distributions in peripheral blood, and lymphocyte
responsiveness to PHA, pokeweed, Concanavalin C, and Influenza
virus antigen.
a
i
a
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iTable 1
Stimulation Indexes for Mitogens
Days of Analyses PHA PW-1
(0.01 ml/ml
MEM)
PW-2
(0.05 ml/ml
MEM
Con-A-1
(25 pg/ml
MEM)
Con A-2
(50 µg/ml
MEM
Pre-bedrest
D-30 64 + 23 30 + 23 37 + 23 117 + 47 59 + 48
D-15 74 +31 36 + 15 23 + 15 52+30 59+24
D-1 25 + 25 79 + 64 19 + 25 56 +32 98 + 112
t
Post-bedrest
D+0 25 +20 17 +12 15 +10 16+12 6 +6
D+3 22 +12 49 +22 23 +8 14+10 9 +5
D+6 12 +1,3 24 +10 21 +10 6+7 5 +4
a
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RED CELL MASS AND BODY VOLUME CHANGES
AFTER 14 DAYS OF BEDREST	 i
Philip C. Johnson, M.D. and Theda Driscoll
Baylor College of Medicine
Houston, Texas
When weighed postlanding, crew members of every space-
flight have lost body weight during their mission. Inflight
measurement of crew members' body masses during Skylab indi-
cates that the weight loss occurs relatively early. Space
and volume studies of Apollo and Skylab crew members which
compare premission values with postmission values indicate
that the weight loss is both a loss of intracellular and
extracellular fluid. These crewmen also showed a dispropor-
tionate loss of red cell mass for the plasma volume lost. (1,2)
The mean values from the Apollo crews 14-17 are a typical
demonstration of this phenomena (Table 9).
Happily these changes are reversed during a relatively
short postmission recovery period, although residual changes 7
may last a month or more. Further study of this fluid and
tissue loss should help determine if counter measures are
indicated for future flights; and from these studies, the 	 j
,i
a
physiology of these rapid changes in fluid volume might be
determined.
The most readily available biological simulation of a
period of weightless flight appears to be a period of bedrest
in which the subjects are not allowed to stand upright during
the study period. Bedrest reproduces many of the cardiovascular
changes found in returning crew members, and it seems to
reproduce the calcium .loss associated with spaceflight.
A two-week bedrest (BR) study has been completed which
attempted to reproduce most of the testing conditions of Skylab
and the last Apollo mission.	 While this study did not reproduce
many mission stresses experienced by the crews, it did faithfully
follow pre- and postflight medical testing profiles so that
direct comparison of the bedrest study results can be made 1
with the medical results from the Skylab and Apollo missions.
METHODS
A brief history and physical for each of the six subjects
and a description of the general experimental design are given
in the introduction.	 The food intake was designed to maintain s
E
body weight.	 Total daily calories exceeded those consumed by
the crew members of many Apollo missions but were not greater
than the caloric intake of Skylab crew members. 	 Electrolyte
intake was regulated as in Skylab producing a metabolic balance 3
study.
` Table 1 contains a listing of the radionuclides used for
these space and vol?.une studies, the dose administered and the
radiation exposure produced.	 Table 2 gives the 'study day each
i test was performed.	 The schedule in Table 2 was designed to
reproduce the protocol used for the Skylab crew members. 	 The
s
P
k
ri	 3
technics for radionuclide determinations have been described
previously. (2) The exact blood sampling schedule and the 	 t
amounts of blood drawn are shown in Table II of Dr. Kimzey's
(M110) hematology report. Shown in Tables 3 and 4 are the
results of the space and volume determinations made on the bed-
rested subjects. At the end of the bedrest study the total body
water (TBW), extracellular fluid_(ECF) and iron turnover doses
were given on the 13th day in the morning ( 7:00 AM) with the
subjects tasting. The subjects remained at bedrest for 24
more hours before the start of the medical testing which included
red cell mass (RCM), plasma volume (PV) and total body exchangeable
potassium (TBEK) . Additional details of these studies are
available in Dr. Leach's report since the space and volume studies
are an integral part of M070.
At the completion of an Apollo or Skylab mission, blood
was drawn at recovery after greeting ceremonies on deck for
the returning crew members. The crew members had been awake
for 8-12 hours performing reentry and recovery chores They
generally had eaten breakfast 4-9 hours before the testing.
The crew members remained quietly recumbent for 30 minutes
before the volume and space studies and for the 30 minute
equilibrium time of the PV, RCM and ECF. After these measure-
ments, the crew members were allowed to be up and about and to
begin lower bodynegative pressure (LBNP) and bicycle ergometry.
The doses for TBW and TBEK were given at the same time as the
r
other radionuclides but require 4-6 hours for TBW and 24-48
i1
IS2
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hours for TBEK prior to equilibrium.
	 A
The major difference between the space and volume studies
postbedrest from those postspaceflight is the amount of stress
the men were subjected to. The PV and RCM were determined for
the bedrested subjects immediately upon awakening after an
overnight sleep and the equilibrium period for the TBW, ECF
and iron turnover did not include the vascular stresses of
upright posture, LBNP and bicycle ergometry.
RESULTS
Tables 3 through 6 show the results of the space and
volume studies. Tables 7 and 8 show the percent change for
each subject and the mean percent change during the study.
Percent change in these studies is defined as the change in
the value compared to the control value 21 days prior to
bedrest.
At the end of bedrest red cell mass had decreased 4.9%
This was less than the 6.9% decrease in plasma volume. Extra
cellular fluid mean decrease was 1.3% All other values
including weight showed less, than a 1% change.- Only the red
cell mass and plasma volume changes are statistically different i
from zero. It can be seen that red cell mass continued to
decrease during the first two weeks of ambulation. This is
in contrast to the plasma volume which increased during that
3
3
5period. By 48 days postbedrest plasma volume had returned to
the prebedrest value while the red cell mass had increased
to above the initial value.
Table 9 compares these mean percent changes with the mean 	 i
percent changes obtained for the crew members of some Apollo
missions. There are significant differences between the two
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situations with the greater change associated with spaceflight.
DISCUSSION
This bedrest study which lasted 14 days was designed to
partially simulate conditions associated with the Skylab
missions. Some differences between bedrest and spaceflight
are obvious such as the lack of weightlessness and acceleration
stress in bedrest. The similarities include the Skylab diet,
electrolyte intake, metabolic balance conditions, and similar
pre- and postmission medical studies. There are other not so
obvious differences. For example, no planned exercise was
performed during bedrest so that the work load of mission
activitiesp was not simulated. The hypobaric atmosphere of
Apollo and Skylab was not simulated nor was the hyperoxic
atmosphere of the Apollo command module. The beginning of 	
-i
bedrest is not associated with tre stomach awareness and
nausea felt during the first few days of weightless flight.
Therefore, voluntary caloric restriction did not occur during
r
the first few days of the bedrest study, while cal
restriction i s a constant feature of a crewman's E
response to spaceflight.
The bedrest study did not attempt to change the circadian
rhythms of the subjects while most space missions are required
to change the day-night cycle to guarantee favorable landing
conditions at the end of the mission. In general, the subjects
were one decade younger than the astronauts. Otherwise they
were of similar-size and relative weight.
Spaceflight obviously causes a loss of body tissues as
is shown by the decrease in weight, TBW, ECF, PV and RCM of
the crew members. (1) The decrease in total body water is
too large to be accounted for by only the extracellular fluid
loss. The 2.7% decrease in ECF would account for only a 1%
decrease in TBW or about one-third of the measured loss. This
occurs even though the diet is adequate as far as the crew
members are concerned. No evidence of tissue loss other than
the red cell mass was noted in the subjects of this bedrest
study. These findings are consistent with other bedrest studies
which show that weight loss does not occur generally. Some
bedrest studies have used exercise programs during the period
of bedrest. it is probable however that the caloric cost of
these inbed exercise regimes is considerably below the caloric
cost of spaceflight activities.
ft
The cause of the red cell mass loss of spaceflight is
still unknown. The loss in Skylab approximated that of
Apollo with a mean red cell mass loss of 11.1 ±1.7%. (2)
However, the various Skylab missions differed considerably
with the least RCM change found after the longest mission.
Reel cell mass had not been determined often after bedrest
using a red cell tracer so the evidence that bedrest causes
a red cell mass decrease is scanty. (3-5) Morse in a study
of Air Force volunteers found a mean RCM decrease of 9.3% at
the end of 35 days of bedrest and a loss 1/3 that large after
a 24-day bedrest. (3) Saltin found a 6.2% decrease in red
cell mass in subjects bedrested for 20 days. (5) In a 6-day
bedre,;t study we found a 2.4% mean decrease in red cell mass.
{
These means are consistently less than the mean change after	 ?
spaceflight.
SMEAT, a 56-day project including a 5 psi atmosphere,
was designed to reproduce the environment of Skylab, but it
did not include weightlessness or bedrest. The three crew
members performed the same type of studies and with the same
equipment used in Skylab. Red call mass loss of 2.7±0.4%
occurred with mean weight loss of 3.7 ±2.0%
In this study the mean red cell mass decrease was greater
13 days after bedrest (-6.5%) than it was at the end of
bedrest (-4.9n) it has been noted by others that the exercise
9
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during the postbedrest period causes a further decrease in
red cell mass. (7) It has been postulated that red cells
are regularly destroyed during exercise. Presumably the lack
of exercise during bedrest conserves fragile red cells which
are more vulnerable to destruction during the early ambulation
period. Addi-'U.Lonal decreases in red, cell mass have not been
found during the first two weeks following return of the
astronauts. (2,8) Whether this indicates that a different
process is operable in the spaceflight induced red cell mass
loss with exercise during flight being great enough to destroy
vulnerable cells, or whether an additional decrease in red
cell mass occurred between the ocean landing and the time when
the red cell mass was measured as it did when we ambulated
these bedrested subjects is unknown since the time course of
the observed spaceflight red cell mass decrease is unknown.
1
While the red cell mass decrease in bedrest seems less
than that of spaceflight, this is not true of plasma volume.
3
a
Generally, plasma volume decreases 10% after several days of
bedrest and continues to decrease slowly thereafter to plateau	 7
at about -20%. (9) The 6.9% decrease found_ in this study while
less than that found in many other bedrest studies is still
	 i
greater than the 4.4% mean decrease of the Apollo crew members.
(8) Aldosterone, a known plasma volume expander, is generally
higher during spaceflight than before, the-premission control
gg^
3
9period and also higher during the mission than in bedrest.
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The Skylab diet has a high salt content. Either factor may
have affected the plasma volume by counteracting bedrest type
decreases during the spaceflight. Dr. Leach has found that
unlike some other bedrest studies, aldosterone levels in the
subjects' plasma and urine during the bedrest period was higher
than it was during the control prebedrest period. The higher
aldosterone levels may have prevented even greater drops in
plasma volume.
Another reason plasma volume does not show a greater
decrease during spaceflight could be a result of the low
atmospheric pressure of the Skylab and Apollo environment.
The low gas pressure would impede body heat loss by convection.
In SMEA'1, the Skylab simulation, mean plasma volume increased
a
2.8 probably reflecting the heat loss difference between 5
i
and 15 psi. (6) The 2.8% increase subtracted from the mean
decrease of Apollo would produce a 7.2% loss which more closelyP	 P	 Y
approaches the predicted 10% decrease of similar time periods
at bedrest and very closely approximates the 6.9% decrease
found in this study.	 1
TBW and TBEK loss measured in the crew members returning 	 3
from spaceflight did not occur in the subjects of this bedrest
s
study, and-ECF decreased a mere 1.3%. However, other bedrest
studies have ;..en associated with larger decreases in extra-
cellular fluid. Hyatt et al. found negative fluid balance in
10
bedrest and noted that ECF decreases were found in the study
of 'Vogt. (10,11) These authors postulated that the ortho-
static cardiovascular sensitivity noted postbedrest could be
a result of extravascular dehydration in response to the lack
of gravity parallel to the long axis of the body during bed-
rest. Orthostatic sensitivity was noted in the subjects of
this bedrest study; yet, the ECF changes were statistically
not significant. This 14-day study agreed with the result of
a six-day 'study in which no change in ECF occurred; yet,
orthostatic intolerance was present in both. Certainly, the
ECF loss of bedrest appears less than after spaceflight; yet,
the changes found during lower body negative pressure and
during bicycle ergometry show similar degrees of orthostatic
intolerance. Therefore, ECF dehydration does not seem to be
the major cause of the orthostatic intolerance noted after
bedrest.
SUMMARY
This 14-day bedrest study was designed to be similar to
Apollo 17 which included the Skylab diet and modified metabolic
balance and was of similar duration. The 'same equipment and
procedures used in the crews pre and postflight medical
examinations were used in this bedrest study so that compari-
sons are possible between the results of each.
t
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The subjects of this bedrest study did not show weight
loss. only a small, transient weight loss was seen during
the first few days of bedrest and even this did not approach
the magnitude of the weight loss of crew members returning
from spaceflight. The mean red cell mass decrease during
bedrest was less than the mean change in Apollo and Skylab
crew members while the plasma volume change was greater. No
statistically significant change occurred in ECF, TBW and
TBEK.
F
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TABLE 1
rem/uCi
Dose/ Tl^ Physical Total Total Total
Nuclide Test Eff Form Critical Organ Body -uC w Body
Fr—em)
125, 2 uCi 30 Albumin Thyroid	 - 0.06-0.2 0.00050 10 0.005
51Cr 25 uCi 28 Chromate Spleen	 - 0.004 0.00036 100 0.036
35S 25 uCi 44 Sulfate Total Body - 0.00009 0 . 00009 75 0.007
3H 25 uCi 12 Water Total Body - 0.00017 0.00017 75 0.012	 C
43K 50 uCi l Chloride Muscle - 0.00094 0.00062 100 0.062	 d
5 9Fe 2 uCi 45 Citrate Spleen	 - 0.24 0.035 2 0.070
or Chloride
0.192
*Total for Prebedrest and Postbed.rest Determinations
Maximum permissible total body occupational exposure is 1.25 rem/quarter.
This can be increased to 3.0 rem/quarter if total for the year is less than 5. 0 rem.
iTABLE 2
RADIONUCLIDE ADMINISTRATION SCHEDULE
Prebedrest Bedrest Postbedrest
Days 21 2	 13 0	 14	 48
Plasma Volume X X X	 X	 X
Red Cell Mass X X	 X	 X
Extracellular Fluid X X X
Total Body Water X X X
Total Body Exchangeable Potassium X X
Iron Turnover X
1
ra	 ^	 1
1-C.4
TABLE _ 3
Subjects	 1	 2	 3	 4	 5	 6
RCM (ml)
BR -21 1821 1905 2230 1889 1744 1709
BR +14 1777 1890 2058 1779 1632 1600
R +13 1701 1899 1975 1794 1584 1599
R +48 2067 1913 2417 1967 1774 1760
PV (ml )
BR -21 3280 3096 3168 2583 2848 3071
BR + 1 3115 3229 3023 2646 2813 2993
aR +14 2644 3060 2940 2560 2711 2836
= R +13 3292 3102 3591 2920 3198 3224
R +48 3063 3038 3114 2.849 2832 3206	 j
TBW (L)
BR -21 43.0 43.2 43:4 41.4 44.8 39.7
BR +14 42.1 43.1 43.4 41.8 44.1 40.5
, '.R +13 46.5 43.3 44.4 41.3 45.0 40.5
ECF (L)
BR -21 16.9 16.3 18.2 14.6 17.0 15.0
BR +14 16.0 16.3 17.1 14.7 16.8 15.6
R +13 15.9 16.55 17.1 15.2 16.7 15.-1
ICF (L)
t	 BR -21 26.1 26.9 25.2 26.8 27.8 24.7
f3R +14 26.1 26.8 26.3 27.1 27.3 24.9
R +13 30.6 26.8 27.3 26.1 28.3 25.1
ISF .(L)
'	
BR -21 13.6 13.2 15.0 12.0 14.2 11.9
8R +14 13:3 13.2 14.2 12.2 14.1 12.8p	
:R +13 12.6 13.4 13.5 12.3 13.5` 12.2
!t i
I
TABLE 4
i
Subjects 1 2	 3 4 5 6	 j
i(
Re'd 'Cell Mass	 (ml/kg)
1
BR -21 26.5 26.8	 32.1 26.8 29.2 21.2
j	 BR +14 25.7 26.6	 29.4 24.4 27.5 19.9
R +14 24.3 26.9	 28.5 24.4 28.3 19.8
R +4.8 29.4 27.2	 35.2 27.7 29.9 21.4
'j PV = (m1/kg) i3
BR --21 47.8 43.5	 45.6 48.2 40.0
i
34.6
BR + 1 44.9 45.2	 43.9 46.5 41.7 34.9
BR +14 38.3 43.2	 42.0 43.2 39.6 33.1
R +13 47.1 43.9	 51.9 49.2 46.1 40.1
R +48 43.5 43.2	 45.4 50.4 43.3 34.2
TBW (m1/kg)
BR --21 627 607	 624 623 640 544
BR +14 609 608	 620 618 646 538
R +13 665 613	 642 618 652 564
ECF ' (ml/kg
'i	 BR -21 246 229	 261 235 226 206
BR +14 232 230	 244 237 227 205
a	 R +13 227 234	 247 235 240 209
ij TCF ' (ml'/k'g )
BR -21 380 378	 362 388 415 338
BR +14 378 378	 376 379 419 333
R +13_ 438 380	 394 383 413 355	 ?,
ISF ' (ml'/k'g )
i
I	 BR -21 198 185	 216 187 186 173
BR +14 192 186	 203 195 188 172
R x-13 180 189	 195 186 194 169
i
r
f
Y
4
1
jIf C
TABLE 5
Subjects 1 2	 3 4 5 6
Exchangeable TBK (meg)
BR -21 3742 3666	 3572 3573 4027 3171
BR +14 3670 3552	 3630 3668 3942 3091
'ExChancgeable TBK ' (meg/kg )
BR -21 54.5 51.5	 51.4 55.3 48.9. 49.8
BR +14 53.1 50.1	 51.8 56.7 48.1 47.0	 j
L'BM '(kg)
y
BR -21 58.9 59.2	 59.4 56.7 61.4 54.4
BR +14 57.7 59.0	 59.4 57.2 60.4 55.5
R +13 63.7 59.3	 60.8 56.6 61.6 55.5
LBM . (% BW )
BR -21 85.9 83.1	 85.5 87.7 74.6 85.4
BR +14 83.5 83.2	 84.8 88.4 73.6 -8`4.5
R +13 91.1 84.0	 87.9 89.4 77.2 84.7
Wt (kg)
BR -21 68.6 71.2	 69.5 64.6 82.3 63.7BR +14 69:1 70.9	 70.0 64.7 82.0 65.7R +13 69.9 70.6	 69.2 63.3 79.8 65.5R +48 70.4-- 70.4	 68.6 65.8 82.8 63.6
i
f
t i
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Subjects
z	
E
1 2	 3 4 5 6
Peripheral Hct
BR -21 40 44	 47 48 41 40	
{
BR +14 45 44	 47 46 42 41
R +13 39 44	 42 42 38 38
R +48 47 45	 50 46 44 40
` f Total Body Hct
BR -21 36 38	 41 42 38 36
BR +14 40 38	 41 41 38 36
R +13 34 38	 36 38 33 33
R +48 40 39	 44 41 39 35
R'a't'io
BR -21 0.90 0.86
	 0.87 0.88 0.92 0.90
BR +14 0.89 0.86
	 0.87 0.89 0.90 0.88
R +13 0.87 0.86	 0.86 0.90 0.87 0.87
R +48 0.85 0.87	 0.88 0.89 0.89 0.88
Serum Iron	 (u*g%)
BR +14 120 71	 131 108 93 119
I'ro'n:' Turnover Rate
	 (mg/kg/day)
BR +14 0.31 0.67	 0.33 0.39 0.45 0.33
'
Fe Plasma T	 (min)
BR +14 148 45.5	 _167- 108 `84.5 126
'%' Fe 'Reappearance in Red Cells
•^	
Day 1 10 19	 11 12 19 183 43 60	 -38 63 60 486 87 96	 66 91 92 9013 100 94	 71 104 97 102
SZCr -Survival	 (days)
< 1
	Pre 23
23
	 30 23 23 28Post
j
^
25 20	 24 24 23 26
a
t
k
ire TABLE 7
Subjects
Mean	 1	 2	 3	 4	 5	 6
PERCENT CHANGE
RCM (ml)
BR +14 95.1 97.6 99.2 92.3 94.2 93.6 93.6
R +13 93.5 93.4 99.7 88.6 95.0 90.8 93.6
R +48 105.2 113.5 100.4 108.4 104.1 101.7 103.0
PV (m1)
BR + 1 97.2 95.0 104.3 95.4 102.4 98.8 97.5
BR +14 93.1 80.6 98.8 92.8 99.1 95.2 92.3
R +13 107.4 100.4 100.2 113.4 113.0 112.3 105.0
R +48 100.6 93.4 98.1 98.3 110.3 99.4 104.4
TBW (L)
BR +14 99.7 97.9 99.8 100.0 100.1 98.4 102:0
R +13 102.1 108.1 100.2 102.3 99.8 100.4 102.0
ECF (L)
BR +14. 98.7 94.7 100.0 94.0 100.7 98.8 104.0
R +13 99.0 94.1 101.2 94,.0 104.1 98.2 102.7
ICF (L)
9
BR +14 100.7 100.0 99.6.- 104.4 101.1 98.2 100.8
R +13 104.3 117.2 99.6 108.3 97.4 101.8 101.6
ISF (L) j
BR'. +14 100.2 97.8 100.0 94.7 -101.7 99.3 107.6
ti	 R- +13 97.4 92.6 101.5 90.0 102.5 95.1 102.5
i
I TBEK (mEq)
BR
I
+14 99.1- 98.1 96.1 101.6 102.6 97.9 97.5
Wt
1
BR +14 100.6 100.7 99.6 100.7 100.2 _99.4 203.1
R +13 99.8 101.9 99.2 - 99.6' 98.0 97.0 102-8
	 j
k	 R +48 100.4 102.6 98.9 98.7 101.8 100.6 99.8
f
I
h
PERCENT CHANGE
RCM ' (ml/kg)
BR +14 94.5 97.0 99.2	 91.6 94.2 93.9 91.0
R +13 93.7 91.7 100.4	 88.8 96.9 93.4 91.0
R +48 104.7 110.9 101.5	 109.6 102.4 100.9 103.4
PV (ml/kg)
BR + 1 99.3 93.9 103.9	 96.3 104.2 100.9 96.5
BR +14 92.6 80.1 99.3	 92.1 99.0 95.7 89.6
R +13 107.7 98.5 100.9	 113.8 115.2 115.9 102.1
R +48 100.2 91.0 99.3	 99.6 108.2 98.8 104.5	 a
TBW . (ml/kg )
i
BR +14 99.3 97.1 100.1	 99.4 100.9 98.9 99.2
R +13 101.5 106.1 101.0	 -102.9 101.9 103.7 99.2	 ti
101.7
ECF ' (ml/kg )
BR +14 98.2 94.3 100.4	 93.5 100.4 99.5 100.8	 {
R +13 99.4 92.3 102.2	 94.6	 - 106.2 101.4 100.0
1
ICF (ml'/k
BR +14 100.1 99.5 100.0	 103.9 100.9 98.5 97.7
R +13 105.1 115.3 100.5	 108.8 99.5 105.0 101.3	 3
103.0
S'SF ' (ml/kg)
BR +14 '99.4 97.0 100.5	 94.0 101.1 99.4 104.3
R +13 97.8 90.9 102.2	 90.3 105.9 97.7 99.5
TBEK ' (mEq/kg)
BR +14 99.8 98.0 99.7	 100.0 100.9 98.4 102.0
LAIL
TABLE 9
MEAN PERCENT CHANGE AT END OF MISSION AND BEDREST*
Apollo 14-Day Bedrest
Red Cell Mass -10.1 ±1.3 -4.9 ±1.1
Plasma Volume - 4.4
	 ±1.7 -6.9 ±2.8
Total Body Water - 2.4 ±0.4 -0.3 ±0.6
Extracellular Fluid - 2.7 ±1.0 -1.3 ±1.6
Intracellular Fluid - 2.1 ±0.8 +0.8 ±0.8 i
Body Weight -	 3.9	 t0.5 +0.6 ±0.5
*Mean ± Standard Error.
i
ii
j
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Biochemical Results
Carolyn S. Leach
•	 1
The biochemical studies were initiated to determine whether extended
F	
,
bedrest produces similar biochemical changes as noted in samples returned
from Skylab flights (first 14 days) and whether final effects are similar
1
to those observed in returning Apollo crewmen..
	
Although numerous bedrest studies have been completed, each study	
a
	
has been designed around a specific area to answer a specific question. 	 '.
.These very necessary studies have produced large volumes of data about
a particular body system response to a certain period in bedrest. How-
ever, the type of results produced by these studies has not made the
comparison of bedrest findings to space flight results possible. In
every case, the biochemical results of the space flight crewmen include
not only the response to the exposure to weightless flight, but also
the biochemical responses to stress, fatigue, and numerous physiological
stress test. For these reasons, it was considered important to conduct
	
this study to more closely simulate the actual space flight experience. 	 a
a
Experimental Protocol and Methods
The control portion of this experiment began 21 days prior to the
test, continued throughout the 14 days of bedrest, and 14 days after
completion of test. Pre- and post urine and fecal collections were
	
accomplished wherever the subjects were residing at that time. During	 a
the collection, the urine specimens were cooled at 4°C. Each morning the
urine collected during the previous day was received in its cooled state
at the laboratory, where it was stabilized. The in-bed collections were
a
maintained in a similar manner,
p 
Complete fecal collections were undertaken. Fecal samples were
frozen and then dehydrated in preparation for analysis.
The metabolic monitoring period also included the rigid control of
dietary intake. All foods were analyzed for major nutrients and the
intake of sodium, potassium, chloride, magnesium, nitrogen, and calcium
was controlled within narrow limits through the design of repetive menu
cycles to which the subjects were required to adhere throughout the
experimental period. In Table 1 are listed the mean sodium and potassium
'	 intake values for all subjects.
For this experiment, fasting blood samples were drawn 30, 21, 7,
and 1 day before the test at approximately 7:00 a.m. Samples drawn
during the bedrest on days 2, 7, and 13 were also drawn with the subjects
fasting and at about 7:30 a.m. Blood samples were drawn immediately
after bedrest and 1, 3, and 14 days later. For this experiment, the
blood volumes for pre-bedrest and post-bedrest analyses were 25 ml and
the in-bedrest plasma averaged 3 ml. Sodium EDTA was used as the
anticoagulant.
Methodology for the more routine clinical biochemical tests was that
in standard use in laboratory medicine
	 For the more involved hormonal
analyses, radioassay, fluorometric, and gas chromatographic methodology
was employed. The measurement of various body compartments was conducted
pre- and post-bedrest utilizing the principle of isotopic'dil ,ution. ' Total
body water was estimated with tritium, extracellular fluid with sodium
sulfate containing 35 S, plasma volume with proteinlabeled with 1251,
a
^  42and potassium with
	
K.
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Since individual variation among normal men has been constantly
observed during previous programs,.each man served as his own control;
his in- bedrest and post-bedrest data were compared with his pre-bedrest
controlled phase. The pretest value each time is given as a mean of
the entire control period as well as individual values.
Results
In the presentation of results, the mean value of each parameter for
each crewman measured prior to flight is compared with that same parameter
measured inflight and postflight. In Tables 2 and 3 are presented the
results of analysesperformed on plasma and serum samples. In- bedrest
and post-bedrest values differing statistically from corresponding
measurements performed pretest are indicated (P<0.05).
Glucose was decreased the last day in bed (R+O) on two of the subjects,
by R+1 the values had returned to normal. The cholesterol, SGOT, BUN,
uric acid, calcium, magnesium, biliriubin, creatinine, osmolality,
sodium, potassium, chloride and triglyceride results were variable.
a
<<	 Alkaline phosphatase and phosphorous values were slightly higher on R+O,
whereas LDH`and CPK results were slightly lower on R+0
Angiotensin I (Renin Activity) was decreased on the second day at
bedrest and then increased. It was generally increased at R+l. ,The
first day up). Three of the six subject had increased insulin on
	 1
I
R+0 day. Cortisol was variable, but Generally decreased during bedrest.
Aldosterone-was decreased during bedrest and elevated post-bedrest.
Thyroxine was generally elevated the last day in bed.
i
A
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Those constituents of the 24-hour urine sample which were changed
during and after bedrest are shown in Tables 4 and 5. Osmolality results
were variable with time showing early increases then decreases. VoTume,
sodium, potassium, chlorine, calcium, magnesium, phosphorous, uric
acid, cortisol, and aldosterone showed overall increases during bedrest.
Hydrogen ion, epinephrine, norepinephrine, and antidiuretic hormone all
showed decreases during bedrest. Post bedrest, overall decreases were
observed in osmolality, sodium ,  potassium, chloride, calcium epinephrine,
I	
while increases were shown in magnesium, phosphorous, uric acid
noreprinephrine and aldosterone.
The results of the pre- and post-bedrest analysis of total body
water, extracellular fluid and exchangeable potassium are shown in
Table 6. The results are variable but show slight decreases in most
subjectsduring bedrest in all 3 measurements.
Table 7 gives the mean body weights for all three subjects each
period, of the study. Only slight increases are observed in 2 subjects
during and post-bedrest.
'	
Discussion
The biochemical changes caused by bedrest are well documented in
the electrolyte area; however, the endocrine studies conducted during
i
bedrest experiments have been limited. Major emphasis has . been placed
on the skeletal and cardiovascular reaction to the hypokinetic environ-'
meet in studies of varying duration due to the clinical findings in these
areas. In reviewing the studies that have been conducted, it is obvious
i	
that the changes which occur in the human body at bedrest are documented.
5It remains to study these changes in a protocol more realistic to actual
space flight mission activities. This study was conducted to simulate
a 14 day space flight without significant exercise. The biochemical
findings are discussed in relation to postflight Apollo results and to
the first 2 weeks of Skylab.
It has been previously demonstrated that exposure to weightlessness
results in a redistribution of the volume of blood within the vascular
0
system. This redistribution is interpreted as an increase in blood volume
by stretch receptors in the left atrium, thus causing a compensatory loss
in water, sodium and potassium from the renal tubules. This loss in water
has been manifested after every space flight as a loss in body weight,
most of which is rapidly regained on the first post-bedrest day. It
should be pointed out, however, that some of this body weight loss is not
regained and is though to be comprised of both fat and proteinaceous
a
material. The decreased adiposity has been attributable to a h.ypocaloric food
intake, while the loss in the elemental constituents of the musculoskeletal
i
system appears to be a more direct consequence of reduced compressional
and tensile forces.
Apollo crewmen showed weight losses which averaged 6 pounds or 3.5%
mean weightloss. Body weight changes are not characteristic of bedrest,
in fact, care must be taken to prevent weight gain during the bedrest-phase.
The subjects in this study (Table 7) did not lost weight, two actually
gained slightly during_bedrest.
^j
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6A comparison of urine volume and sodium excretion in the 9 Skylab crew-
men and the 6 subjects of this bedrest shows sodium excretion elevated
in both groups about the same from control values. The differences in
the magnitude of the sodium changes appear in days 2-7 in Skylab. This
is the same period when the intake was generally decreased in those crewmen.
Twenty-four hour urine volumes are elevated the first two days of bedrest,
but not in space flight. With the exception of this initial period, sub-
sequent 24 hour urine volumes were not significantly different from those
obtained pre- and post-bedrest.
Urinary ADH showed an overall elevation on 4 out of the first 5 days
in bedrest. It was decreased on day 3.
The pre- and post bedrest analysis of total body water and extracellular
fluid did not reveal significant changes. Considering the environment
control, the lack of stress and the diminished exercise during the bedrest
phase these results are not unexpected. It is important to note a slight
decrease in all subjects. These data again show the same direction but
different magnitude than . the space flight results.
The concentration of serum sodium was not altered with two weeks of
bedrest.- Using 27 Apollo crewmen for statistical analysis, a postflight
decrease of 0.99 was observed. Three of the bedrest subjects showed
postflight increase, one a decrease and one no change from preflight mean.
Serum potassium was ,slightly decreased in 4 of the 6 subjects. The magnitude
of the potassium was about the same as observed in the returning Apollo
crewmen. Urinary potassium was elevated in bedrest and total body
exchangeable potassium was decreased in most of the subjects, again these
results compare favorably in direction if not in magnitude to the Apollo
0f
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results. The rigid adherence to the control diet (Table 1) during all
phases of the study adds to the significance of the loss in both sodium
and potassium.
The negative sodium . and potassium balances have been accompanied by
increased aldosterone excretion in space flight crewmen. An overall 37%
increase was observed during this bedrest study which believed to be
the only time that aldosterone has been shown to be elevated in bedrest
in subjects on controlled diet and no medication. The magnitude of this
,increase, however, is not as great as that (84%) shown during the first
two weeks of the Skylab flights. This finding of a slight increase in
6 subjects is unexpected and will allow us to examine new areas of
commonality between bedrest and space flight:
Plasma aldosterone and renin activity were variable as with space
flight but were generally decreased early then increased.
Blood urea nitrogen has been decreased following space flight. it
was very slightly increased in 5 of the 6 bedrest subjects. Urinary
creatinine was not altered during or post-bedrest and plasma creatinine
was not effected by the two weeks of bedrest. These results are comparable
to other bedrest findings.
Uric acid excretion was increased in 4 of the 6 subJects during this
bedrest. This is unlike space flight where the excretion of uric acid
was decreased. Plasma levels were not significantly changed with bedrest.
Following space flight serum uric acid, has generally been found to be decreased.
Bedrest has been used as an analog of space flight for the last fifteen
years. With the more involved Skylab flight, the calcium metabolism has
r	 been shown to be very similarily effected by bedrest and space flight.
3
Urinary calcium and phosphorous were elevated throughout the bedrest
r8
as they were during the first two weeks of the Skylab flights.
Serum calcium showed little effect; however. it is of interest that
serum phosphorous was elevated in all of the 6 subjects after bedrest.
Adrenal hormones from the medulla and cortex have been of significant
concern since early space flight. The findings during and following
bedrest have been variable. This study showed overall increases In
urinary cortisol with slight decreases during bedrest in plasma cortisol.
Post bedrest plasma cortisol was slightly increased.
Epinephrine and norepinephrine was decreased during bedrest in all
of the subjects. This is similar to,the Sky1U ,- flights. The decrease
in norepinephrine has been reported during bedrest. The very significant
decrease in all crewmen is probably related to the complete absence of
exercise during the bedrest phase.
To examine the reported decreases of plasma glucose with bedrest,
insulin, growth hormone and glucose were measured before and following
bedrest. Glucose was decreased in 3 of the subjects after 14 days of
bedrest and insulin was slightly elevated in 5 of the 6. Human growth
hormone was more variable but generallly post-bedrest values were higher
than pre-values.
Cholesterol were also variable (3 higher and 3 lower than pre-values).
This study did not show the decreased cholesterol which has been
w	
observed following space fl ight for as long as 3 weeks. Howc ,^i-.r, 5 of the
F	
,
subjects did show slight increases in throxine. Apollo and Skylab
results have also found increased thyroxine after space flight.
f,	
Alkaline phosphatase was increased "in all 6 subjects after 2 weeks
t	 of bedrest. This enzyme has shown variable results after bedrest and
has not been changed die to space flight. The role of alkaline phosphate
1;.y
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as they were during the first two weeks of the Skylab flights.
in calcium metabolism would support the elevation of this enzyme in
light of the increased calcium and phosphorous excretion. Following
Apollo flights alkaline phosphatase was slightly increased; however it
was slightly though not significantly decreased following Skylab.
Creatinine phosphokinase (CPK) and lactic dehydrogenase (LDH) were
decreased following this bedrest study. Apollo results showed decreases
postflight in both of these enzymes. After Skylab,CPK was generally
increased during the recovery phase. This finding was supported by
0	 results of.2 of the bedrest subjects. Both the CPK and LDH results are
intepreted to be related to decreased muscle activity during bedrest
and Apollo flights and an increase during the post phase.
Significant biochemical changes have occurred during and after
two weeks of absolute bedrest. Most of these changes are similar in
direction if not magnitude to those observed during flight on the
Skylab crewmen and postflight on the Apollo astronauts.
TABLE l
' SODIUM AND POTASSIUM INTAKE
(mEq/Day) 1
Mean + S.D.
gLJljJE CT SODIUM POTASSIUM
PRE IN POST PRE IN POST
270+22 272+24 265+22 99+9 96+8 95+8
2 204+21 212+29 203+27 88+10 86+11 95+8
3 268+21 280+19 264+20 107+9 112+6 113+31
4 252+27 247+21 243+25 84+11 83+ 12 81 +14
5 257+20 256+20 257+17 87+7 83+9 85+5
b 242+36 222+13 219+16 84+8 81+7 82+7 C
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Subject 1 TABLE 2
SERUM BIOCHEkISTRY RESULTS
URIC ALK. BILI
GLU	 C F (!'. SG'3T KN ACID PROS. Ca No Pn,4 T. CREAT CPK LOK OS ,O Na K Cl TRIGLY
rt% IU mg rig 14mg mgn o:U/ml mu/ml mOsmo mEq/1 mEq/1 mEq/1 mgt
F-30 68.98	 164 11 14 5.9 21 9.0 1.8 3.0 0.5 1.0 88 181 285 137 4.4 -102
-21; 100	 155 11 19 6.3 19 8.5 1.8 3.3 0.5 1.1 115 185 %90 139 4.2 104 •29
-7 99	 -173 10 18 6.3 22 8.9 1'.7 3.2 0.3 1.0 71 116 286 139 4.7 100 18
-1 93	 1?5 9 14 7.2 18 9.0 1.7 3.1 0.2 1.2 57 142 293 143 4.5 105 35
MEA.16D 99+1	 167 4-9 10+1 16+3 6.4+.6 20+2 8.9+.2 1.8+.1 3.2+.1 .4+.2 1,1+1 83+25 156+33 289+4 140+3 4.5+.2 103+2 38+22
R+O 86	 194 20 19 6.5 27 9.1 1.5 3.4 0.4 1.2 48 138 291 143 4.3 100 32
+1 99	 180 17 19 6.8 28 9.2 1.6 3.9. 0.2 1.2 150 115 292 143 4.5 100 56
+3 97	 172 20 19 6-.4 25 8.6 1.6 4.1 0.3 1.1 129 172 288 141 4.2 103 48
+14 100 	 167 12 15 6.8 22 3.8 1.5 3.8 0.2 1.0
_74 159 290 142 4.4 102 55	 J
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Sulbj ecz 2 TAULE 2
SEPUN BIOCHEMISTRY RESULTS CONTINUED
UgT C ^,LK BILI
GL" C .'3L SGOT	 BUN ACi0 PHICS. Ca t.'.; F0, T. CREAT CPK LDH OSNO Na K Cl TRIGLY
rrt ul,. r,,IU/:nl	 Ing% IU ::-.g V^ mgr mgz m9W 1'.19% mU/ml mu/ml mUsmo mEq/1 . mEq/1 mEq/1 mg%
F-303' i 17i 12	 15 6.1 1.1 9.3 2.0 3.3 1.1 1.1 -_ 1 4 88108 284 138 4.0 100
-2; 92 150 12	 11 5.0 14 8.7 1.9 2.3 0.8 1.0 62 86 281 139 3.8 99 67
-7 98 160 15	 13 6.1 16 E,9 2.0 3.2 0.4 1.1 154 82 280 139 4.3 99 47
-1 156 13'	 i5 6,1 i2 9.1 1.8 3.3 0.4* 1.1 106 77 296 144 4.2 103 58
•lCAX+SD 9a-3 161_13 ',3+1	 14+2 6,C+,3 14+2 9.0+.3 1.9_.1 3.L+.2 .7+.3 1.1+.1 92+49 88'14 285*7 140+3 4.1+.2 100+2 65+17
n+G 85 146 12	 13 5.1 19 8.7 1.9 3,5 0.6 1.1 43 82 286 142 3.9 99 74
+1 47 140 12-	 16 5.8 1fi 8.8 1.9 3.5 : 0.7 1.1 41 69 289 142 4.3 99 88
+3 90 135 12	 14 5,5 15 8.4 c.0 3.7 0.6 1.1 44 86 285 142 3.9 100 ^91
+14G 87 152 14	 11 5.8 11 8.7 1.9 3.9 0.8 0.9 32 60 290 141 4.1 99 73
•a
j'
^ a
i
N
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3 ^TABLE 2
'
5ER:^ BIOCHEMISTRY R17SULT] CONTINUED
'	 . URIC ALK. ClLl
/^ U cPOL ^^0T 8UCN ^	 D PROS. C^ Ng PG T. CRE^T CPK L8H UsM0 Na K Cl
mg% ma^ mU/mz mg%	
'
mg% IU mg% zg10 mp m^% ng^ MU/ml mU/ml_ mOsmo mEq/1 mEq/l mEq/l
' F-20 99 254 l5 ll 7.4 18 9.3 1.9 3.7 G_3
'
]'U 35 170 286 138 4'3 701
"	
-14 88 208 12 16 7.7 ^ l3 8.Y l.O 2.^ D.^ l-1 44 l5^ 235 l35 3.8 102
^	 -7 QD '	 2^l ^Z l9 7.8 '	 l8 0.O }-8 3.8 8.2 1.2 46 1E5 283 138
~
4,5 102
-1 '96
'	
210 O
'	 '
17 9.3 19 9.4 l.8 4] C-1	 ' 1'2 141 151 294 143 4.2 105
r 94±522l-22 15^4 16+3 8.1+.9 17+3 9.2+.2 1.8+.l 3.0+. .2+.l l ^ l+,l 67+50 158+12 287±5 135±3 4 ' 2+.3 103+2
p+^
`
69 ^^4 ^4 l7 8i2 ^2" 9.2 1.9 ^.^ G^3 l.2	 . ^5 l29 29D  142 4.0 101
+l lOD 2 1 7 23 22 8,2 29 8.9 1.8 S'O 0.2 1'3 48 lS3 297' 142 4'8 102
+3 104 2 1 1 23 2l 8'1 27 9 ^ 0 l-& 4.9 C.3 1.5 53 155 288 14l 4.2  lUU
i^+14 91 210 12 22	
'
8.0 19 9 ` 3 1-9 4.7 0.2 ^,O 53 129 290 140 4'3 103
|
T0GLY
92
153 |
119
^ .
g]
7l4+29
ldl ------
%32
174 .
2]Q
^
^
u,
,
`
^
------``----^=
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Subj ect 4 CABLE 2
SERUM 83004Ev;ISTRY RESULTS CONTINUED
U1?TC AL K. 8;x`1
CLI) CIVII ;IJUf BUN ACID PH-DS. Ca X. p0	 T. CREAT CPK LD.H OSt•iO Na K Cl TRIGLYI,Ig
n n'! 16 iag:Z 1,c.% yr	 r mg7 niU ml mrJ/ml t:,Osm.o mEq/1 mEq/1 mEq/1 mg%
F-20	 68
82
117 17 9 5.0 13 S.3 2,.1 3.3	 0.9 :i.1 SO 138 282 139 4.3 101
-14	 36 145 11 13 5.1 9 9.2 2.0 3.2	 0.5 1.1 35 iC3 279 134 3.7 103 56
-7	 86 119 13 14 5.2 11 9.4 2.0 3.8	 0.33 1.1 0'S 6"s 279 i33 4,3 101 50
-i	 76
f
i51 12 :1 5.0 10 9.c 2.1 7	 C.'_ 1.2 46 i3 2S5 143 4.1 103 107
vLAl!+SD 84_5 156'15 13;• 3 1=-2 5."-.1 is*2 9.5=.3 2.1+.1 3.E-r.7	 .5+.3 1.'._.1 59+24 3 1-_34 2'S=_8 73ti_4 4.1±.3
+
102+1 74+26
r
k+O	 87 161 13 16 4.7 13 9.5 1.9 4.7	 .;.4 1.2
-
21 63 2'91 132 4.2 104
-
74
+1	 90 151 10 19 5.4 11 9.4 2_.1 4.8	 3.3 1.2 106 1-:, 304 142 4.3 102 95
+3	 80
I
146 9 13 4.8 9 9.2 1.9 3.6	 0.6 1.1 53 65 287 139 4.1 104 46
+14	 87 154 10 11 5.7 9 9.0 2.0 4.7	 0.4 1.4 . 42 90 282 141 3.7 104 71
i
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Subject 5 TABLE
I
SERUM BIOCHEMISTRY RESULTS CONTINUED
3R 7,C AL:K. BILI
G': U CHOL :;OT Hill ACID PhDS. Ca :. P0, T. CREAT CPK LD;1 OS':0 Na K Cl TRIGLY
nt;, r.;gX mU/rrsl T. :;^c; IU m9 [ gN I gti no o mg ^ MU/ml trU/r:;l r10ss:o mEq/1 mEq/1 mEq/1 mg%
JF-21' 102100 246 13 19 7.8 7 9.5 2.0 3.6 0.5 1.2 62 219 139 4.4 101
- 11 92 219 14 14 6.6 7 9.Cl 2.0 2.8 0.3 1.0 51 193 283 133 4.4 102 206
-7 93 223 i2 13 6.7 10 9.0 2.1 3.4 0.3 l.1 55 151 282 ..,,l'` -.. i 99 132
	 .
-1 94 204 13 17 6.3 8 9.2 2.1 4.2 0.1 1.2 99 130 9-52 142 4.2 103 268
RAN fSD 9514 2-'4 1.18 13+1 17+2- 7.0•x.6 ::^-1 9.2-x.2 2. i±.l 3.5+.6 3+-R 1 .1+.1 67+22 1431- ,=1 288+7 138+4 4.3+.2 102m 177+75
R+3 98 214 10 19 6.6 11 8.9 2.0 4.5 0.4 1.1 34 123 288 139 4.2 99 154
+1 100 11,97 10 13 7.1 8 3.9 2.0 4.5 0.2 1.2 80 ':59 Q'r,S 141 4.5 106 159
+3 8c 191 9 18 7.1 8 8.8 2.0 4.5 0.2 1.1 39 146 287 139 4.2 103 105
+14' 98 _ 200 0 19 7.2 7 c.6 2.2 4.0 0.2 1.0 42 138 291 140 4.1 106 136
4
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Subject 6
MILE 2
SERUM QIOCEEt4ISTRY RESULTS CONTINUED
U _C ALK. .SILL
C: CV.L SCUT -	 P11"i ACID PROS. Ca +.r; P0a i CREAT LN OSmO Na K Cl TRIGLY
xg i rr,'J/r,il n:5 r,^c , IU nig;a .,,-`o mg r.g;> mks q	 -..11 ni"iml r0smo rEq/1 mEq/1 mEq/1 mgn
F-20	 J2 98203 12 18 5.8 42 9.6 2.1 3.4 0.4 , 1.0 60 168 294 140 4.4 101
-14
	 1.32 2v2 9 17 4.7 37 9.1 1,7 3. 1 0.4 1.0 46 144 282 133 3.8 103 '62
-'	 107 '211 13 15 4.8 39 9.3 2.4 3.6 0.2 1.0 51 120 285 138 4.1 101 51
-1	 94 19; 11 10 5.4 31 9.3 2.0 3.1 0.3 1.1 57 129 295 144 4.0 104 69
Cn.";-SD 101+5 204'7 11+2 15_+' 5.x_.5 37+5 9.3Y.2 2.0+.2 3.3+.2 .3_.1 1.0+.1 54+6 140+21 284=6 139+5 4.1+.3 102+2 7C+20
R+O	 102 234 17 17 5.8 45 9.4 2.0 4.0 0.3 1.1 32. 125 290 139 4.2 101 113
+1	 98 217 1b' 16 5.9 36 5.0 2.0 3.5 0.3 1.0 53 129 .304 140 4.1 104 88
z	 +3	 94 214 17 14 5.9 34 8,7 1.9 3.7 0.3 1.0 53 138 285 140 4.0 105 92
+14	 96 217 13 15 5.5 38 9.G 2.1 3.5 0.5 1.0 41 129 2E8 140 4.2 103 57
♦ '
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Sub ject 1 PLASMA HORMONE RESULTS
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4	 --
mug/ml/Hour uUg /cal ug/100ml mg/ml pg/ml pg/ml % Uptake ug/100m1
F-30 0.35 11 14.2 2.6 415 32.0
F-21 0.45 10 15.5 1.9 259 20.5 35.4 9.1
F-7 0.57 10 19.0 1.9 242 32.0 33.5 9.1
F-1 0.56 8 10.7 1.9 290 17.8 34.2 6.2	 -
MEAN +SD .48±.10 10+2 14.9+3.4 2,1+.4 302+78 25.6+7.5 34.4+1.0 8.1+1.7
BR+2 0.42 - 13.7 - 129 - -^
B'R+7 1.35 - 12.0 - 192 - -
BR+14 0.96 - 14.0 - 163 -
-	 y_,
R+0 1.07 15 19.0 2.4 238 33.1 8.9
R+1 0.94 12 14.1 3.5 256 33.5 7.9
R+3 0.48 9 15.0 12.4 197 34.6 7.5
R+13 0.76 10 10.3 1.9 155 32.3 7.0
f
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Subject 2
PLASMA HORMONE RESULTS CONTINUED
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4
mug/ml/Hour uug/ml ug/lOOml mg/ml pg/ml pg/ml % Uptake ug/100ml
F-30 0.81 9 12,5 2.2 467
10.8
F-21 0.21 10 13.0 2.2 191 9.8 32.3 12.7
F-7 0.54 9 13.5 3.1 150 16.1 34.2 13.1
F-1 0.49 7 10.8 1.9 182 14.4 33.8 10.9
MEAN+SD 0.51+0.25 9+1 12,.5+1.2 2.4+^5 248+147 12.8+3.0 33.4+1.0 12.2+1.2
BR+2 0.29 - 10.7 - 154 - -
BR+7 0.70 - 10.7 - 140 - -
BR+14 0.03 - 8.5 - 148 - -
R+0 0.57 11 11.3 1.5 161 35.4 9.8
R+1 1.07 11 10.6 2.4 222 31.2 12.3
R+3 0.37 9 9.2 2.8 162 33.8 10•.1
R+13 0.26 9 8.0 1.9 168 32.3 9.8
,
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Subj act 3
PLASMA HORMONE RESULTS CONTINUED
k
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4
mug/ml/Hour Wg/ml ug/1OOml mg/ml pg/ml pg/ml % Uptake ug/100ml
F-30 0.45 9 18.5 3.1 420 16.1
F-21 0.31 8 17.0 2.6 270 25.4 35.8 7.7
F-7 0.81 9 13.7 2.2 225 17.5 36.5 8.4
F-1 1.28 7 8.8 2.6 215 20.0 35.0 6.8
MEAN+SD .71±.43 8±1 14.5±4.3 2.6+.4 283+95 19.8+4.1 35.8+.8 7.6+.8	 --
B R+2 0.42 13.0 - 149 - -
BR+7 0.63 - 16.0 - 179
BR+14 0.84 - 13.7 - 138 - -
R+0
0.85 15 19.5 2.4 164 31.9 11.8
R+1 1.46 14 16.7 3.5 220 31.9 9.9
R+3 1.00 7 8.2 3.5 192 28.5 8.9
R+13 0.39 9 13.5' 2.4 165 32.7 7.9
1-
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Subject 4
PLASMA HORMONE RESULTS CONTINUED
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4
mug/ml/Hour uUg/ml ugil00ml mg/ml pg/ml pg/ml % Uptake ug/100m1
F- 30 0.30 10 14.2 2.2 399 14.1
F-21 0.29 9 11.0 2.2 578 11.1 35.8 6.8
F
-7 0.70 7 16.7 1.9 150 18.6 33.8 7.9
F-1 0.33 10 14.0 2.2 212 18.9 33.8 8.2
MEAN+SD .41±.20 9+1 14.,0+2.3 2.1+.2 335±194 15.7+3.8 34.5+1.2 7.6+.7
BR+2 0.84 - 8.1 - 233 - -
BR+T 0.86 - 7.4 - 227 -. -
BR+14 0.60 - 12.0 - 227 - -
R+O 0.68 10 10.0 3.5 239 33.8 8.9
R+1 0.95 9 12.8 3.9 234 35.8 10.4
R+3 0.73 7 7.4 2.4 147 36.2 8.5
R+13 0.87 .9 15.0 2.4 177 34.2 7.6	 ^^r
TX-c' 3
Subject: S PLASM; HORMONE RESULTS CONTINUED _.
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4
mug/ml/Hour uUg/ml ug/10Oml mg/ml pg/ml pg/ml % Uptake ug/lOOm1
F-30 0.57 12 14.2 1.9 298 18.3
F=31 0.03 9 12.0 1.9 410 18.0 35.8 8.7
F-7 0.20 6 12.3 2.2 114 20.5, 30.8 9.4
• F-1 0.03 10 6.6 2.6 131 14.4 33.8 8.6
MEAN+SD .21+,25 9+3 11.3+3.3 2.2+.3 238+141 17.8+2.5
-
33.5+2.5
, 8.9+.4	 --
BR+2 0.16 - 7.0 - 137
--
-_
BR+7 0.67 - 8.8 - 176 - -
BR+14 0.44 - 9.0 - 147 - -
R+O 0.77 10 6.2 2.8 116 35.0 9.9
R+1 0.43 10 8.6 2.8 104 34.6 9.8	 .
R+3 0.19 10 9.8 1.9 130 32.3 7.5
R+13 0.17 8 14.0 2.4 134 35.8 8.9	 4.
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Subject 6
PLASMA
3-
HORMONE RESULTS CONTINUED
'
ANGIO I INSULIN CORTISOL HGH ALDO ACTH T3 T4
mug/ml/Hour uUg/ml ug/l00ml m9/ml pg/ml p9/ml % Uptake ug/100ml
F-30 1.04 10 11.0 1.9 329 18.0
F-21 0.35' 4` 10.3 1.9 615 16.9 35.0 8.8
F-7 0.23 8 13.2 2.6 165 15.2 31.9 8.8
F-1 0.34 11 7.4 2.6 205 23.3 30.8 6.9
MEAN+SD .49+.37 10+1 10.5+2.4 2.3+.4 329+203 18.4+3.5 32.6+2.2 8.2+1.1
BR+2 0.19 - 12.5 - 182 -
BR+7 0.31 - 8.1 - 174 - -
BR+14 0.22 6.2,, - 157 - -
R+0 0.33 10 11.0 1.9 226 29.2 9.2
R+l 0.48 11 5.6 2.8 213 34.6 9.0
R+3 0.33 9 8.0 1.5 170 33.5 7.0
R+13 0.27 9 10.0 2.8 139 33.8 7.0
rADLI: 4
2	 hv'uR URINI- RESULTS
Subject 1
SP GR OSI:OL `iA K CL CA MSG IPO4 URIC ACID CREATINJUE HOPRO	 H+
?E GM/L M05M NE0 J24 HR MEQ/24 KR MIEC,/24 HR HEQ/24 HR MEQ/24 HR MG/24 HR MG124 HR MG/24 HR MG/24 HR
F-21	 221 1.010 434 2'•0 6i, 175 6.1 12.6 1108 841 1905	 _ 34
-20	 lc'55 1.017 7,C 83 281 9.9 13.6 1192 960 1920 18
-19	 3 1.'125 966 149 3 118 5.3 10.8 980 720 ]828 141
-i8	 915' 1.025 1071 214 81 157 6.7 •11.8 1226 805 1702 143
-1'7
	
2' 60 1.013 589 '-'3 79 294 5.6 13.5 10--.6 959 1744 0
I	 -16	 12 CO 1.014 551 1=4 45 163 10.7 7.9 219 7;2 2125 113
-15	 1;70 1.008 639 250 73 223 6.2 10.9 885 853 1947 40
-14	 1760 1.M E5 24' 07 "J: o.0 ..5 iGSo ;45 1935 11
-13	 1800 1.014 5_.1 210 67 184 21.3 13.0 1188 972 2268 •115
-12	 17 *20 1.012 545 "6 57 229 5.5 12.5 722 825 1410 35
-11
	
1380 1.014 62'0' 2:.4 51 122 7.6 12.5 718 800 1518 63
-10	 1120 1.019 8 C l i6 6S 143 5.7 ii .0 1*0193 739 1994 159
	
4
W
-9	 1510 1.016 TO 238 91 217 8.2 10.6 i0c7 815, i72i i2
-8	 1535 1.018 803 X37 89 255 8.1 15.1 1289 952 21"18 63
-7	 1 60 1.015 673 170 G3 1.^s 5.9 3.9 857 731 1739 82
-6	 17715 1.G15 65:6 257 82 261 7.6 10.2 934 959 21034 71
-5	 1i"-:9 1.015 656 21- 4 6 +3 5.9 9.5 924 2Ci 1879 24
-4	 1030 1 .020 871 2`.5 73 1	 , 2 4.7 1.L 1037 734 1836 11
-3	 1;:?0 ;.013. 571 233 59 210 7.7 10.3 961 748 1709 50
-2	 12223 1.017 735 16;% 65 1	 0 S.Y 8.2 976 708 1854 108
-1	 335 1.613 7GO li5 41 93 4.5 6.3 752 632 1522 93
h;EAN+SO 1483+400 1.016+^.JO" 694+148 220+;9 70+15 19-6f" 7.4+3.6 10•:6+2.2 993_164 816+78 1849+2I1 66T49
	 " --
Q
j^ N
iI
W
;'iBLE 4
24 HOUR URINE P.ESULTS CONTINUED
Subject ,1
3P GR "'OL f1 ; ?: C.L CA '1G 'POa URIC ACID CRE^TItiInt HOPRO H+
VOL l;ME G•3/L N,^;''	 MEQ/ 24 HR MEQ/24' 'n.R ME- Q/24 HR ME t/24 HR MEQ/24 HR XG/24 _HR MG/24 HR Nu/24 NR MG/24 HR
BRI 2180 1.013 605 346 76 294 10.4 13.4 1134 1046 2093 16
2 3230 7.003 331 392 81 3:,0 12.4 12.7 969 9C4 2003 . 0
3 1400 1.011 539 191 52 169 5.7 8.3 672 532 1176 17
4 1450 1.019 816 2='1 99 213 7.9 14.4 1102 870 2146 19
5 93rl ' 1.024 1043 1:5 66 1014 6.4 9.8' 1x79 707 1730 149
6' 1100 1.419 852 134' 72 178 8.1 7.4 83; 704 1518 86
7 X530' 1.077 744 229 98 183 -12.4 8.6` 1201 916 2180 54
8 1-.-60 1.01i 689 259 64 211 9.0 13.0 874 81? 1522 16
9 2355 1.011 557 287 101 253 10.1 13.0 1313 902 2345 65
10 1400 1.01E 688 210 5: 175 10.5 9.3 952 755 1624 45
71 130- 0 - 1.022 92? 255 95 237 9.4 14.3 1352 933 2070 118
12 1.).:0 1.075 E 7 244 87 237 9.1 13.7 1235 9 26 2277 I94
13 1505 1.017 758 241 E 212 9.1 12.6 1294 63 1306 93
14 15_0 1.020 770 258 18 234 8.3 9.8 1216 942 1842 28
MEAN-'D	 16797 :"'1.022-.020 712+177
	 253+53 80+16 225+54 9.2+1.9 11.5+2 .4 1088+202 8567136' 1888+330 57+45
E
S
N
li
TABLE 4
24 HOUR, URINE RESATS CONTINUED
Subject 1
p GR r;:3L t>A K CL CA Mc IPO_ URIC ACID CREATININE HO?RO H+
VOLUME G !j/L Mcls"ll MEQ/2,i HR N.E?/2µ HR HR. MEQ/24 HR IMEQ/24 HR MG/24 NR_ MG,'24 HR MG/24 HR MG/24 HR
R+O 1250 1:020 741 130 E3 145 9.6 11 0.3 950 800 1830 118
1 1230 1, 020 175' 90 I9 8.1 8.6 1C3 1834 44
2 925 1.027 1007 172 67 162 5.8 11.5 1240 925 1776 155
3 1660 1.015 696 262 SQ 239 10.2 12.9 1328 1:29 2058 101
'	 4 1360 1.014 373 i79 53 192 9.5 9.8 1C04 lii5 2033 195
5 2920 1.011 253 2y8 58 25; 9.4 13,3 1225 1226 1986 24
0 1:;:5 1.014 492 224 51 I94 8.8 11.2 754 E61 1903 58
7 2r'3 1.014 300 _53 62 234 6.0 10.5 33194 86S 2-•29 56
8 1880 1.013' 560 232 77 222 5.8 10.9 865 790 1842 44
9 2410 1.014 356 35^ 109 325 8.5 13.8 1253 1169 2458 20
10 ';J 1.914 473 189 61: 172 6.4 11.1 1;58 950 2099 122
	
t	
_ -	
i
11 i.Gig 6 1 3' :7 139 5.7 12.3 3. =96 1316 181
	 r"^
12 31: ;.OiC 675 225 61 ls7 6.1 11.0 SS1 842 1894 55
13 141 1.017 552 211 85 1•=0 4.5 7.7 979 770 1785 73
101-PAN-6D
I
1'G9--539 1.017+.001 572+207 221=59 7i-14
2
197•-,53 7..5.1.9 11.1±1.7 1053+167 911+175 1959+183 92+56
i
N
tTA3LE 4
24 HOUR URINE RESULTS CONTINUED
Subject 2
VOLU.,E
SP GR
,	 G! , !/'L
0S";0L
110SIM
NA
MEQ/24 HR
g
MEQ/24 HR
CL
NEQ/24 i1R
CA
M=Q/24 HR
M3
MEQ/24 HR
1?04
MG/24 HR_
URIC ACID
MG/24 HR
CREATININE
MG/24 HR
F-21 2760 1.004 394 255 80 215 10.6 11.1 1104 1325 2318
-20 171.0 1.014 525 i	 0 72 154 8.2	 ^ 8.2 1060 1094 2018
-19 >1400' 1,013 510 99 60 91 9.2 7.4 1035 1008 1904
-?8 1395 1.0:5 5122 i71 73 ?2Y 12.2 9.9 11 44 1200 2009
-17 2610 1.010 468 266 84 253 12.6 10.6 1096 1201 2036
-16 1520 1.016 530 159 65 161 8.1 7.5 790 882 173
-15 1670 1.012 4U8 16.3 52 132 10.4 7.9 868 1035• 2037
-14 15EJS 1.016 715 261 77 2"4 11.4 7.4 10714 ??38 2212
-13 S60 1.024 337 51 ?J 53 10.0 13.6 946 1221 2236
-12 1320 1.016 637 168 45 1s3 8.5 7.4 1G21 1242 1877
-11 3030 1.009 401 332 73 294 13.6 10.3 848 1394 1939
-10 930 1.016 640 7Y 47 83 6.3 7.5 818 800 1748
-9 1600 1.012 525 168 69 157 8.9 5.9 896 1055 1769
-8 lti:D 1.017 5?6 90 c3 16'2 11.5 7.0 1232 1120 20;4
-7 7200 1,.016 E5 155 56 129 9.9 6,5 270 1173 1c38
-6 2-30 1.010 3E8 221 73 !97 11.8 7.1 -1113 1316 2125
-5 1700 1.014 592 K9 5 120 9,9 9.6 1122 1258 1972
-4 1.019 6:2 11-3 76 125 S.0 8.1 1104 JGOS 1920
=3 1:;0 ?'.013 517 501 c 1-- 10.9 9.5 12-74 1353 2149
-2 680 1.025 915 774 65- 6..4 5.8 S26 911 1€63
-1 810 1.025 956 125 52 11;6 8.3 7.8 1037 1702 1863
MEAN=SD 1621±646 1.015+10.005 597+162 174+70 65+14 1 0:63 9.8+2.0 8.4+1.9 10151?32 1135=159 1971+177
HOPRO	 H+
MG/24 HR
0
.45
105	 -
-37J
5
64
75
0
277
80
0
T ^
	 i190
71
126
fi0
49
65
147
51
268
191
92+82
	
k	 i
N
C1
V Lt1J G t... 4 4
UOL ,.1E
	
8R1'	 2000
	
2	 26] 5
	
3	 16'LO
	
4	 1970
	
5	 1515
	
6	 2'j50
	
7	 1760
	
8	 1 6 10
	9	 2655
	
10	 1670
	
11 '	 1450
	
1,2	 1 2.;
	13	 2325
	
14	 2580
MEAN-.'SD 1991-403
SP GR	 051110L
GX/L	 NOSM
1.011	 606
1.009	 395
1.015	 468
1.611	 382
1.017	 698
1.010	 443
1.010	 H2
1.014	 504
1.009	 r17
1.011	 4667
1.0;4	 C06
1.012
	 5^3
1.005
	 4.:8
1.013	 131
1.012+0:003 50Z+95
C)
rd
	
Pil o	 l'	 "L	 CA
	
ME79/24
	 HR	 MEQ/ 24	 HR ME0/24	 HR 111E4/24 HR
	3 	 62	 244
	 13.3'
	
260	 53	 220
	 13.4
	1 	 71 	 159	 10.2
	
161	 83	 153	 10.8
	
195	 74	 167	 11.5
	
?6;	 82	 12	 11.6
	
1&8	 79	 169
	 9.5
]51	 67	 17i	 11.9
	23 	 74	 228	 14.7
	
14"	 43	 127	 7.5
	
.76	 72	 1^6	 9.7
	
183	 50"	 162	 8.7
	
2^6	 77	 1a3	 13.4
	
239	 77	 2G6	 14.2
	
20448
	 71+1.0	 180-35	 11.4+2.2
	
VG	 I'0gg
	
URIC ACID
ME7/24 HR MG/24 HR	 11G/24 P..R
	
7.2
	 1640	 1400
	
8.6	 994	 M
	
9.4	 1069	 IOC4
	
6.9	 906	 1024
	
8.1	 1212	 1182
	
10.3
	 934
	 1025
	
6.7'	 1^21
	 1G9]
	
9.6	 1035	 969
	
9.7	 1062	 1115
	
4.4	 835	 935
	
9.5	 1154	 995
	
7.9	 ICO	 ?128
	
5.1	 1070	 1 1 63
	
10.6	 1238	 i496
	
8.4+1,7	 1050-108
	 1109+163
CREATININE
MG/24 HR
2160
1726
1879
1891
2060
2050
1971
1837
2071
]703
1966
2168
2185
2%70
1988+168
HOPRO	 H+
MG/24 HR
8
.18
102
55
47
36
24
58
37
76
94 
^i
61
44
36
50+2T
NV
^- T
EAGLE 4
: 24 HOUR URINE RESULTS CONTINUED
Subject 2
5P GR OSuOL "tfi K CL CA MIG IPQz z URIC ACID
aVJ	 ^;',c GM/L 1^'.CSfi^t M	 l2I.E. ^4 HR tin Er^ l2^ ;;=HR	 ::I?/24 HR t1EQf'"4 HR "'EQ/-4 4R„ 14G/24	 _ HR MG 2=I/	 HR
R+0 810 1:023 757 i8 54 83 8,8 6.6 859 1279
1 1030 1.024 829 122 63 102 10.4 10.0 1195 1751'
2' 1010 1.025 E35 172. 536 ';5 3.9 8.1 1151 1273
3 '123 i66 46 1"1 13.'0 10. 1142 441
4 1150 1.023 8- 177 _58 170 9.2 11. 8 1008 2394
`	 5 lt•d0 1.0'5 399 197 55 167 11.3 11.2 1177 1214
6 2375 1.012 383 286 64 264 10.9 7.9	 ' 808' 1,092
7 1520 1'.015 492 126 6 1 121 7.7 8.0 1071 11:2
8 1240 1.022 732 „ ? 83 162 8.5 3.8 1240 1250
9 1185 1.021 712 133 53 124 8.2 9.9 1303 1322
10 1590 1.016 566 186 70 134 10.9 9.8 1073 1272
11 i--L 1.019 681 165 57- 150 9.2 9.7 952 1G74
12 2175 1.013 293 215 54 196 8.8 8.4 1175 1088
13 1570 1.014 480 1;3 86 176 12.7 8.5 105 1122
p.EkN+SD
I
1448+463 1.019-.004 606+195 169749 63+11 156+415 9.7+1.4 9.2+1.4 1085+142 1346+352
i
^i
r
{
CREATININE HOPRO	 H+
MG/ter HR MG/24 HR
1571 270
2060 232
l yi9 211	 {
2203 °187
2058 110
2024 103
2138 27
2050 144
2083 194
21 09 2266
2099 100	 Cr^
1976 134
2028 77
2057 82
2031±149 T50+71
Co
N
CREATININE
MG/24 HR
1991
1980
2000
1879
1955
1 -r-•4
2452
16686
2528
1946
2058
1377
1509
2621
1805
3-
. J
1990
2208
1927
2203
226I
2030+285
H0PRO	 H+
MG/24 HR
129
	
• 111	 -------
114
122
129
Yl
T32
99
137
127
67
130
87
655
133
74
142
94
198
270
206
128+50
24 HIM URINE RESULTS CONTINUED
Subject 3
iP C OVOL NA n U-C_ CA x!G I?04
VOLUME	 fwl/1. Muss NEi ; 24 HR M=Q/24 HR MEQ/24 HR MEO/24 HR MEQ/24 HR f iG/24 HR
F-21 1810	 1.013 =96 M 58 154 8.8 12.7 1158
-20 1800	 1.014 603 2E5 83 50 8.1 12.9 1260
-19 2 G	 1.393 552 206 C2 102 8.1 10.9 1240
-18 1620	 1.015 66-0 234 73 18 7.9 13.5 1231
-17 1715	 1.014 611 2.1 62 1%a 8.2 1=;.3 995
-16 1 e G 0	 1.011 491 2 72 193 12.0 9.2 756
-15 2270'	 1.013 566 250 73 220 9.8 15.9 1271
-14 1720	 1.014 595 234 77 206 8.3 10.4 963
,13 ?5Sv	 1.013 527 253 101 194 9.2 12.8 1651
-1'
f
1.012 X95 190 72 167 5.2 11.4 1142
-1' ;3	 1.033 521 273' 10" 242 8.6 14,3 103=
1.014 554 149 64 127 5.8 10.3 894
=5 1840	 1.012 545 221 70 201 8.1 8.9 846
-8 2	 0	 1.01ti 572 264 58 234 13.2 14.'. i.-
-7 1830	 1..013 568
212
7) 19C 9.2 10.2 i G52
-6 2990	 1.010 4';8 2; 4 1:,3 275 10.4 12.0 1C; 5
i	
-5 1990	 1.012 5C" lyl 78 149 7.1 11.2 915
rI	 -4i 2:3.3	 1.012 522 276 34 238 10.11V 13.6 1056
-3 14EJ	 1.^15 656 170 59 1:49 6.0 9.7 993
-2 1620	 1,016 479 173 C6 144 9.4 9.6 1,E5
-1 1r23	 1.010 583 169 K 151 5.5 7.6 1181
MEAN+SD 1973+3921612+0.003 547+58 220+39 79+1+ 181-51 8.6+1.9 11 '.7+2 2 1127+316
a
URIC ACID
MG/24 HR
833
364
920
1-037
1 e^^
1 090
E26
184
1053
1123
77=
846
1170
902
8't ^
960
701
X51
943±130
HOPRO	 H+
MG/24 HR
107
117
91
125
150
98
126
1 02 ^,V
89
10'3
`"r
155
105
105
102+27
CP.EATININE
MG/24 HR
3288
2691
1949
2270
26;5
2340
2150
2995
2419
1923
2103
2:,24
2134
2072
2392_398
TABLE 4
24 HOUR URINE RESULTS CONTINUED
Subject 3
Sp CR iS1401-	 V K CL CA ':v Ipp4 JRIC P,C,O
VOLUME GM/L 110SM MEQ/24 HR MEQ/24 HR	 MEQ/24 HR MEQ/ 24 HR MEQ/24 HR MG/24 HR _ 11G/24 HR
BR1 2740 1.010 324 31C 99 279 9.6 12.1 12:-0 1115
2 3457 1.007 3'9 7;G 10 25S 7.8 14..0 1035 966
3 1740 6%0 253 8; 218 6.5 13.7 94D 76C
4 2L70 1.014 250 102 243 8.3 15.3 1135 913
5 2615 1.013 559 309 1v6 ?'71?
 12.4 16.1 141" 1C-6
6 3	 F} 1.012 5^13 2_10 1C3 2C6 9.0 11.7 1310 1030
7 2249 1.013 5=C %5u 9"-
=2 6.7 12.9 1165 1039 .
8 it	 3 1.012 532 349 134 321 15.3 15.6 1010 1373
9 'cJ 1.011 "78 262 1O! -'-8 0,2 13.0 1267 1L37
10 2113 1.005 3y5 260 82 214 '1.1 11.9 1u^27 9C5
1.0:0 441 217 83 193 0.3 10.7 z^5 i;.
_ 1.01-' " 2%4 92 242 10.2 14.2 -Z'.63 1	 _
`	 13
k
_" 1:012 E17 X57 104 233 10.8 12.2 1154 110?
ly 3;4J 1.011 ?13 283 97 267 9.1 12.5 1319 1058
MEAN+SD 2651+-:4S 1.011+.0021 487,79 272+35 98+14 245+34 9.E+2.3
-
73.3+7 .7
- +1233+213 1035+136
t
i
CREATININE
MG/24 HR
1562
2214
2223
2251
2135
%2c3
2083
2245
2419
2002
19-,•3
1984
2041
2130+148
HOPRO	 H+
wG/24 HR
'171
151
201
156
170
117
246
161 2
145
162
142
298
204
174+50 i
24 HOUR URINE RESULTS CONTINUED
Subject 3'
S,; ;,R OSMOL N.I. c: CL CA MG IPO4 URIC ACID
VOLE; E Cr,^L " 03?? ? E(,i24 HR ME4/2-'. HR	 IME^i•'_4 FR MEQJ24 HR MEQ/24 i'R MG/24 HR	 _ MG 24 HR
Rr0 2130 1.013 445 136 89 -1;3 2.9- i0.1 1090 1003
1 1730 1.02Ll 650 ?50 97 1 C 6,1 111.0 1314 1246
2 2183- 1.M 5 5;4 216- 85 205 9.8 12.9 1352 1221
3 1680 1.019 688 216 66 223 7.9 10.8 1411 1243
q 6230 1.0?6 3i7 22) ss"1 28'2 ?2.3 13.1 1293 1249
5 IL, 030 1 133 7.6 10.' 11"s7 '`.
6 222:51 1.015 ^ 2.a 10.7 10.7 11;3 1%.52
7 l2Eu 1.0 2 756 7 5 57 143 S.2 11.3 918 942
8
245
1.014 491 234 72 243 3.8 12.6 1257 1078
9 2--:0 1.016 57: ? 5 90 2=-', I?. 70.6 1312 11-3
10 1 1.017
`.,Vj
r 78 2_9 ?.6 11.5 li65 K53
11 i_:.S 1.C1 525 202 72 194 8.4 13.4 1105 353
12 1C:9J 1.024 237 177 77 155 7.4 12.0 1221 937
13 ?_ O 1.023 39 232 83 232 7.1 10.5 958 1109
SEA`+SD1851-390' 1.017+.Ou'36 605+130
:
2 1 0-34 83+12 203'7'2 8.6+1.5 11.6+1.1 1189+145 1104-123
a
i
w
J
as
1
07	 2442	
_	 212
5s	 2100	 0
74	 1879	 98
X87	 2059	 13
95	 2367	 22
S3%	 2GE6	 160
93-	 2x39	 23	 ---
0 ;4	 2327	 0
8-3	 1959	 74	 i3
78	 1522	 30
Sul	 18.99	 12
C _=	 2=56	 8i'
8s2	 2290	 137
102	 2203	 26
714	 1842	 152
253	 3G i6	 255
12N	 234
9 1 3	 2231	 81
S73	 2137	 89
015	 2415	 74
791	 2064	 14
95+159
	
213.1+488	 88+82
wN
i
.w
	
s
I
i
a
TABLE 4
24 HOUR URINE RESULTS CMIT-NUED
Subject 4
:C	 CL	 CIA
' HR 
	
',G	 1P0-a	 URIC ACID	 CREATININE	
HOPRO	 H+
S" GR	 OS,SOLa
^	 P`=C ^4 tiR hi`^ 24 HRt?EO/24 F:R	 MG/24 HR	 _ MS/24 9R	
MG/24 HR	 MG/24 HR
VOWNE GM/L "'4S + i ^OJ^ .^ INK PiEQ/ > -!/-
F- 21 925 1.025 IW O
158 60 i	 6 9 1 12.5
1271 9
-20 875 1.022 1089
2'32 63 1i0 8.7 5.7 8-3
8
1105 1.019 823 291
4E 197 10.3 8.7 801
7
-19
14-3 6 1.012 695 22& 62
200. 9.8 10.1 915
-
-17 ' 171 5 1.015 6%: 298
65 271 11.3 7.i 1132 S
'	
-1b; 1260 1.017' 6E4 162
62 159 7.0 8.6 1084
{	
-15 1415 1.017 i 65 264 71
T r'-.7 7.8 *
_14 2`{75 LCQ7' 551 -Z:;i 79 239 i.^..0 9.1 Sub
1.
-13 12P-0 1.017
: 3 236 57 208 9.0 10.1 1166
-12- 1780 1.011 519 198
6G 12,'5 7.0 7.3 926
_17 1^_
u j
1.021 834 197 76 175 ^.9
6.8 992
-10' 1 1	 ? 13•:9 :7S 7U 1E2 :.3 12.2
11-".Q 1
- 9 1x35 1.017 53? 139 E3
133 7.1 7.9 1036
-8 '1620 1.015 646 237" 62
178 5.3 10.7 97c - 1
- 7 ' .;z3 l.Qi9 812 175 EO lE 11.4
11.6 959
-6 1-160 1.026 1057 2;;6 74
194 9.0 12.3 1=25 1
-5 400 1.027 110, 3a 29 8 4.c,
3.0 290
-4' 1690 1.012 543 197 59 164
2.0 7.5 1032
-3 970 1.021 910 222 58 176 7,6
8.5 834
-2 1750 1.014 v28
271 74 210 E.4 9.7 108- 1
-1 1720 1.014 622 292 77 225 E.8 7..0 929
MEAN+SD 1350+4291.017+0.005 751+198 215+52 637:2 185-`s9 8.6+1,7 9.1+3.0 992+224 8
1
Subject 4
Si GR GS'•;OL ,	 NI A K CA
I 
p01 q URIC ACID CREATININE	 HOPRO
VOLt`:,!	 Gm/L IMOSM MED:/'24 NR t7EQ/2-°. HR M..Q/j4 HR ME4/24 HR MEQ/24 HR MG/24 HR	 - MG/24 HR MG/24 HR	 MG/24 HR
8R', 1490	 7.018 609 271 70 200 6.5 8.1 1341 1013 2354
610	 1.023 1191 .!3 57 1:Iw 5.5- 6.5 708 683 1513
7.10'	 1.029 1192 159 64 i	 :2 6.6 7.7 858 ,5a 13 6
4 1020	 1.025 107i 275 237 12.0 6.6 1122 559 2183
.	 5 800	 1.014 iES 153 51 130 2.4 2.4 443 550 v56
6 1345	 1.020 E8- 2E: c2 ?r7 10.9 10.9 +076 9?5 2233
7 9660	 I . G26 10:93' -:5 2i3 S.E 4.1 1075 8= IM
650
	
1.029 1 122 1'75 5 155 E.3 7.7 767 Z33 1€6'
9 760	 1.028 1155` 16 -7 14= 8.5 9.1 973 745 1520
10 1255 	 1.028 1161 287 10- 267 13.0 14.1 17?6 1255 2560
11 1195	 1.022 813 5,15 63 22-3'2 9.1 9.3 1123" 1CG
12 910	 1.024 373 i85 62 1.83 7.9 3.2 892 72,3 162.0
13 870	 1.029 1111 211 4 1'5 4.1 8.8 1096 940 a93Y
14 '2210	 1.016 573 ' 287 84 257 11.5 12.1 1252 1159 23;.7
rEAN+SG 1059=425 1.024±.005 984+222 218+54 67+15 194+47 3.5+2.9 8.3+3.0 1040+320 852+226 1938+478
wf,..
H+
106
197
218
100
0
100
86
154
229
61
76
117
43
120=69
J
J
W
W
3,	 .1_ 'awe.,....,........a::.^....,.,.,.e.....:^.,._,^,._._..._... ..._,....,.^...:..^ ...^^...:.,^-......«...,,::,.w-..._..,_-
-.;.:^_a......_..,...^:_,..
	 -
i
"	 1
TABLE 4
24. HGL'R 'URINE RESULTS CONTINUED
24 HOUR UR ME RESULTS CONTINUED
Subject 4'
SR GR C%-12L N,4 Cc C MG
TG04
URIC ACID CREATININE HOPRO
	 H+
I VOLUME GM/L 1<04 MEQ/24 HR M}Q/24' HR ^,?F„2''. HR , ME Q,'2--, HR	 MEQ124_ HR MG/24 HR _ MG/24 HR MG/24 HR MG/24 HR
R-0 67G 1.032 1145 125 70 130 F.8 -7.9 101'5
-1085 1970 326
i ISO 1.031 1135 .59 fit 144 61.7 8..8 998 1154 1872 I26
2 1vC0 1.021 783 2E4 75 225 10.5 10.0 1230 1200 2070 46
3 1905 1.016 370 290 50_, 220 9.2 9.8 1029 953 1867 15
4 21510 1.013 482 241 6?, 217' 10.0 10,2 1205 12C5 2314 103
5 1635 1.015 535 18 49 159' 8.8 10.3 818 1112 1831 77
6 10>0 1.024' S41-4 K9 ' 43 :8 8. 11.5	 ' 132? 1239. 2415 253
7 715 1.023 529 -'1';v G6 161 E.7 3.3 458 901 1344' 0
8 1610 1.01t 512 1o0 53 177 7.0 8.0 837 966 1596 93	 E.^
9 1180 1.022 '92 181 44 i	 5 11.5 19.8
1345
1912 2242 242
10 1120 1.023 833 1Q-7 49 161 9.8 14.0 1075 1523 2106 238
11 1590 1.017 610 234 54 195 6.6 8.5 1113 1031 1940 88
-	 12 990 1.0^1 784 158 56 15E- 5.5 7.3 752 950 2020 171
1:3 1370 1.019 700 .21 73 134 8,6 7.4 986 1059 20233 25
MEANT-So 1323+492	 1.021+.006 730+240 197+48 59+12 177+41 8.2+1.9 9.8+3.7 1015+240 1168+266 2001+255 129+102	 1
a
ed
4
W
i A' 	 4
TM-LE 4
24 uL z^ v:c'_t;F  RES ULTS CONTINUED
Subject '5
v
S  GR. =,	 O K l- U-CA U-MG U IPO^ U-URIC AC I D U-CREATINIME	 U-HOPRO
{ O!1	 v?it G', r	 C.,,:	 M '	 I	 u,:,...	 _ .	 t ;R ME Q/24- _ 	HR ^GCn/^
	
1MEQ r^ 7QMEQ/^ 	 HR M EQ! 24EQ/  HR 'SMG/ 2 .. R t'rG/24 HR fr ^^	 rP..:/2+ HR	 MG/24 HR
F-21 :270 71.019 832 250 85 ` 234 5.3 10.8 1118 555 2184
- 20' 1645 1.023 928 173 88 155` S.5	 1 10.9 1170 961 2341
-19 1020 1.0021 °263 182 54 137 10.3 10.5 1204' 7175 1836
-18 1375 1.0': 9 a:5 273 84 249..' 10.2 9.5 it 2g 93; 1980
-17 13671 1.v^3 572 246' 74 212 11.4 14.7 1--'.20 1010 2375
-15 1600 1	 024 567 183 73 173 9.4 10.5 1320 920 2300
-15 71135 1.022 ` 944 2-20 59 199 7.7 9;' 1112 863 - 1521
-14
a
9,03 1.023 338 1Eu 5;_ 129 9.6 10.4 11	 2 7 2 1980
-13' IC30 1.023 > <1 i91 75 1:,2 10.9 10.4 1092 S-1-5 2225
-12 860 1.025 iO-Js 153 E2 12E 0.8 10.3 1135 740 1961
-11 1130 1.C22 055 S01	 "- 72 225 10.66 b.4 1175 M4 2079
Lp	 -10 1120 1.021 911 230 55 2C5 13.1 12.8 1058 896 2218
€	 -9 1 40 1.0?2 962 230 267 18:' 9-.4 3 ;144 680 1914
-8' 1150 1.329- 525 265
_6 23.
10.3 y.4 1150 871 2070
k	 -7 it	 0 l.0 ;T4 b ;,'c 2-^ 1	 .2 9.3 1204 226 1959
k	
-J 5<;J 1..:?.b 10;:. 1-0 7^ 1=1 i -.i 1[.y t'':5- Lag 2215 4k
-5 " ?GJ 1.'J21
.
7171,47 92 53 -u' 7.4 6.1 812 686 1988
-4 c?r 1.02$ 1C v cy
- 70
8.1
8.0 1026 783 19C4
-3 1C''.^ l.v<Y ,'j "a 22 7 ' -3 9 7 o ? 7117-
I=,J
2262
-2 C. 1.022 ^y :? 73 175 7.J 7.4 7^C. 8i,"^ 1,969
_^
_
i 1	 ^')..VLY JJJ ^.;? ^.- 178 13.9 0.E1 ' J4T 9211 2112
t?=AN+SD104o=1$0 1.G23+.072
-
959--62 
_
2"5+57 69+713 177-48_ 9.8+1.5_ 9.8+2.4 1158+122 860+93 2068+202
}l
i
H+
85
221
167
100	 y
105
303
199
292
2245
308
139
235	
1
`^6
187
1C9
392	 t
441
265
290
253	
3
244+106	 W^
L43
Ln
TABLE 4
24 HOUR URINE RESULTS CONTINU ED
Subject 5
U -5P GR U- pl- l: L-:,n U -MIG U-1P0 U-URIC-ACID U-CREATIRINE U-HOPRO H+
VOLUME Gir/L roJ,m M	 „'?4 HR MEQ/24 HR .` --Q/24 HI? MEQ/24 HR MEQ/2 4 HR MG/ 2-4 NR., MG/24 HR MG/24 HR MG/24 HR
`	
36.11 1110 1.022 952 2=O 76 202 10.4 9.2 1199 844 2020 219
H	 2 1015 1. d'17 771 220 43 163 9.3
J
6.9 774 645 7527 101
	 - -- --
I	 3 970 1.018 S64 Jr! E3 161 3.8 8.3 1OL4 73'. 2088 390
4 ^?0 ^.t.	 27 Sri ,d 51 uY 10. 1 .3 E39 735 1417 37
5 71 vA7 1.021 41 2,9 66 223 10.7 8.2 X36 845 16=7 108
I_	 6, i 65
"L_ '1.0., i ,-,:9 ';'70_ _ 96 250
7 
.14 7.6 1802 1092 28,2 375
7 1620 1.019 875. 2Jc 91 217 116.0 111.7' 12664 1037 2560 144
8 945 1.017 731, 154 133 9.7 6.6 7014 58, 124 155
9 103G 1.021 ::i3 i66 65 151 11.1 13.2 1u3Q 8u3 7833 263
10 1700 1.{021 8_6 3=' 126 31:6 16.3 17.0 1632 12 9- 4 282-0 -.1ISO	 ('^
71 1190 1.024 912 254 74 219 12.4 i1.9 11l9 1333, 1952 127	 (7)
12 11F0 1.025 921 211 81 196 12.1 11.5 1322 1160 2178 278
13 1390 1.0°0 743 205 66
-170 10.0 9.6 9S8 968 1572 178'
^i	 14 1150 1.423 53, 232 75 218 11.4 10.6 952
-1023 1923 174
MEA?++SD 1179+2471,"021-0.002 863+115 230=51 73+21 202+47 11.9+2.8 10.0=2.9 1108+317 932+225 1992+489 195+101
•
1
Q1
i
TP^i;i.^	 4
24 HOUR URINLE RESiLTS CONT'MI-D
Subject K
U-'_ It	 Gil ti- GS :3 1 U-t'ti U-K U-CL t:-Cn U U-ISOf- L,'-t;RIC ACID U-CREATMINE U-HOPRO	 H+
t`iL ;t^E G;;/L .. r3 M^' /2Y HR IMSQ/2-? HR tip:°'24 HR f<rQ/24 HR MEQ/24 HR MG/24 HR i!u/2 =. UR tiu/24 HR MG/24 HR
R+0	 si" 1.OZ6 917 1'2 65 113: i0.$ ia.9 1152 1280 2052 324
l	 {0 1.0?C 962 19'3 76 % a IO.0 i0.7 9'.2 ?0;5 1900' 1$5
1130 1. 025 9513 ? i4 75 202 13. 5 12.9 1107 1255 21; 0 179
3	 815 1.023 9:'.3 253 63 151. 7.1 5.4 676 777 1453 66
4	 1^4` 1.024 °s1 ^''d 8$ 25^ 12.2 15.fi 1 -4 J '.c^oo 205
5	 88:0 1.020
1
7 r 5 1 E9 8.3 9.4 M . u _. 1 3a 76
6	 060 i3O2$ l	 := 173 :,`2 i70 S.7 12.+ 1+40 1,229' 2688 46$
7	 1490 1.022 552 234 79 218 11.7 13.1 1460 1252 2712 196
8	 6csO "1.030 1059 79 64 ,3 5.6 9.5 1132 1297
	 - 2070 534
9	 715 1.0-99 6.12 & : 53 5q 6.E 11.7 1115 872 1859 360
i;.. 10	 1250 1.025 670 90 255 10.2 1--', . 9 ? i =+0 1 ? 75 2250 90
it	 910 1.026; S36 209 61 198 8.2 9.6 1001 783 1911 257
12	 7660
t
1.029 1034 154 62 139 6.5 9.7 11/13 973 2204 436
13	 610 1.032 1125 86 62 56 5.4 9.6 952 9?5 1530 537
l%'MN+SD 961-259 1.026-0.M3 893+171 181+69 59+13 167+64 9.0+2.6 11.2+2.5 1089_256 1054_2 11 7 2079+419 249+161
a
o
S
a
l
1
W
V
r
P
rzF..^
24 HOUR URINE RES,ILTS CONTINUED
Subject 6
:'OLF, l' l!-K .-E" -LA U-.MG L'-I?OY J-'iR?u "CID U-CREA :MINE U-HO:PRO H+
VC`!JV.E G`: /L MOM i^ .,, _t: i R ,F-Q/24 HR	 ME", /2 HR ME,)/Z'--• HR MEQ/24 :HR i1^/2	 :1R MS124 HR MG/24 NR MG/24 HR
BR1 1375 1.0;5 667 2^!4 53 15S 10.0 8.8 790 743 1660 87
2 1665 1.021 S%2 2:.2 53 199 11.;' 9.0 111 29 E95 1739 1182
3 1;8r" 1 .018 730 !P5 74 185 i9 . 8 1	 . "s 1154 9^.' 2250 218
4 Q 0 1.	 31 2C' 151 50 49 3, b.9 750 655 1161 218
k	 5 17=.0 1.015 6 -57 y+5,, 95 234 14.1 11,1 1G73 1073 2284 18
6 1.1 0 1.021 8-1-t ?EG r^ i^7 8.6 9.4 923 E70 145$ 191
r	 7 11 ,1^ll4 i .5115 3`i?A 2	 1 r9 V7 11.8 8 95C 11'8 1795 97
6 1'I	 0 1.019 1 r5 237 79 cl 12.4 11.0 1092 931 s•^'E`" 101
9 111110 1.013 733 11-19 E21 i	 O 11.2 10.5 7-3E 772 1755 178
1J 970 1.017 884 157 62 164 11.5 11.5 b'92 834 1E FS 127
11 14'31 1.01,8 663 2125 76 219 12.0 9.2 515 915 19113 0	
i12 1,'',;J 1.319 707 205 53 157 11.9 7.0 912 888 1655 0
13 9: 11013 E82 221 64 203 12.7 111.6 745 G17 1668
QY
114 1=	 5 1.Ol5 733 213 E8 132 ':1.1 11.7 11156 1040 ??62 105
t. ! :'AN-tSO 1250-2601.016J-0.002 759+95 207+35 64+14 184+32 11.9+2.7 10.1+1.9 935+182 868=1128 1782+?57_ _
- -
- 115+75
. 1	 -e
1
)
w
Co
4TarELE_
24 HOUR URINE Rcc ;3 r..TS COh'TIMUED
Subject 6
11-2v GX U - C L L,-	 G. U-;iG U-IPO4 U-URIC ACID U-CREATIVIINE U-HOPRO H+
lrL'_l ` E G;1/L 13 S *rl E;/	 •"':	 HR hE x!24 Fc2	 _, 2=: HR PQ/24 :,3 14EQ/24  HR t1G/2 4.	 R 116/24 :Hr3 P1G/21r HR HG/24,4R
F-21 1455` 1.'^3 9y 257 EO 270 12.0 14.5 1^^7 1150 2755 230
-20 1.95 1.J," 7Z; _'-v 5+ 2
 10.2 , 1G.8 932 1839 17
-i9 121;80 .012 39 =2e 53 7.8 6666 666 1510 29
r
_?8 1C;0 1:C?? 91'': 2C5 70 175:9 8.9 945 $?9 2GlE 33
f -17 116J 1.02J c 7 `2'_5 ^7 215 11:1 8.8 812 76C 1750 i?
-.5 i0510 1.01-'1 851 " : 67 19[ ?. 8.5 9u7 778 1879 93
-15 :4^_5 1.020 871 3 12.2 ' 13E8 103 5 2337 88
ff ?:'a t: 0C9 E°9
6'
_2 3
-
1 i 
.3 8.2 847 8.2 1765 21
-13 11 } 0 l :'J? o ^^0 a S ri 49 ?2=} 7.7 7.8 83, 733 11843 145 --
!,
-12 13 0 1.015 6B 2 3
.7	 . 5.0 £04 691 1528 0
- 1 1, 15 -s 1:.01' S:3 2- A 73 :.3 9.0 7.9 134i 890 18863 100
- -10 2 1.L21 5 ? .9 7.2 8 -.7 055 1411 228
1 120 1:U19 7 u :i 73 ?	 9 6.4 7.8 :1075 805 725
y 1
-8 1610' IX14 E3i 241 93 1:'5 8.7 8.5 1127 837 2061 87
I
-7 1!2p 1.0?' 629 2;17
-
57 1F2 5.9 7.66 952 E83 1313 105
-5 11139 1.P-2t 9:3 007 71 18i 7.5 11.3 1050 EE5 18854 174
r
5 1',C_'l 58 10.6 1,126 827 1725 419
K
1.019 802 58 18 r 8 ?._ 2.9 346 256 E83 210
-3 6;.i! 1.0233 953 198 52 ?60 7.0 7.2 1033 845 1707 80
-2 `c 4, 1.022 c"89 T11I 56 141 6.2 7.1 869 692 1707 299
-1 13G0 1.017 712 235 55 ?:= 8 8.5 10.1 a38 8"84 1876 10$
-w-•-
zA; z Sr
_
1146r'^,Si.019 =0.00? +812 125 2095_ 63+16 ? 80+>8
y
8. 6.2.7 8.6-2.5 969-t-254 794+173 1773+4p2 124+1 C6
8
t
TAPL E 4
24 HOUR U2It,E RESULTS CO;^.TDIU_D
Subject 6«
U-SP G U''"10L `.;-;.i, U-IPO4 U-G:?IC ACID U-CRSAT£:,IfE U-HOPRO H+
V0LU E GIM/L t	 SH V. 	 02)4 P. ;I64	 4 a MEQ/24 iR J,-Q/24 HR 1iEQ/24 HR MG/24 HR ^ MG124 HR MG/24 HR Mu124 HR
RYO	 11 10 l . C20 6 9 1.^ 7n 119 £:.7 8.y 844 ' ' &83 1 bo y :. 2231	
720 1,027 T-i6 1	 3 -_70 112 15,0 7.8 873 752 1584 •120
9	 1260 1.019 678 227 s3 176 7.7 8.2 958 983 '865 2
I:	 3	 15;3^. 1.017 623 `'=6 65 ' 2i2 r.5 9.4 1082 i 0 51 1751 ^ 104
4	 1370 1'.016 3 -. .2•=l 77 2C7 7_.0 7.9 986 959 12263 22
S	 810 1.026 953 ?50 51 --i 7:2 9.3 1134 1037 1652 375
6	 400 1. ,28 10" 173 ^ 6 1_^5 7.4 8.0 894 ' 998 1617 311
7 1'.026 a-^7 239 76 7 .1 9.8 11-6 7106 1839 109
8	 7 3 ,	 ^:., 22 =? ,2_ E•.0 11.2 926 1250 1852 4412
91015 1.021 i,5 43 ?'	 9 E.5 8.8 731 1096 1604 188
s
10	 11,790 1.020 :;7 '0 222 E.8 9.7 1036 1?40 2035 124
11	 1 ?30 1.025 956 27 70 223 ;•.7 9.3 1333 1107 1853 110
12	 ? 150 1.022 5'7' 182 60 118 E.1 9.9 1012 983 1817 262'
k	 73'K	 L10 1'.02; 9.70' 74 29 72 -2.2 5.2 538 500 943 415	 1
M_E
 N+SD' =5+2611.021+0.006 78>+134 193+57 65+11 1711-4Z 3.0 *-2.2 9. C+1.0 1000+155 1030`117 1776-145 201+142
*Mission Day R+13 Not included in ;!lean + SD Calculation
0
TAB"';5
URINARY >HORMONE RESULTS -^- -
CORTISOL EPI NOR ALDO ADH
Subject 1 VOLUME* ug/TV ug/TV ug/TV u9/TV mU/TV
F-21 2215 94.1 40.6 45.7 6.2
48.2
-20 1655 95.2 11.5 41.6 5.8
105.6
-19 800 52.0 2.6 27.0 7.7 56.2
-18 915 59.0 6.2 35.9 5.7 42.7
-17'; 2180 112.3 7.7 39.6 3.5 43.5
-16 1280 68.5 12.8 47.0 7.7 57:8
F:
-15 1770 97.4 7.2 36.2 11.3 56.6
-14 1760 82.7 8.9 36.2 12.8 33.9
-13 1800 63.9 21.6 66.6 12.6 31.2
-12 1720 28.4 15.7 22.0 6.2 23.0
-11, 1380 69.0 15.7 29.7 7.5 27.6
-10' 1120 104.7 15.8 37.0 3.6 27.8
-9 1510 14.7 LTD 37.4 17.0 24.2 }-^
• -8 ` 1535 42.2 17.1 41.4 10.8 33.7
-7 1260 48.5 11.6 44.0 12.1 62.2
-6 1775 54.1 38.5 36.6 6.6 89.7
-5 1540 39.3 24.1 34.3 9.9 31.9
F
-4 1080 45.9 11.0 24.5 13.4 43.2
-3 1780 51.6 42.6 30.5 13.1 29.8
-2' 1220 36.6 23.9 40.1 18.3 23.5
-1 855 33.8> 1.4 28.5 11.3 27.4
MEAN+SD 1483+400 61.6+27 16-.0+12 37.2+10 9.7+4 48.5+23
BR1 2180 41.4 15.5 21.4 11.5 40.6
2 ` 3230 77.5 20.3 22.0 11.4' 37.8
3 1400- 65.8 13.2 14.3 9.5 17.9
e 4 1450 77.6 21.7 31.5 25.0 67.9	 -w - --
5' 930 79.0 11.1 21.6 12.9 24.8
6
1100 56.7 26.9 21.7 11.8 36.5
1580 77.4 8.3 21.3 16.4 56.7
8 1670 .40.5 1.4 22.3 11.9 44.7
9 2345 84.0 7.1 31.5 20.2 45.2
10 1400 40.6 5.8 18.8 11. 2 31:6
;Mf 11- 1380 92.5 8.2 46.2 15.4 26.7
•SV'*+r+.IM	 ',w	 .-.	 .	 : 	 ...
{
a ..	 .r .'.Y.	 ar.	 «..:. ..+..eYM1HTi'»'i
_	
.........-.	 ._..	 _	 ....	
._._......	 _
E +
T
.
Jj r
URINARY HORMONE RESULTS CONTINUED ---	 -
CORTISOL EPI NOR ALDO	
- ADH
Subj ect 1 VOLUME • ug/TV ug/TV ug/TV ug/TV mU/TV
BR12
43.9
42.01930
111.0 5.1
26.2
r	 30.2
9.8
22.5
13.0
13
14'
1505
1520
59.7
91.2 15.0 27.6 12.4 29.3
R+O 1250 30.6' LTD 62.8 23.5 26.6
1 1'230 48.0 19.9
40.8 18.2 23.8
2, 925 62.9 15.2 36.2 9.8 3'4.7	 s
3 1660 64.7 LTD 78.0
16.7 41.1
4'' 1860 59.5 25.2 45.0
11.1 32.2
5 2920' 27.7 37.8 27.3 9.2 29.6
6; 1795' 29.6 LTD 42.5 9.4
57.6
7 2070 50.7 7.8 35.2
9.2 23.7
8' 1880! 150.4 2.8 45.8 11.3
20.0
9 2410' 36.2 LTD 194.3 7.4 33.8-^
.10.
f.
1980 75.2 2.1 52.8 9.4
7.1
40.9
20.01195 56.8 4.2 41.3
I	 12 1315 75.6 LTD 50.7 6.4
38.7
E	 i3r  1440' 46.1` LTD 60.3 6.7
59.5
iURINARY HORMONE KASULTS CONTINUEp
CORTISOL E?I NOR ALDO ADH
Subject 2 VOLUME us/TV ug/TV u9/TV u9/TV ` mU/TV
F-21 2760 138.0 38.0 67.1 16.6 42.3
-20 1710 100.0 40.3 61.5 17.3 54.7
-19 1480 101.5 22.2 51.2 4.5 26.0
-18 - 1395 104.6 20.0 73.5 20.6 48.4
-17 2610 144.9, 17.0 59.2 16.2 36.5 --
-16 1520' 88.2 9.2 55.0 13.2 38.4
-15 1670 112.7 13.0 71.9 19.8 36.6
-14 1580' 104.3 13.8 68.2 15.1 41.0
-1'3 860 16.8 22.3 117.1 8.0 18.8
-12 1380'; 151.1 19.0 72.3 5.3 41.4
-11 3030 92.4 21.6 62.7 17.4 33.9
_10 930' 83.7 3.1 62.3 22.2 18.0
-9' 1600 12.6 6.1 54.3 19.3 33.2
'-8 1400 84.0 23.2 70.2 24.5 40.9
-7 1280> 76.8 LTD 95.4 25.9 38.3 ;,	 -
-6 2530 46.8 38.0 63.1 16.1 52.4 G.r
-5 1700 60.4 6.6 95.3 21.2 23.7
-4, 1200, 11.3 53.3 34.0 40.0
-3 1990` 122.4 36.8 79.3 33.7 57.2_
-2 680 46.6 14.5 54.3 18.7 18.9
-1; 810 ` 54.3 LTD 64.7 20.6 1.3y
: MEAN+SD 1625+Fa5 86,0+38 17.9+12	 69.1+16
_	 -
18.6+8 35.1+15
BR1 2000 75.0 21.1 43.9 20.9 57.2 -
2 2615 83.7 19.0 31.4 19.8 43.5
3 1620' 85.0' 19.1 29.6 41.1 33.5
4 1970 101.5 13.9 37.9 41.4 55.0
5 1515 113.6' 15.2 26.9 27.3' 34.3
6 2050' 143.5 14.2 64.4 38.4 48:07 1760 120.5 8.5 27.6 28.4 53.88 1670 -112.7 7.4 29.9 27.6 56.69 2655 192.5 0.2 47.2 20.9 42.510 1670' 40.9- 6.9 22.5 25.5. 37.7 {,11 1560- 106.9 11.7 48.9 23.6` 48.9 I
ca
TA?7', 5
e.
f'
t
Subj ect 2 VOLUME °
URINARY
OORTISOL
ug/TV
HORMONE
EPI
ug/TV
RESULTS CONTINUED
NOR
ug/TV
FLDO
ug/TV
 ADH
mU/TV
BR12 1,880 105.3 5.0 29.4 250 40.0
13 2325 131.4 24.8 21.5 20.9 57.4
14 2580 80.0 36.3 24.2 30.5 89.4R+O ` . 810 30.0 16.5 41.4 23.0 7.6
1' 1030 29.9 12. 1 64.5 22..7 28.3
2 1010 20.7 8.8 45.2 16.1 33.53 1360 44.2 29.3 33.3 17.4 30. 0
4 1050 52.5 15.6 60.0 28.2 37.8
5 1840 156.4 23.1 49.9 23.5 51.76 2375 71 .2 0.2 70.0 20.3 50.07 1<520 53.2 13.9 62.1 38.5 39.4
I
8 1240 89.9 3.3 69.3 29.3 44.8
9 1185 80.0 LTD 85.6 12.7 37.1
• 10 1590 56.4 LTD 108.3 13.4 47.7
11	 . 1220 54.9 16.4 60.1 12.3 77.812 2175 57.6 11.1 73.1 10.4 50.8
r
f.
k
I
13	 '' 1870 105.7 LTD 135.0 16.9 65.0
cr -
^
i
URINARY HORMONE RESULTS CONTINUED"
CORTISOL EPI NOR ALDO ADH
Subject 3 VOLUME'- u9/TV ug/TV u9/TV ug/TV mU/TV
F-21 1810 52.5 4.9 73.6 3.5 23.2
1800 82.8 10.7 61.8 3.4 24.3
-19 2000_ 67.0 24.9 43.3 1.0 29.3
-18 1620 70.5 71.5 39.1 3.8 23.8
-17 1715' 77.2 62,4 42.4 4.7 14.1
-16 1800 63.9 34.7 36.7 3.7 39.6
_15 2270 80.6 35.1 55.1 8.9 43.8
-14 1720 71.4 28.1 34.4 4.4 31.1
-13 2580 58.1 77.7 56.6 10.9 44.7
-12 2115 33.8 30.0 40.7 7.2 29.6
-11' 2350 98.7 47.0 54.3 10.4 31.4
-10 1490' 43.2 36.1 35.6 7.2 27.7
-9 1840 27.6 9.5 52.7 8.5 19.2
. _8 2340 76.0 61.1 69.7. 14.4 60.8
.7 1880' 25.4 26.9 26.6 7.1 38.8
-6 2990 26.9 57.2 52.1 8.2 24.7
-5 1900 26.6 52.4 62.3 9.1 57.2
;i	 -4 2400 21.6 20.2 53.1 8.2 33.6
-3 1460 21.2 35.2 32.2 11.4 39.8
-2 1620 31.6 22.6 54.4 13.0 73.4
_1 1640' 20.5 20.6 50.4 11.5 45.8
MEAN+SD 1969+392 51.3+25 36.6+21 48.9+13 7.6+4 43.7+18
BR1 2740 31.5 34.1 37.2 10.8 24.2
a'
	 2 3450 63.8 28.2 42.4 13.2 37.7
3 1740 38.3 26.6 33.7 10.6 36.0
4 2270' 124.9 42.6 30.6 14.7 34.7
5 2615 69.3 80.7 37.6 20.2 41.8
6 2340 90.1 43.1 74.1 19.8 48.4
7 2240 70.6 9.0 45.1 14.9 41.7
8 3120 166.9 10.4 55.8 22.7 64.8
..	 9 2880 40.3 LTD 57.5 16.1 27.6
10 3020 19.6 5.9 40.4 13.4 ` 23.3
t,
2510,. 59.0 35.9 45.7 11.7 32.1
TA(": 5
a
I
i
i
IVA-
6 
t
TA	 5
URINARY HORMONE RESULTS CONTINUED
CORTISOL EPI NOR ALDO ADH
Subject 3 VOLUME • ug/TV u9/TV u9/TV ug/TV mU/TV
8812 2630 35.5 33.3 71.1 15.8 31.5
13 2425 59.4 36.9 22.9 7.1 20.1
14 3140, 98.9 40.6 29.4 12.9 26.8
R+0 2180 52.3 41.2 33.8 18.1 46.4
1 1730 90.0 65.8 63.9 17.1 47.2
2 2180 117.1 35.9 85.2 15.6 52.2
3 1680 90.7 44.5 56..3 12.8 47.0
4 2230 27.9 48.6 67.8 15.8 34.3
5 2030 44.7 46.6 61.8 14.2 31.1
6 2235 57.0 LTD 124.0 13.5 43.27 1280' 50.8 9.9 76.4 8.2 32.4'
g 2245 76.3 9.7 67.3 19.2 45.0
9 2050 53.3 26.7 108.2 4.7 79.5
.10 1820 22.8 35.9 84.0 5.4 30.3
11 1905 33.3 61.8 44.3 5..6 44.5
12 1090 52.3 14.8 90.3 7.7 57.7
13 1260 69.3 36.1 87.8 6.9 12.1
G<
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URINARY HORMONE RESULTS CONTINUED
CORTISOL EPI NOR ALDO ADH
Subject 4 VOLUME u ug/TV u9/TV ug/TV u9/TV mU/TV
F-21 925 76.3 3.2 46.5 18.9
19.8
-20 875 79.6 7.2 32.5 13.7 78.9
-19 1105 88.4 8.1 35.7 15.7 36.3
-18 1430 125.1 6.9 38.9 17.4 28.5
-17 1715 63.5 I	 2.2 42.0 24.2 57,0
-; 16 1260 74.3 10.8 48.8 17.1 38.6
-15 1415  31.8 2.7 39.7 18.4 33.8
-14 2195 85.6 15.7 45.4 36.6 36.5
-13 1240 103.5 7.4 42.5 13.3 19.1
-12 1780 40.0 1.3 34.7 21.1 23.3
-11 1055 23.7 7.4 36.4 10.1 29.4
-10 1900 44.7 7.0 48.6 21.7 121.9
-9 1205 25.9 9.9 51.9 13.7 38.4
-8 1620 35.6 3.6 72.4 20.2 49.7
-7 940 31.0 11.8 28.8 13.4 27.1
-6 1160 51.0 30.3 57.5 25.2 16.2
-5 400 23.6 3.6 35.3 10.2 27.5
-4 1690 39.9 7.5 31.2 19.9 58.8
-3 970 35.4 11.9 27.2 19.9 28.6
-2 1750 93.6 4.4 39.0 21.4 51.5
1720 110.1 12.1 33.1 20.3 71.3
MEAN+SD 1350+429 61.1+31 8.3+6 41.3+11 18.7+6 45.3+29
BR1 1490 62.5 14.2 22.6 27.3 54.5
2 610 68.3 7.8 14.3 15.8 48.4
740 70.3 6.2 33.1 20.4 17.6
4 1020 137.7 6.8 18.3 '19.0 47.6
5 800 45.2 1.6 10.7 9.7 30.7
6 1345 104.2 LTD 29.9 27.6 36.0
7 960 79.2 0.3 21.3 18.2 23.0
8 650 87.8 0.4 17.3 15.8 41.3
9 760 93.1 2.1 20.3 27.2 24.0
10 1265 86.6 1.4 33.8 44.2
S
URINARY 'HORMONE RESULTS CONTINUED
CORTISOL EPI NOR ALDO ADH
Subject 4 VOLUME* ug/TV u9/TV u9/TV u9/TV mu/TV
BRIT 1195 164.3 10.4 21.6 20.3
25.6
12 910 88.7 1.0 24.3 18.1
14.6
13 870_ 63.5 7.8 20.9 13.2 40.6
14 2210 116.0 8.4 19.9 18.4 108.8
R+O 670 127.3	 J 15.7 28.4 23.9 30..6
780' 50.7 12.9 32.8 18.5 31.2
2' 1500 112.5 21-.9 31.9 17.6 68.0
3 1905 138.1 4.1 41.6 18.0 47.0
4' 2410: 69.9 1.1 46.5 19.7 37.0
5 1635 95.6 LTD 61.1 19.4 65.4
6 1050< 60.4 LTD 75.1 14.5 46.9
7 715 68.6 2.5 25.0 5.2 49.0
8 1610 84.5 0.3 42.5 9.2 55.6
•;9 1180 83.2 0.3 63.4 12.2 41.9
10 1120 61.6 LTD 66.2 14.2 38.3
11 1590; 58.0 7.3 47.6 10.6 63.6
1-2 990' 43.1 0.7 33.8 14.5 23.8
13
fI
1370 113.0 LTD 54.7 10..7 51.5
y{
_ r
I
c
co	 '
TAB. 15
t
URINARY HORMONE RESULTS CONTINUED
Subject 5 CORTISOL EPI NOR ALDO ADHVOLUME ug/TV ug/TV uc,/TV ug/TV mU/TV
F-21 1270 58.4 LTD 52.7 4.4 88.4
-20 1045 54.3 17.4 48.3 7.9 39.9
-19 1020 90.6 3.2 39.2 2.6 42.8
4	 -18 1375 31.6 0.4 54.7 3.0 52.4
-17 1365 118.1 7.1 55.3 6.2 62,8
-16 1000 61.0 11.7 59.1 7.4 42.9j	 -15' 1135 62.4 LTD 56.0 3.0 41.8
-14 900 64.8 LTD 61 .4 5.4 28.8
-l3' 1030 45.8 LTD 83.9 5.0 29.7
-12 860 36.6 LTD 58.7 4.6 36.5
-11 1?30 15.8 2.4 66.1 5.0 117.0
-10 1120 44.8 6.1 50.7 5.0 217.5
-9 1040 17.7 LTD 57.3 3.4 45.5
--8 1150 24.2 LTD 63.5 5.0 200.2
-7 1180 31.3 1.0 49.2 6.4 60.0
-6 980 34.8 20.3 87.6' 13.4 44.2
-5 700 20.7 16.1 56.2 13 .0 16.5
-4 675 10.5 11.9 26.7 6.5 48.6
-3 1010 32.3 13.9 40.2 9.8 29.5
-2 920 67.6 15.3 31.7 6.0 75.6
-1' 1100 73.2 7.6 34.6 5.7 45.3
MEAN+SD 1048+180 47.5+27 6.4+7 54.0+15 6.1+3 78.0+66
BR1- 1110 50.0 LTD 66.6 6.5 155.4
2 1075 45.7 _ 6.3 41.3 4.2 165.6
3 870 51.7 6.8 46.6 7.0 40.6
4 920 24.4 3.1 16.4 2.1 128.15 1030, 39.1 LTD 29.6 5.6 138.06 -1365 81.9 LTD 51.3 29.3 41.0
7 1620 68.9 LTD 43.2' 11.8 87.58' 650 19.4 0.4 18.9 3.2 44.19 1030 49.4 LTD 34.3 11.2 40.0
10 1700 46.8 4.2 55.6
_
10.0 74.6
^I
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URINARY HORMONE RESULTS CONTINUED "J
I
I
CORTISOL EPI NOR ALDO ADN
Subject 5 VOLUME ug/TV ug/TV u9/TV u9/TV ---;mU/TV	 {
BR11 1190 55.9 LTD 35.2 5.8 72.7
12 1160 81.2 6.6 31.2 7.6 37.0
13 1300 51.4 26.1 20.2 5.2 66.1
14 1190 32.7 7.8 25.0 3.8 82.2	 --^	 q
R+O 900 62.1 10.9 40.4 11.4 56.4	 I1 950 35.2 LTD 69.9 6-.3 41.6
2 1130 28.8 LTD 53.9 6.3 40.5
3 845 22.4 2.8 21.0 2.7 32.5
r, 4 1360 34.7 LTD 58.8 7.8 56.4
f 5 880 49.7 2.4 34.4 4.5 59.0
6 960 37.0 0.2 92.0 7.2 101.1
7 1490 58.1 2.1 61.3 8.3 71.3t .8 690 46.6 5.1 72.6 11.8 31.3
g 715 32.2 LTD 79.4 10.2 31.7	 7
10 1250 68.8 LTD 93.9 6.3 sic415.0
11 910 47.8 LTD 66.0 3.2 51.2
' 12 760 45.6 LTD 88.2 4.0 36.2G 13 610 41.8 LTD 9.7.7 7.3 31.2	 1{
f rv^x^-ate
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URINARY
-d
HORMONE RESULTS
.-
CONTINUED w
I
CORTISOL EPI NOR ALDO ADH
Subj ect 6 VOLUME ugjTV ug/TV ug/TV ug /TV mU/TV
F-21 1450 183.4 11.3 62.4 10.8 19.0
-20 1295 114.6 9.4 47.9 0.8 29.2
- 19 1280 56.5 4.8 40:3 5.6" 33.2
-1`8 1050 49.4 3.4 58.4 14.5 20.3
-17 1160 63.8 5.4 44.3 9.5 24.6
-16 1080 54.0 20.1 64.8 13. 6 25.2
-15 1425 44.9 5.9 72.1 17.2 47,5
-14 1765 105.9 12.4 60.9 12.5 34.2
-13 1110 55.5 13.6 44.9 14.3 19.2
-12 1340 77.0 LTD 47.9 21.9 33.8
-11 1035 34.7 12.5 48.5 14.3 24.8
-10 840' ;21.8 6.9 47.8 9.1 14.0
-9 1120' 31.4 2.2 56,.2 12.3 30.0
'-8' 1610 51.0 8.3 49.3 19.1 34.2	
-;
-7 1220 64.1 0.3 32.9 13.3 59.9	 wAl
-6 1030' 34.0 16.1 47.7 15.2 22.1
-5 880" 28.2 6.1 27.7 12:.1 40.1
-4 360 9.0 4.3 10.1 3.9 11.0
-3 880 26.0 12.9 27.5 11.4 33.0
.-2 805 46.3 12.8 21.6 1.6 20.5
-1 ,,1340 100.5 15.8 24.5 14.8 24.9
MEAN+SD 1146+308 50.1+40 8.8+6 44.7+16 11.8+5 29.0+13
BR1 1375 59.8 LTD 55.0 13.8' 38.2
2 1065' 54.8 11.4 45.1 12.8 79.53
1480 81.4 5.2 69.2 16.9 46.5
4 840 60.9 4.9 18.8 10.6 60.5	 +	 ^^
5 1730 79.6 2.7 27.0 12.9 96.6
6 810' 45.4 ,, LTD 26.9 16.8 38.9
7 1320 48.2_ LTD 26.4 8.9 39.6
8 1270 106.0 LTD 47.9 16.8 37.4
9 1170 76.1 LTD 28.6 19.5 37.4
1'0 970 6,6.4 15.1 17.8 8_.5 23..4
TABLE 5
URINARY HORMONE RESULTS CONTINUED
CORTISOL EPI NOR ALDO ADH
Subject 6 VOLUME " ug/TV u9 /TV u9/TV ug/TV mU/TV
8811 1430 40.8 14.1 25.9 13.5 44.7
12 1200 28.2 5.0 21.5 12.1 16.8
13 1390 76.5 7.5 29.1 14.2 53.9
14 1445 59.2 7:5 21.7 _11.3 27.4
R+0 1110 62.2 15.0 26.8 23.6 15,9
1 720 32.4 4.1 40.7 13.0 27.8
e 2 1260 34.7 1.0 33.9 9.3 62.2
3 1545 38.6 LTD 51.0 12.7 40.7
4' 1370 28.0 0.1 59.2 14.7 56.4
5 810 72,9 LTD 52.3 19.4 18.4
6 860 50.3 1.8 27.7 7.6 17.7
r{ 7 1005 65.3 0.3 53.1 8.6 60.3
8 735 44.1 5.5 49.1 9.4 35.3
. 9 1015 60,9 LTD 54..0 7.5 59.8
10 1390 62.6 LTD 82.2 10.1 78.1 i
11 1130 60.5 1.1 61.3 6.3 42.0v -
12 1150 48.9 LTD 70.2 9.4 34.7
f
410 33.8 LTD 51.7- 6.0 11.1
N i
TABLE 6
BODY COMPARTMENT RESULTS
SUBJECT i 2 3	 6< 4 5
Total Body Water
(Liter)
BR -21 43.0 43...2 43.4	 39.7 41.4 44.8
BR 1-14 42.1 43.1 43.3	 40.5 41.8 44.1
R +13 46.5 43.3 44.4	 40.5 41.3 45.0
. Extra Cellular Fluid{ (Liter) : J
BR -21 16.9 16.3 18.2	 15.0 14.6 17.0.
BR +14 16.0 16.3 17.1	 15.6 14.7 16.8
I	 R
€
t
+13 15.9 16.5 17.1	 15.4 15.2 16.7
 
1{
Exchangeable Total Body.Potassium
(mEq)
BR -21 3742 3666 3572	 3171 3573 4027
BR +14 3670 3552 3630	 3091 3668 3942 ------a
s
W	 i
i
TABLE. 7
BODY ' WEIGHT
(K9)
Mean + S.D.
SUBJECT PRE
-	
IN POST
Z 68.7+.3 69.1+,4 69.7+.4
2 71.0+.3 71.1+.3 70.8+.5
3 1 69.4+.5 69.6+.4 69.7+.3
4 64.6+.3 64.2+.3 64.0+.6
5 81.7+.7 x81.6+.5 $1.0+3
6 64<4+.4 65.2+.9 65.6+.5
^ N
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SUMMARY OF STATISTICAL RESULTS ON 24-HOUR URINE SAMPLES
(Paired t-test;	 6 Day Means)
LAST 6 DAYS PRE FIRST 6 DAYS IN SECOND 6 DAYS IN
i	 SUBST MEANSE+_ MEAN+SE P MEAN+SE_ P
Volume 1321+99 1580+120 <0.1 1621+111 <0.1
SpGr 1.019+.001 1.017+.001 <0.4 1.017+.001 <0.5
Osmol 768+36 729+40 <0.5 732+37 >0.5
rl	 Na
188+10 233+10 <0.01 225+8 <0.02
K 65+3 73+3 <0.01 77+4 <0.01
Cl 163+9
_
206+9 <0.005 201+8 <0.005
Ca 7.9+0.4 10.0+0.6 <0.05 10.8+0.4 <0.005
Mg 8.8+0.4 9.7+0.6 <0.40 10.6+0.5 <0.025	 ^ J
IPO4 1020+40 1024+41 >0.5 1104+45 <0.20	 aI1
.	 Uri c Aci d' 883+36 883+34 >0.5 960+30 <0.20
Creatinine 1958+62 1973+78 >0.5 2023+67 <0.50
Cortisol 45.6+4 71.7+5 <0.01 77.9+7 <0.01'	
- -- -
a	 Epinephrine 18.9+2 15..1+3 >0.2 6.4+1 <0.01
Norepi nephri ne 43.6+3 34.6+3 >0.2 33.8+2 >0.3
Aldosterone 14.1+1 17.2+2 <0.05 17.1+1 <0.05
ADH 38.6+3 55.1+6 <0.4 40.8+3 <0.8
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INTRODUCTION
The Baylor University School of Medicine Bed Rest Study - Phase I was
i
initiated as a result and in an attempt to elucidate the cause(s) of the
E
variability in biological data obtained from humans in space travel. 	 This
t
variability in data could be attributed to either individual variability in
:j nutrient utilization, individualistic development of a functional metabolic
or dietary deficiency in essential ingestible nutrients and/or to a mani-
festation of the human organism in response when subjected to the weight-
less condition of space flight.	 To duplicate as closely as possible the
organismic effects of space flight in a groundbased study subject to the
gravitational forces, the individual must be subjected to a regimen of muscle
! inamination.	 This can be accomplished by subjecting the individuals to a
regimen of total residence in a horizontal position for a specified period
of time.	 Because of the physiologically significant questions posed by the
Skylab missions, six (6) individuals were subjected to bedrest aftor under-
 
the S kylab p rotocol of p reflight  and postflight    feedi n	 and biol ogical-
   
going 
	
	 p	 g
sample collection in support of the M070 experimental series "(nutrition and
a
Musculosl e letal 	 Function."	 1
In support of the Bed lest Study - Phase I, menus were designed according
to the Skylab_ nutritional requirements, utilizing Lot B Skylab foods.
	
Menus
were planned on a 6--day cycle for each of the 6 subjects, with the assump-
tion that each subject repeated the menu cycle g times.	 These menus
met the National Research Council requirements for nutrient requirements
for adults.	 The pre-bed and post-bed menus were similar, but the in-bed
menus with respect to energy values were decreased by 300 Calories/days
I
k
-^.-.wwear..^:sr:,_;Hww9tt'... >t«.,.a.,..u61[O,w+41.Lc..w.... a..a.,Lit.e:+u^+C^ddMJ 4«.+.e:x.ra..i •.w.ayeYi'Yi;9r: u.F+....., w...uvr : .,, ",•.•
Controlled nutri ents incluoea nitrogen, souium, potassium, magnesium, calciuwi and
chloride, Training of personnel performing the meal assembly, preparation,
service, and residual food documentation were subjected to several training
sessions.
r
Food and Nutrition Laboratory support was provided for the analysis of
biological speciments obtained from the Bedrest Study - Phase I, by analyses,
preparation, and/or storage of the samples. Analyses were performed for
fecal nitrogen, calcium, phosphorus, magnesium, sodium, potassium, and
chloride and urinary nitrogen. Complete details on the analytical proce-^
dunes and data submission are given in Section III. Tabulation and cal-
culation of the metabolic balance of the aforementioned nutrients was
then accomplished.
I	 ^	 ;
Therefore, this document outlines the procedures utilized by the NASA,-.MSC
Food and Nutrition Branch for supporting the Baylor College of Medicine
Bed Rest Study - Phase I, during the pre-bed, bed, and post-bed phases
of the study. Specific procedures used to support the Pi070 series of
}	 experimental protocol are given and include menu design, meal asse:bly,
preparation, and service; residual food handling; collection and processing
of feces, vomitus, and urine; sample storage and docu ► ,zntation; fecal and
i
urine analytical procedures; data review; and summarization of the
metabolic balance data. i
j	 ^
MATERIAL AND METHODS
FOOD AND NUTRITION LABORATORY
!
Redrost; support was provided during the prAed, had, and post-bed
periods for the processing, storage, and analysis of feces and!/or vomitun and
the storage and analysis of urine specimens. Suppoi`t r e quiroNnn s includo,,
the processing of feces and/or vomitus for laboratory analysis; labur4ory
anal ys is for nitrogon, phosphorus, calcium, potassium, sodium, magncs its n,
chlorides, and pQ st;orare of processed speci mans ; and data tabul at •i pn
Analyses of urine nitrogen were made on 10 ml aliquots
disbursed from the 24•-hour pool obtainou from each subject,
Collection of R iol ogica 1 Sr,ecir^;nils
_---- 	 _- _ __	
l
i
To fa cil. itatc tho proper col lcction of 'fece and/or vomitus end ur'ir t,
specimens, a briefing o.4, Baylor collection personnel was conducted key
i Dr. Whcclder° (NASA) ino L);,% Smith (T.W. As a result, a detailed fecal
and/or vomitus c:ol l ecti on protocol were transmitted to Baylor.
Urine bottles were supplied to the Baylor University School of Wdicine
at the s tart of the hedre st study ford collection of i n:1-i vi dual urine:
i
specimc n; for inclusion i nto the 24-hour pool	 A 10 r,l aliquot of this
24-hour urine pool was supplied to the rood and Nutrition Lahore=tory for
analysis. the Good and Nutrition Laboratory maint:ained the urine spec =im n
at 4	 2% prior to analysis and at -17	 2°C thereafter in sto" ge.
Processi n q and Storage of Fecal_ and/or VGmi tus Socciin-ens
i
Processing and storage of fecal and/or vomitus sawpl es r':as conducted in
the Food and Nutrition Laboratory in Building 37, Room 1-125, l,ASA-JSC, on
pre-bcd, bud, and post-W samples.  A total of 243 fecal sampl c.s ,'r re
1	 I s
t 1 GIBNAL PAGE IS
Ir' POOL QUALITY
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I
i
i
i
r' o-l_
collected during the D ayl ov 0dres ;. Study-Phase 1. No vc mi t us sawpl es ware
receiv^d, All specimens warn processed as follows, regardlEss of the uriVin.,
Upon receipt of the fecal spocimens at the Fond and Nutrition Laboratory,
Bldg. 37, P,oEam 1-125,  the plastic  izt.g with  t:i.,o q,i, t..ii :.n „i •t.,, i i; was a°e- ►.aovr-;z
from tho fecal tub and the fol l r;: i nit i nf orNat:i on recorded into a bound
no uebook lab I vd	 FOrnO S udy .. Frcral Lon Poole:
I	 Subject
2) (date of bowel movement
5) lime of bowel movement
4) Subjective color and description of physical appearance, i.e., solid,
a
soft, di arrhea'I
5) Weight of sample plus plastic hag	 -i
6) Gight of plastic bag
,
7) Weight of fecal sFmpl e
0) Laboratory nU;IIhCr
Aftar logging in Steps 1-4, visible extraneous oateri al such as 'ti ssve
paper were removed and the fecal specidan 1,ni gh d in the plastic bag on t.
top-loading Leal anco O lettl tar, i yodel P1200) to an vccuracy of Sl g
The specimen encascd in the plastic bag was thou kneadw,_',
to mix and pressed into a vafer-like mass of less than 1/2 'inch thickness,
The specimen was then frozen by placing in a -20 Y 5% freezer. Accumulated
frozen fecal specimens were placed in the Virtio frceze-drying apparatus on
Monday end Thursday of each week and removed on the following Thursday and
Monc;,y, respectively. * Procedures for start-up and shut -down of the 'free,-,-
dryer are given,
x
ARESULTS AND DISCUSSION
In support of the Baylor Bed Rest Phase I study, various elemental
compounds were determined as to intake, excretion, and retention. These
elemental detCrllriflations included water, sodium, calcium, potassium,
chloride, magnesium, nitrogen, and phosphorus.
The six subjects exposed to the experimental regimen had positive water
balances, with water intake exceeding urinary and fecal water excretion.
i
The calcium balance of the six subjects was negative in the total time
of the bed rest study.	 The physiologic effects of the continued loss
of 'endogenous calcium by these individuals and the effects on various
homostatic mechanisms has not been elucidated. 	 The continual degradational
I
y loss in calcium from the individual 	 subjects tends to verify the results
l
previously obtained from crewmen of the Skylab missions.	 Under the con-
ditions of this study, no relationship existed between water excretion
►
and the elimination of calcium.	 However, urinary calcium excretion1 etas
increased during the bedrest phase of the study.	 Similarly, the source
and level of intake of Vitamin D and relative intake of certain constituents
of pro4einaceous nature by altering the gastro-intestinal
	
uptake and the
disuse atrophy of masculature may have contributed to the endogenous calci117
loss exceeding the ingestion of the calcium nutrient.
Sodium balance was not changed by subjecting the individuals to thei
experimental	 regimen.	 As the subjects were in positive v;ater balance
the positive electrolytes balance, which includes potassium and chloride,
in addition to sodium, indicates that no significant avera ge effect on
the physiological 	 homeostasis (if the individual has occurred.
4
}
i f
A positive magnesium balance was observed in the individual subjects
during all phases of the Bed Best Study. No detectable changes in they
metabolism of magnesium were found, but as a result of the negative
calcium balance, a potential exists for a magnesium metabolic alteration.
These results tend to agree with the results previously submitted for
the Skylab and Apollo missions. The importance of the positive maynesim-,
balance in the subjects undergoing negative calcium balance is aug,rented b,
i
th e magnesium regulation of renal calcium transport, in conjunction with
Vitamin D.
Nitrogen balance, as an indicator of muscular physiology, was positive in
the, subjects. No change was detected during each of the three phases
of the study.
Phosphorus intake was greater than phosphorus excretion in the subjects
being studied during the prebed phase of the study. However, as the
s	 laboratory analyses of phosphorus has not been completed, no furth r-
trend implications could be deducted,
1	 The preliminary nature of the data presented is emphasized. Furth,.
evaluation of the data must be accomplished before definitive state-ents
as to the pertinence of certain elemental trends may be Nade ,	 a
l	 {
l
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BAYLOR BED REST	 PHASE I
Body Weights ' (Kg)
SUBJECTS
1 2 3 6 4 5	 --
STUDY DAY BODY WT BODY WT BODE WT BODY WT BODY WT BODY WT
PRE-
01 68.6 7T.1 69.3 63.6 64.8 82.3
02 68.5 71.1 69.3 64 64.9 82.7
03 68.2 70.9 69.1 64.4 65 81.8
04 68.9 71.2 69.5 63.7 64.5 82.7
05 69.1 71 .7 71.1 64 65 82.7
06 69.1 71 69.8 64.9 64.9 82.7
07 68.4 70.7 68.9 64.1 65 81.8
08 68.5 71 69.7 64.5 65 82.3
09 68.6 71 69.7 64.4 64.5 81.5
10 68.8 70.9 69 64.7 64.4 88.9
11 69.i_ 71.8 69.8 64.7 64.3 81.7
` 12 69.1 70.6 69.5 64.2 64.5 82.3	 t'^
13 69 71.1 69.5 64.7 64.4 81.1	 C:
1 68.9 71.1 69.0 64.4 64.4 81
15 68.4 68.4 69.5 64 64.3 80.9
10 68.4 70.8 69.5' 64.1 64.5 80
17 68.8 70.7 68.4 64.1. 64.4 80.5
18' 68.9 70.5 69.5 64.7 64.4 81.6	 !
19 68.6 70.5 69.1' 64.7 64.7 8146
20 68.2 71 69.1 64.9 64.7 81.8
21 69.3 71 69.5 64.8 64.2 81.6
MEAN 68.7381 70.8381' 69.4619 64.3619 64.6095 81.6904
SDEV .321825 .652832 .514087 .385758 .265024 .763762
SIZE 21 21 21 21 21 21	
-- - ---;
sum 1443.50 1487.60 1458.70 1351.60 1356.80 1715.50
i
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BAYLOR BED REST - DHASE'I
Body Weights (`Kg) 
SUBJECTS
1 2 3- 6 4 5
STUDY DAY BODY 14T BODY 14T BODY WT BODY WT BODY 14T BODY	 i;1'
BED
01 69.5 71.1 69.5 64.8 64.2 81.1
02 69.5 71.5 69 64.4 63.5 80.7
03 68.4 71.5 69 64.7 64 80.9
04 68.5 '11.5 69.5 65.2 64.7 81.5
05 68.8 71.1 69.4 65.2 64.6 81.6
06 69 71.2 69.1 65.3 64.3 81.8
07 69.2 , 70.6 69.5 65.3 64.2 82.5
08 69.4 71 69.9 65.4 64.2 81.9
09 69.5 71 69.5 65.1 64.2 82
10" 69.6 70.5 69.9 65.7 64.3 82
11 , 69.2 70.8 69.9 66 64.4 81.6
12 69.2 71 69.9 66.1 64.2 81_.5
1 68.9 71 69.9 66.9- 64.1 32.1
14 69 70.8- 70.2 66.8 64.2 81.8
:1VV)l 601214 71.0500 69.SU57 65.3500 64.2214 81.5357
SDEV .374312 .314485 .374312 .505464 .274862 .488887
SIZE 1.4 14 14 14 14 14
sum 967.700 994.700 974.200 914.900 89.9,.100 1142.90
IF
BAYLOR BED l:F'jl	 - PHASE T
Body Weights (Kg)
SUBJ.ECTS
2 3 6 4 5	
_ _--
STUDY	 lilt! BODY WT BODY WT BODY WT 806Y 'WT BODY WT BODY WT
POST
01 69.1 71.1 70 65.7 64.7 82
02 69.4 71.25 69.4 65.7 fj4.8 82.3
03 69.5 71.1 69.9 65.5 64.4 21.9	 --
70 71.5 69.8 65.8 64.7 8.5
0569.5 70.7 69.8 65.7 63.8 80.006 , 70 71.4 69.8 64.2 62.8 80.2
07 69.7 70.9 70 65.5 63.6 20.6
08 70 70.1 7O 65.5 63.9
09 70 70.1 70 65.5 63.6 80.5
10 69.8 70.2 69.4 66 64.1 80 .7
11 68.9 70.3 69.4 66.5 64.2 81.2
12 69.5 70.6 69.7 65.8 63.9 80.5
13 70 70.7_ 69.3 65.5 63.6 80.5
T4 69.9 70.7 69.3 65.5' 63.4 79.3
czr^
69.6643 70.7607 69.7000 65.6000 63.9643 80.8999	 G1
4Drt' .357417 .470269 ,274862 .487480 .566946 .80606
sUI` 975.300 990.650- 975.800 918.400 095.500 1132.60
..e	 ...^.	 Y	 ...	 .,..i•«w.'.fm.sr e.
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BAYLOR QED REST STUDY 	 PHASE
Body Weight, Fecal Vicight, Water Balance & Nitrogen Balance
Statistics
SUBJECT: l
STUDY DAY TOTAL BED REST STUDY
BODY WEIGHT	 FECAL WT	 W-DELTA
	 N-DELTAA	
.-- ---	 ---	 --
MEAN	 69.1122	 117.740	 1290.67	 2.11326
SDEV	 .515078	 53.9276	 738.767	 2.46889
SIZE	 49	 44	 49	 49
sum	 3386.50	 5180.60	 63243,2	 103.550
---	 ------- --	
--_- ----	 -- - - - -- --- ---
	
- -
STUDY DPY: PRE 01 TO PRE 21
MEAN	 68.7381	 108.3337	 1510.20	 2.38524
SDEV	 321825	 46.5546	 743.172	 2.28737
SIZE	 21	 21	 21	 21
SUM	 1443.50	 2275.00	 31714.2	 50.090e
---- - --- - -- ----- ---- - --------- - 	 ------ ---- ----- -----
STUDY DAY: BED 01 TO BED 14
~	 MEAN	 69.1214	 117.433	 786.142	 1.49642
r	 SDEV	 .374312	 47.1963	 529.250	 3.03682
SIZE	 14	 9	 14	 14
SUM,	 967.700	 1056.90
1
 0306.
0
	20.9500
---	 -	
-------•- -- -	 --	 -	 - -
	
-
i
STUDY DAY: POST 01 TO POST 14
I MEAT	 09.664.3 "	 132,G50	 151E.92	 2,32214	 1
SDEV	 .357417 	 67.4592	 649.397	 2.15549
SIZE	 14	 14	 14	 14
SUM	 975,300	 1848.70	 21223.0	 32.5100
_	 _ .	 ___	 _	 _ _	 _ __	 -__	 _	 _ -
3
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BAYLOR BED REST _- PHASE I
Mineral
	 Statistics
SUBJECT:
STUDY DAY	 TOTAL BED REST STUDY
CA-DELTA P DELTA NA-DELTA K-DELTA MO-DELTA CL-DELTA
----- ---	 --------- ---- -------- ------- -	 --	 -----._ ---_---- -- --	 -----
t1EAN -24,3133 243.735 36.8420 12,5904 8,37714 37.9404
SDEV 353.339 317.122 58,4395 17,6511 8.70576 54.2300
SIZE 49 24 49 49 49 49
-Y
SUM -1191.35 5849.65 1805.26 616.930 410.480 1859.08
--- --	 ---------
- -	 --- --	 -------- ---	 ---- -----	 ----
`' STUDY DAY:	 PRE 01 1'0 PRE 21
MEAN 58.6838 128..823 46.5357 .17.6709 8.74524 45.9438
SDEV 259.265 233.154 60.2265 16.0485 12.1312 54.5148
SIZE 21 19 21_ 21 21 21
SUM 1232.35 2447.G5 977.250 371.090 183.650 964.820
STUDY DAY:	 BED 01 TO BED 14
MEAN -102.692 680.399 18.4078 ' 7,17642 8.55500 22.1771
SDEV 497.040 180.456 57.7652 19.9449 5.91475 53.1722
SIZE 14 5 t4 14 14 14
SUM -1437.70 3402.00 257.710 100.470 119.770 310.480
STUDY DAY:	 POST 01 TO POST 14
MEAN -70.4293 0 40.7357• 10. 3835- 7.6n714 41.6'9'2'r-
SDEV 300.805 0 56.2015 16.6683 4.19748 55.4350
SIZE _14 0 14 14 14 14
x SUM -986.010 0 570.300 145, 300 107.060 583.781
-	 - --	 -- -- -- -	 -	 -	 --- -	 -- -	 ----- - --
	 -
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BAYLOR ['ED REST - PHASE I
Water Balance	 (nil)
SUBJECT:	 1
' STUDY DAY JUL DAY Vl=I11 W-FECAL I4—URI NE ` W7DELTA
PRE 01 119 4151 77.72 2215 1858,20
02 120 2467 82.12 1655 729.88
03 121 3827 137.2 800 2889.8
04 122 2744 40.63— 915 1788.37
05 123 3162 67.16 2180 914.84_
06 124 3613 81.34— 1280 2251.66
07 125 2727 84.47 1770 872.53
08 126 3002 104.66 1760 1137.34	 -a
09 127 4267 56 1800 2411
10 128 2811 26.41 1720 1064.59
11 129 3331° 137 1380 1814
12 130 2422 47 1120 1255
13 131 2159 97 1510 552
14 132 _2184 48	 -_ 1535 605,
15 133 3751 59 1260 2432
16 134 3364 83 1775 1506	 j
17 135 2373 171 1540 662
18 136 2012 54 1080 878
19 137 3078 82 1780 1216
20 138 3527 88 1320 2119
.21 139 3670 58_ 855 2757
?	 3
BED 01 140 2896 78 2180 638'
02 141 3011 ND 3230 —219
i^i 03 142 2163 ND 1400 76304 143 _ 2118 ND 1450 668
05 144 1883 ND 930 953
06 145 3169 160 1100 1909
07 146 2473 64 1580 829
08 147 1923 72 1560 291
09 148 2297 45 2345 -93
10 149 2143 ND 1400 743
11 150 2364 66 1330 918
12 151 3324 62 1930 1332,
13 152 2321 73 1505 743
14 153 2454 103 1520 831 a
POST
01 154 2710 72 1250 1388
02 155 2649 27 1230 1392
03 156 2747 52 925- 1770°
04 157 3871 97 1660 2114
05 158 3588 145 1860 1583
06 159 3393 89 2920 383
# 07, 160 3370 33 1795 1542
08 161 2832 70 2070 692
E 09 162 2898 80 1880 .938
' 10 163 5233 101 2410 2722
11 164 4421 183 1980 2258
1 12 165 3436 70 1195• 2171
f
i 13 160 2584 167 1315 1182
14 167 2003 195 1440 116G
{
^
w
!	 "I
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BAYLOR BED REST - PHASE I
Calcium Balance (mg)SUBJECT:	 1
STUDY DAY JUL DAY CA-IN CA-FECAL CA-URI(JE CA-DELTA
PRE 01 119 772 240.83 244.49 280.7
02 120 791 494.31 325
-27.9
03 121- 791 825.07 212;
-246.5
04 122 786 276.73 269 240.7
05 123 808 400.58 265 142.9
e 06 124 784 451.54 429
-96.4
07 125 801 272.87 248 279.6
08 126 801 200.38_ 241 360
09 127 817 141.9 854 -178.6
10 128 792 70.73 220 500.8
11 129 818 457.74 305 55.6
12 130 793 215.1 228 349.19 13 131 808 313.87 329 165.5
14 132 788 509.89 325
-46.5
15 133 795 562 236
-3.47
16 134 802 620 305
-122.6
17 135 801 1181 236 -616.47
18 136 785 372 188 224.6
19 137 797 665 309 -176.6
	 '1
20 138 801 678 216 -93.4
21 139 795 373.5 180 241
BED 01 140 799 585 417
	 ' -202.8
02 141 826 ND .497 329
03 142 784 ND 228 555
m 04 143 789 14D 317 472
05 144 782 HD 257; 525
06 145 788 1646.9 325
-1183.5
07 146 794 733.9 497- -437
	
1
08 147 794 813.6 361 -380
X15' 148 783 520.7 401
-138.5
10 149 792_
IND
421 371
11 1';, 827 805 377 -355
12 151 792 611,6 365 -184
13< 152 781 712:2 365 -292.9
14 153 310 990.6 333 -513
I POST 01 154 777 639.5 385 -247
02 155 792 233;02 325 233.98
03 156 806 598.7 232 -25.2
04 157 811 765..6 409 45.4
05 158 775 1096.8 381 -702.6
06 159 830- 594.4 371 -1 =1 , 4
07 160 788 214.8 353 2210.2
O8' 161 809 553.6 240 15,0
09' 162 818 609.6 232 =23.6
' 10, 163 780 699.5 345 -264.5`
11 164 776 1138.1 257 -619.1
s 12' 165 791 282.49 228 280.51g 13 166 774 448.9 244 81,.1
z 14` 167 797 452.2 184 160.8
lima
;
!
'40
I
BAYLOR BEU PEST - PHASE I
3 Sodium Balance (mEq)
SUBJECT:	 1
STUDY DAY JUL DAY NA-I11 NA-FECAL NA-URINE NA-DELTA,
PRE 01 119 286 3.26 216 66.75
02 120 282 1.78 348 -67.78
03 121 287 3.403 149 134.54
f 04 122 288 .84 214 73.16
05 123 288 1.93 334 -47.93
06 124 244 2.07 140 101.93
07 125 243 2.4 -250 -9.4
08 126 245 5.61 241 -1.61
09 127 290 1.2 210 78.8
10 128 287 .78 236 50.22
11 129 293 4.9 204 84.1
12 130 245 1.38 165 78.62
13 131 244 1.88 238 4.12
14 132 245 .96 237 -42.96
15 133 283 1.09 17C 111.91
16, 134 298 1.74 257 39.26
' 17 135 290 3.22 234 52.78
18 136 252 .89 215 36.11
1 19 137 234 1.34 233 -,34
20	 - 138 246 1.09 167 77.91
21 _139 273 .94- _115 157.06-
BED 01 140 290 1.47 346 -57.47
02 141 290 ND 392 -102
r 03 142 244 ND 191 53
04 143 243 14D 241 -4
05 144 273 ND` _196 77
06 145 286 3.58 184 98.42
OT 146 288 1.19 229 67.81
08 147 292 1.73 259 31,27
1 09 148 219 .95 287 -68.9
10 149 243 ND 210 33
11 150 275 1.14 255 18.8!
a 12 151 282 .93 244 37.07
13 152 287 1.72 241 44.28
14 153 290, 2.58 258 29.42
POST 01 154; 243 .99 130 112.01
1 02 155 234 .44 175 5",501 03 156 283 l	 . 'i 172 109 , c.
04 157 290 1.74 262 26.26
05 158 287 3.57 199 84.43
06 159 289 2.41 298 -1	 ."?
07 160 24.1 1 224 16
f 161 246 1.91 268 -23.9'
162 276 2.04 232
41.9`.,
163 283 2.84 354 -73.8-`
` 164 283 6.55 189 87_.45
165 269; 1.2 158 109.4
k 166 246 6.22 223 16.79 
1 167 235 7.7 211 16',3
(w {
f
-.
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BAYLOR [')I'D	 REST
	 - PHASE I
PotassiUm Balance (mEq)
SUBJECT.	 1
STUDY DAY JUL DAY (- IN K-FECAL K-URINE K-DELTAF
PRE 01 119 87 6.82 60 20.18
02 120 101 111.75 83 6.25
03 121 94 12.36 63 18.14
04 122 108 4.94 81 22.06
05 123 101 8.95 79 13.05
06 124 91 9.4 46 35.6
07 125 91 10.86 73 7.14
08 126 103 10.52 97
-4.52
09 127 104 8.68 67 28.32
10 128 112 4.53 57 50.42
11 129 110 20.97
_
51 38.03
12 130 90 7.45 65 17.55
13 131 89 13.12 91
-15.12
14 132 99 6.19 89 3.9
15 133 95 8.78 68 18.22
16 134 11.2 13.65 82 16.3517 135 101' 22.45 69 9.55
18 136 90 6.17 78 5.83
19 137 88 10.27 69 8.73
1 20 138 101 11.36 65 24,64
21 139 95 7.23 41 46.77
BED Ol 140 108 10.96 76 21.04
z 02 141 104 ND 81 23
i 03 142 91 ND 52 39
04 143 _ _ 87 IUD -12
05 144 98 ND	 - 66 32
06 145 89 25.93 72 -8.93
07 146 107 9.79 98 -.79
08 147 97 11 .41 64 19.59
09 148 84 7.58 101 -24.58
10 149 87 1111D 59 28
11 150 94-_ 9.67 95
-10.67
12 151 92 9.42 87
-4.42
{ 13 152 107 12.3 84 10.714 153 96 19.47 88 -11.47
c
a POST; 01 154 89 11 ,1 88 -10.1
02 155 87 3.19 90
-6.19
03 156 94 8.27 67 18.73
04 157 100' 14.57 83 2.43
05` , 158 118 26.54 63 20.46
06 159 100 8.28 58 28.13
07 160 92 4.27 56 31.73
08 161 91 9.67 62 19.33
09' 162 98 11.83 77 9.17
10
-163 93 16.48 89 -12.46'
11 164 ill	 a 24.15 61 25.215
r	 ; 12 165	 - 86 9.88 47 29.12
13 166 85 18.93 61 5.07
14 , 167 88 1 85 -15.88
a
Ix
BAYLOR BED REST - PHASE I
Chloride balance (mEq)
SUBJECT:
STUDY DAY- JUL DAY CL-IN CL-FECAL CL-URINE CL-DELTA
PRE 01 119 255 1.36 175 78.64
02 120 221 1.11 281 -61.11
03 121 250 1.18 118 130.82
04 122 261 .32 157 103..68
05 123 267 .65 294 -27.G5
06 124 217 .94 153 63.00
07 125 238 .81 220 17.19
08 126 222 1,73 236 -15.73
09 127 256 .93 184 71.07
10 128 260 .7 229 30.3
11 129 270 3.52 182 84.48
12 130 217 1.76 143 72.24
13 131 239 3.71 217 18.29
14 132 222 .32 255 -33.32
15 133 251 .39 158 92.61
16 134 270 .77 261 8.23
17 135 267 1.91 202 63.09
18 136 223 .46 192 30.54
19 137 229 .97 210 18.03
20 138 223 1.02 149 72.98
21 139 241 .62 93 147.38
BED 01 140 263 .88 294 -31.88
_
02 141` 268 ND- 368 -100
03 142 217 ND 169 48
- 	 .
04 143 238 ND' 213 25
05 144 ?_46 ND 184 62
06 145 253 1.01 178; 73.99
07 146 261 .38 183 77,62-
08 147 270 .3 211 58.7
09 148 192	 - .19 253 -61.19
10 149 239 ND 175 64
11 150 251 2.87 237 11.13
12 151 250 .57 237 12.43,
13 152 260 .63 212 47.37y 14 153 258 69 234 23.31
POST 01 154 216 .58 145 70,42
02 155 229 .27 159 69.73
1 03 156 259 .37 162 96,63
04 157 253 1,09 239 12,91
j 05 158 260 1.49 192 66,51
06 159 254 .92 254 -.92
I	 ± 07
160 213 .39 194 18.61
i 08 161 234 .73 234 -.73
09 162 252 .92 222 28.08
j 10 163 229 1.17 325 -97.17
11 164 256 2.04 172 81.96s
_12 165 _236 .73 -139 123,3
1 13 166 219 2.12 187 201.88
» k
3
-14 167 > 227 2.44 140 84.57
I	
!!
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BAYLOR BED REST - PHASE I
M	 YB 1	 t r)i ac31Z ^ Um	 a	 ance1U m qF
SUBJECT:
STUDY DAY JUL DAY MG- IN MG-FECAL MG-URINE MG-DELItti
PRE 01 119 29 2.72 12.6 13.68
02 120 29 6.19 63.6 -40.79
03 121 30 10.17 10.8 9.03
04 122 30 3.1 11.8 15.1
a 05 123 27 5.74 13..5 7.76	 !
OG 124 26, 6.63 7.9 10.47
07 125 29 6.85 10.9 11.25
08 126 29 5.73 9.5 13.77
09 127 35 4.78 13 17.22
j { 10 128 31 2.28 12.5 16.22
11 129 29 13.56 12.5 2.94
12 130 25 5.81 -	 11 8.19
j 13 131 28 8.46 10.6 8.94
7 14 132 29 6.3 15.1 7..6
15 133 31 8.35 8.9 13.75
16 134 31 9.05 10.2 11.75	 i
17 135 27 15.92 9.5 1.58
18 136 25 4.56 7.9 12.54
19 137 29 7.32 10.3 11.38
20 138 29 8.67 8.2 12.13
21 139 31 4.96 6.9 19.14
BED 01 140 30 8.01 13.4 8.59
C 02 141 27 NO 12.7 14.3
03 142 25 ND 8.3 6:7'
04 143 28 NO ' 14.4 13.606 144 28 ND- 9.8 18.2
06 145 30 21.36 7.4 1.24
07 146' 29 9.75 8.6 10.65
08 147 25 10.99 13 1.01
09- 148 23 7 13 3
10 -149 28 ND 9.3 18.7
1 11 150 31 10.47 14.3 6.23
12 151 31 8.37 13.7 8.93
13 152 29 9,89 12.6 6.51
i 14, 153 26 14.09 9.8 2.11
POST 01 154 24' 8.84 10.3 4.86
02; 155` 29 3.13 8.6 17.27
03 156 27 6.75 11 .5 8.75
04 157 32 10.81 12.9 8.29
05 -158 28 15 .31 9.8 2.89	
1
OG 159 28- 8.28 13.3 6.42
07 160 25 3.1 11.2	 ' 10.7
08 161 28 7.95 10.5 9.55	 f
09 162 28; 7.17 10.9 9.93	 a
i 10' 163 30 9.61 13.8 6.59	 -j
11, 164 28 15.811, 11.1 1.06
12 165 25 .73 12.3 7.35
13 166 24 10.68 11 2.32 
3
14 167 _ 2 7.7
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BAYLOR 43 ED REST	 PHASE I
Nitrogen Balance	 (gm)
SUBJECT:	 7
' STUDY DAY JUL DAY N_ IN N-FECAL N-URINE N- DELTA
PRE 01 119 17.82 1.85 13,6 3.17
02 120 17.89 1.78 15 1.11
03 121 17.97 2.87 12.6 2.5
04 122 18.4 .95 13.7 3.75
05 123 17.5 1.4 16.2 M.10
06 124 16.22 1.63 10.1 4.49
07 125 17.23 2.22 16.9 -1.84
08 126 17.89 1.86 14.1 1.93E
09 127 18.93- 1.61 15.8 1.52
10 128 18.32 .85 11.1 6.37
11 129 17.57 3.22 11.2 3.15
12 130 16.19 1.54 13.`5 1 .15
13 131 17.22 2.22 14.3 ,7	 i
14 132 18.05 1.63 17.2 -.78
15 133 18.06 1.82 11.93 4.31
16 134 18.27 2.06 14.45 1.-76	
-;
17 135 17.62 3.74 13 .88
13 136 16.48 1.2 11.96 3.32
19 137 17.33 2.03 13.42 1.88
:
20 138 18.05 2.07 13,26 2.72
21 - 139 18.06 1.26 8.7 8.1
-` BED 01 140 18.14 1.94 15.63 .83
02 141 17. 38 ND 12.89 4.49
03 142 16.22 1dU 8.81 7.41
04 143 17.26 IUD 16.2 1.05
-1 05 144 19.95 Id0 13.85 6.1
06 145 18.14 4.09 12.77 1.23
07 146 18.16 1.76 16.83' -.43
08 147 17.14 2.15 13.67 1_.32,
09 148 16.14 1.42 17.52 -2,8
10 149 17.28 ND 13.5 3.78
11 150 20.22 2.1 .17.18 .94	 i4 12 151' 18.14 1.69 16.89 -.44
13 152 18.16 1.94 15.62 6
1 14 153 16.17 2;87 16.49 -3.19
POST
01 154 16.14 1.95 14.9 --.71
8 02 155 17.38 .65 14.4 2.33
03 156 20.06 1.54 14.13 4.39
04 157 18.14 2.16 14.71 1,27
05 158 18.16 3.18 14.84 .1 4
06 159 16.42 1.92 14.45 .05
07 160 15.98 .77 11.02 4,.19
08 ' 161 17.65 2.77 12.77 2.11
09 162 20.3 1.78 10.89 7.63
10 _ 163 18.38 2.28 13.28 2.82
}
^.
11 164 18 4.08 13.44 .48
12 165 16..26 1 .55 11.65 3.06
_13 166 16.3 2.89 11.03 2.38
14 167 17.49 2.45 12.67 2.371
t ^
4BAYLOR BED REST	 PRASE i
Phosphorus Balance (mg)
SUBJECT.	 1.
STUDY DAY JUL DAY P- IIN P-FECAL P-URINE P-DELTA
PRE 01 119 1629 215.28 1108 305.72
02 120 1669 449.,87 1192 27.13
03 121 1669 696.82 960 12.18
04 122 1721 213.3 1226 2.81.7
05 123 1583 344.59 1046 192.41
06 '124 16616 416.07 819 308.93
` 07 125 1576 619.79 885 71.21
g 08 126 1771 514.34 1056 200.66
09 127 1 795 688.16 1188 -61.16
10 128 1713 239.17 722 751.83
11 129 1613 891.09 718 -120. 09
12 130 1617 576.23 1098 -57.23
13 131 1572 588.58 1087 -103.53
14 132 1781 439.69 1289 75.15
15 133 17 O6 533.48 857 315.52
16 134 1723 587.66 994 191.31
17 135 1610 1023.71 924 --337.71
18 136 1631 321.12 1037 272.88
19 137 1563 560.21 961 120.79
20 138 1790 TF 976 TF
21 139 1704 TF 752 TF
BED 01 140 1726 TF 1134 TF
02 141 1602 ND 969 633
1 03 142 l G1 G NID 672 94
04 143 1562' ND 1102 460
05 144 1832 HD 1079 753
Ou 145 1683 TF' 836 TF
07 146 1701 TF 1201 TF
08 147, 1552 TF 874 TF
09 148 1587 TF 1313 TF
10 149 1564 ND 952 612
11` 150 1838 TF 1352 TF
12 151 16187 TF- 1235 TF
1 13 152 1694 TF 1294 TF
14 153 1652 TF 1216 TF
- i POST 01 154 1607 TF 950 TF
02 155 1559 TF 175 Tr	 i
03 156 1838 TF 1240 TF
04 157 1718 TF 1328 TF
I 05 158 1712 TF 1004 TF
06 159 1680 TF 1226 TF
07 160 ' 1611 IT 754 TF
08- 161 1613 TF 994 TF
09 162 1880 TF 865 TF
10 163 1718 TF 1253 TF
11' 164 1702 "	 TF 1183 TF	 a
12' 165 1631 TF 932	
- TF
13 166 1595 TF 999 TF
TF14- 167 1591 TF 211f	 ^
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BAYLOR DEG RLST STUDY - E':!ASC'"
 1.
Eody Weight, Fecal 1,lei ght, 1!oter ;ol anco & f li tragon '.< l arcs
Statistics
SUBJECT:	 2
STUDY DAY: TOTAL BED RLST STUDY
------
--^I;-l ---
_	
----_._
	 --
1_-
---- -- 1_--
--T-------
-".-------
'iEAfY
-----
x;765 171.4070. 	,
.	
—
1283: 04
—^—
1	 O =2%^6
SUED .5265e8 56.019 802. 1 .9a; r:7
SIZE 49 46 49 49
sum 3472.95 7884.67 628C8,8, 51.IIGO
-	 -- ------
-------
	
-	 -- -- --	 - --- - --- --- -------- ----- -.-
	 ----
STUDY DPY: PRE 01 TO PRE 21
Sf
IEAH 70.8381 176.972 1429.23 .794,.5
SDEO .6528312 57.0253 879. 070 2. C8II"^ e,
SIZE 21 19 21 21
SUl1 1481 .60 3362.47 30513.8 16.68010
II`
	 `
I
STUDY DAY: HD 01	 1-0 [)'ED 14 ;
1E.Af; 71.0500 140.750 746.6 Z .72E,"'71
.314485 °84.03
SIZE 11
446..132 1,1C1^`2
SUl 994.700 168' OC 10453. 0 lC 2000
_----	
-------------------------- ---
---	 --
----_--__
i STUDY DAY: POST O1	 TO POST 14 1
'IEAk 75.0707 1x;8.142 1600.14 1.72271
3
S Di.1! .470209 "	 3. 0319 699.406 1 .33769
SIZE 14 14 14 14
SUM 990,650
---;---------.-------2634.00------ --- 2.M2 . C,
-	 --	 -
24 < 2 CO
S
e
cj
r
^
;
i
i
r
t1
: a
^tiiAl, ]PAGE
r
r,
,r,
rip P90R QU$I,ITY
JL^
1
e
r
Ei BAYLOR BED REST - PHASE IH neral Statistics
SUBJECT:
STUDY DAY:	 TOTAL BED REST STUDY
1 CA-[)ELTA P-DELTA PIA-DELTA K»DELTA MG-DELTA CL-CELTA
MEAN -146.374 103.308 18.3871 5.99010 7.80531 12.1343
SDEV 255.969 241.176 56.3632 15.1858 5.11554 56.6481
SIZE 49 21 49 49 49 49
SUM
---------------
-7172.34
I --------------------
2169.48 900.971 293w515
 ----------------------------------------
382.460 594.580
STUDY DAY:
	
PRE 01 'to PRE 21
MEAN -78.9405 68.0252 21.7702 6.61429 8,18643 16.9728
SDEV 266.371 225.457 67.6875 15.7941 5.25992 67,4905
1 SIZE 21 19 21 21 21:" -21
sum
--__...
-1657.75
---------------
1292.48
----....__--
457.174
_--_---_.._
138.900
»_-	 .._	 _
171.915
-	 _	 _
356,"30
_	 -
STUDY DAY:	 BED 01 TO QED 14
MEAN -•232.810 438.500 6.98785 1.54285- 7.65429 -1.174
LL SDEV 317.306 2.12131 43.6765 17.5688 4.45717 43.4992
SIZE 14 2 14 14 14 14
sum -3259.34 877.000 97.8300 21.6000 107,160 -16,43
STUDY DAY:
	
POST 01 TO POST 14
-j
MEAN -161.089 0 24.7119 9.50107 7.38464 18.1850
SDEV 128.274 0 50.7147 11.1282	 - 5.80889 51.7761
SIZE 14 0 -14 14 14 14
SUM -2255.25
- -	
-------
0 345.967
---------------------------------------------------
133.015 103.385 254.59E
7
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BAYLOR BED REST - PHASE T
r Wator Bal ance (ml )
SUBJECT:	 2
STUDY DAY JUL DAY Wl- IN W-FECAL W-URIidE W-DELTA
PRE 01 '11119 4349 14D 2760 1589
02 120 3030 218.31 1710 1101.69
03 121 4139 ND 1400 2739
04 122 2588 69.68 1395 1123
05 123 3120 135.84 2610 374.16
06 124 2809 89.83 1520 1199
07 12.5 2699 21G.01 1670 813
08 12.6 2758 133.6 1580 10.44
.' 09 127 4,174 168 860 3146
10 128 2947 100 1380 1467
11 129 3209	 - -192 3030 -13
12 130 2587 121 930 1536
13 131 2784 177 1600 1007
14 132 2594 181.86 1400 1012
15 133 3380 200 1280 1900
16
17
134
135
2997
2.650
100
145
2530
1700
367
805
18 136 2971 99 1200 1672
19 137 3334 95 1990 1249
20 138 3904 179 680 3045
21 139 3720 72 810 2838
BED 01 140 2779 156 2000 623
02 141 3120 ND 2615 505
03 142 2651 [iS 1620 1031-
04 143 2370 87 1970 313
05 144 , 2464 8tl 1515 869
a 06 145 3243 146 2050; 1047
07 146 2900 84 1760 1056
08 147 2656 r0 1670 906
09
10
148
149_
2289
3052
162
53
2655
1670 -
-528
1329
11 150 2493 158 1560 775
12 151 3462 121 1880 1461
13 152 3156 118 2325 713
14 153 2976 43 2580 353
POST Ol 154 2857 189 810 1585
02 165 2705 113 1 030 1562
03 156 3149 138 1010 2001
04. 157 41.79 194 1360 2625
05 158 4197 147 1050 3000	 j
06' 159 3110 157 1840 1113
07 160 2856 180 2375 ; 301	 _	 I
08 161 2839 116 1520 1203
09 162 2925 179 1220 1506
10 163 3438 184 1185 2069
i 11 164 3415 32 1580 1803
12 165 3023 126 1220 1677
3 14 167 3205 190 1870 1145
I
'1
or
 ... ,.. 
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BAYLOR BED REST -PHASE I
Calcium Balance (mg)
A SUBJECT:	 2
STUDY DAY JUL DAY CA-IN CA-F=ECAL CA-URINE CA-DELTA
s PRE 01 119 772 ND 425 347
I 02 120 765 994.39 329 -558
03 121 778 NU 369 419.3
04 122 792 427.32 489 -124.3
05 123 790 757.99 505 -473
06 124 773 752.03 325 -303.7
07 125 760 372.14 417 -28.9
OR 126 760_	 - 228.42 451 74.67`
09 127 782- 747.1 401 -365.9
10 1,28 790_ 262.97 341 186.35
11 129 788 534.9 549 -296
12 130_ 774 243,66 253 277.8
a 13 131 770 289.48 _357 123.8
14 132 790 240.31 461 88.77
4 15 133 766 _489 397 -119.8
16 13 4 72 496 473 -
17 135 650 397 -2867.8
18 136 764 457 321- -13.64
19 137 777 504" 437 -163,8
20	 - 138 763 820 2 13 7 -313.5
21 139 786 413.4 333 39.9
BED 01
02
140
141
792
779
847.8
MD
533
537
-598.8
242
^i
1
03 142 785 NU 409 376
04 143 746 779.8 433 -466.7
05 144 763 721 461 -400
06 145 760 931.5 465 -636
a 07 146 781 529.6 381 -129
08 147 766, 517.6 477 -228.5
09 148 762 751 589 -578
10 149- 761 317.5 301 142.9
1 11 150 767 758.8 389 - 380.6
z 12 151 776 582.6 349 -155.3
' 13 '152 773 590.9 537 -35514
153 776 299.2 569 -92<34
POST 01 154 765 741- 353 -328.7
l 02 155 746 513.6 417 - 184	 j
03 156 795; 598.7 357 -160
04 157 776 776.9 425 -425.8
{ 05 158 787 - 653.6 369 -241
06 159 810 535.1 457 -182.',
07_ , lGO 770, 534.3 437 -201.3
08 161 749 527.2 309 ,-87.2
09 162 767 513.6 345 -91.6
10 163 761 648.2 329 -216.2
` 11 164 793 242.9 437 113.1
12 165 775 486.3 369 -80.3I
13 166 773 514.65 353 -94.65
^.
14 167 771 337.5 509 -75.5
.u.	 .e	 tiws. M. -... ^r A . . ..=tww.L.Yud... A'x. .. 	 r	 . ... .rr »r.f+I...rrw	 w...,...w:..?.w.y.u:.L1.k.:.;LLuwk +•....:.:1.....4S.J4l-aw.. ^•... u.. .. i.ti.rut. Ftkw.... A..'.4:'u
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r BAYLOR BED REST - PHASE Il
Sodium Balance (riEq )
SUBJECT: 2
STUDY DAY JUL DAY NA-IN NA-FECAL	 NA-URINE NA-DELTA
PRE 01 119 185 - ND 255 '- 70
02 120 210 7.114 180 22.9
03 121 186 ND 99 87
04 122 246 .431 171 74.57
^. 05 123 218 2.213 266 -50.12
06 124 187 6.926 159 21.074
07 125 171 8.88 150 12.12
08 126 207 8.39 261 -62.39
09 127 186 3.48 ' 51 131.5
10 128 230 4.06 168 57.94
11 129 214 15.8 332 -133.8
r 12 130 187 1.2.59 74 100.4
13 131 184 13.72 168 2.28
14 132 211 15.28 190 -5.72
15 133 180 12.32 156 11.68
16 134 231 2:44 221 7.56
17 135` 213 2.88 209 1.12
18 136 187 2.19 138 46.81
19 137 186 1.49 201 -16.49
20 138 224 3.22 77 143.78
-21 139 190 1.48 125 63.52
BED ^.1 14O 239 4.91 319 84.91
02 141 220 ND 260 -40_
03 142 196 ND 168 28
04 143 174 1.06 161 11.94
I 05 144 253 .5; 195 57.5
< 06 145 179 1.72 160 17.28
07 146 228 .82 188 39.18
08 147 228 .55 191 36.45'
09 148 185 3,.88 236 -53.88
10 149 177 1.04 144 31.96
11 150 253 4.81 176' 72.19
12 151 101 2.,94 188
13 152' 223 3.,41 226 " -6.41
14 153 239 1.53 239 -1.53
POST 01 154 186 9.66 78 98.34
02 155 - 1`74 4.75 122 47.25
03 156 265 1.1 172 91.9
04 157 177 10.53 166 .47
E 05 158 223 8.59 177 37.41
06 159 223 10.43 197 15.57
I 07 160 195 10.55 236 -.101.508 161 175 5.12 126 43.88'
09 162 231 14.18 174 42.82
10 163 182 12.23 133 36.77
11 164 224 2.42 186 35.58
f 12 165 212 6.947 165 40.053, i
13 166 '186 12.344 215 -41.344
14 167 188 16.232 172 -1.232r
{
r
BAYLOP, (,f:D REST - PRASE I
Potassium Balance (mEq)
SUBJECT:
	
2
j STUDY DAY JUL DAY K- IN K- FECAL K- URINE K-DELTA
PRE 01 119 82 ND 80 2
02 120 93 26.979 72 -5,98
-
a 03 121 81 ND 60 21t. 04 122 101 9.506 73 18.5
1
L 05 123 78 18.654 84 -24.606 124 81` 20.31 65 -4.3
07 125 90 25.31 52 12.69
1 08 126 89 12.43 77 -,4309 127 82" 19.01 40 22,99
10 128 103 12.14 45 45.86
1T 129 78 16.16 73 -11.16j 12 130 77 10.22' 47 19.88
13 131 93 z127 69 2.73
14 132 132 94 22.03 63	 8.'
15 133 74 16.47 57 12.15
16 134 101 13.71 78 9:29
17 135 75 17.57 63 -5.57;. 18 136 80 12.69 76 -8.69
19 137 90 14.98 86 -10.98
20 138 86 23.56 44 18.44
21 139 79, 10.89 52 16.11
BED- 01 140 103 19.43 62 21.57	 1.
- 02 141 77 ND 58 19
03 142 80 ND 71 9
04 143 87 14.49 83 -10.49
05 144 91 14.56 74 2.44
06 145 77 23.47 82 •-28.47	 ;.
07 '146,> 105 12.97 79 13.03
08- -147 69 13.16 67 -11.16
09_ 148 78 21.9 74 -17.9
10 149 91 8.08 48 34.92
11 150 93' 20.99 72 .01
12- 151 82 15.73 66 .27
' 13 152 101 16.f,3 77 7.37
14 153, 75 15.99 77 -17.99
POST 01 154 78 17.52 54 6.48
02 155 87 12.96 63 11.04
03 156 96 8.27 56 31,73
04 157 77 20.55 46 10.15
_05 158 ; 103 17.00 68 18.0
06 "159 81 16.12 -55 9.88
l 07 160 83 19.34 64 -.34
08 161 88 12.65 61 14,35'
09 162 91 16.22 83 8.22
10 163 73 19.85 58 -4.85
11 164 102 4.59 7`0 27.41
12- 165 75 16.314 57 1.686
- 13; 166 82 20.763 54 7.237
.. 14 167 98 15.278 86 -0:278,
x
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1	 BAYLOR BED REST
	 PHASE I
a	 Chloride Balance (nnEq )
^- SUBJECT:
	
2
STUDY DAY
	 JUL DAY	 CL- IN
	
CL-FECAL	 CL-URINE
	 CL-DELTA
PRE	 01	 119	 136	 ND	 215	 079
02	 120	 185	 2.86	 154	 28.1+
03	 121	 154	 ND	 91	 63
1	 04	 122	 216	 .7	 124	 91.3
05	 123	 156	 1.62	 253	 --98.62
j	 06	 124	 160	 2.39	 161	 -3.39
07	 125	 161	 3.39	 132	 25.61
08	 126	 186	 2.13	 224	 40.13{	
09	 127	 154	 1.4	 53-	 99.6
f 10	 128-	 203	 .69	 133	 69.31
11	 129	 153	 1.18	 294	 -142
12	 130	 160	 ,89	 83	 76.11
13	 -131	 169 -	 .88`_	 157	 11.12
14	 132	 189	 4.32	 162	 22.68
15	 133	 152	 5.57	 129	 17.43
16	 134	 206-	 2.19	 T97"	 6:81
17	 135	 152	 2	 188	 -30
18	 136	 186	 1.76	 125	 59.24
19	 137	 174•	 1.78	 169	 3.22
20	 138	 202	 2.96	 65	 134
21	 139	 159	 .98	 116	 42
BED	 01	 140	 209	 2.71	 244	 -37.71
02	 141	 157	 ND	 230	 -73
03	 142 	 167	 ND	 159	 8
04-
	
143	 166	 .83	 _ 158	 7.17
05	 144	 227	 .7	 167	 59.3
1	 06	 145	 152	 1.-81	 152	 1.81
07	 146	 204	 1.05	 169	 33.95
08	 147	 167	 .92	 174	 7.92
09_	
14E	 159	 2.06	 228	 -71.06
10	 14'1	 167	 .55
	
127	 39.45
11	 IED	 228	 2.85	 156	 69.15
a 12	 1c1	 153	 1,32	 162	 -10.32
13	 1 ^2	 201	 1.22	 193	 6.78
14	 1t,3	 168	 .42	 206	 -38.42	 a
^	 POST 01	 154	 159	 2.88.	 83	 73..12
02	 155	 166`	 1.12	 1-02	 62.88
03	 156	 235	 2.05'	 145	 87.95
I( 	 04	 157	 152	 2.98	 141	 8.02
05	 158	 200	 2.65	 170	 27.35s	
06	 159	 157	 3.18	 167	 -13.18,
07	 160	 169	 2.99	 264	 97.99	 1
08	 161	 166°	 1.54	 120	 44.46
c	 09	 162	 206	 4.69	 162	 39.31
10	 163	 153	 3.4	 124	 25.6
11	 164	 256	 .66	 184	 71.34
12	 165	 149	 2.011	 150	 -3.011
t3	 166	 159	 3.113	 196	 -40.173
''	 14	 167	 175 -	 4.086	 202	 31.086
I.-..-..tiw...rn.Mru+ao..,...-.:..:^..,.c...:wat<.w4.:.L.<•;.:.,.t....a..:,w.u.....,,..:..,„.w...' 3.uN..:..uA4<....'..,....._.n.u.w,.^...t,^.a......+:w'.t.+/.^.,,.:..w.....,....:.,.:., nie',a. w,.t^9. 	 ..::. ,...r« - .. R.. ri. !,
BAYLOR BED REST	 PHASE I
Magnesium Balance (mEq)
SUBJECT; 2
STUDY DAY JUL DAY MG-111 MG-FECAL MG-URINE 1v1G-DELTA
l	 PRE 01 119 28 ND 11.1 16.9
02 12.0 24 15.44 8.2 .36
03 121 28 NO 7.4 20.6
04 122 25 5.952 9.9 9.148
05 123 24 10.835 10.6 2.565
06 124 20 11.698 7.5 .802
07 125 24 10.98 7.9 5.12
08 126 22 5.5 7.4 9.1
09 127 28 9.16 13.6 5.24'
10 128 25 6.64 7.4 10.96
11 129 24 9.35 10.3 4.35
12 130 18 6.63 7.5 3.87
13 131 24 7.03 5.9 11.07
S 14 132 8.22 7.6 9.18_
15 133 26 7.35 6.5 12.15
16 134 2_5 7.34 7.1 10.56_	 {
17 135 23 9.25 9.6 4.15
18 136 19 6.65 8.1 4.25
19 137 24 4.87 9.5 9.63
20 138 21 8.44 5.8 6.76
21 139 27 4.05 7.6 15.15
BED 01 140 25 10.09 7.2	 ' 7.71
02: 141 24 NI) 8.6 15.4
=
03 142 19
04 14.3 23 11.40 6.9 4.7	 1
05 144 22; 8.75 8.1 5.15
06 145 26 9.43 152 -1.81
07 146 26 6.08 6.7 13.22 3
08 147 22 7.41 9.6 4.99
09 __ 148 18 10.25 9.7 --1.95
10 149 24 3.61 11.9 8.49
11 150 23 9.67 9.6 3.73
12 151 28 7.00 7.9 13.1	 e
3 13 152' 25 8.00 9.1 7.9	 j
14 153 24 4.55 10.6 8..85
POST 01 154 18 12.05 66 -.65
02 155 23 5.81 10.0 7.19
03 156' r4.. 6.75 8.1 9.15
04 157 27 8.42 10.0 8,58
05 158 25 9.38 11.8 3.82
06' 159 24 -	 8.49 11.2 4.31
07 160 20 8.58 7.9 3.52
08 161 23 5.86 8.0 9,14
09 162 22 7.17 8.8 . 6. 0^	 ro
10 163' 26 7.65 9.9 8.45
11 164= 26 2.84 9.8 13.26
12 165 33 ; 10.564 9.7 22.436'
13 166 19 11.133 8.4 -•533
14 167	 - 24 6.913 8.5 8.582
^ 1
a
BAYLOR f 6AEST - PHASE I
Nitrogen Balance (p)
SUBJECT;
	 2
I STUDY DAY JUL DAY N-IN N-FECAL N-URINE N -DELTA
PRE 01 119 15.63 ND 14.5 1.13
02 1201 15.76 3.5 13.8 -1.54
03 121 15.68 14D 12 3.68
04 122 16.43 1.5 13.6 1.33
.; 05 123 15.76 2.5 15.5 -2.24
k 06 124 14.64 2.63 10.1 1.91
` 07 125 17.3 3.24 12.6 1.46
08 12.6 15.94 4.73 15.3 -4.09
09 127 15.87 2.70 14.6	 - -1.43
10, 128 15.86 1.37 13.7 .79
11 129 15.54' 2.34 13.7 -.5
12 130' 16.19 1.73 10.2 4.26
13 131 17.22 2.28 11.1 3.84
14 132 16.43 2.08 14.5, -.15
15 133 15.84 2.24 12.83 .77
16 134 16.03 1.46 14.45 .12
17 135 15.26 2.2 13.58 -.•52
18 136-' 14.3 1.55 11.77 .98
19 137 17.68 1.24 14.55 1.89
20 133 15.6 2.31 10.81 2.48
21 139 16.59 1.23 12.85 2.51
BED 01 140 .16.02 2.25 14.5 -.73
02 141 15.1 ND 11.51 3.59
03 142 14.36 ND 12. 136 3
04 143 16._67 2.43 12.47 1.77
05 144 17.31 2.19 16.04 -.92 
06 145 15.6 2.79 13.1 -.29
07 146 15.62 1.39 13.73 .5
08 _147 15.02 1.65 13.74 -.37
09 148 14.37 2.39 14.36 -2.38
10 149 16.99 .92 -'10.74 5.33
11 150 17.89 -2.66 12.85 2.38
12 151 15.84 2.06 13.69 ::09
13 152 15`.45 1.71 14.3 -.56	 s
14 153 15..02 1.01 15.22 -1,21
POST 01 154 14..37 2.47 10.1 1.8
02' 155 16.67 1.59 15 .08
03 156 18.8 1.55 13.72 3.53
04 157 15.6 2.44 11.98 1.18	 _	 a
' 05 158 15:46 1.83 11.94 1.69
06 159 15..39 1.91 12.57, .91
3 - 07 160 14.48 2.53 10.12 1.83	 j
08 161 16.67 1.66 11.14 3.8'7
09 762' 17.81 1.78 14.56 1.47
10 163 16.00 2,10 13.58 0.32
11 164 15.38 .71 12.24 2.43
12 165 15.02 1.86 11.77 1.3913 166 `='37 2230 12.33 -0.26
14 167, .l4 1.86 11.29 3.99
I
iE	 ^	 i
BAYLOR BED REST - PHASE I
Phosphorus Balance (mg)
SUBJECT: 2
STUDY DAY JUL DAY P-IN P-FECAL P-URINE P-DELTA
PRE	 01 119 1508 ND 1104 404
02 120 1521 777.58 1060 -316.58
03 121 1514 ND _1036 478
04 122 1732 386.39 1144 201.61
05 123 1478 753.66 1096 0397
06 124 1453 724.94 790 -61.94
07 125 1620 865.04 868 -113.04	 -
08 126 1584 419.05 1074- 90.95
09 127 1526 578.55 946 1.45
10 128 1677 371.71 1021 284.29
11 129 1476 759.02 848 -131.02
12 130 1435 572.88 818 39.11
13 131 1631 669.85 896 75.15
14 132 1635 522.68 1232 -199.68
15 133 1522 424.42 870 227.58
16 134 1704 391.65 1113- 199.45
17 135 1455 553.77 1122 -220.77
18 136 1446 388.96 1104 -46.96
-19 137 1645 394-.88 1234 -16.12
20 138 1565 TF 925 TF
21 139 1575 TF 1037 TF
BED
	 01 140 1698 TF 1040 TF
02 141 1434 IUD' 994 440
03 142 1506 ND 1069 437
04 143 1568 TF 906 TF
a 05 144 1668 TF 1212` TF
.06 145 1500 TF 984 TF
07 146 1684 TF 1021 TF
08 147 1400 TF 1035 TF
09 148 1430 TF 1062 TF
10' 149 1605 TF 835 TF
11- 150 1G76 TF 1154 TF
12 151 1540 TF 1090 TF
13 152 - 1649 TF 1070 ; TF i
14 153 1427 TF 1238 TF
POST	 01 154 1431 TF 859 TF
02 155 1568 TF _	 1195 TF	 1
03 156 1754 TF 1151 TF
04, 157 1507 TF 1142 TF
05 158 1659 TF 1008 TF	 j
06 159 1477 TF 1177 TF
07` 160 1457 TF 808 TF
08` 161 1569 TF` 1071 TF
09 162 1675 TF 1240 TF
10 163 1534 TF 1303 TF
11; 164 1648 TF 1018 TF
12 165 1431 TF 952 TF
13 166 1442 TF 1175 TF
14, 167 1618 TF 1085 TF
kI
3
	
t
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BAYLOR BED REST STUDY - PHASE I
Body Weight, Fecal Weight, hater'Dalance & Nitrogen Balance
'
	
Statistics
a
i
SUBJECT:	 3
STUDY DAY: TOTAL BED REST STUDY
I
----- -----
BODY WEIGHT
------------------
	 -------------
FECAL WT td- DELTA
-----_ - ---------
14-1EL.T
-	 -	 -------
ME.Aw 69.5652 192.674 1536.':8 1.22979
SDEV .428571 104.692 847.487 3.31610
SIZE 49 39 49 49
SUM 3408,69 7`514.30 75278.1 60.26CO
- --
-	 _	 -- -	 ----- ---------- - ------	 -- ---	 --	 -------	 -- ---- -- -	 -
STUDY DPY: PRE 01 TO PRE 21
MEAN 69.4619 158.411 1663.43 1.269C4
SDEC .514087 61.7763 900.100 3.15657
SIZE 21 18 21 21
-	 SUPT
--	
--- ----
1458.70
--- -----
	
--------------
2851.40
------
34932.1 >
-	
- --------
	 ----
26,.6500;
--	 -	 --	
-_.._
 t
STUDY DAY: BED Ol	 TO BED 14
i
HEAN 69.5857 196.350 889.357- 1 . z30,";?
SL'EV .374312 130.228` 553.905' 4.20547'
SIZE 14 10 14 14
SUM 974.200 1963.50
------------------- -------------------------------------
12451.0 17.2200
1
STUDY DAY: POST 01	 TO 'POST 14
j
HEAN 69.7000 262.630 1992.50 1. 17071
{ SDL-V .274862 112.783 630.654 2.r	 51
SIZE 14 no 14	 _ 14
SUt 975.800 2626.30 27895.0 1639G.
---- - - ----	 -	 -- -	 -- -
I	
^
a
I	 j i
j^
j
k
[
s
L'AY1.0 BED PEST - PHASE T
MinoI"al	 Statistics
SUBJECT: 3
f STUDY DAY:	 TOTAL 111 1) REST STUDY
i
-----
CA-DL-LTA
-_	 -----	 ---
[l -DLLTA
------	 -
[ A-[;[.'LTA
-------- --
K-DELTA
--- -
	
----
[;C- 3ELT4,
-	 ---------
CL- r LLTA
------	
-
MMI -111.150 215.780 36.0943 7.53812 9.01130 36.5319
SDEV 508.795 490,753 44.0246 28.97.29 8.23097 48.`2257
SIZE 49 27 49 49 49 49
} SUM -5446.38 5826.06 1768.62 369.368 441.554 1790.06 
----------------------------------------- ---------------------------------
 STUDY DAY:	 PRE 01 to PRE 21
MEAN -39.2557 22.7931-- 48.0194 11.8270 9.45243 .59,0019
SDEV 313. E+74 445.790 44.1369 17.1402 6.126192 51.7378
{ SIZE 21 19 21 21 21 21
i SUM -824..370 433.070 1008.40 24.8.367 -198.501 1255.84
STUDY - DAY:
	
BEC 01 TO EKED 1
y MEAN -131.485 713.250 5.02285 -2.92143 8.97858 7.0435
•,> SDEV _578.145 274.458 41.9837 25.9468 8.41925 32.4495
Y.	 u- SIZE 14 4 14 14 14 14
SUi li
-_-----
-1840.80
------	 ---
2853.00
---------
70,3199
--	 ---------------
--40.9000
-^-
125.7000
---	 --------
98.6 ,9
--	 -	 -
STUDY DAY:	 POST 01 TC POST 14
1,11EAN --198.658 635,000 49.2781 11.5643 8.38236 31.1153
[ SDEV 673.324 139.257 38.1924 42.5350 10.9096 39.5657
i SIZE 14 4 14 14 14 14
s
SU[ll
-'781.21
-
2540.00 689;893 1G1,901 117.353 435.614
.
l
`	
7
{
'	 ^
a,
a
i-, ,.. ...r ..__	 ...	 .	 •.xi.^n.el•:w... x+r,.r wa.u.V.»:.....::.a.a-..^.—..... ^.[:a.:3:v..e ,x ^._ 	 rh.;	 ^..
BAYLOR QED REST	 PHASE I
Water Balance (ml)
'i SUBJECT:	
3
STUDY DAY JUL DAY Vl_IN W-FECAL W-URINE W-DELTA
PRE 01 119 4715 ND 1810 2905
02 120 3110 48.79 1800 1261.21
03 121 4570 187.25 2000 2382.75
04 122 3532 56.89 1620 1855.11
05 123 4013 72.25 1715 2225.75
06 124 3402 161.33 1800 1440.67
1 07 125 2061 113.51 2270 -322.51
08 126 3464 ND 1720 1744	 a
09 127 4792 195.55 2580 2016.45
10 128 3883 76.27 2115 1691.73
11 129 4568 ND 2350 2218
12 130 3390 155 1490 1745
13 131 2025 115 1840 70
14	 - 132 3721 169 2340 1212
15 133 3804 34 1880 1890
16 134 3552 125 2990, 437
17 135 3531 93 1900 1538
18 136 3240 161 2400 679
19 137 3794 138 1460 2196	 j
20 138 4071 167 1620 2284
' 21 139 5189 86 1640 3463
BED 01 140 3357 272 2740 345
02 - 141 4160 ND 3450 710
03 142 3537 ND 1740 1797	
{
s 04 143 3468 114 2270 1198
05 144 3549 69 2615 865i
.06 145 4321 157 2340 1824
07 146 3357 115 2240 1002
08 147 3762 355 3120 - 287
1 Q9	
- 148 3014 12 2881 121
10 149 3717 119 578
11 150 3474 ND 25010 964
12 151 4485 276 2.630 1579
13 152- 3342 58 2425 859
i 14 153 3462 ND 3140 32?.
l POST 01 154 3926 327 2180 1,419
02 155 4081 55 1730 2296
t 03` 156 3512 ND- 2180 1332
04 157 4335 114 1680 2541
05 158 3903 293 2230 1380
06 159_ 4807 ND -2030 2777
07 160	 - 3366 228 2235 903
08 161 3418 ND 1240 2178	 a
09 162 3372 222 2245 3150
-10 163 4460 232' 2050 2178
11„ 164
	
`` 4234 145 1820 2414
12 165 3587 161 1905 1521
13 166 3184 120 1090 1974
14 167 3389 297; 1260 1832
t
w
r`	 I
i
1
r	 t	 - awe	 ._ ..w.. ..u+i. +Y...	 v	 ..	 .. .. .. W - i	 ..	 •., ....	 a.	 ..-s 	 A. w. W;•a• ^	
I4 \ !
.ai.:a.3w. -
I
BAYLOR BED REST PHASE I
Calcium Balance (mg)
SUBJECT:	 3
STUDY DAY JUL DAY CA- IN CA-FECAL CA-URINE CA-DELTAi PRE 01 119 785 ND 353 43.23
02 120 789 300.1. 397 92.12
-03 121 800 969.15 325 -494.13
at 04 122 825 440.35 277
108.1
05 123 821 443 329 49. 3
06 124 824 465,29 489 -130.3
07 125 808 291.9 393 123. 3
08 126 830 PID 333 497.3
09- 127 826 424.55 369 32.7
10 128 837 132.41 248 456.1
11 129 822 ND 345 477.3j
12 130 821 524.52 232 64
13 131 833 394.38 325 114
14 -132 825 417 529 --121
1.5 133 312 595 369 -151.74
16 134 841 804 417 -380
17 135` 824 780 285 -240.5
18 136 827 1101, 417 -690.8
19 137 827 953 240 -366.5
20 138 831 828 377 -373.7
21 139 837 545.7 224 66.85
QED 01 140 843 317.8 385 140.4
02 141
142
820
885
ND
ND
313
261
507.4
624.503
04 143 8`17 1016.1 333 -5311.7
05 144 837 637 497 -297
06 145 849 1217.9 361 -729.6
07 146 840 856.9 269 -285
08 147 818 1316.4 613 -1111.6
09 143 832 92.7 409 330.5
1 10 149 820 771` 445 -395.9
11 150 850 ND 413 437.2
s 12 151 838 1431.8 409 -1001.6
13 152 835 419-.8 433 --17.7
14 153 854 ND 365 489.3
POST 01 154 841 2100 357 -1615.7
02 155 800' 201.3 277 321.7
a
03 156 842 ND 393 449
04 157 815 599.9 317 -101.5
05 158 827 103119 493 -747.9
3 06 159 837_ ND 305 532.4
07 160 827 1520.4 '429 -1122.4
08 161 812 HD 369 443
1 09 '162 849 1278.5 353 -782.5
10 163 825 986.2 337 -498.2
11 164 851 ND 305 546
` 12 7G5 831- 730.79 337 -236.73	
1
13 166 818 448.79 297 72.21
14' 167 802 - 556.53 285 -40.53
t j 3 i	 i
'.	 _x	 i .V.L,vwY n.v.«.v. ••n. 	 rr'w.L +i+x.iY.:, ..:. 	 .x. a.xa,a xWar1t, ,'n
	
..M`>.aMS .S.xG- '.lLSa.t+.. a^^.MS.M.YH-.d i+YM Sx'ni n.	 +W.. 1..«-n.	 n. w	 ..	 .	 r
l	 ^n
BAYLOR BED REST -	 Pf7A,SE I
Sodium Bal ance
	
( ►nEy )
SUBJECT:	 3
" STUDY DAY JUL DAY NA- Iii NA- FECAL NA-URINE HIA-DELTA
PRE 01 119 287 dD 192 95
02 120 252 .597 266 -14.597
03 121 284 4,355 206 73.645
04 1? : 281 .496 234 46.501"
05 123 289 .914 217 71.OE6
06 124 245 1.191 202 41,800
07 125 237 1.52 250 -14.52
08 126 241 ND 234 ..7
09 127 287 3.31 253 30.69
(0 128 280 1.22 190 88.78
i 11 129 289 NU 270 19
12 130 246 3,71. 149 93.29
13 131 247 2,05 221 23.95
14 132 240 2.25 254 16.25
15 133 287 .99 212 74.01
16 134 287 1.31 284 1..69
17 135 285 2.14 191 91.86
18 136 252 2.53 246 3.47
19 137 247 1.55 170 75.45
20 138 242 4.12 173 64.88
21 139 289 .84 169 119.1E
3 BED 01 140 295 9.29 310 -24.29j
02 141 290 ND 285 5
03 142 288 ND 250 38
04 143 246 1.75 280 -35.75
05 144 275 .82 309 -34.82
06 145 297 1:91 22.0 75.09
07 i 4G 289 1, 4.7 256 31.53
08 147 285 17.01 349 -81.01
# 09 148 277 .23 282 -5.23	
j
10 149 236 1.69 260 -25.69
j 11 150 270 140 217 53
3 12 151 289 5.41 254 29.59
13 152 289 1.1 257 30.9
14 153 297 ND 283 14
POST nl 1E4 276 4.61 186 85.39	
g
02 155 232 2.53 196 33.47	 -
03 156 265 ND 216 49
1 04 157 286 2.5 216 67.5
1 05 158 283 5.13 220 57.87
06 159 288 ND' 161 127	 {
07 160 275 5.04 267,_ 2.96
08 161 231 1-4D 159 72
09 162 252 7.32 234 10.68
10 163 273 9.77 265 -1.77
11 164 269 114D 242 27
12 165 258 3.316 202 52.684
13 i 66 275 2.119 177 95.881
14 167 232 19.772- 202 10.228<
s
.,.a....:.,.. ...,. _:...._» ,,..:...r:;wt^...a..^a....a:,. ^...n....;.,a,.a,s...... 	 ......,...a.1.::r...r..:^....?vrr.:,u.,.nc,........,...,+. rs,.:a.:.:.... u<..... ,...,.. ' ..:.,.,... ... i.,..:. _..
	 ,. «..-,,... ....-..	 ...^. x.	 ..c^.. ,.	 ..^,
BAYLOR BED REST - PHASE i
Potassium Balance (Q)
SUBJECT	 3
STUDY DAY JUL DAY K- IN K-FECAL K-URINE K-DELTA
PRE 01 1 19 93 ND 58 35{
i 02 120 101 7.683 83 10.317
03 121 95 23.415 82 -10.415
` 04 122 120 8.556 78 33.444
05 123 112 11.364 62 38.636
06 124 106 11 .815 73 21.185
i	 l 07 125 94- 15.81 73 5.1908 -126 106 14D 77 29
j 09 127 102 32.24 101 -31.24
j 10 128 117 12.48 72 32.52
11 129 113 _ND 101 12
12 130 102 27,67 64 10.33
13 131 105 20.92 70 14.08
14 132'- 109 10.84 98 .16
1 15 133 99 16..37 79 3.63
16 134 123 17.55 108 -2.55
17 135 115 21.31 78 15.69
18 136 107 30.65 84 -7.65
19 137 98 24.11 69 4.89
20 138 112 24.96 66 21.04
s
21 139 108 14.89 8o 13.11
EKED 01 140 120 30.51 99 -9.51
02 141 112 ND 90 22
03 142 119 ND 84 35
04 143 105 21-.51 102 -18.51
05 144 116 11.88 105 -.88	 3
06 '145 105 27.87 103 -25.87
07 146 210 21.09 94 4.91
08- 147 110 40.21 134 -64.21
09 148 109 1.82 104 3.18
10 149 101 18.42 82 .58
a 11 150 110 ND 83 27	 a
12 151 106. 45.45 92 -31.45	 -
13 152 118 10,14 104 3.86
14 153 110 ND _97 13	 1
POST 01 154 114 47.9 89 -22.9
02 155 94 5.78 97 -8.78
03 156 107 ND 85 22
04 157 97 17.32 66 13:68
05 158 115 36.44 _	 91 -12,44
06 159 107 HD 69 38-
07 - 160 110 42.78 96 -28.78
` 08 161 95 ND 57 38
09 162 110 36.03 72 1.97
10 163 105 33.56 90 -18.56
11	 - 164 218 ND 7$ 140
12 165 105 30.258 72 2.742
13 166 106 18.51.2 77 10.488
14 167 97 27.519 83 -13.519
t-	 .rE...,.:.:;.-,.,,.. x.i..,.s.+.^..-.-'_s ....._v.,.....i.:xr:.+.+....r. ......	 ....a.......r.:.::. ».-	 -	 ,-:	 tes,r..i.,.,.• .....`a..e. ., is	 .n>c.a., ..	 ...	 ...	 .
4 BAYLOR BED REST - PHASE I
Chloride Balance (mEq)
SUBJECT:	 3
STUDY DAY JUL DAY CL-III CL-FECAL CL-URINE CL-DELTA
I z _ PRE" 01 ` 119 254 ND 154 100
02 120 225 .12 50 174.88
03 121 247 2.43 102 142.57
04 122 253 .32 198 54.68
05 123 267 .78 185 81.22
06 12.4 213 .86 193 19.14
07 125 224 .96 220 3.04
08 126 220 ND 206 14
09 127 254 1.91 194 58.09
10 128 253 1.54 167 84.46
11 129 266 IND 212 54
12 130 213 .24 127` 85.76
13 131 233 .82 201 31.18
14 132 219 2.1 234'
'.`
-17.1_
15 133 255 .85 199 55.15
16 134 261 .5 275 -14.5
17 135 263 .69 159 103.31
18 136 215 .95 238 -23.95
19 137 231 .84 149 81.16
20 138 220 1.71 144 ` 74.29
:. 21 139 256 .54 161 94.46
,A
BED 01 140 266 3.01 279 -16.01
02 141 266 ND 266 0
03 142 248 ND 219 29
04 143 232 .18 243 -11.18	 ,
-^ 05 144 248 .25 272 -24.25,} 06 145 262 1- 206 55
07 146 262 .87 224 37-.13
08 147 262 6.55 321 -65.55
09 148 240 .07 , 248 -8.07
10 149 222 .92 214 7.08
11 150 246 ND 193 53
12 151 255 2.23 242 10.77
	 1.
13 152 262 .31 233 28.69
14 153 270 ' i^D 267 3
POST 01 154 239 3.31 185 50.69
02 155 220' .63 180 39.37
} 03 '156 242 ND 205 37
04 157 254 1.18 223 29.82
05 158 257 1.53 228 27,47
06 159 264 No 158 106
07 160 239 1.59 268	 - -30.59
08 161 220 ND 148 72`'
09 162 229 1.97 243 -20.97
10 163 240- 2.9 258 -20.9
11 164 241 ' IID 229 12`
12 165 234 1.74 194 33.26
13 166 239 1.062 155 82.93u
14 167 221 -6.474 202 12.526
y
4I 4 ^
i
^	 t
BAYLOR BED REST . PHASE I
i^lactiaes •i um	 Balance (i^Eq )
r SUBJ E CT :
k ' STUDY DAY JUL DAY	 MG-I11 MG--FECAL MG-URINE h,1G-DELTA
PRE 01 11.9 31 ND 12.7 18.3
02 120 27 4.422 11.9 9.678
03 121 31 14.826 10.9 5.274
04 122 32	 ' 6.18 13.5 12.32
05 123 30 5.999 14.3 9.701
06 124 15 7.072 9.2 -1.212
07 125 32 8.28 15.9 7.82
08 126 28 ND 10.4 17.6
09 127 35 15.26 12.8 6,94
10 128 31 4.88 11 ,4 14.72
11 129 30 ND 14.3 15.7
' 12 130 28 14.99 10.3 2.71
13 131 34 10.47 8.9 14.63
14 132 28 5.11 14.5 8.39
15 133 33 9.39 10.2 13.41
16 134 32 12.78 12 7.22
I 17 135 30 13.48 11.2 5.32
i 18 136 29 17.43 13.6 -2.03
19 137 33 13.-73 9.7 9.57i k
20 138 28 15.52 9.6 2.88
21 - 139 36 8.78 7.6 19.62
BED 01 140 32 17.69 12.1 2.21
02 141 30 ND 14 16
I j 03 142 34 ND 13.7 , 20.3
04 143 34 13.31 15.8 4.89
05 144 29 7.61 16.1 5.29
i 06 145 36 17.51 11.7 6.79
07 146 32 12.83 12.9 6.27
08 147 29 21.07 15.6 -7.67
(19 148 30 1.24 13 15.76
' 10 149 34 10.3 11.9 11.8	 i
j 11 150 28, ND 10.7	 - 17.3	
3
4 12 151 36 25.25 14.2 -3.45	 1
13 152 31 7.29 12.2 11.51
14 153 31 ND 13.3 18.7
POST 01 154 31 32.44 10.1 -11,54`
02' 155 32 3.31 11 17.69
03 156 27 ND 12.9 14.1	 di
04' 157 33 11.3 10.8 10.9
1 05 158 31 17.32 13.1
,58
06 159 30 HD 10.3 1X1.7
07 160 31 24.18 10.7 -3.88
08 161 33 ND 11.8 21.2
09 162 28- 21.47 12.6 --G.0",
10 163 35 16.13 10.6 8.27
11 164 34 ND 11.5 22.5
' 12 165 29 16.484 13.4 .11811
f 13 166 29 12.091 12 16,981
14 167 32 15.062 10.9 6.03
t
^I
f
DAYLOR4SEST - PHASE I
Hi 1:rogen Balance (gm )
SUBJECT:
	 3
STUDY DAY Jul.	 CLAY fl-IN N-FOCAL N-URII;E N-DELTA
r^	 I^ PRE 01 119 17.97 ND 12.9 5.07
02 120 15.97 1.05 13.8 1.12
03 "121 18.03 3.53 13.6 .9
04 122 19.34 1.46 15.4 2.48
05 123 17.36 1.59 15 .77
06 124 18.77 1.79 10.6 6.38
l 07 125 19.62 2.77 20 ..3.15
08 126 19.76 ND 13.7 6.05
09 127 18.43 4.68 21.1 -7.35
10 128 19.18 1.67 16 1.51
11 129 17.55 HD 16.4 1.15
1I 12 130 18.69 3.88 12.4 2.4113 - 131 20 2.87 14.3 2.83
14 132 19.78 3.43 19.7 -3.35
15 133 18:29 2.34 14.2 1.75
16 134 19.38 1,.9 16.06 1.42
{ 17 135 17,47 3.11 1`3.57 .79
1 18 136 18.60 3.9 16.35 -1.56
19 137 20.86 3.3 14.05 3.51
20 138 19.68 3.27 14.94 1.47
21 139 18.67 2.18 14.05 2.44
n BED 01 140 19.74 1.3 15.1 3.34
02 141 17.44 ND 13.63 3.81
03 142 21.,98 ND 13 8.98a
04 143 19.9 2.87 18.1`8 -1.15
05 144 22`.16 1.82 19.9 .44
06 145 19.44 3.79 17.67 4.02
07 146 19.5 2.78 16.67 ,05
08 147 17 .28 2.48 21.09 -6.29
09 148 21.15 .33 18.44 2.38
10 149 20.03 2.7 15.49 1.84
11 -150 22.1 ND 14.51 7,59
12 151 18.77 5.59 18.83 -5.65
13 152 19.42 1.57 16.05 1.8
' 14 153 18.62 _	 ND 16.52 2.1
POST 01 154 21.07 7.39` 13.86 -.18
02 155 19.63 .77 19.44 -.58
03 156 21.94 ND 17.92 4.02
04 157 18.29 2.28 17.91 -1,9
05 158 19.1 3.99 16.99 -1,.88
06 1-59 17. 54 ND 14.47 .307
07 160 21.07 4.97 16.4 -.3
08 161 19.79 ND 15.45 4.34
09 162 22.02 4.34 15.09 2.59
10 163 13.37 4.01 15.66 -1.3
11 164 19.55 ND 13.98 5.57
1?_ 165 17.55 3.6 14.08 - .13
	
1
13 166 20.91 2.91 13.73 4.27	 l
14 IG7 19.63 4.1 16.73 -1.2i
i	 t }	 r
BAYLOR BED REST - PHASE I
Phosphorus Balance	 (wg)
SUBJECT:
^^
STUDY DAY JUL DAY P- I(; P-FECAL P-URINE P-DELTA
PRE 01 119 1651 ND 1158 493
02 120 1 554 262.07 1260 31.93
03 121 1659 848.27 1240 -429.27
04 122 1742 352.49, 1231 158,51
_	 1 05 123 1600 376.72 995 228.28
1 06 124 1741 393.74 756 591.26
07 125 1743 591.22 1271 -119,22
03 126 1817 ND 963 854
09 127 1176_ 1155.61 1651 -1030.61
10 128 1758 412,81 1142 203.19
11 129 1611 ND -1034 577
12 130 1731 961.62 894 -124.62
13 131 1797 724.87 846 226.13
14 132 1823 900.56 1404 -481.56
15 133 1771 605,91 1052 113.09
16 134 1803 988.71 1075 -260.77
17 135 1609 851.18 915 -157.13
1 18 136 1735 1058.81 1056 -379.81
19 137 1833 902.36 993 -60.34
20 138 1844 TF 1555 TF
21 139 1828 TF 1181 TF
BED 01 140 1810 TF 1260 TF
02 141 1601 HD 1035 566
03 142 1938 IUD 940 998
04 143 1786 TF 1135 TF
05 _144 1945 TF 1412 TF
06 145 1851 TF 1310 TF
5 07 _146 1793 TF 1165 TF
08 147 1574 TF 1810 TF
09' 148 1867 TF 1267 TF
10 149 1763 TF 1027 TF
11 -	 150 ` 1937 14D 1054 " 883
12 151 1812 TF 1368 TF
? 13 152 1785 TF 1164 TF
14 153 1725 14D 1319 406
POST 01 154 1860 TF 1090 TF
02 155 1739 TF 1314 TF
4 03 156- 1920 HD - 1352' 568j' 04" 157 1758 TF _1411 TF
I 05 158 1743 TF 1293 TF
06 159 1635 HD 1137 498
07 160 1847 TF 1118 TF
08 161 1739 HD 918 821
09 162 1933 TF 1257 TF
j 10 163 1791 TF 1312 TF
11 164 1818 (ID 1165 653
12 165 1640 TF 1105 TF
-? 13 166 1831 TF 1221 TF`
14 167 1760 TF 958 TF
I	 ;
66
a
k3AYL0('<	 [3Ci; IZk- ST	 STUDY	 - PHASL 1
Body 41ei c,ht,_ fecal
	 Weight, t,late ►^ 13a1.ince & Nitrogen Gal ance
Statistics
SUBJECT- 4
STUDY DAY: TOTAL BED PEST STUDY"
-----_ -----------
13ODY WEIGHI T FEGAI	 WT
-- ---------------------------------------------------------
tr-DELTA 1-I)LL1'/
MEAN' 64.3196 193.480 1226.11 2.23760
SDEV .448089 64.4659 682.258 2.73805
SIZE 51 20 51 50
1
j_
SUl-t
-- ----------
3280.30
----•-	 --	 ---
-	 3869.60
_----------.
62532.0
---_ -------_-^---	 --
111.880
..---------
STUDY 1',p Y: 11RE 01 TO PRE 21
{tEAl4 64.6095 172.030 1464.05 1.98809
SDEV .265024 73.8150 672.451 2.02839
`y SIZE 21 10 21 21
SUM 1356.80 1720.30 30745.1 41.7500
------------------------------------
-	 ----------- ------
	
-- - 
l
STUDY DAY: BED 01	 TO [QED 14
^ JEAf; 64.2214 173.825 925.714 2.39143
SUEV .274862 24.3171 549.081 3.21486
SIZE 14 4 14 14
SU1
-----..._,.------------
899.100
_----_-------
695.300
_--_--	 ---
12960,0
------- --------
33,4800
-.
STUDY DAY: POST 01 TO POST 14
^EF,h 63.9076 249.025 1221.84 2.57833
'
SDEV 5548891 43.6026- 768.594. 3.35862
SIZE 13 4 13 12j SUM 830.800 996.100' 15884.0 30.9400
-------------...__.-.---------------------- ------ ----------- a
ii
7
ry
7
r
3
Yi
r
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DAYLOR P)ED RI r I- P IASL	 T
Hi neral Statistics
1
SUDJECT:	 4
S1UDY DAY:	 DOTAL BED REST STUDY
'f
----
CA 0 1`  L7A
--	 ----
	
-------
P-DLLTA
.---------
IiA-l,["I.TA
------	 ---
k:-l)l:Ll"/^
-- -
	
------------
HG-DELTA
-•---_
CL--.'
----	 --
hI[:i'til
-9.68687 402.138 36.1041 11.6401 8.13627 36.9=.09
SDEV 635.421 405.233 54.7037 19.1928 9.73542 49.1:1'31
SIZE; 51 39 51 51 51 51
SUI'-i
------
-494.030
---	 -- ---
15683.4
--	 -- --------
1 841.31
------
593.650
-------------
414.950
--	 --•----
1883.99
------	 --
1 STUDY DAY:	 PRE 01 to 
PRE 
21
d,
MEAN 73..2633 218,495 33.8152 11.81E6 8.54333 -40.8319
} SDEV 472.596 432.694 55.2259 16.4910 6.83128 42.9=17
SIZE 21 19 21 21 21 21
SUN
---	 -
1538.53
 - - -	 -----.-
4151.41
-- -------
710.120
----	 - -• - - -
248.150
- - - - - - - 	
- -
179.410
- - - - -
	 ---.----
857.-`70
----_.
	 --
1 STUDY DAY:	 BED 01 TO BED 14y
a
MEAN 6.85575 543.699 28.6542 10.7307 10.0657 31.0957
SDLV 633.783 299.263 57. 54 .15 15.7808 X9.78534 49.2-,=1
SI<< 14 10 -14 14 14 14
SUI ll 95.9805 5437.00 401.160 150.229 140.920 435.~•;0
STUDY DAY:	 POST 01	 T%01 	 POST 14
iitF+l'.
-110.662 624.333 45.0242 12.6207 5.60857 34.9:50
SDEV 846.269 310.867 48.8993 27.3079 13.-236 53.x"4'1
SIZE 14 9 14 14 T4 14t SUM
-1549.27
-	
-
5619.00
--	 ^,
630. 340
... ..-----
176.600
-------
78.5200
«---	 -	 ---
489,F10
  
------
	 -	 -
A
4
j
F
j
i
4	 ^	 ^ ^ t
T C
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I BAYLOR BED REST - PHASE I
SUBJECT:
	
4 Water Balance	 (ml)
STUDY DAY JUL DAY W-IN W-FECAL W-URINE
d
W-DELTA
PRE 01 122 3409 64.42 925 2419.58
02 123 2046 186.51 875 984.49
03 124 2224 ND 1105 1119
j 04 125 2715 46.69 1430 1265.31
05 126 2462 ND 1715 747
06 127 3931 157.28 1260 2513.72
07 128 2626 69 1415 1142
08 129 2776 ND 2195 581
09 130 2029 ND 1240 789
10 131 2580 173 1780 627
11 132 2654 83 1055 1516
12 133 4299 ND 1900 2399
13 134 3803 ND 1205 2598
14 135 2390 160 1620 610
15 136 2473 ND 940 1533
16 137 2984 ND 1160 1824
17 138 2955 196 400 2359
18 139 3704 166 1690 1848-
19 140 2172 ND 970 .1202
20 141 3016 ND 1750 1266
21 142 3122 ND 1720 1402
BED 01 143 2009 115 1490 404	 !.
02 144 1461 ND 610 851
03 145 _3063 ND 750 2323
04 146 1698 ND 102.0 678
05. 147 1857 138 800 919
06 148 1817 ND 1345 472
07 149 1551 ND 960 591
08 150 1640 ND 650 990
09 151 2604 ND 760 1844
10 152 1928 ND 1265 663
11 153 2139 93 1195 851
12	 ` 154 1953 ND 910 1043
13 155 2007 126 870 1011
14 ; 156 2530 ND 221`0 320
POST Ol 157 2395 173 670 1552
02 158 3276 ND 780 2496
03 159 2338 ND 1500 838
w 04 160 :2089 217 1905 -33	 j
05 161; 3093 ND 2410 683	 3
06 162 2985 ND 1635 1350
07 163 3538 ND 1050 2488
08 164 2968 715 ??5?
` 10 166 2711 155 1180 137E
11 167 2136 151 1120 865
` 12 168 2.846 197 1590 1059
s. 13 160 1676 ND 990 686
! 1'4 170 2519 ND 1370 1149 
BAYLOR BED REST PHASE I
° Nitrogen Balance (gm)
SUBJECT:	 4
STUDY DAY JUL DAY N-IN N-fEj^L N-UR4NF5
PRE 01 122 17.68
N-DELTA
02 123 16.98 2.7 12,7 1.58
03 124 14.38 ND 12.2 2.18j	 04 125 17.63 1.24 14.2 2.19
05 126 16.26 ND 14.1 2.16
06 127 17.66 3.09 12.7 1.87
07 128 17.1 1.65 14.1 1.35
08 129 17.89 ND 16.1 1.79
09 130 13.06 ND 11.6 1.46
10 131 16.66 3.71 11.6 1 .35
11 132 16.06 1.67 13.2 1.19
12 133 17.1 ND 15.35 1.75	 1
13 134 17.12' ND 12.69 4.43
14 135 16.83 3.65 15.12 -1.94
15 136 15.2 ND 10.05 5.15
16 137 16.8 ND 19.24 -2.44
17 138 16.06 4.39 6.12 5.55
j	 18 139 16.1 3.2 13.01 -.11
19 140 16.88 ND 11.52 5.36
20 141 16.83 ND 14.16 2.67
21 142 15.2 ND 12.76 2.44
BED 01 143 16.46 3.07 15.56 -2.17
'	 02 144 16.06 ND 9.89 6.17
03 145 16.1 ND 13.14
13.48
2.96
3.404 146 16.88 ND
05 147 16.83 3.35 7.77 5.71
i	 06 148 15.54 ND -14.67 .87
07 149 16.8 ND 14.29 2.51
'	 08 150 18.29 ND 10.69 7.6
09 151 15.86 ND 12.63 3.23
10 152 16.72 ND 20.85 -4,13	 j
11 153 16.83 2.5 13.84 .49
12, 154 15.54 ND 10.62 4.92
13 155 16.8 -2.69 13.4 .71
14 156 18.29 ND _17.08 1.21
POST 01 157 15.49 4.25 12.11 -.87
02 158 1`6.88 ND 13.45 3.43
03 159 16.77 ND 16.44 . 33
i	 04 160 15.54 ' TF 13.85, TF
05` 161 16.8 ND 17.62 -.82
06 162 18.77 ND 13.33 5.44
07 163 15.86 ND 13,79 2.07
08 164 16.88 ND 7.57 9.31
09 165 16.83 ND 11.46 5.37
1 0 166 15.54 3.39' 14.54' -2.39
11 167 16.8 -3.59 14.6 -1.39-.
12 168 18.29 3.42 13.12 1.7513 1`69 15.49 ND 11.08 4.41
'	
14 1-70 16.88 ND
13.45 3.43
-
•=alt
BAYLOR BED REST PHASE I
Calcium Balance (mg)
SUBJECT:	 4
STUDY DAY JUL DAY CA-IN %FECAL CA-URINE CA-DELTA
PRE 01 122' 774 423.66 365 -14.3
02 123 767 837.54 349 -419.2
03 124 713 ND 413 300.17
04 125 772 167.9 393 211.3
05 126 743 ND 453 290.1
06 127 745 293.78 281 170.66
07 128 769 283.43 309 176.9
08 129 783 ND 417 366.17
09 130 698 ND 361 337.28
10 131 738 657.91 281 -200.47
11 132 751 297.07 236 217.46
12 133 779 ND 373 406-
13 134 782 ND 285 497.4
14 135 773 1499 373 -1099
15 136 747 ND 457 290.09
16 137 755 ND 361 394.28
17 138 740 1639.1 184 -1083.47
18 139 741 934.8 321 -514.819 140 708 ND 389 403.4
20 141 762 ND 337 425.33
21 142 736 ND 353 383.23
BED 01 143 737 1183.6 261 -707.12
02 144 747 ND 220 526.56
03 145 760 ND 265 495.47
04 146 770 ND 481 289.04
05 147 758 1560.2 96 -898.4
0 148 758 ND
385
319.
352.2307 149 737 ND
08 150 759 ND 273 486.4
09 151 738 ND, 341 397.32y 10 152 767 ND 521 245..9611 153 776 1368.9 365 -957.63
12 154 767 ND 317 450.37
13 155 758 1586.4 365 -1193.4
14 156 751 ND 461 290.08
POST Ol 157_ 739 2287.8 273 -1821.3
02 158 785 ND 269 516.46
03 159 768 ND 421 347.16
04 160 747 2110.7 389 -1752.705 161 748 ND 401 347.2
06 162 758 ND 353 405.3
07 163 737 ND 341 396.3-
08 164 769 5A1)
r
10
1v
747 1003 461 -711
11
166
167 737 826.85 393 482.85
12_ 158 748 7226.3 265 -743.3;.
13 169 736 ND 220 515.56
14 ' 170' 769 ND 345 424
 li y
BAYLOR BED REST - PHASE I
SUBJECT:	 4
Phosphorus Balance (mg)
DAY; DAY
P611
E
P301CAL
uuggii
P1277NE
P DDEE TT
32^9ASTUDY 122
02 123 1463 725,74 823 -85.74
03 124 1389 ND 915
228g
336.1704 125 1553 301.83
1132 41305
06
126
127
1545
1602
ND
705.9 1084 -187.9
07 128 1549 439.41 877
235.59
08 129 1553 ND 9661166
587
14509
10
130
131
1311
1533
ND
1131.81 926 -524.81
11 i32 1564 506.68 992
65.32
12 133 1689 ND 11401036
549
64913
14
134
135
1685
1463
NO
1434.12 972 -943.12
15 136 1522 ND,
959
1485
563
93 16
17
137
138
1578
1552
ND
TF 296 TF
18 139 1568- TF 1082834
TF>
749
19
20
140
141
1583
1451
ND
ND 1085 366
21 142 1510 ND 929
581
BED 01 143 `1522 TF 1341 TF870
02 144 1578 ND_ 708
 716
03 145 1574 N0 858 3
04 146 1666 ND 1122
544
05 147 1440 _TF 448
TF
06 148 1552; ND 1076 465
07 149 1540 ND 1075 905
08 150 1672 ND 767 544
09 151 1517 ND 973
-150 
10 152 1646 ND 1796 TF
11 153 1464 TF 1123
12 154 1579 ND 892 687
13 155 1554 TF 1096 TF
14 156 1662 ND 1282 380
POST 01 157 1482. TF 1045 TF!	 02 158 1659 ND 995 661
03 159 1553 ND 1230 323
04 160 1540 TF 1029 TF
i	 05 161 1552 ND 1205 347
06 162 1713 ND 818 895
07 163 1515 ND 1323 192
08 164 1657 ND 458 1199
09 ` 165 1439 ND 837 602
10 1,66 1540 TF 1345 TF
11 167 1540 TF 1075
TF
12 168 1660 TF 1113 TF
13 169' 1481 ND 752 729
14 170 1657 -ND 986
671
1
BAYLOR BED REST - PHASE I
Sodium Balance (mEq)SUBJECT:	 4
NA-FECAL NA-URINE NA-DELTASTUDY DAY DAYJUL NA-IN
PRE 01 122 287 .43_ 158 128.57
02 123 286 2.28 232 51.72 
03 124 192 ND 221 -29
04 125 244 .81 228 15.19
05 126 239 ND 298 -59
06 127 279 2.06 162 114.94
07 128 276 1.14 264 10.86
08 129 290 ND 281 9Og 130 216 ND 236 -20
10 131 232 4.22 198 29.78
11 132 232 6.58 197 28.42
12 133 242 ND 179 63
13 134 _ 256 ND 139 117
14 135 283 2.73 233 47.27
15 136 238 ND 175 63
16 137 233 ND 236
-3
17 138 231 3:17 96 131.83
18- 139 232 4.46 197 30.54
19 140
245 ND 222 23
20 141 282 ND 271 11
21 142 238 ND 292 -54
BED 01 143 232 1`.06 274 -43.06
02 144 232 ND 148 84`-
03 145 240 ND 159 81
04 146 247 "ND 275 -28
05 147 282 1.36 153 127.69
06 148 238 ND 266 -28
07 149 231 ND :248 -17
08 150 269 ND 175 94
09 151 213 ND 168 45
10 152 245 ND 287 -42
11 153_ 283 1.6 215 66.4
12 154 239 ND 185 54
13 87
211 25
-18.1314 156, 269 ND 287
POST 01 157 225 3.45 125169
96.55
12002
03 ,
158
159
289
286
ND
ND 264 22	
{
04 160 237 4.07 290 -57.07
05 161' 232 ND 241 -9
06 ' 162 232 ND 168 64
07 163 213 ND 139 74
08 164_ 249 ND 200 49
09 165 282 ND 180 10210 166 237 5.2 181 50.8
11 167` 231 4.27 187 39.73
12 168 228 9.67 234 -15.67
13 169 224 ND 158 _'66
14 170 249 ND 221 28
gBAYLOR BED REST - PHASE Y
Potassium Balance	 (mEq)
SUBJECT:	 4
STUDY DAY JUL DAY K-IN K-FECAL K-URINE K-DELTA
PRE 01 122 82 7.37 60 14.63
02 123 90 15.77 63 11.2-3
03 124 66 ND 46 20
04 125 78 6.94 62 9.06
05 -126 83 ND 65 18
06 127 76 16.53 62 -2.53
07 128 95 7.63 71 16.37
08 129 92 ND 79 13
09 130 70 ND 57 13
10 131 69 25.88 60 -16.88
11 132 76 24.35 76 -24.35
12 133 86 ND 70 16
13 134 105 ND 63 42
14 135 93 24.07 62 6.93
1.5 136 89 ND 50 39
16 137 75 ND 74 1
17 138 72 33.76 29 9.24
18	 -- 139 78 21.55 59 -2.55-
19 140 -100 _ND 58 42
20 141 89 ND 7'4_ 15
21 142 85 ND 77 8
BED 01 143 69 20.55- 70 -21.55
02 144 77 ND 57 20	 j
o3 145 80 ND 64 16
04 146 103 ND 68 35
86 23.42 51 11.58
06 148 89 ND 82. 707 149 72 ND 58 14
08 150 81 ND 55 26
Og 151 69 ND 57 12 
10 152 102 ND 106 -4
1 T 153 93 16.08 63 13.921 1 153 94 ND 62 32
13 155 71 21.72 54 -4.72
14 156 77 ND 84 "7
POST 01 157 66 33.76 70 ..37.76
02 158 106 ND 61 45
03 159 96 ND 75 21
04 160 85 38.89 80 -33.89
05 161 69 ND 63 6
06 162 78 ND 49 29	 -
07 163` ` 68 ND 48 20
08 164; 102 ND 46 56
09 165 _85 ND 53 32
10 166 85 23.43 44 17.57
11 167` 65 29.56 49 -13.56
12 168' 77 26.67 54 -3.67
13 169` 66 ND 56 10
14 170 102 ND 73 29
r
BAYLOR BED REST - PHASE I
Magnesium Balance (mEq)
SUBJECT: 4
STUDY DAY JUL DAY MG-IN MG-FECAL MG-URINE MG-DELTA
PRE 01 122 27 3.95 12.5 10.55
02 123 23 10.48 5.7 6.82
03 124 17 ND 8.7 8.3
04 125 22 3.67 10.1 8.23
05 126 21 ND 7.1 1`3.9
06 127 24 7.11 8.6 8.29
07 128 24 6.1 7.8 10.1
08 129 25 ND 9.1 15.9
09 130 16 NO 10.1 5.9
10 131 17 14.37 7.3 -4.67
11 132 22 13.49 6.8 1.71
12 133 29 NO 12.2 16.8
13 134 26 ND 7.9 18.1
14 135 24 16.52 10.7 -3.22
15 136 24 NO 17.6 6.4
16 137 19 NO 12.3 6.7
17 138 21 20.47 3.5 -3.07
18 139 25 12.03 7.5 5.47
19 140 26 NO 8.5 17.5
20 141 23 ND 9.7 13.7	 1
21 142 23 ND 7 16
BED 01 143 17 15.39 8.1 -6.49
02 -144 22 NO 6.9 15.3
03 145 25 NO 7.7 17:3
04 146 26 ND 6.6 19.4
05 147 23 18.6 2.4 2
06 148 25 NO _ 10.9 14.1
- 07 149 22 NO 4.1 17.9
08 150 25 ND 7.7 17.3
09 151 25 NO 9.1 15.9
10 152 26 ND 14.1 11.9
11 153 24 17.18 9,8 -2.98	 i
12 154 26 ND 8.2 17.8
13 155 19 18.61 8.8 -8.41
14 156 22 ND 12.1 9.9
f	
POST 01 157 20 24.64	 - 7.9 -12.54
02, 158 26 NO 8.8 17.2
03 159 23 ND 10	 - 13
04 _ 160 25 27.29 9.8 -12.09
05 161 18 NO 10.2 7.8
_	 06 162 23 NO 10.3 12.7
`	 07 163 25 NO 11.5 13.5
08 164 25 NO 3.8 22.2
pg 165 23 ND 8 15
10 166 18.64 19.8 -13.44
11 167_ 18 18.17 14 -14.17,
.	
12 168 22 15.44 8.5 -1.94
13 169 20 ND 7.3 12.7
14 170 , 26 NO 7.4 , 18.6
^	 ..1'^ k,N'	 x'f4	 }+e. gwp[MI 9P.%mIDNBim'3ir[-f4a°°°`^` 	
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'BAYLOR "o ED REST - PHASE I
Chloride Balance (mEq)
SUBJECT:	 4
STUDY DAY JUL DAY CL-IN CL-FECAL CL-URINE CL-DELTA	 j
PRE 01 122 250 .7 166 83.3
02 123 265 2.01 180 82.99
03 124 168 ND 197 -29
04 125 227 .72 200 26.28
05 126 218 ND 271 -53
06 127 248 2.73 159 86.27
07 128 248 2.24 224 21.76
08 129 268 ND 239 29
09 130 198 ND 208 -10
10 131 218 1.43 185 31.57
11 132 208 1.12 175 31.88
12 133 207 ND 162 45
13 134 227 ND 133 94
14 135 263 1.73 178 E1.27
15 136 218 ND 161 57
i' 16 137 218 ND 194 24
17 138 208 1.14 86- 120.86
18 139 204 1.71 164 38.29
19 140 224 ND 176 48
' 20 141 263 ND 210 53
21 142 218 ND 225 -7
BED 01 143 218 .72 200
17.28'
02 144 208 ND 146 62
03 145 205 ND 142 63
04 146 223 ND 237 -14
e 05 147 263 .33 130
132.67
06 148 218 ND 249
-31
i 07 149 227 ND 203 24'
08 150 240 ND 155 85	 1t
09 151' 186 ND 144
42
10 152, 221 ND 267 -46
11 153 263 .32 202 60.68
12 154 219 ND 188 31
13 155 220 .29 185
34.71
14	 - 156 241< ND 267 -25`
POST 01 157 203 .59 130 72.41
02 158 255 ND__ 144 11T
03 159 263 ND 225 38
04	 - 160 218 1.49 280 -63.49
05 161 217 ND 217 0
06 - 162 78>, ND- 159 -81
E 07 163 186 ND 128 58e
08 164 224 ND' 161 63
09 1'65 263 NO 177 86
10 166 218 1.3 155 61.7
11 167 217 .6 161 55.4
12 168 200 2.51 196 11.49
13 169 203 ND 156 4714 170 224 ND` 184 40 	 i
r- - - --	 --------
r
^
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BAYLOR BEL REST STUDY - PHASE I
P.ody Weight,	 Fecal	 Weight, Water 'Balance & Nitrogen Balance
Statistics
SUBJECT: 5
r
1
' STUDY DAY: TOTAL BEI) REST STUDY
M BODY WEIGHT FECAL WT W-DELTA N-DELTA
---	 -
MEAN
-	
----
---.-_	 _.--	 _	
-----_
	 -
81.4320
.---.-_-•--
	 -
183.787
-----_-_-----•---	
----
1645.27
-_----
	 -.-.-
.988800
j
l
SDEV .784544 64.2959 835.618 3.24192
^ SIZE 50 26 50 50
SUM
----- -----
4071.59
------	 ---------- - -
4778.47
-- ------------
82263.9
--------- --- ----
49.4400
----- ----_
STUDY DPY: PRE 01 TO PRE 21
1
MEAN 81.6904 168.755 1819.90 .500952
SDEV .763762
21
59.2784
12
540.750
21
2.44580
21SIZE
SUM 1715.50 2025.07 38217.9 10.5200
----
----_
---	 --------- ------------ ------	 - --	 ---	 -•------------.----	 --•----
STUDY DAY: BED 01 TO BED 14
MEAN' 81.6357 243.700 993.571 1.41571
SDEV 488887 8.20441 446.422 3.76049
SIZE 14 2 14 14
' S 	 ia 1142.90 487.400 13910.0 19.8200
STUDY DAY: POST 01 TO POST 14
MEAN 80.8999 189.618 1955`.78 1.27285
_ SDEV .806906 73.7232 -1130.27 3,949 23
SIZE 14 11 i4 14
SUM
__----------------------
1132.60_	 -
----------------------
2085.80
-._
27381.0
---	 -----
	 -•------
17. 8200
------
	 --
3
fi
.. Ata..14.-...r. ..rte	 .ua-..: 3-a.	 .u...-. . . L^w'^^Y+.^.	 r . Jw	 ..... ,.	 r a 4M	 . .v..	 a. an w. nFh^...I... -.... ..iunrti4. ^a --.	 e.u.	 v. .. a .Wt:.^F.•..Ja^» .. .
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BAYLOR BED RCST •. PHASE I
4 Hineral	 Statistics
SUBJECT:	 5
STUDY DA":	 TOTAL BED REST STUDY
.; 0	 :);.LTA f'-t)Ll.'fA IAA-DELTA K-DELTA MG -DELTA CL-i;ELTA
------ -----------
--•	 -	 ---- --	 ---------------- -- ----	 ----	 -------- ------
I•',EF•.,; -80.0568 201.033 41.9490 5.19200 7.69919 47.7546
SUf.`t 637.719 453.145 123.558 22.3329 10.1274 57,8474
' SIN 50 32 50 50 50 50
SUM
-4CO2.84 6433.06 2097.45 2.59.600 384.959 2387.73
STUDY DAY:	 PRE 01 to	 [I RE	 21
"EA(1 28.6424 -23.7018 30.6090 7.94618 8.33666 48.3742
SDE II 397.046 420.957 173.664 18.3135 6.317.52 54.9108
a SIZE 21 17 21 21 21 21
SUM 601.491
---------------------------------------------------------
-402.932 642.790 166.869 175.070
--
10'15.86
--- -	 ---	
-
j STUDY DAY:	 BEL 01 TO HD 14
MEAN 82.4243 480.583 25.4564 5.81213 11.9364 30. 9100
_ r SDEV 604.897 37x.229 59.9547 30.1083 10.6346 53.E113
t SIZE 14 12 14 14 14 14
SUh1
- 1153.94 5767.00
`-----------
356.390 81.3699
-
167.110 432.740
-
----- -----	 -	 -	 -	 --
-	 -------- --	 - -- ------------ _-----_	
1
STUDY DAY:	 POST 01	 TC POST 14
a i^EAI
-402.097 356.333 70.9493 .924283 2.54000 61.3721
SDEV 874.682 199,475 76.4097 20.5339 12.7 ,335 67.1912
SIZE 14 3- 14 14 14 14
SU1
-5629.37
=--T_^-------------------------------------
1069.00 993.290
-
12.9399
--	 -	 -------
35.5EOO
------	 --
859.210
-- ----
t ^
j
Y
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OF POOR QUALITY
BAYLOR BED REST - PHASE I
Water Balance
	
(ml)SUBJECT:
STUDY DAY JUL DAY WIN W-FECAL W—URINE W-DELTA
PRE 01 122 3456 ND 1270 2186	 a
02 123 3627 105.43 1045 2476.57
03 124 2716 ND 1020 1696
04 125 3253 174.36 1375 1703.64
05 126 2210 ND 1365 845
06 127 3691 101.86 1000 2589.14
-1 ND
190008 129 2957 2057
09 130 3150 195 1020 1935
10 131 3011 ND 860 2151
11 132 2651 172 1130 1349
12 133 3207 ND 1120 2087
13 134 2536 46.43 1040 1449.6
14 135 2728 96 1150 1482
15 136 2219 ND 1180 1039
16 137 3399 162 980 2257
17 138 2431 97 700 1634
18 139 3601 76 675 2850
-19 140 2782 152 1010 1620	 ;.
20 141 3052 ND- 920 2132
21 142 1943 ND 1100 843
BED 01 143 2122 188 1110 824
02 144 1551 ND 1075 476
03 145 2865 ND 870 1995
04 146 2001 ND 920 1081
05 . 147 1833 ND 1030 803
06 148 2493 ND 1365 1128
07 149 2187 159 1620 408
08 150 1901, ND 945 956
E, 09 15i 2826 ND 1030 1796
10 152 2302 ND 1700 602
11 153 1962 ND 1190 772
12 154 2173 ND - 1160 1013
1.3 155 _2194 ND 1390 894
14 156 2352 .ND 1190 1162
POST 01 157 3679 201 900 2578
02 158 2036 '221 950 865
03 159 2.038 135 1130 773
° 04 160 1591	 - 187 345 1059
05 161 2277 ND 1360 917	 _3
06 162 1991 177 880 934
07 163 3898 143 960 2755
08 164 3266 113 1490 1663
`
09 165 4055 ND 690 3365
" 10 166 3713 106 715 2892
11 167 2450 101 1250 1099	 a`
12 168 2220 79 910 1231	 1
13 169 4763 ND 760 4003
k	 , 14 170 3923 66 6`10 3247
 1 	
}}
	 r
I	 t
BAYLOR BED REST - PHASE I
`	 SUBJECT:	 5
.^ Nitrogen Balance (gmi
STUDY DAY JUL DAY N-IN N-FECAL N-URINE N--DELTA
PRE 01 122 17.68 ND 13.7 3.98
02 123 16.99 2.75 15.6 -1.36
x	 03 124 14.3 ND 14.2 •1
04 125 17.63 3.12 16 -1.49
05
S
15.62 ND 15.2 .42
06 17 17.66 2.32 11.3 1. 04
07 128 17.1 3.09 16,7 -2.69
08 129 16,98 ND 13.9 3.08
_-09- 130 14.48 3.65 15.4 -4.57
10 131 17.62 ND 15 2.62
11 132 15.6 3.11 14.1 -1.61
12 133 17.66 ND 15.1 2.56
13 134 17.1 1.16 13.49 2.45
14 135 15.76 2.45 15.19 -1.88
15 136 16.29 NP 14.44 1.85
16 137 17.63 3.22 16.25 -1.84
17 138 15.34 1.67 12.64 1.03
18 139 17.66 1.19 13.45 3.02
1 9 140 17.33 3.06 - 14.2 .07
20 141 17,36 ND 12.91 4.75
21 142 14.14 ND 15.15 -1.01
BED 01 143 17.63 4.14 14.24 -.75
02 144 15.58 _ND 10.16 5.42
03 145 17.66 ND 12.27 5.39
04 146 17.57 ND 10.24 7.33
05' 147 17.6 ND 16.75 .85
". 06 148 16.29 ND 19.06 -2.77
07 1' 49 17.71 4.03 18.52 -4.84
08 150 15.34 ND 9.72 5,62	 j
09 151 17.66_ ND 13.15 4.51
10 152 16.5 > ND 19.62 -3,12
11 153 17.36 ND 15.67 1.69
12 154 16.29 ND 17.12 -.83
13 155 15.76 ND 14.3 1.46
i4 156 14.78 ND 14.92 -.14
POST 01 157 17,66 4.78 ,"	 14.01 -1 .13	 1
02 158 16.5 4.6 13.48 -1.58
03 159 17.36 3.46 15.18 _1.28	 i
04 160 14.48 2.85 3.91 7._72	 S
05 161 15.76 ND 17.72 -1.96
06 162 -15.34 3.47 9.06 2.81
07 163 17.66 2.1 14.28 1.28	
ti
08 164 16.98 1.89 17.58 -2.49	 1
09 165 17.36 ND 13,6 3.76
i0 166 14.48 3.08 13.36 -1.96
11 167 15.6 2.28 16.6 -3.28	 a
_	 12 168 15.34 1.8 12.31 1.23
13 169 17.66 ND 11.44 6.22
14 170 16.5 1,82 6.2 8.48	 1
a
tG
BAYLOR BED REST PHASE I
Calcium Balance (mg)
SUBJECT: 5
STUDY DAY JUL DAY CA-IN CA-FECAL CA-URINE CA-DELTA
PRE 01 122 781 ND 372 408.2
02 123 797 -857.51 341 -408
03 124 799 ND 413 386.17
04 125 782 403.77 409 -30.58
05 126 756 ND 457 299.1
06 12.7 773 235.01 377 161.2,3
07 128 769 241.42 309 218.96
08 129 769 ND 385 384.2
09 130 761 -1100.6 437 -776.5
10 131 779 ND 433 396
11 132 757 921 425 -588.85
12 133 773 ND 525 247.9
13 134 768 351 377 40.25
14 135 643 709 413 -478.8
15 136 750 ND 409 341.18
16 137 772 - 903 469 -599.9
17 138 781 384.5 297 99.91
18 139 773 365.1 321 87.26
19 140 776 771.1 389 -383.8
20 141 778 ND 285 493.43'
21 142 741 ND 437 304.13'
BED 01 143 767 1304.4 417 -954`.2
02 144 776 ND 373 403.26
_
03 145 _766 N0 353 413.3
04 146 791 ND 405 386.2
05' 147" 789 ND 429; 360.14
06 148 772 ND 697 74.61
07 149 762 1748.4 641 -1627.7
08 150 772 ND 389 383.2
09 151 772 ND 445 327,.11
10 152 786 ND 653 132.7
17 153 755- ND 497 268
12 154 772 ND 485 287.03
13 155 791 ND 401 390.2
14 156 767 ND 457 310.09	 1
J	 POST 01 157 773 2851.2 433 -2511.6
02 158 775 2184.8 401 -1810.6
j	 03 159 776 '1375.5 541 -1140.5	 -^
04 160 771 834.5 285 -348. 5
05 161 816 ND 48y 327
!	 06 162 772 1119.6 333 -680.6
07 163 775 -514.8 389 -128.9
08 164 786 429.08 469 -112.08
09 165 777 ND 224 552.55
10 166 772 547.08 265 -40.08
11 167 789 403.9 409 -23.9
12 168 774 601.23 329 -156.23
13 169 775 ND 261 514,48
14 170 843 ' 697.41 216 -70.41
BAYLOR BED REST — PHASE I
Phosphorus Balance (mg)
k	
, SUBJECT:
	
5
STUDY DAY JUL DAY P-IN P—FECAL P-URINE P—DELTA
PRE 01 122 1637 NO 1118 519
02 123 1521 648.11 1170 -297.17
03 124 1436 ND 1204 232
04 125 1556 885.79 1128 —427.79
05 126 1503 NO 1420 83
06 127 1611 631.88 1320 —340.88
07 128 1550 819.57 1112 —381.57
08 129 1457 ND 1152 305
09 130 1436 1049.95 1092 -705.95
10 131 1554 NO 1135 419
11 132 1503 845.82 1175 —517.82
12 133 1611 ND 1098 513
13 134 1559 302.85 1144 —387.85
14 135 1408 631.96 1150 —373.96
15 136 1571 ND 1204 367
16 137 1551 TF 1215 TF
17 138 1584 TF 812 TF
18 139 1612 TF 1026 TF
19 140 1622 TF 1172 TF
20 141 1604 ND 1104 500
21 142 1406 NO 1364 92
BED 01 143 1526 TF 1199 TF
02 144 1584 ND 774 810
03 145 1610 ND 1044 566
04 146 1652 ND 699 953
05 147 1633 ND 886 747	 -
06 148 1579 ND 1802 -223
07 149 1533 TF 1264 TF
08 150 1558 ND 794 764`
09 151 1611 ND 1030 581
10 152 1385 NO 1632 —247
11 153 1601 ND 1119 482 a
12 154 1579 ND 1322
13 155 1511 ND 988 52314 156 1506 ND 952 554
POST 01 157 1611 TF 1152 TF
02 158 1380 TF 912 TF
03 159 1602 TF 1107 TF
04 160 1391 TF 676 TF05 161 1540 ND 1414 126
_	 06 162 1558 TF 598 TF
07 163 1611 TF 1440 TF
08 164 1436 TF 1460 TF
09' 165 1604 ND 1132 472,
10 166 1393 TF 1115 TF
r 11 167 1505 TF 1150 TF
12 168 1559 TF 1001 TF
13 759 1611 .ND 1140 471
14 170 1457 TF 952 TF '
BAYLOR BED REST - PHASE I
Sodium Balance	 (mEq)
SUBJECT:	 5
STUDY DAY JUL DAY NA-IN NA-FECAL. NA-URINE NA-DELTA
PRE Ol 122 288 ND 250 38
02 123 290 .92 173 116.08
03 124 254 ND 182 72
04 125 244 4.52 272 -32.52
-r	 05 126 243 ND 246 -3
06 127 287 1.29 183 102.71
07 128 247 4.26 220 22.79
08 129 287 ND 158 129
09 130 243 7.38 10.9 224.72
10 131 250 ND 158 92	 v
11 132 244 4.1 301 -661
12 133 2n7 ND 230 57	 a
13 134 237 1.94 230 5.06
14 135 262 3.22 265 -6.22
15 136 243 ND 268 -25
16 137 245 6.83 146 92.17
17 138 245 2.53 92 150.47	 g
18 139 287 2.06 89 195.94	 !
19 140 244 4.41 225 14.59
20 141 263 ND 197 66
21 142 223 ND 231 -8
BED 01 143 244 3.9 240 .1
02 144 245 ND 220 25
03 145 281 ND 151 130	 1
04 146 247 ND 248 -1
05' 147 290 ND 249 41
06 148 244 ND 272 -28_
07 149 237 6.71 258 -27.71
08 150 243 ND 164 79
09 151 286 ND 166 120	 s
10 152 2.45 ND 347 -102
11 153 290 ND 254 35
12 154 244 ND 211 33
13 155	 `' 244. ND 206- 38
14 156 245 ND 232 13
POST 01 157 287 10.62 122 154.38
02 158 244 7`.32 193 43.68
03 159 263 3.39 234 25.61
04 160 247 12.52 233 1.48
05 161 249 ND 280 -31
06 162 243 5.02 171 66.98
07 163 287 9.02 173 104.98
08 164 241 3.53 234 3.47
09 165 263 ND 79 184
10 166" 247 2.35 84" 160.65
11 167 245 2.68 281 -38.68
12 168 244. 2.13 209 32.88
13 169 278 ND 154 124
14 170 248 1.15 86 160.86
LL
l !
.9
i
BAYLOR BED REST - PHASE I
Potassium Balance (mEq) j
^-
SUBJECT: 5
_	
STUDY DAY JUL DAY K-IN K-FECAL K-URINE K-DELTA
PRE 01 122 88 ND 85 3
02 123 100 11.64 88 .36
03 124 77 ND 54 23
04 125 77 22.86 84 -29.86
05 126 88 ND 76 12
06 127 82 16.55 73 -7.55
07 128 95 22.56 69 3.44
08 129 86 ND 58 28
09 130 76 22.87 75 -21.87
10 131 80 ND 52 28
11 132 88 22.28 72 -6.28
12 133 82 ND 55 27
13 134 96 16.11 67 12..89
14 135 93 10.71 76 6. 21 	 j
15 136 89 ND 84 5
16 137 77 20.53 78 -21.53
17 138 96 11' . 59 53 31.41
18 139 82 10.3 37 34.7
19 140 91_ 15.13 70 5.87
20 141 87 ND 78 g
21 142 85 ND 61 24
BED 01 143 71 27.01 76 -32.1
02 144 91 ND 48 43
03 145 81 ND 68 13
04 146 91 ND 51 40
05 147 87 ND 66 21
06 148 94 ND 96 -2
07 149 72 29.53 91 -48.53
08 150 90 ND 42 48
09 151 82 ND ' 65 17
10 152 83 ND 126 -43
11 153 83 ND 74 9	 a
12 154 94 ND 81 13
13 155 75 ND 66 9	 al
14 156 69` ND 75 -6
POST 01 157 82 41.96 65 -24.96
02 158 83 40.87 76 -33.87
03 159 87 22.87 75 -10.87
04 160 89 17.31 63 8.69
05 161 82 ND 88 -6
06 162 90 22.73 45 22.?.7
07 163 82 8? -I 
a8 E :2 1 ";.
	
l 79 1t	 ft
19 1E: 88
,y,` 64
10 166 90 1 1 53
11 167 74 1's.l'1 0
12 168 9.0 }0 2ss '61
_..	
13 1>69 82 I4D 62 20
14 170 85 10.98 62 12.02
g
3BAYLOR BED REST - PHASE I
Magnesium Balance (mEq
SUBJECT:	 5
STUDY DAY JUL DAY MG-IN MG-FECAL MG-URINE MG-DELTA
PRE 01 122 28, ND 10.8 17.2
02 123 25 10.69 10.9 3.41
03 124 18 ND 10.5 7.5
04 125 22 10.63 9.5 1.87
05i 126 23 ND 14.7 8.306 127 27 6.26 10.5 10.-24
07 128 24 7.5 9.4 7.1
08 129 23 ND 10.4 12,6
09 130 18 14.07 10.4 -6.47
10 131 22 ND 10.3 11.7
11 132 23 10.63
e.4
3.97
12 133 27 ND 12.8 14.2
13 134 24 11.18 3.2 9.62
14 1`35 24 8.49 9.8 5.71
15 136 23 ND 9.8 13.2
16 137- 22 11.99 12.9 -2.89
17 138 29 6.32 6.1 16.58
18 139 27 4.67 8 14.33
19 140 25 13.1 9.1 2.8
20 141 23 ND 7.4 15.6
21 142 19 ND 10.5 8.5
r
	BED 01 143 21 14.34 9.2`' -2.54
02 144 28 ND 6.4 21.6
03 145 27 ND 8.3 18.7
04 146 25 NO 7.3 17.7
05 147 23 ND 8.2 19.8
06 148 25 ND 7.6 17.4
07 149 22 25.25 11.7 -14.95
08 150 28 ND 6.8 21.2
09 151 27 ND 13.2 13.8
10 152 31 _ ND 17 14
11 153 23 ND 11.9 11.1
12 154 25 ND 11.5 13.5
13- 155 26 ND 9.6 16.4
14 156 10 ND 10.6 -.6
POST 01 157 27 38.25 10.9 -22.15
02' 158 31 32.71 10.7 -12.41
03 159 23 21.31 12.9
-11.21
04 160 32 12.38 6.4 13.22
05 161 26 ND 15.6 10.4
06 162 28 20.11 9.4 ` -15.1
07 163 27 7.38 12.4 7.22
08 164 32 8.21 13.1 10.69
09, 165 23 ND 9.5 13.5
10 166 32 16.36 11.7 3.94
11 167 24 11,35 14,9
-2.25
r	 12 168 28 9.83 9.6 8.57
13 169 27 ND 9.7 17.3
14 170 _31 7.56 9.6 13.84
t	 ;
r-
RV•
i
BAYLOR BED REST - PHASE I
Chloride Balance (mEq)SUBJECT: 5
STUDY DAY JUL DAY CL-IN CL--FECAL CL-URINE CL-DMA
PRE 01 122 251 NO 234 17
02 123 267 .96 155 11,04
03 124 222 ND 137 85
04 125 228 2.71 249 -23.7105 126 218 NO 212 6
06 127 250 ,41 173 76.59
07 128 219 .86 199 19.14
08 129 266 NO 129 137
09 130 218 2,16- 182 33.84
10 131 229 ND 128 101
11 132 219 -	 2.05 225 -8.05
12 133 250 NO 205 45
13 134 209 1.91 189 18.09
14 135 248 .85 231 16.15
15 136 212 NO 223 -11
16 137 229 1.78 140 87i22
17
_138 ' 228 1.4 90 136.6
18 139 251 1.04 70 179.96
19 140 217 2.01 193 21.99
20 141 227 NO 175 52
21 142 193 NO 178 15
BED 01 143 229, 2.15 202 24.85
02_ , 144_ 228 NO 163 65
03 145 250 NO 161 107.7
04 146 219 NO 204 15
05 147 253 NO 223 30
06 148 213 ND 250 -37
07 149 227 .81 217 9.19
08 150 227 NO 133 94
09 151 251 NO 151 100
10 152 225 NO 316 -91
11 153 254 ND 219` 35
12 154 213 ND 196_ 17
13 155 225 NO 170
S8f	 14 156 226 NO 218'
POST 01 157 251 .65 113 137.35_
02, 158 224 2-.05 208 13.95
03 159 227 12.01 208 6.99	 '.
04 160 224 2.36 199 22.64
i	 05 161 228 NO 253
-06 162 227 2.39 159 65.61_,	 .
07 163 252 2.08 170 79.92;
:. 08 164 225 1.36 218` 5.64
09 165 227 _ NO 73 154
10 166 224 -486 64' 159.15
11 167 226 1.23, 255 -30.23
12 168 227 1.02 198 , 27.98
13 169 242 NO 139 103
14 170 225 .79 86 138.21
9' A
E BAYLOR BEL RLS T STUDY - F}`aiSE:	 1
_ Cody Weight,	 Fecal	 Wf ei c ht, ^dcitcr	 E;^:l ance Fx ^'J iron
 en E;,al ance
Statistics
f
t SUOAI ECT :	 6
STUDY [fit Y:	 TOTAL. I)ED LEST STUDY 1
1
13ODY	 WLI(:1iT FECAL WT W-CELTA Il-	 LLTT
MEAIN	 64.9860 106.392 959.538 1	 012020
3 SDLV	 .711422 49.3827 655.976 4.50078
SIZL	 50 39 50 50
SUM3249.30 4149.30 4.7976.9 54.0100
I
STUDY VY:	 PRE 01 TO PRE 2.1
HEAN	 64.3619 101.368 939.220 1.74F;5
SDEC	 .385758 61.3810 678.483 4.139 *111
` SIZE	 21 16 21 21
SUM	 1351.60 1621.90 19723,6 36.7203)
}
------	
------------------- - -- - - -------- -	 --	 -- --- ------	 --- --
STUDY DAY:
	
['ED 01
	
TO bEU 14
a 1EA„	 65.3500 101.760 706.785
SCEI'	 .505464 33.4240 427.404 6.5021
SIZE	 14 10 14 14
SUM,	 914.900
---	 -------	 -----	 -	 -	 -- -
1017.60
------	 --
03C- S.00
--	 ---
	 -- ---	 -	 -----
STUDY DAY:
	
POST 01 TO POST 14
65.6000 111.116 1304.5 1
SDE1	 .4740 42.9721 60?. v(-" 2.	 : `r{
SIZE
	
14 12 14 14
SUM	 918,400
---------------------------------------------------------
1333.40 1 t 263,.0
---------------
19.	 -2{ r.
_
s
ORIGIN
'
PAGE ISOF PWPVQU.AL T
,
f ^	 I
I	 ii
i
I I r
	 .1 A
BAYLOR LIED RLS1 - PHASE I
Hinerill	 StaListics
l
i SUBJECT:	 6
STUDY DAY , 	TOTAL BED (ZEST STUDYI
S
C!,- DFITA  P-DELTA	 NA-DELTA K-DELTA
 -
MG-DELTA
-
CL-CE LTA
-----____ -- ---____ --.._--____
E;CIf; -45.3050 215.104	 24.2192 5.91572 7.53034 26.1508
x SpE'V 420.318 411.1 64 	 54.0032 18.0805 7.99245 46.1995
I1. 50 25	 50 50 50 50
-2265,25 5377.62	 1210.96 295.786 376.517 1307.54
t--- - -----..__--- ------	 ----	 ------__ ---	 -- ----------- ----- ..--__	 ---
4
STUDY DAY:	 PRE	 01 to PRE ,21
';EA(d 34.9272 170.110	 25.7271 8.02695 9.59272 29,7800
SDCV 379.029 408,045	 47.4271 19.3005 8.06994 •41.2562
S I 7-E: 21 16	 21 21 21 21
SUIl 733.471 2721,76	 540.270 168,566 201.447 625.380
-_..------------- ------- --.._-_--_-----__-____ --__-
_	 -	
-_-_--_ -_	 -	
.
STUDY DAY:	 BED 01 TO BED 1
IMEAN •-212.665 354.020	 14.0514 6.46500 4.99071 18.5835
SDEV 427.475 484.536	 40.3125 18.2658 9.3W6 33.7617	 j
SI7F 1 4 5	 14 14 14 14
_
--.-------
SUi 2977.31
------ -	 --
1770.10	 196.720
--,--------
	
----	 -----------
90.5100
---------
69.8699
---__- --
260.17(1	 1
------ ---_
	 j
STL1vY DAY:	 POST 01 1C POST 14
^^^th+^MIN ; t	 549.2^C^ ..374.000	 3 f .6978 3.09 f 71 r r7.8 ^f43 00	 I22 01. 1 000
SDEV 42".738 325.887	 73. £3743 17.2409 5.22275 64,6b37
t
-SIZE: 14 3 -	 14 14 14 14
SL^ • 4 689.591 1122_.00	 499.770 43.3400 109.990 407.40
;
w
,
ORIGINAI FAGS
a
OF POOR QUALM
r
i	 1
y	 i
j
BAYLOR BED REST - PHASE I
SUBJECT; 6
	 Water Balance (ml)
STUDY DAY JUL DAY W-IN W-FECAL W-URINE W-DELTA
PRE 01 122 3085 51.94 1450 1583
02 123 2559 45.72 1295 1218
03 124 1497 121.73 1280 95.27
04 125 2061 36.44 1050 974.56
05 126 1809 ND 1160 649
06 127 2910 150.21 1080 1679.8
07 128 1974 ND 1425 549
08 129 2482 32 1765 685
09 130 2031 81 1110 840
10 131 2025 72 1340 613
11 132 597 ND 1035 -43812 133 2970 16 840 2114
13 134 2169 45 1120 1004
14 135 1929 ND 1610 319
15 136 1812 24 1220 568
16 137 1806 113 1030 663
17 138 1748 55 880 813
18 139 3015 69 360 2586
19 140 2169 55 880 1234
20 141 2367 165 805 1397
21 142 1917 ND 1340 577
BED 01 143 1764 39 1375 350
02 144 1896 ND 1065 831
03 145 3229 34 1480 1715
04 146 1938 ND 840 1098
05` 147 2367 87 1730 550
06 148 1800 58 810 932
07 149 2130 87 1320 723
08 150 1677 ND 12713 407
09 151 3129 88 3170 -129
10 152 1974 43 970 961
11 153 2148 84 1430 634
12 154 2148 88 1200 860
13 155 1914 ND 1390 524_
14 156 1956 72 1445 439
POST 01 157 3464 86 11`10 2268`
02 158 1905 75 '720 1110
03 159 2148 94 1260 794
04 160 1791 ND 1545 246
05 161 1892 134 1370 388
06 162 2243 38 810 1395
07 163 3204 55 860 2289
08 164 2315 82 1005 1228
09 165 2732 36 735 1961
10 166 2034 89 1015 930
11 157 2136 ND 1390 746`
12 168 2071 _ 36 1130 905
13' 169 3282 95 '1150 203714 170 2499 123 410 1966
6.
BAYLOR BED REST - PHASE I
Nitrogen Balance (gm)
SUBJECT:	 6
STUDY DAY JUL DAY N-IN N-FECAL N-URINE N-DELTA
PRE 01 122 17.66 1.39 21.2 -4.93
02 123_ 16.99 1.1 -	 14.2 -1.69t
03 124 14.43 2,85 11,1 4804 125 18.22 .95 14.4 2.87
05 126 16.02 ND 13.6 2.42
06 127 14.61 3.52 12.7 -1.61
07 128 14.45 ND 1.67 12:78
'
08 129 14.34 .82 1' 1.6 1.92'
09 130 15.78 1.97 10.7 3.11
10 131 15.09 1.82 11.8 1.47
11 132. 14.82 '	 ND 13.9 .92
12 133 14.61 .84 10.18
_3.59
13 134 14.72 3.09 11.53
-.1
14 135 13.95 ND 12.17 1.78
15 136 _	 15.78 .71 10.99 4.08
16 137 15.09 9.05 13.4 -7.36
-
17 -138 14.82 1.47 12.2_ 1.15
18 139 14.61 1.92 4.11
_8.58
19 140 14.4 1.16 11.14 2.1
20 141 13.95 3.19 9.51 1.25
21 142 15.98 ND 12.07 3.91
BED 0; 143 15.09 1.04 10.66 3.39
02 144 14.82 ND 12.18
-2.64
03 145 14.61 .96 15.9
-2.25
04 146 12.29 ND 9.31 2.98
05 147 13.95 2.38 14.76
-3._19
`	
k 06 148 15.74 1.41 8.96 5.37
07 149 15.09' 2.18 11.14 1.77
08 150 14.82 ND 13.34 1.48
09 151 14.61 2.41 33.51
-21.31
10 152 14.61` 1.11 11.17 2.33
11 153 13.95 1.88 11.87 .2	 x
12 154 15.78 2.06 11.54 2.18	 $
13 1:55 15.09 ND 12.02 3.07
14 156 14.82 1.67 13.94 -.79
POST 01 157 14.61 1.98 11.89
02 15.8 12.3. 1.58 9.71 1.01
03 159 13.95 1.8 10.89 1.26
04 160 15.74 ND 11.62 4.12
05 161 15.09 2.77 11.52 .8
06 162 14.82' 1.59 11.19 2.54
07 163 14.61 1.37 12.15 1.09
08 164 14.4 1.65 12.18 .57
09 165 13.95 .93 10.17 2.85
10 166 15.79 1.72 11 3.07
a 11 167 15.09 ND 17.5
-2.41
> 12 168 14.82 1 14.5 =.68
13 169 14.61, 2.26 14.34
-1.97
14 170 14.45 2.57 5.85 6.03=
T
tBAYLOR BED REST - PHASE I
Calcium Balance (m9)
SUBJECT:	 6
STUDY DAY JUL DAY CA-IN CA-FECAL'	 -CA-URINE CA-DELTA	 y
PRE 01 122 775 571.9 481 -277.86
02 123 780 420.64 409 -49.45
J3 124 724 1098.32 337 -711
04 125 793 162.15 361 270.13
05 126 781 ND 401 376.19
0E 127 812 468.45- 317 26.92
07 128 825 ND 373 452.25
08 129 814 156.4 683 -25.4
09 130 821_ 390.59 309 121.41
10_ 131 796 352.39 389 54.61
11 132 772 ND 361 411.28
12 133 820 207 277 336
13 134 816 412 257 147.4914 135 801 ND 349 452.3
15 136 817 - 332 277 208
16 137 -794 1244 301 -750.6
17 138 781 611.8 361 -191.8	 3
18 139 820 826.5 128 =134.76	 7
19 140 813 317.8 281 214.64
20 141 806 1221.7 248 -664.2
21 - 142 808. ND 341 467.32
BED 01 143 799 430.2 401 -32.2
02 144 797 ND 457 340
03 .145 815 479.7 794 -462.7
04 146 764 ND 345 419
05 , 147 _ 806 1178.7 565 -937.7
06 148 809 629.3 345 -165.3
07 149 804 929.7 473 -598.7
08 150 795 ND 497 298.09
09 151, 814 1038.6 449 -673.5
10 152 827 496.1- 461 -130`
11 153 804 801.9 481 -478.9
12 154 799 741.5 479 -419.4
13 155 804 ND 509 295
14 156 773 759 445 -431
POST 01 157 819 849.5 349 -379.2
02 158 783 705.8 601 =524
03 159 804 787.2 309 -291.8
04` 160 806 ND 341 465.32
05 161 799 1151.5 281 518.44!	 06 162 781 498.6 289 492.4
07 163 815 570.72 297 -52.72
08_ : 164 810 656.3 285 525.4
09 165 806 301.94 240 264;06j	 10 166 823 467.26' 261 94.74
11 167 809 ND 273 536.46
12 168- 776 470.86 309 -3.86
13 169 817 1050.3 325 -558.3
14 170 826 1095.1 128.25 -397:35
Phosphorus Balance (mg)
SUBJECT:	 6
STUDY DAY JUL DAY P- IN P-FECAL P-URINE P-DELTA
PRE 01 122 1612 469.1 1537
-394.1
02 123 1464 356.24 932 175.76
03 124 1412 982.24 666
-236.24
04 125 1595 349.68 945 300.32 
05	 - 126 1539 ND 812 727
06 127 1476 1267.93 907
-698.93
07 128 1711 ND 1368 343
08 129 1568 237.46 847 483.54
09 130 1689 719.47 843 126.53
10 131 1572 724.87 804 43-.13
11 132 1537 ND 1346 191
12 133 1477 221.51 857 398.49
13 1`34 1722 988.71 1075
-341.71
14 135 1543 ND 1127 416-
I	 15 136 1687 301.03 952 433.97
16 137 1572 TF 1030 TF
17 138 1538 TF_ 1126 TF
'ff	 18 139 1477 TF 346' - TF
19 140 1701 TF 1038 TF
20 141 1544 TF 869 TF
j	 21
I
142 1692 ND 938 75¢
_.	 BED 01 143 1544 TF 798 TF
i 02 144 1546 ND 1129 417
03 145 1477 TF 1154 TF
04 146 1504 ND 756 74805 147 - .1544 TF
_ 1073 _ - TF
-06 148 1682 TF 923 TF
07 149 1573 TF 950 TF
08 _150 1546 ND 1092 454
09 '151 1477 TF 796 TF10 152 1722 TF_ -	 892
y11 1533 1544 TF 515
-478.9
f	 12 154 1668 TF 912 TF13 155 1575 ND 945 630
14 156 1539 TF 1156 TF
POST 01
f
157 1479 TF 484;D
02 158 1464 TF 893 TF	 ;
03 159 Z^ 44 TF 958 TF
04 160 1679 ND , 1082 597
05 161 1579 TF '986 TF
06 162 1541 TF 1134 TF
07 163 1477 TF_ 894 TF08 164 1700 TF - 1146 TF
09 165 1544 TF 926 ' TF	 #a
10 166 1690 TF '`731 TF
I
11 167 1581 ND 1056 525
12 168 153$ TF 1333 TF
13 169 1477 TF 1012 TF
14 170 1712 TF 508 TF
{f
3 1
7
BAYLOR BED REST - PHASE I
`'
Sodium Balance	 (mEq)SUBJECT: 6
` STUDY DAY JUL DAY NA-IN NA-FECAL NA-URINE NA-DELTA
PRE 01 122 287 1.089 267 18.9
02 123 293 _ 1.365 246 45.6
03 124 203 2.83 226 -25.83
04 125 249 .51 206 42.4905 126 250- ND 235 15
06 127 218 2.1 204 11.90 128 308 ND 296 12
J
08
900
129
130
218 1.01
2
265
150
-48
67
. 131 212 1.71 233 -22.71
` 11 132 215 ND 214 1
12 133 224 .69 145 78.3
13 134 _270 .69- 215 54.3
14 135 216, ND 241 -25
15 136 219 .51 207 11.49
16 137 -211 1.73 207 2.2717 138 222 .76 192 29.24
18 139 224 1.24 58 164.76
19 140 258. 9.29 198 50.71
20 141 217 2.15 -141 73-.85
21 142 218 ND 235 -17
BED 01 143 217 .86 244 -27.86
02 144 217 ND 244 -27
03 145 218 .8 185 32.2
04 146 239 ND 168 71
05• 147 217 2.16 250 -35.16
06 148 218 1.58 166 50.42
07 149 218 2.06 210 5.94
	
;.
08 150 216_. ND 237 -21
09 151 218 2.41 129 86.59
10 152 263 .84 197 65.16
1.1 153 217 2.06 226 -11.06
1.2 154 220 1.92 205 13.08
	
a
13 155 218 ND 221 -3,
14 156 217 1.59` -218 -2.59
POST 01 157 219 1.96 105 112.04
	 $
02 158 238 1.38 123 113.62
03 159 217 2.14 227 -12,.19
04 160 217 NO 246 -29,
05 161 211 2.94 241 -32.94
o6 162 217 1.08 160 55.92
07 164 18 1.15 178 38.8508 _58 2.03' 239 16.97
09 165 217 1.49 120 95.51
10 166 919 2.93 165 51,0711
12
167
168 9-18185
ND
1 .66
248 -30	 i
280 -96.6613 169 919 2.53 182 34-.47
14 170 259 2.89' 74 182.11
SAYLOR BED REST - PHASE I
Potassium Balance (mEq
\> SUBJECT:
	
6
STUDY DAY JUL DAY K-IN K-FECAL K-URINE K-DELTA
PRE 01 122 82 10.338 80 -8.34
02 123 92 7,844 64 20.15603 124 70 23.63 53 -6.63
04 125 79 7.58 70 1.42
05 126 91 ND 57 34
06 127 90 30.18 67 -7.18
07 128 92 ND 84 g
08 129 82 6.74 60 15.26
09 130 82 -	 18.31 49 14.69
10 131 79 16.66 56 6.34
11 132 69 ND 78 -9
12 133 92 3.34 48 40.16
13' 134 91 10.56' 78 2.44
14 135 81 ND 93 -12
15 136 81 5.75
_57 18.25
16 137 79 27.66 71 -19,66
17 138 71 13.25 58 -.2518 139 92 ' 16.57 18 57.43
19 140 91 30.51 62 -1.51
20 141 81 34.01 56 -9.01
21 142 79 ND 55 24
BED 01 143 76 9.73 53 13.27
02 144 73 ND 53 20
03 145 90 8.74 74 7.26
r	 04 146 83 ND 50 33
05 147 81 19.29 95 -33.29
06 148 80 13.09' 41 25.91
07 149 81 20.21 59 1.79	 a
08 150 73 ND 79 -6
09 - 151 90 20.78 - 62 9..22
10 152 93 10.59 62 20.41
11	
-
153 80 21.59 76 -17.59
12 154 85 20.28 53 11:•72
13 155 81 ND 64 17
14 156 69 13.19 68 -12:.19
POST 01 157 90 17.15 76 -3.15
02 158 81 19.44 70 -8.44
03 159 81 21.62 58 1.38
I`	 04 160' 80 ND	 - 96 -16
05 161 79 26.21 77 -24.21
06 162 69 8.87 61 -.87
07 163 90 13.4 66 10.6
08 _ 164 90 19.07 75 -4.07
09 165 .81 8.23 44 28.77
10 166 82 19.2 43 19.8
11 167 81 ND 70 11
12 168 69 8.46 76
r
-15.46
	
4 a
13 169 90 22.08 60 7:92
14 170 92 26.93 29 36.07
^
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SUMMARY'
Philip C. Johnson, M.D. and Cheryl Mitchell_
The Methodist Hospital	 -
Houston, Texas
From the initial examination of the bedrested subjects'
data, it seems that many of the changes were similar in kind,
if not degree, to those of the crew members postflight.-
i
Changes produced by this bedrest study similar to those found
in crew members returning from spaceflight include responses
of cardiovascular, endocrine, hematopoietic and neuromuscular
systems. The bedrest period produced responses in these
systems without the weight loss which characterizes a'return
from spaceflight.
Two out of six subjects in this study had`presyncopal
episodes during the first LBNP test postbedrest compared with
four of the nine Skylab crew members. The mean decrease in
calf circumference during the bedrest period was -2.6 ±0.3
9
(p.< 0.05), which is considerably less than the -7.6 ±0.5%
decrease found in the Skylab crew members at recovery, but
greater than the --1.4o found in a 7-day study. These results
are directly comparable since the three studies were performed
by the 'same investigators., (1,2) During maximal stress (-50
mm Hg) of the lower body negative pressure test (LBNP), the 1
changes in leg volume were not statistically different from
those seen during the control period, and the magnitude of
2individual change did not correlate well with the occurance
of syncope.- These findings are consistent with those of
Bartok et al., and M€nninger et al., who found the maximum
change in leg volume during tilt or LBNP to be the same pre-
and postbedrest. (3,4)
While calf size decrease is greater in spaceflight than
i in bedrest, the changes in calf size produced by LBNP post-
flight and postbedrest are only slightly different. Crews of
Apollo and Skylab missions showed only a 10% greater increase
in leg volume postflight during maximum LBNP This contrasts
with Skylab inflight measurements which showed an 83% greater
calf LBNP volume. (5) It appears, therefore, that large shifts
in blood volume are more easily produced inflight. The fluid
which shifts headward either remains in the vascular system or is
available to it in that it produces a significantly greater dis-
tension of the calves during LBNP. The shift of blood volume is
greater than the horizontal position produces either postflight or
postbedrest. Because the calf distension during LBNP is not
greater postbedrest and only slightly greater postflight, and
because an antigravity suit only partially prevents orthostatic
intolerance, venous pooling does not seem a completely adequate`
explanation for the similar degree of orthostatic intolerance
)
3seen in the crews and bedrested subjects.
I+ During maximum LBNP stress the increase in heart rate (I-iR)
from the resting value for all six subjects was greater post-
bedrest:
	
averaging +28o prebedrest and +42.5	 postbedrest.
Subjects 3 and 4, who were presyncopal on the first postbedrest
day, showed the l;._gest incremental increase in HR both during
the control phase and on R +0.	 Chobanian found similar HR
directional increases'' with tilting, but his subjects were less
stressed during control tilting (130 increase). 	 After one week
of bedrest the tilt-induced increase in HR was greater.	 He
found a 32% increase following 3 days of bedrest, 62% after
one week and 89% after three weeks.	 (6)
r Basal heart rate during sleep was not measured, but no
significant change was found with bedrest in the radial pulse
j
measured daily at 0700.	 Other investigators have found a ;a
gradual increase of 0.4 beats/day beginning with the fourteenth
day of bedrest.	 (7,8)	 This study was probably too shortto
record this change.	 The mean heart rate measured at 0700 on
R +0 by the nurse was 68.3'±7.8, while during the rest period
i
prior to LBNP, it was 75.2 ±5.8 postbedrest on R +0.	 The
change of posture from the supine to the sitting position
before the exercise testing produced a 23 beats/minute increase,
li
while in the control tests it had produced only a 13.5 beats/ 1
minute increase.	 During bicycle ergometer testing, heart rates
f
C
a
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were elevated at each work load on R +0 with-a mean heart
rate at 75 watts equal to that observed at the highest work
load prior to bedrest.
	 This was 100 watts for three subjects
and 125 for two.
The 'subjects increased their mechanical efficiency on the
bicycle ergometer during the three control studies indicating
a learning effect (p < 0.05).	 Presumably, since they were for
the most part nonbicyclers, they were able to decrease the
amount of extraneous or nonmeasured`work associated with
pedaling the bicycle.	 Although there was-a change in mechanical
efficiency during the control phase, there was no change pre-
,
and postbedrest- when the last control test is compared to the
postbedrest test. 	 These findings are in agreement with those
of I3yatt and Salti:n, who also found no change pre- and post-
bedrest.	 (7,9)	 Saltin did not even find changes in mechanical 	 a
efficiency after an extensive training program.	 The changes	 {
noted in this study thus appear to be an initial acclimation
process which disappears after the first couple of test periods
on the bike.
a
A decreased plasma volume or a decreased plasma volume
with extravascular dehydration and thus increased plasma
A
?s
extravasation during tilt or exercise have been popular
exaplanations for the orthostatic intolerance and decreased 	 1
exercise tolerance seen postflight and postbedrest.
	 Hyatt
a
ti
F
5
postulated that extravasulcar dehydration produced increased
k	 capillary filtration during tilt postbedrest further diminishing
the already reduced volume of blood available to the heart.
This theory was based primarily on water balances and deter-
minations of extracellular fluid (ECF) and total body water
(TBW). Average positive water balance of his subjects decreased
from 738 ±226 ml/day to 439 ±104 ml/day (0 300 ml/day) during
bedrest. (9) This statistically significant decrease was
interpreted by him as coming from the interstitial fluid. In
a later study, he found a 6% decrease in ECF which supported
this theory. (10) In our _study the net change in water balance
was 630 ml/day, approximately two times greater than the change
noted by Hyatt in his bedrested subjects. We found however a j
a
nonsignificant 1% decrease in extracellular fluid with no
weight loss, although the classical postrecumbency cardiovascular
changes were present. We believe that the water balance
changes in this study resulted from differences in insensible
water loss between the control period when the subjects
exercised outside in Houston's warm weather and the bedrest
period when the subjects were confined to airconditioned
quarters. The experimental design could be partially responsible
for our finding of no change in ECF. Control values for ECF
and TBW were measured three weeks prior to bedrest on the day
that the subjects began the relatively high salt content
i
6
study diet. Thus small changes in ECF during bedrest could
have been masked by slight increases in ECF during the three
week control phase on a high salt diet. However, no weight
gain was recorded. The ECF results are at least equivocal and
do not support the postulated theory of extravascular dehydra-
tion.
The centrifugation studies of van Beaumont, Greenleaf and
Juhos also indicate that the absolute decrease in plasma volume
is more important than is transfer of Fluids out of the vascular
system. They found a two-fold greater loss of plasma volume
during centrifugation prebedrest than postbedrest, although
acceleration tolerance was significantly reduced postbedrest
and in centrifugation studies of experimentally dehydrated
i individuals, they found progressively smaller losses of plasma
volume with increasing levels of dehydration. (11) If there
is a correlation between centrifugation tolerance and tilt
tolerance and the mechanisms associated with them, then the
transfer of fluids out of the vascular system during 'tilt 'does
j
	
	 not seem to be a definitive reason for the orthostatic intol-
erance.
During the submaximal. exercise, plasma extravasation is
J
	
	
also unlikely in that plasma seems to be pumped back into the
vascular system even in the presence of extr_avascular dehydra-
tion. After submaximal exercise van Beaumont et al., like
i
l
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Astrand and Saltin.'s cross-country skiers in a cold environ-
ment showed an 11% plasma volume increase even after having
lost 5.50 of their body weight, and steel workers in a hot
3
environment increased plasma volume 5% while losing 1.90
body weight.	 (12,13)
In van Beaumont's study there did appear to be a correla-
tion between the decrease in measured plasma volume postbedrest
1
and acceleration tolerance.,	 They overlooked this correlation,
however, because they ,tended to doubt their measured plasma
volumes and preferred to use the calculated ones.	 The difference
_j
between their measured and calculated plasma volume could have
resulted easily from a decrease in red cell mass 'which is now
known to occur during bedrest.
In our study both the red cell.-mass and plasma volume
decreased during the bedrest period. 	 The mean plasma volume
decrease was 6.90. 	 This is somewhat less than the mean decrease
found in subjects of other bedrest studies which approaches
100, but it is greater than the mean decrease recorded in the
returning Apollo and Skylab crew members_	 Hoffler has found
a very significant negative correlation (r = -0.54, p < 0.005)
between the orthostatically stressed heart rate and decrease in
plasma volume postflight.	 (5')	 The plasma volume changes appear
related to the`orthostatic instability seen postbedrest and
decreased exercise tolerance;y et, the exact relationship is
f
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unclear and perhaps complicated.
	
The literature gives a
I
complex and sometimes confused picture.
Saltin thermally dehydrated healthy males before having
ahem exercise.	 (14)	 Their 5.2% decrease in body weight was
associated with up to 25% decrease in plasma volume. 	 In these
studies he found a very strong correlation between the decrease
in plasma volume and stroke volume at submaximal levels of
s
3
exercise in the sitting position.	 When the subjects exercised
supine, however, the increase in heart rate and decrease in
stroke volume disappeared.
	
These results are in contrast t0
a later study of his when he bedrested individuals.
	
Postbedrest
he found significant increases in heart rate and decreases in
stroke volume not only with upright treadmill exercise, but
_j
also with supine bicycle exercise.
	
(7)	 Hyatt found similar	 s
results in supine exercised subjects postbedrest. 	 (9)	 If
I
plasma volume were the only factor operative, one would expect
I that facilitating venous 'return by having the subject exercise 	 3
1
j in the supine position would normalize heart rate and stroke
1
volume as it did in the dehydrated subj ects.
i t Chobanian felt that plasma volume decreases contributed,
a
but did ' not "explain totally the orthostasis following bedrest.
-J With increasing periods of recumbency he found partial return
of the plasma volume toward control values even while the
i
j tachycardia induced during tilt was increasing. 	 On the other
a
t	 L
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hand, Bohnn et al. have used 9-alpha flurohydrocortisone
(9-alpha) to prevent both the plasma volume decrease and
the orthostatic instability of bedrest. (15) Stevens et
al. used both occlusive cuffs and 9-alpha during the last
few days of bedrest to restore the bedrest decrease in plasma
volume; yet, they found no significant effect on orthostatic
intolerance. (16) It is possible that 9--alpha may have
pharmacological effects other than those recorded in the plasma
volume which are a result of sodium retention. For example,
changes in the sodium content of the vascular system may
account in part for the prevention of the cardiovascular
changes.
Saltia, because he found decreased stroke volume even when
a
venous return was facilitated by the supine position, postu-
lated an unidentified cardiac effect as the cause of the
impaired circulatory adaptation to muscular exercise post
bedrest. He thought that blood volume decreases of the magnitude
seen in his study could not totally explain -the cardiovascular
	 3
effects noted. (7) Decreases in cardiac size <were_seen in this
study and postflight., Since no measurements were made in Hyatt's
k	 or Stevens' studies, it is unknown what portion of the decrease
E 
r
	
	
in heart size can be attributed to the decrease in blood volume
and whether the cardiac size would be normal when 9-alpha is
used to restore the blood volume to normal
t	 1
d
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Aldosterone urinary excretion was increased during
flight when measured in the Skylab crew members. Generally,
aldosterone excretion is not increased in bedrested subjects.
In this study a statistically significant increase in urinary
aldosterone excretion was noted when the first and second six
days_ of bedrest (17 ±2 ug/day SE) were compared to the last
six days of the control period (14 ±1 Vg/day SE). This was
accompanied by a statistically significant increase in urinary
free cortisol from 45 ±4 pg/day to 71 ±5-ug/day during the
first six days and 77 ±7 ug/day during the second six days of
bedrest. Both aldosterone and cortisol should hi=ve produced
sodium retention; yet, mean urinary sodium increased signifi-
cantly, about 40 mec(/day (p < 0.05) during bedrest even though 	 a
dietary intake did not change. This was accompanied by a ,10
-1
meq/day increase in potassium excretion. Other bedrest studies
have shown similar results. Thus even an increase in salt
retaining steroids did not prevent the negative sodium balance	 3
which characterizes bedrested subjects. The mean daily dif-
ference in sodium balances was 17.9 meq/day when the control
period is compared with the bedrest period. This agrees closely
with. the 18.3 meq_/day found by Hyatt. An 18 meq/day mean loss
in sodium could translate into a 225 meq loss or 1.67 liter loss
in ECF if the sodium loss were entirely from the extracellular
space. This would have produced a nearly 10% decrease in ECF,
yi
1
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but only a statistically insignificant 1% decrease was found
indicating much of the sodium loss was from bone The small.
or no loss in ECF found in this study contrasts with IIyatt's
bedrest study where the ECF loss was statistically signifi
cant being about one liter or 6%. It is possible that the
difference between the two studies could be ascribed to the
increased aldosterone and, free cortisol excretion of the
subjects in this bedrest study. Increased aldosterone secre-
tion would have protected against a loss of ECF volume but
not against sodium loss from bone. The present study does 	 t
not furnish support to the theory that the water `and 'sodium	 a
loss of bedrested subjects results from decreased ADH and
- aldosterone excretion since statistically significant increases
in aldosterone occurred with no change in antidiuretic hormone
during the bedrest period. Therefore, a nonhornomal cause for
the sodium loss must be sought. If the sodium loss is mostly
i
osseous in origin, it would be reflecting atrophy of bone.
Bone atrophy would be accompanied by a loss of calcium.
Urinary calcium increased from 7.9 _+0.4 to 10 . 0 +0.6 meq/
day the first six bedrest days and 10.8 ±0..4 me(^/day during
i
the second six-day period of bedrest. This was accompanied
s
t
	
	 by a mean change in calcium balance of 111 mg/day or 5.5 meq/
day. his modest increase in calcium loss would not be
i
I	 y•	 a
`	 expected to produce the degree of naturesis and water diuresis
r
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found in the bedrest period.-
	
Unlike Skylab, no increase in
urinary phosphorus was found in the bedrest period. 	 Net
i
balance measured from the diet and urinary and fecal excretion
actually became more positive.
	
This is difficult to reconcile
I
i with the calcium and sodium results.	 It may indicate a proce-
dural error in the phosphorus determinations.
The vestibular, postural and electromyography findings do
not parallel closely the findings of the Skylab crew members.
	
3
i
The subjects' sensitivity to motion sickness
	
ostbedrest varied.J	
y	
p
I
{ The number of head movements a subject could do prebedrest
varied considerably on different days. 	 Therefore, it is not
possible to say whether an increased susceptibility occurred.
All subjects exhibited mild ataxia for several hours upon
getting out of bed, ,which was particularly noticeable when
I
j they turned corners. 	 In the future, dynamic balancing tests
! might be necessary to document this deficit since the static
balancing tests did not show it.	 The amplitude of the mono.--]	 I
i
synaptic muscle potentials was increased, although no decrease
in reflex reaction time was noted.
	
During bedrest mean urinary
r
norepineph.rine decreased from 44 +3 to 32 ±3 V g/day but this
change was not significant statistically.	 Urinary _norepine--
phrine excretion would be expected to decrease during bedrest
since rising from the supine position causes norepinephrine
i
levels to increase significantly and acutely. 	 Relatively
13
higher norepinephrine levels could be a cause of the increased,
i
amplitude in the monosynaptic muscle potentials recorded in
this study.
This 14-day bedrest study of six- subjects faithfully
i
followed the dietary, specimen collection routine and medicalj
testing of Skylab. Our study was designed to prepare the
personnel and facilities for a full-scale 28-day simulation
of Skylab TI. A large body of useful data was collected. The
results have shown that this study design can produce biochem-
ical and physiological responses which are similar in kind to
other bedrest studies. The quality of accumulated data
furnished by the various Skylab investigators and their
personnel have made it a study whose total contribution compares
a
favorably with other studies of similar length, even though
it was designed as only a preliminary study.
Analyses of these results have helped confirm many post-
bedrest findings described in the medical literature. The
results have raised questions also about theories formulated
to explain the findings; recorded when bedrested subjects
attempt to return to upright activities.
r
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